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During vascular injury blood coagulation is initiated by the interaction of factor VIIa 
(FVIIa) present in blood with freshly exposed tissue factor (TF) forming TF-FVIIa 
complex. As, unwanted clot formation leads to death and debilitation due to vascular 
occlusion; hence anticoagulants are pivotal for treating thromboembolic disorders. Snake 
venoms are veritable gold mines of pharmacologically active polypeptide and proteins 
many of which exhibit anticoagulant activity. 
Two synergistically acting anticoagulant three-finger proteins, hemextin A and hemextin 
B were purified from the venom of the elapid Hemachatus haemachatus (African 
Ringhals cobra) using standard chromatographic procedures. Hemextin A, but not 
hemextin B has mild anticoagulant activity. However, hemextin B forms a complex 
(hemextin AB complex) with hemextin A and enhances its anticoagulant potency. Using 
biophysical techniques including circular dichroism, dynamic light scattering, isothermal 
titration calorimetry, mass spectrometry and nuclear magnetic resonance, the molecular 
interactions participating in complex formation were elucidated. Hemextin AB complex 
exists as a tetramer. Complex formation is enthalpically driven with a negative change in 
heat capacity, indicating the burial of hydrophobic surface area. The tetrameric complex 
behaves differently in buffers of higher ionic strength. It is also sensitive to the presence 
of glycerol in the buffer solution. Thus, a complex interplay of electrostatic and 
hydrophobic interactions drives the formation and stabilization of this novel 
anticoagulant protein complex. Based on the results of the above studies, a model was 
proposed for the assembly of this unique anticoagulant complex.  
 ix
Coagulation and kinetic assays showed that hemextin AB complex and hemextin A 
inhibit clot formation by inhibiting TF-FVIIa activity. Their specificity of inhibition was 
demonstrated by studying their effects on 12 serine proteases; hemextin AB complex 
potently inhibits the amidolytic activity of FVIIa either in the presence or in the absence 
of soluble tissue factor (sTF). This was further confirmed with biophysical experiments. 
The complex inhibits FVIIa-sTF non-competitively (Ki - 25 nM) and is the first natural 
inhibitor of FVIIa, which unlike tissue factor pathway and nematode anticoagulant 
peptide c2 does not use FXa as a scaffold for its inhibitory activity. 
Molecular interactions involved in the formation of hemextin AB-FVIIa complex and 
hemextin A-FVIIa complex were also investigated using size-exclusion chromatography 
and isothermal titration calorimetry.  Hemextin A and hemextin AB complex bind to the 
heavy chain of FVIIa. Binding to FVIIa takes place with equal affinity irrespective of the 
presence or absence of co-factor. Binding also takes place even when the active site of 
FVIIa is blocked; this highlights the non-competitive nature of inhibition both for the 
anticoagulant protein and its complex, which is also supported by enzyme kinetic studies. 
Since, hemextin A is the only known protein belonging to the three-finger toxin family 
that exhibits FVIIa inhibitory activity, its three-dimensional strucuture was determined 
using X-ray crystallography. Hemextin A exhibits the characteristic three-finger fold 
consisting of six β-strands (β2↓β1↑β4↓β3↑β6↓β5↑) which forms two β-sheets. 
In conclusion, the present study provides a detailed characterization of an three-finger 
toxin, hemextin A and its synergistic complex with another three-finger toxin hemextin 
B. Hemextin AB complex is the only known heterotetrameric complex of three-finger 
 x
toxins and also the only known specific inhibitor of FVIIa. Molecular interactions of the 
hemextin A and hemextin AB complex with FVIIa/TF-FVIIa, provides a new paradigm 
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The circulation of blood is pivotal for the 
survival of an organism. In vertebrates 
the circulation of blood occurs in a 
closed circulatory system i.e. the volume 
of blood fairly remains constant inside 
the body of the organism. The word 
“Hemostasis” refers to the complex interaction between vessels, platelets, coagulation 
factors, coagulation inhibitors and fibrinolytic proteins to maintain the blood within 
the vascular compartment in a fluid state. The hemostatic system has evolved over 
millions of years from the much simpler system. In limulus, a 400 million-year old 
fossil, the entire haemostatic system is contained within a single cell (the amebocyte) 
that in response to endotoxin (elaborated by bacteria) engulfs the organism and forms 
a coagulant from the intracellular constituent. This single cell can be viewed as the 
progenitor of both leukocyte and platelet, serving both haemostatic and inflammatory 
functions. The haemostatic system that has evolved in humans features extracellular 
coagulation proteins. This system not only maintains blood in a fluid state under 
physiologic conditions, but also is primed to react to vascular injury to stem blood 
loss. 
Following vascular injury, several steps occur to staunch the flow of blood. These 
steps are synergistic and simultaneous. 
Vasoconstriction lessens the diameter of the vessel slowing the loss of blood.  
Primary hemostasis occurs, wherein platelets bind to collagen in the exposed walls of 
the blood vessel to form a hemostatic plug.  
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Introduction 
Secondary hemostasis or coagulation occurs, where in zymogens of serine proteases 
circulating in the plasma are sequentially activated by limited proteolysis culminating 
in the formation of fibrin clot.  
The coagulation cascade involves more than 20 proteases, cofactors and inhibitors. 
The term “cascade” was first used in 1964 by MacFarlane in describing a proposal for 
the mechanism of blood clotting* (MACFARLANE, 1964b) (Figure 1.1). This 
cascade is a sequence of enzyme reactions, each being activated by the previous one, 
which once initiated proceeds to the final one. The essential advantage inherent in this 
process is the rapid biochemical amplification of a response. In such systems, proteins 
operate in pairs, one acting as enzyme, the other as substrate in turn (Kerr et al., 
1975;Mullertz et al., 1984).  
The formation of blood clot is a carefully regulated process; in 1964, two similar 
proposals were made independently (DAVIE and RATNOFF, 1964;MACFARLANE, 
1964a) which from the basis of the modern day theory of the clotting process. They 
suggested that the whole process of clot formation, starting from surface contact to 
fibrin clot formation occurred by the sequential activation of proteins (clotting 
factors) present in the blood. Each of the clotting factors (except fibrinogen) was 
proposed to exist as an inert pro-enzyme (zymogen) in the plasma milieu, which on 
activation activated the next member in the chain. This hypothetical system became 
popular under the name of the “waterfall” or the “cascade” hypothesis. Over the years 
                                                 
* “AFTER years of confusion, it seems that a relatively simple pattern is emerging from present 
theories of blood coagulation. Its recognition is assisted by the Roman numeral terminology of the 
International Committee on Blood Clotting Factors, which, by displacing a profusion of synonyms, 
allows the basis of factual agreement to be seen. Physiological clotting seems to be initiated by contact 
of the blood with the 'foreign' surfaces presented by many substances and tissues other than normal 
vascular endothelium.” 
---   “An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier” 
Nature 202, 498 - 499 (02 May 1964) 
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Introduction 
the waterfall or cascade hypothesis has undergone multiple amendments (Gailani and 
Broze, Jr., 1991;Sekiya et al., 1996;Schmaier, 1997a;Schmaier, 1998). 
The current model of blood coagulation involves two distinct pathways (Figure 1.2): 
The primary pathway commonly known as the “extrinsic or the tissue factor pathway” 
and the “intrinsic or the contact activation pathway”. These two pathways merge 
together with the formation of factor Xa (FXa), the serine protease in the 
prothrombinase complex responsible for the conversion of prothrombin to thrombin. 
Thrombin cleaves fibrinogen to fibrin, which polymerizes to form an insoluble fibrin 
clot. In addition, thrombin is the key activator of platelet aggregation at the site of 
injury (Davey and Luscher, 1967;Brass, 2003b). Platelets form a plug that stops the 
hemorrhage and prevents further blood loss. Also, during the activation process a 
multitude of proteins is released at the site of injury that initiate the process of tissue 
repair. These include plasma proteins such as von Willebrand factor (vWF), which 
plays an important role in forming a bridge between the activated platelets and the 
subendothelium (Girma et al., 1987;de Groot, 2002). Platelet aggregation also 
promotes the clotting process, since activated platelets provide the phospholipid base 
required for the formation of the vitamin–K dependent coagulation enzyme 
complexes. The fibrin clot formed by the clotting cascade, complementarily 
strengthens the platelet plug. 
The tissue factor pathway acts as a “prima ballerina” in clot initiation, and the 
intrinsic pathway plays a more important role in the propagation of the coagulation 
(Luchtman-Jones and Broze, Jr., 1995;Schmaier, 1997b). A comprehensive 






















































































Figure 1.2 The current model of the blood coagulation cascade. There are 2 pathways, 
the contact activation or intrinsic pathway and the primary or extrinsic pathway. These 
multicomponent processes are illustrated as enzymes, inhibitors, zymogens, or complexes. 
The contact activation pathway has no known bleeding cause associated with it, thus this path 
is considered accessory to hemostasis. On injury to the vessel wall, tissue factor, the cofactor 
for the extrinsic tenase complex, is exposed to circulating FVIIa and forms the the extrinsic 
tenase. FIX and FX are converted to their serine proteases FIXa and FXa, which then form the 
intrinsic tenase and the prothrombinase complexes, respectively. The combined actions of the 
intrinsic and extrinsic tenase and the prothrombinase complexes lead to an explosive burst of 
the enzyme thrombin (IIa). In addition to its multiple procoagulant roles, thrombin also acts in 
an anticoagulant capacity when combined with the cofactor thrombomodulin in the protein 
Case complex. The product of the protein Case reaction, APC, inactivates the cofactors FVa 
and FVIIIa. The cleaved species, FVai and FVIIIai, no longer support the respective 
procoagulant activities. Once thrombin is generated through procoagulant mechanisms, 
thrombin cleaves fibrinogen (releasing fibrinopeptide A and B [FPA and FPB]) as well as 
activates FXIII to form a cross-linked fibrin clot. Thrombin–thrombomodulin also activates 
thrombin activate-able fibrinolysis inhibitor that slows fibrin degradation by plasmin. The 
procoagulant response is downregulated by the stoichiometric inhibitor tissue factor pathway 
inhibitor (TFPI) and antithrombin III (AT-III). TFPI serves to attenuate the activity of the 
extrinsic tenase trigger of coagulation. AT-III directly inhibits thrombin, FIXa, and FXa. The 
accessory pathway provides an alternate route for the generation of FIXa. Thrombin has also 
been shown to activate FXI. The fibrin clot is eventually degraded by plasmin yielding 
soluble fibrin peptides. (Redrawn with modifications from Statins and Blood Coagulation 
(2005) by Anetta Undas, K.E. Brummel-Ziedins and Kenneth G Mann)  
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Although it has been traditional to divide the coagulation system into intrinsic and 
extrinsic pathways, such a division does not occur in vivo, because the TF-FVIIa 
complex is the potent activator of both FIX and FX. 
The primary pathway (The extrinsic pathway/The tissue factor pathway) 
The extrinsic pathway was first formulated by Schmidt and Morawitz as early as 1892 
and 1905 respectively; they proposed that thromboplastin released from the tissues, 
converts prothrombin to thrombin in the presence of Ca2+. Thrombin then converts 
fibrinogen to insoluble fibrin by a proteolytic cleavage (Blomback et al., 1978;Marsh, 
Jr. et al., 1983). The classic theory remained accepted for over 50 years, till other 
blood coagulation factors were discovered mainly between 1940 and 1960 
(Macfarlane, 1972). 
The term “extrinsic” came from the observation that one of the factors (tissue factor – 
TF) participating in the initiation of the clotting process is extrinsic to the circulating 
blood. The pathway is initiated when subendothelial TF is exposed or expressed to 
blood flow following either damage or activation of the endothelium. This may occur 
due to the perforation of the vessel wall or activation of the endothelium (Geczy, 
1994). Upon activation of endothelial cells (EC) by an injury, ECs immediately 
release vasoactive agents, such as endothelin (ET) (a potent vasoconstrictor) and nitric 
oxide (NO) that counteracts endothelin. In states of EC dysfunction the concentrations 
of bioactive NO are reduced. This leads to the relatively unopposed actions of ET 
which may promote the generation of pathological vasoconstriction and 
atherosclerosis formation leading to thrombophilia (Lopez et al., 1990). Other 
responsive mechanisms of the activated endothelial cells are exhibited by a distinct 
expression of cytokines, growth factors, and their receptors, including vascular 
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endothelial growth factor (VEGF) and its two tyrosine kinase receptors VEGFR-1 and 
-2 (Matsumoto and Mugishima, 2006). 
TF binds to zymogen factor VII (FVII) (Morrissey and Neuenschwander, 1996;Rao et 
al., 1996). However, small amounts of FVII is present in already activated form in the 
plasma milieu (Radcliffe and Nemerson, 1975b), which also bind to TF to form a 
complex known as the extrinsic tenase complex. It is to be noted that, the vast 
majority of enzyme-cofactor complexes that are formed are TF-FVII, but only a small 
number is TF-FVIIa (Rao and Rapaport, 1988). A trace concentration of FXa is 
generated by the small number of TF-FVIIa complexes (Butenas et al., 1997). The 
FXa so formed preferentially and rapidly activates only the FVII of TF-FVII 
complexes in a key amplifying step of the initiation sequence (Radcliffe and 
Nemerson, 1976). The activation of FVII by FXa is greatly accelerated following 
complex formation of FVII with TF (Nemerson and Repke, 1985). TF-FVII complex 
is also converted to the enzymatically active TF-FVIIa auto-catalytically by TF-FVIIa 
(Pedersen et al., 1989;Nakagaki et al., 1991;Yamamoto et al., 1992). Thrombin, FIXa 
and FXIIa also convert FVII to FVIIa (Kisiel et al., 1977;Broze, Jr. and Majerus, 
1980a). Recently, a plasmatic serine protease (FVII activating protease or FSAP) has 
been recognized which also converts FVII to FVIIa (Miura et al., 1996) 
The extrinsic tenase complex catalyzes the activation of both FX (Di Scipio et al., 
1977a) and FIX (Di Scipio et al., 1978a), the former being the more efficient 
substrate. Thus, the initial product formed by the activity of extrinsic tenase is FXa; 
formed by the cleavage of a single bond in FX (Arg52-Ile53 of the heavy chain), a 52-
residue activation peptide is concomitantly released during the process (Di Scipio et 
al., 1977b). The FIX zymogen is a competitive substrate with FX and requires two 
peptide bond cleavages (at Arg145 and Arg180) for activity. While both of these 
cleavages are being catalyzed by the extrinsic tenase complex, FXa bound to the 
membrane can also catalyze one (at Arg145) of the two required cleavages to generate 
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an intermediate. The final cleavage then occurs at Arg180, leading to the formation of 
FIXa. Thus, this feed back cleavage of FIX by membrane bound FXa enhances the 
rate of FIXa generation. (Lawson and Mann, 1991). 
The initial FXa that is produced, when bound to membrane activates minute quantities 
of prothrombin to thrombin, albeit rather inefficiently; this initial thrombin provides 
the impetus to the propagation of clotting cascade by activating the platelets (Brass, 
2003a), FV (Kane and DAVIE, 1988) and FVIII (Osterud et al., 1971). 
The intrinsic pathway/The contact activation pathway 
The term “intrinsic” or “contact activation” pathway arose from the observation that 
coagulation occurred spontaneously when blood was placed in glass test tubes. The 
trigger mechanism of the intrinsic pathway has been studied in great detail on 
negatively charged surfaces. The main proteins participating in the contact system are 
– coagulation factors XII (FXII) and XI (FXI), high molecular weight kininogen 
(HMWK), and prekallikrein (PK). 
During injury, negatively charged physiological surfaces such as sulfatides, 
phospholipids, urates, cholesterol and chondritin sulfates and other glycosamines are 
exposed. Zymogen FXII binds directly to these surfaces, promoting a conformational 
change in the molecule. This conformational change in FXII increases its sensitivity 
to proteolytic activation. Zymogens PK and FXI, circulate in the blood as complexes 
with HMWK, as PK-HMWK and FIX-HMWK respectively. FXI and PK attach to the 
negatively charged exposed membrane through their interactions with HMWK. It has 
been shown that HMWK binds to these surfaces through glycoproteins identical to 
receptor binding the globular regions of the complement C1-q component (Herwald et 
al., 1996). Colman has shown that HMWK interacts with the receptor of the 
urokinase-like plasminogen activator on the surface of the endothelial cells (Ferguson, 
1996). This binding brings both the zymogens to the site of injury and in direct 
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proximity to FXII. The membrane-bound activated form of FXII activates PK to 
kallikrein by cleaving the Arg371-Arg372 bond (Imamura et al., 2004).  Kallikrein 
formed activates FXII; HMWK increases the rate of the reaction (Fujikawa et al., 
1980). This result in the successive generation of two active forms of the factor: 
aFXIIa and bFXIIa. The cleavage of the Arg353-Val354 bond of FXII results in the 
formation of aFXIIa form of the enzyme, which consists of a heavy and a light chain 
(353 and 243 amino acid residues, respectively) bound by a disulfide bond. The 
bFXIIa form of the enzyme is generated after the hydrolysis of two more peptide 
bonds Arg334-Asn335 and Arg343-Leu344. These cleavages result in the formation 
of a 30 kDa enzyme, consisting of the light chain of the enzyme supplemented with a 
small fragment of the heavy chain (Cochrane et al., 1973;Revak and Cochrane, 
1976;Revak et al., 1977;Revak et al., 1978). Both the forms of FXIIa, activate FXI to 
FXIa by the hydrolysis of the Arg369-Ile370 bond in the presence of HMWK (Bouma 
and Griffin, 1977). FXIa activates FIX to FIXa by the hydrolysis of the Arg180-
Ile181 bond (Di Scipio et al., 1978b). FIXa forms a complex with its non-enzymatic 
cofactor FVIIIa (already activated by thrombin), on the activated platelet membrane 
to form the FVIIIa-FIXa complex also known as “intrinsic tenase complex”. This 
complex becomes the principal activator of FX.  The FVIIIa-FIXa complex is 105 to 
106 times more efficient than FIXa alone as FX activator and ~50 times more efficient 
than the TF-FVIIa in catalyzing FX activation (Hockin et al., 2002). As a 
consequence most (>90%) of the FXa is produced due the catalytic activity of the 
intrinsic tenase complex in the TF initiated hemostatic process. Some mutations in 
FVIII or FIX proteins interfere in the formation of the intrinsic tenase complex 
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resulting in either no or poor amplification of FXa generation. This is the principal 
defect observed in hemophilia A and hemophilia B† (Palmer et al., 1989). 
Convergence of the pathways and fibrin clot formation 
FXa formed in the above pathways complexes with FVa (already activated by 
thrombin) on the activated platelet membrane surface in the presence of Ca2+ to form 
FVa-FXa complex (Swords and Mann, 1993). This complex activates prothrombin to 
thrombin and hence known as the prothrombinase complex.  This complex is 300,000 
fold more active than FXa alone in catalyzing prothrombin activation (Krishnaswamy 
et al., 1987). The principal function of thrombin formed during clotting is the 
conversion of fibrinogen to fibrin by limited proteolysis.  
Fibrinogen is a 340 kDa protein having a symmetrical dimeric structure with two sets 
of three intertwined polypeptide chains, designated as Aα, Bβ, and γ, linked together 
by 29 disulfide bonds (Henschen and Lottspeich, 1977;Lottspeich and Henschen, 
1977;Doolittle et al., 1979). The Bβ and γ chains also contain two pairs of 
carbohydrate side chains, each of molecular weight 2500 Da. Fibrinogen has three 
globular domains, one on each end and one in the middle where the chains are linked. 
Rod-like domains separate the globular domains. During the conversion of fibrinogen 
to fibrin, thrombin cleaves the fibrinopeptides (the short acidic NH2-terminal 
sequences on the fibrinogen Aα- and Bβ-chain that shield specific polymerisation 
sites), which results in a dramatic change in solubility that causes the molecules to 
aggregate and form fibrin fibers. Thrombin cleaves the fibrinogen between Arg16 and 
Gly17 and the Bβ chain between Arg14 and Gly15. The cleavage in the Aα chain 
                                                 
† ‘occasionally (in vitro) the blood of some of the haemophilic patients with a greatly prolonged clotting 
time…when added to other haemophilic blood possessed a coagulant action nearly as effective as normal 
blood’ 




leads to the formation of double-stranded twisting fibrils which are arranged in a half-
staggered overlapping domain arrangement. Fibrils branch out and create structures 
that result in a complex network of fibers. There are likely to be two different types of 
branching that define the structure of the clot: In the first type, double-stranded fibrils 
line up side-to-side and form a tetra-molecular or bilateral branch-point. This kind of 
branching supports strength and rigidity in the clot. The second kind of branching is 
trimolecular or equilateral. This is formed by the coalescence of three fibrin 
molecules that conjoin three double-stranded protofibrils of equal width and probably 
occurs more often when the rate of fibrinopeptide release is slow. The cleavage in the 
Bβ is associated with the lateral aggregation of protofibrils. (Krakow et al., 
1972;Williams, 1981;Weisel et al., 1981;Fowler et al., 1981;Weisel et al., 
1985;Weisel, 1986) 
During clot formation, thrombin catalyzes the conversion of factor XIII (FXIII) to 
factor XIIIa (FXIIIa) in the presence of Ca2+. FXIIIa is a transglutaminase that 
catalyzes the formation of intermolecular γ-glutamyl-ε -lysine crosslinks in the fibrin 
network, producing an insoluble, pliant blood clot (Ware et al., 1999). Covalent 
crosslinks occur between opposing chains and involve γ−γ, γ−α, and α−α interactions. 
These covalent links lead to the formation of a very strong fibrin clot.  
Lysis of fibrin clot 
Once haemostasis is restored and the tissue is repaired, the clot or thrombus must be 
removed from the injured tissue. This is achieved by a process known as fibrinolysis. 
Lysis or dissolution of fibrin clots is brought about by serine protease plasmin. 
Plasmin circulates as inactive zymogen, plasminogen in the blood (Plow and Collen, 
1981). Plasminogen contains secondary structure motifs known as kringles, which 
bind specifically to lysine and arginine residues in both fibrinogen and fibrin. Tissue 
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plasminogen activator (tPA) (released from vascular endothelial cells following 
injury) and, to a lesser degree, urokinase (synthesized as a zymogen prourokinase by 
epithelial cells lining excretory ducts and is activated by proteolytic cleavage between 
Leu158 and Ile159) convert plasminogen to plasmin by the cleavage of Arg28-Val29 
bond (Robbins et al., 1967;Summaria et al., 1967). Plasmin specifically cleaves the 
COOH-terminal to the lysine and arginine residues producing fibrin degradation 
products (FDPs). FDPs compete with thrombin, and slow down the conversion of 
fibrinogen to fibrin (thus slowing down clot formation) (Merskey et al., 1966;Marder 
et al., 1971).  
After clot lysis, plasmin is released from the clot and is inactivated by α2-antiplasmin 
(a serine protease inhibitor) (Moroi and Aoki, 1976). Also, thrombin-activatable 
fibrinolysis inhibitor (TAFI) (a plasma carboxypeptidase B2 that is activated by a 
cleavage at Arg92 by the thrombin-thrombomodulin complex) (Tan and Eaton, 
1995;Redlitz et al., 1995) cleaves C-terminal Arg residues from fibrin rendering it 
less succeptible to plasmin. 
Regulation of Blood coagulation 
Blood coagulation is pivotal for hemostasis and unwanted clot formation can lead to 
death and debilitation. Therefore control is exerted at each level of the coagulation 
pathway through inactivation of cofactors and inhibition of enzymes. The protein C 
anticoagulant pathway plays a major role in the regulation of blood coagulation (For 
details refer to the recent review by (Mosnier and Griffin, 2006)) (Figure 1.3). Protein 
C (Stenflo, 1976;Esmon et al., 1976), is activated by thrombin that is bound to the 
membrane protein thrombomodulin (TM) (Esmon, 1995) on the surface of intact 
endothelial cells. This complex cleaves at Arg169 to remove the activation peptide 
and generate activated protein C (APC). A recently described endothelial protein C 
receptor (EPCR) also stimulates protein C activation (Esmon et al., 1999). Platelet 
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factor 4 (PF4), released from the platelets during activation also enhances APC 
generation (Slungaard et al., 2003). APC proteolytically inactivates phospholipid 
membrane-bound cofactors FVa and FVIIIa and inhibits coagulation. Inactivation of 
FVa involves three cleavages at Arg306, Arg506 and Arg679 (Kalafatis et al., 
1994;Heeb et al., 1995), whereas that of FVIIIa involves two cleavages at Arg336 and 
Arg562 (O'Brien et al., 2000). Protein S, a vitamin K-dependent plasma protein, acts 
as a cofactor to APC, and further increases the degradation of FVa and FVIIIa 
(Walker, 1980). Protein S also exhibits anticoagulant activity individually and can 
bind to FXa, FVa and FVIIIa, thereby inhibiting prothrombinase and intrinsic tenase 
activity (Heeb et al., 1993;Heeb et al., 1994). Protein S also competes for 
procoagulant phospholipid surfaces thereby mediating anticoagulant activity(van 
Wijnen et al., 1996).  
Coagulation is also regulated by the inhibition of active proteases in the cascade. The 
tissue Factor Pathway Inhibitor (TFPI), a protein produced by the endothelial cells 
and consisting of three kunitz domains binds to and inhibits the ternary complex TF-
FVIIa-FXa (Rao and Rapaport, 1987). Antithrombin (AT) is a serpin (SErine Protease 
INhibitor) that inhibits thrombin, FXa, FVIIa and to a lesser extent FIXa. However, 
thrombin bound to fibrin clot is relatively protected by AT (Weitz et al., 1990). 
Circulating AT is a relatively inefficient, but its activity is stimulated by heparin, 
heparan sulphates or chondroitine sulphates that are present on the surface of 
endothelial cells (Weitz, 2003). The potentiation of AT efficiency by heparin is the 
molecular basis for the use of heparin as a therapeutic anticoagulant. FX as well as 
FXa is also inhibited by AT but not as potently by a serpin Z protease inhibitor (ZPI). 
The activity of ZPI is enhanced 1000 fold by vitamin K-dependent protein Z in the 





Figure 1.3 Schematic representation of the protein C anticoagulant system. (Redrawn 
with kind permission from “The Protein C Pathway” by Charles T Esmon, Chest:2003 
Supplement; 26S-32S). In the presence of intact endothelium, thrombin binds to 
thrombomodulin and activates protein C. Endothelial protein C receptor (EPCR) stimulates 
the activation of protein C. Activated protein C counteracts coagulation by cleaving and 
inhibiting the cofactors FVa and FVIIIa. The free form of protein S in blood serves as 
cofactor to activated protein C. In the regulation of the tenase complex, FV plays an 




The “extrinsic tenase complex”: macromolecular complex initiating coagulation 
As highlighted above the formation of macromolecular enzyme complexes is one of 
the hallmarks of the coagulation cascade. Since the focus of this thesis relates to the 
characterization of a protein complex that interferes at this step of the coagulation 
cascade, viz., the extrinsic tenase complex, it will be described separately in greater 
detail. The extrinsic tenase complex, the principal initiator of coagulation in vivo, 
consists of TF and FVIIa. 
Tissue Factor 
TF also known as thromboplastin, CD142 and coagulation factor III is mainly found 
on the surface of the cells in which it is synthesized. It is abundant in a variety of cell 
types distributed through out the body, including adventitial cells surrounding all 
blood vessels larger than capillaries; differentiating keratinocytes in the skin and a 
large number of epithelial cell types, including those present in mucous membranes 
and many organ capsules (Drake et al., 1989;Wilcox et al., 1989b;Fleck et al., 1990). 
It is a glycosylated membrane protein consisting of a single polypeptide chain of 261 
to 263 amino acids (the two forms are nearly equal in abundance), with variability in 
length owing to the microhetrogeneity at the NH2-terminus (Spicer et al., 
1987;Morrissey et al., 1987). The calculated molecular weight of the polypeptide is 
29,447 Da and 29,593 Da, where as the mobility of the fully glycosylated protein on 
SDS gels suggests a molecular weight of approximately 45, 0000 Da (Broze, Jr. et al., 
1985). TF belongs to the class 2 cytokine receptor superfamily (Bazan, 1990). Three 
potential N-linked glycolsylation sites are available in the extracellular domain of 
human TF (Paborsky and Harris, 1990), but they are dispensable for clotting activity 
because the recombinant form produced in bacteria is fully functional (Paborsky et 
al., 1989). The extracellular domain consists of two fibronectin type III repeats, which 
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are a variation of the immunoglobulin fold. The extracellular domain has two 
disulfide bonds (Bach et al., 1988b), at last one of which is important for activity. TF 
has a typical membrane-spanning domain that anchors the protein to the cell surface. 
Membrane anchoring of TF is essential for full procoagulant activity, although the 
exact nature of the membrane anchor does not appear to be important (Paborsky et al., 
1991b). The short cytoplasmic domain of TF (23 amino acid long) contains a cysteine 
residue to which a fatty acyl chain (palmitate or stearate) is attached by thioester 
linkage (Bach et al., 1988a). In addition the cytoplasmic domain can be 
phosphorylated on serine (Zioncheck et al., 1992). Deletion of the cytoplasmic 
domain has no discernible effect on procoagulant activity of TF (Paborsky et al., 
1991a), making its role in blood clotting unclear, but recent studies indicate that it 
may be involved in other non-hemostatic function such as signal transduction 
(Rottingen et al., 1995;Nystedt et al., 1996;Pendurthi et al., 1997;Poulsen et al., 
1998).  
Recent studies have shown that, much of TF remains in the ‘cryptic stage’ meaning 
that moleucules are procoagulantly active. Certain stimuli such as vascular injury 
‘dencrypt’ or make them active. Protein disulfide isomerase (PDI) is a critical player 
which is involved in the activation process, it activity involves the breaking or 
forming a critical disulfide bond (Ruf et al., 2006). 
 The crystal structure of soluble tissue factor (sTF) (only the extracellular domain) has 
been solved (Figure 1.4) (Harlos et al., 1994;Muller et al., 1994;Muller et al., 
1996;Muller et al., 1998;Huang et al., 1998b). sTF is an elongated rather rigid 
molecule in which the two fibronectin domains have an interdomain angle of 120 
degrees (Harlos et al., 1994;Muller et al., 1998), which corroborates well with the 
structural proximity of TF with other cytokine receptors.  
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Factor VII/ VIIa  
FVII is synthesized in the liver and secreted as a single-chain glycoprotein of 48 kDa. 
It consists of an NH2-terminal γ-carboxyglutamic acid (Gla) domain, two epidermal 
growth factor–like domains and COOH-terminal serine protease domain (catalytic 
domain) (Kisiel and DAVIE, 1975;Radcliffe and Nemerson, 1975a;Broze, Jr. and 
Majerus, 1980b). It is activated to FVIIa by a cleavage of a peptide bond between 
Arg152-Ile53 (Wildgoose et al., 1992;Butenas and Mann, 1996). The newly formed 
NH2-terminal residue Ile153 buries its side chain in a hydrophobic environment, 
whilst establishing a salt bridge between its α-amino nitrogen atom and the side chain 
of residue Asp194. Residue Asp194 is adjacent to the catalytic Ser195, and this salt-
bridge contributes to efficient catalysis. In addition, three nearby loops undergo 
conformational changes to form the substrate-binding cleft (Higashi et al., 1994). In 
classical serine proteases like trypsin or chymotrypsin, these series of events produces 
the final active enzyme. FVIIa individually has zymogen like activity and the binding 
of TF is a pre-requisite for its full enzymatic activity (Higashi et al., 1996). It has 
been observed that the α-amino nitrogen is relatively susceptible to chemical 
modification, until TF binds and hence the insertion of Ile153 into FVIIa core appears 
to be incomplete (Higashi et al., 1994). TF drives the equilibrium between partially 
and fully active forms towards the active enzyme (Higashi et al., 1996). FVIIa 
consists of an NH2-derived light chain (relative molecular mass, 20,000) consisting of 
152 amino acid residues and a COOH terminal–derived heavy chain (relative 
molecular mass, 30,000) consisting of 254 amino acid residues linked via a single 
disulfide bond (Cys135 to Cys262). The light chain contains the membrane-binding 
Gla domain (containing 10 γ-carboxyglutamic acid residues) and two EGF domains, 
while the heavy chain contains the catalytic protease domain (Persson, 2006). 
TF-FVIIa complex – “A Classical Allosteric Pair” 
Allostery involves changes in the conformation or activity of an enzyme or other 
protein that arise from its combination with another molecule at a point other than its 
“chemically active” site.  FVIIa is subject to numerous allosteric influences. The ones 
































Figure 1.4 Overall view of the (A) The extracellular domain of tissue factor. Note the 
interdomain angle is 120 degrees. (B) TF-FVIIa complex as determined by Banner et al. 
(1996). The membrane is presumed to be at the bottom of this view. The three FVIIa light 
chain domains, Gla, EGF1, and EGF2, are shown. The FVIIa protease domain (heavy chain) 
is at the top. Carbohydrate moieties attached to the EGF1 and protease domains are however 
not depicted. (C) FVIIai without TF. (D) Inhibitory peptide A-183 (green tube) 




EGF1 domains. However, the exact mechanisms by which these events alter 
enzymatic activity at the distant active site (Persson et al., 1997;Kelly et al., 
1997;Freskgard et al., 1998;Jin et al., 1999;Leonard et al., 2000) still remain unclear. 
The allosteric sites localized in the trypsin homology protease domain are somewhat 
more tractable, since these sites are localized in close proximity to each other. The 
protease domain contains three TF binding regions localized specifically in the active 
site binding cleft, and the macromolecular substrate exosite (Dickinson et al., 1996). 
Binding events at any of these three sites induces changes at the other two. Over the 
years, new allosteric sites have been discovered using random peptide libraries 
displayed on phage (Dennis et al., 2000).  
TF enhances the catalytic activities of FVIIa, but there are imperative differences in 
the magnitudes of these changes. There is an approximate105 fold enhancement of 
proteolytic activity when FVIIa combines with membrane bound TF (Bom and 
Bertina, 1990;Ruf, 1998), while sTF increases amidolytic activity by only about 50 
fold (Butenas et al., 1993;Neuenschwander et al., 1993). The allosteric influences of 
TF have been brought forward by several X-ray crystal structures of FVIIai (FVIIa 
with a covalently attached inhibitor in the active site), sTF, and their complex. These 
studies are also supported by site-directed mutagenesis data.  
Banner and colleagues solved the structure of sTF-FVIIa complex at 2.0 Å resolution 
(Banner et al., 1996) (Figure 1.4). It shows the fully activated enzyme-cofactor 
complex with a pseudosubstrate covalently attached to active site residues, revealing 
details of the substrate binding subsites on the NH2-terminal side of the scissile 
peptide bond. In the complex, the overall conformation of sTF remains unchanged 
from its un-complexed form (Harlos et al., 1994). The two fibronectin domains of sTF 
contact all main domains of FVIIai. The first three domains of FVIIai are connected 
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via short linker regions and are aligned in a linear fashion, leading up and along the 
cofactor to place the FVIIai protease domain on top of sTF. The catalytic active site is 
found about 80 Å above the presumed cell membrane position (McCallum et al., 
1996). Recently, it has been shown that the maintenance of this specific distance of  
80 Å is crucial for the enzymatic activity of FVIIa (Waters et al., 2006). The NH2-
terminal Gla domain of FVIIa is fully loaded with seven Ca+2 ions and projects three 
hydrophobic side chains in the presumed direction of the cell membrane. It also has 
significant contact with the COOH-terminal domain of TF. The first EGF domain 
(EGF1) has extensive contact with TF. It also contains a single Ca2+ ion and two 
glycosylation sites projecting away from TF. The EGF2 domain and the catalytic 
domains are connected by disulfide bonds. Both domains also contact TF, although 
the mutational data show the greatest contributions to TF affinity come from the Gla 
and EGF1 domains (Higashi et al., 1996;Dickinson et al., 1996). The protease domain 
has a high-affinity Ca+2 binding site (Wildgoose et al., 1990), localized in the loop 
from Glu70 to Glu80. A significant feature of this complex structure is the large 
distance between the protease domain NH2-terminal Ile153 and TF, which eliminated 
any possibility that the connection between TF binding and NH2-terminus insertion 
(detected by resistance to chemical modification of the NH2-terminus) was allosteric 
in nature. The authors’ speculation as to the allosteric effects of TF binding on the 
active site geometry was two-fold. The FVIIai loop Cys168-Cys182 (known as 
classically as the “methionine loop”) is longer in FVII than in related proteins, and 
lies “between” the TF binding region on the protease domain and the substrate 
binding cleft. It has been suggested that without TF this loop might occlude the cleft 
or contact the NH2-terminal Ile153, thus preventing its insertion and partnering with 
Asp194. An additional possibility, that without TF the Gla and EGF domains could 
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occlude the active site, has also been postulated. Recent work describing effects of 
mutations in the methionine loop continue to suggest some role for it in catalysis 
(Soejima et al., 2001). Later, Zhang et al. reported the structure of TF-FVIIa-BPTI 
complex (BPTI is basic pancreatic trypsin inhibitor) at 2.1 Å resolution (Zhang et al., 
1999b) confirming all the highlights observed in the complex structure reported by 
Banner and his colleagues.  
Two contemporaneous reports of nearly identical FVIIai molecules by Pike et al. and 
Kemball-Cook et al. showed the true nature of conformational changes in FVIIa 
caused by TF binding (Pike et al., 1999;Kemball-Cook et al., 1999) (Figure 1.4). Both 
structures revealed unchanged EGF2 and protease domains that were arranged in 
essentially the same manner as in the TF-FVIIai complex. Changes were observed in 
the TF binding region of the protease domain. Both the papers postulate the 
involvement of the methionine loop in the above change; however they are not 
conclusive on this point. One emanating point about these structures is the observed 
“allosteric cross-talk” between the substrate binding cleft and the TF binding region. 
The simplest interpretation is occupancy of the substrate binding cleft increases TF 
affinity by conditioning the TF binding region for interaction with the cofactor. 
However, to assess these conformational changes in FVIIa caused by TF binding 
and/or by occupancy of the substrate binding cleft, the lone structure of FVIIa has to 
be there. The recently reported FVII zymogen structure by Eigenbrot et al. is close to 
this ideal, lacking both TF and substrate mimic, but it deviates from the ideal in 
having an intact connection between EGF2 and the protease domain (Eigenbrot et al., 




Anticoagulants‡ are crucial for prevention and 
treatment of thromboembolic disorders and ~0.7% of 
the western population receives oral anticoagulant 
treatment. Heparin and coumarins discovered more 
than 60 years ago, are the most widely used 
anticoagulants. However, the non-specific mode of 
action of these anticoagulants accounts for their 
therapeutic limitations in maintaining a balance between thrombosis and hemostasis.  
This limitation has provided the impetus for the design of new anticoagulants that 
target specific coagulation enzymes or steps in the coagulation pathway. These 
anticoagulants have been developed from proteins isolated and characterized from 
hematophagous organisms, using recombinant DNA technology, or by structure-based 
drug design. A comprehensive discussion of each of these anticoagulants with a focus 
on the ones targeting TF-FVIIa complex is given below. 
The TF-FVIIa complex is an interesting target in thrombosis-related diseases because 
the inhibitors targeting TF-FVIIa might achieve anticoagulant efficacy without 
significantly interfering with normal hemostasis (Harker et al., 1996;Himber et al., 
1997). This unusual separation of antithrombotic and antihemostatic effects in 
experimental models may be related to the recently discovered role of circulating TF 
in thrombosis (Giesen et al., 1999;Rauch et al., 2000;Balasubramanian et al., 2002).  
In circulation “Blood borne” TF is associated with monocyte derived microparticles, 
                                                 
‡ “An anticoagulant is a substance that prevents coagulation that is, it stops blood from clotting.”  





which localize to form platelet thrombus through interaction of P-selectin 
glycoprotein ligand-1 (PSGL-1) with P-selectin on the surface of activate platelets 
(Falati et al., 2003). Thus, antibody specific to P-selectin exhibits remarkable 
antithrombotic properties (Palabrica et al., 1992). Therefore, specific inhibitors of TF-
FVIIa complex may cause less bleeding because they inhibit intravascular TF at 
concentrations that are far below those necessary to block the high amounts of the 
hemostatic extravascular TF (Giesen et al., 1999). 
TF-FVIIa specific inhibitors are also useful for the treatment of a multitude of 
ailments. The complex is an important contributor to diseases pertaining to the cardio-
vascular system such as angina and myocardial infarction. Atherosclerotic plaque 
have been shown to contain TF (Wilcox et al., 1989a), which on rupture lead to 
occlusive thrombus formation thereby triggering myocardial infarction (Badimon et 
al., 1999). TF-FVIIa is also involved in myocardial ischemia-reperfusion injury, since 
specific inhibitors of the complex reduce the infarct size in experimental models 
(Erlich et al., 2000). TF-FVIIa is also thought to participate in restenosis (Jang et al., 
1995), venous thrombosis (Lee et al., 2001a), sepsis (Taylor, Jr. et al., 1991), 
glomerulonephritis (Tipping et al., 1995), rheumatoid arthritis (Bokarewa et al., 
2002), sickle cell anaemia (Belcher et al., 2000) and tumor growth and metastasis 
(Rickles et al., 2003).  
Inhibitors of TF and FVIIa 
A wide variety of strategic approaches have been availed for the design and synthesis 
of inhibitors targeting TF-FVIIa complex, as shown in Figure 1.5.  
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Figure 1.5 Schematic representation of the approaches for TF-FVIIa inhibition. A cartoon of 
the TF-FVIIa complex on a phospholipid membrane showing the FVIIa domains and the potential 







Tissue factor pathway inhibitor (TFPI)
TFPI is a 42 kDa naturally occurring endogenous plasma glycoprotein having 276 
amino acid residues. It is a Kunitz-type protease inhibitor consisting of three tandem 
Kunitz inhibitor domains, the first and second of which inhibit TF-FVIIa complex and 
FXa, respectively (Bajaj et al., 2001). The third domain has no inhibitory activity and 
contains the heparin-binding sites (Hamamoto et al., 1993). Similar heparin binding 
site is also localized in the COOH-terminal basic region of the molecule. Interaction 
of the these TFPI regions with heparin enhances its anticoagulant potency (Hamamoto 
et al., 1993). The complete structure of TFPI has not been solved, but the structures of 
the individual second and third kunitz domains are available (Figure1.6) (Burgering et 
al., 1997;Mine et al., 2002).  
The anticoagulant action of TFPI is a two-stage process. The second Kunitz domain 
first binds to a molecule of FXa and deactivates it. The first domain then rapidly binds 
to an adjacent  TF-FVIIa complex, preventing further activation of FX (Figure1.6) 
(Baugh et al., 1998;Panteleev et al., 2002). Interestingly, the first kunitz domain of 
TFPI itself inhibits TF-FVIIa with a Ki of 250 nM (Petersen et al., 1996a). A chimeric 
protein has been designed by linking the first Kunitz domain of TFPI to the COOH-
terminal of the light chain of FX. The chimera potently inhibits TF-FVIIa in the 
absence of FX/FXa with 14 times more potency than TFPI (Girard et al., 1990). 
Recombinant TFPI (tifacogin) has been compared with placebo in phase 2 (Abraham 
et al., 2001) and phase 3 (Abraham et al., 2003) clinical trials. The promising results 
of the phase 2 trial were not confirmed in the phase 3. Thus, further development of 
TFPI for anticoagulant therapy has been halted.  A highly homologous protein termed 
TFPI-2 has also been characterized (Petersen et al., 1996b), though its use as an 
antithrombotic is still to be tested. A truncated version of TFPI containing only the 
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first and second Kunitz domains has also demonstrated antithrombotic effects in 
animal models (Holst et al., 1994).  
 
Nematode anticoagulant protein c2 (NAPc2) 
NAPc2 is an 8 kDa polypeptide originally isolated from the canine hookworm, 
Ancylostoma caninum (Cappello et al., 1995). The recombinant protein, rNAPc2, is 
now expressed in yeast. The protein contains two antiparallel β-sheets and a short 
helix (Duggan et al., 1999) (Figure 1.6). Both natural and recombinant NAPc2 
potently inhibit TF-FVIIa complex by a unique mechanism, which requires the initial 
anchoring of the protein to FX or FXa prior to the formation of a final quaternary 
inhibitory complex with TF-FVIIa (TF-VIIa-Xa-NAPc2). The use of FXa as an 
inhibitory scaffold for the inhibition of TF-FVIIa complex by NAPc2 appears similar 
to the mechanism of TF-FVIIa inhibition by TFPI (discussed above). However, unlike 
TFPI, which specifically requires an un-occupied active site on FXa to allow binding, 
NAPc2 interacts with FX or FXa via an extended binding site or exo-site. In addition, 
the unique interaction of NAPc2 with FXa allows the catalytic site of the FXa to 
remain unobstructed and thus enzymatically active in the quaternary inhibitory 
complex. However, FXa bound to NAPc2 can cleave only peptidyl substrates but not 
prothrombin (Lee and Vlasuk, 2003). The proposed sequential mechanism for the 














Figure 1.6 (A) Ribbon diagrams 
of the second and third kuniz 
domain of TFPI (B) Mechanism 
of action of TFPI: Inhibitory 
mechanisms of the initial reaction 
of blood coagulation by TFPI on 
cell surface. TFPI binds to factor 
VIIa and Xa via K1 and K2 
domains and to proteoglycans via 
K3 and C-terminal domains (K 
denotes kunitz domain) (diagram 
kindly provided by Dr. Jun 
Mizuguchi). (C) Ribbon diagram 
of the minimized mean 
structures of NAPc2 (Kindly 
provided by Dr. Peter E Wright). 
The molecules on the right have 
been rotated about the vertical axis 
by 90°. β-strands are shown in 
cyan and helices in red and 
yellow. The cysteine side chains 
are shown in gold. (C) 
Mechanism of action of rNAPc2 
(Adapted with permission from 
Rezende et al., 2004). In step 1 of 
the scheme, rNAPc2 binds with 
high affinity to zymogen FX in 
solution (binding to FXa as an 
inhibitory scaffold is not shown). 
The resulting stable bimolecular 
complex between rNAPc2-FX 
serves as an inhibitory scaffold 
that facilitates docking to the 
membrane-bound TF-FVIIa. In 
this way, the inhibitory scaffold 
uses both a similar docking 
mechanism as the natural substrate 
(FX) and subsequent presentation 
to the active site of TF-FVIIa. In 
the last step of the mechanistic 
scheme, the canonical reactive loop of rNAPc2 docks into the active site of FVIIa/TF, 
allowing for the formation of tightly bound quaternary inhibitory complex. 
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NAPc2 has a half-life of approximately 50 hours after subcutaneous injection. Its 
anticoagulant activity was evaluated in an open-label phase 2 dose-finding study of 
293 patients undergoing elective knee arthroplasty and showed promising results. The 
safety of NAPc2 has also been assessed in a randomized, double-blind, placebo-
controlled dose-escalation study of 154 subjects undergoing elective coronary 
angiography (Lee et al., 2001b). The prolonged half-life of NAPc2 raised the concern 
of the reversibility of its anticoagulant effect. However, in a phase I trial in healthy 
volunteers, it was demonstrated that the use of a pro-haemostatic agent recombinant 
FVIIa (NovoSeven®; Novo Nordisk, Princeton, NJ, USA) effectively reversed the 
anticoagulant effects of the protein by inducing a transient procoagulant state (Moons 
et al., 2003). 
Ixolaris 
This anticoagulant has been isolated from hard tick and Lyme disease vector, Ixodes 
scapularis (Francischetti et al., 2002). It has been shown to inhibit TF-FVIIa induced 
FX activation with an inhibitory concentration of 50% (IC50) in the picomolar range. 
At high concentration, Ixolaris attenuates the amidolytic activity of TF-FVIIa; 
however, in the presence of DEGR-FX or DEGR-FXa (but not des-Gla-DEGR-FXa), 
Ixolaris becomes a tight inhibitor of TF-FVIIa as assessed by recombinant FIX 
activation assays. This indicates that FX and FXa are scaffolds for Ixolaris in the 
inhibition of TF-FVIIa and implies that the Gla domain is necessary for TF-FVIIa-
Ixolaris-FX(a) complex formation. 
Active site inhibitors 
Certain proteins inhibit FVIIa by directly binding to the active site. These are Kunitz 
type inhibitors, containing about 58 amino acid residues and three conserved disulfide 
bonds. They are slow tight binding, reversible inhibitors of serine proteases that bind 
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to the active site and inhibit according to the standard mechanism (Bode and Huber, 
1992). Kunitz domain inhibitors of TF-FVIIa has also been selected from Alzheimer’s 
amyloid beta-protein precursor inhibitor (APPI) and basic pancreatic trypsin inhibitor 
Kunitz domain libraries displayed on phage. An overall consensus inhibitor 
designated as TF7I-C, differing from APPI in four residues inhibited TF-FVIIa with 
an apparent Ki of 1.9 nM. But it also inhibited FXIa, plasma kallikrein and plasmin 
(Dennis and Lazarus, 1994). Later, the Kunitz domain of TF7I-C was utilized to 
develop a bifunctional inhibitor by covalently linking it to the TF mutant TFAA. The 
bivalent fusion protein inhibited TF-FVIIa activity specifically with 200 fold more 
potency than the individual components (Lee et al., 1997).  
A bovine pancreatic trypsin inhibitor (BPTI) variant designated as 5LI5, selected from 
phage display libraries and differing in 8 residues from BPTI inhibited TF-FVIIa with 
a Ki of 0.4 nM (Stassen et al., 1995a). The crystal structure of the complex of 5LI5 
with FVIIa has been solved, shading important lights on the mechanism of action 
(Zhang et al., 1999a). Also, 5LI5 has been studied in platelet rich venous thrombosis 
models in hamsters yielding promising results (Stassen et al., 1995b). 
 
Active site inhibited FVIIa (Factor VIIai) 
Factor VIIai (FVIIai) is inactivated FVIIa where either dansyl-L-Glu-L-Gly-L-Arg or 
D-Phe-L-Phe-L-Arg chloromethyl ketone have been used to alkylate the active site 
(Taylor, Jr., 1996). Enzyme kinetic data indicate that FVIIai behaves completely as a 
non-competitive inhibitor of FX activation; where the inhibition reaction proceeds 
through a non productive ternary TF-FVIIai-FX complex (Nemerson and Gentry, 
1986). Interestingly, the affinity of TF is five-fold higher for FVIIai than FVIIa itself 
(Sorensen et al., 1997). 
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Based on promising results in animal models of thrombosis (Jang et al., 1995), 
treatment with FVIIai, in doses ranging from 50 to 400 µg/kg with or without 
adjunctive heparin, was compared with treatment with heparin alone in patients 
undergoing elective percutaneous coronary interventions. The rates of major bleeding 
were similar with therapy with FVIIai plus heparin and heparin alone. Because of 
these disappointing results, FVIIai has not been developed further (Lincoff AM, 
2000). 
Modified TF 
Lysine residues at positions 165 and 166 of TF are important for substrate recognition 
by the TF-FVIIa complex (Roy et al., 1991;Ruf et al., 1992).  A soluble TF mutant 
(TFAA; Alanine at both these positions), containing alanines at the above positions 
was constructed for use as a specific anticoagulant. TFAA binds to FVIIa and the 
resultant complex lacks FX activation activity. Moreover, in the plasma TFAA forms 
complex with FVII and this phenomenon further attenuates its anticoagulant function 
as evident from in vitro studies. Studies conducted in arterial thrombosis models in 
rabbit with TFAA have shown anti-thrombotic activity with reduced bleeding in 
comparison to heparin. Further, amino acid substitutions were made in TFAA, 
increasing its affinity for FVIIa by 20 fold.   
 
Antibody to FVII/FVIIa (Corsevin M™) 
A monoclonal antibody to FVII/FVIIa (Corsevin M™, licensed from Corvas 
International (San Diego, CA), is being studied by Johnson & Johnson in clinical 
trials. The antibody binds to the protease domain of both FVII and FVIIa in the 
presence or absence of TF with high affinity and shows mixed type of inhibition for 
FX activation. A Fab fragment of the antibody reduced circulating FVII and FVIIa 
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levels (Dickinson et al., 1998). In a phase I study, Corsevin M™ showed immediate 
and dose-related anticoagulation without adverse effects (Biemond et al., 1995).  
Antibody to TF 
Two different antibodies that specifically recognize TF at the site of thrombogenesis 
have been studied in experimental thrombosis modes. The first type interferes with 
the binding of TF to FVIIa (Pawashe et al., 1994;Golino et al., 1996), whereas the 
second type interferes with substrate docking without affecting the TF binding to 
FVIIa (Huang et al., 1998a). 
Inhibitor of TF synthesis 
A hairpin ribozyme has been designed that destroys TF mRNA, abrogating the 
induction of TF protein expression and activity in vascular smooth muscle cells 
(Cavusoglu et al., 2002). However, the clinical applicability of this approach has not 
yet been examined. 
Peptide exosite inhibitors 
Two different classes of peptide inhibitors (A-series and E-series peptides) of FVIIa 
inhibitors have recently been discovered using phage display libraries. (Dennis et al., 
2000;Roberge et al., 2001;Eigenbrot et al., 2001b). A and E series of peptides have no 
sequence identity. Both classes of peptides bound to the protease domain of FVIIa, to 
two distinct exosites to inhibit extrinsic tenase activity. .  
The A-series represented by the 15-mer cyclic peptide A-183 
(EEWEVLCWTWETCER) is a mixed type inhibitor (Ki ~200 pM) of FX activation 
with an IC50 of 1.6 nM. (Eigenbrot et al., 2001b). Structural studies showed that the 
binding of A-183 causes a conformational change in FVII, which disrupts the 
potential substrate binding sites (Eigenbrot et al., 2001b). 
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The E-series of peptides represented by 18 residue peptide E-76 (Ac-
ALCDDPRVDRWYCQFVEG-NH2), has a Kd of 8.5 nM for FVIIa and TF-FVIIa 
complex (Dennis et al., 2000) and inhibits both enzymatic and amidolytic activity of 
TF-FVIIa (IC50 of ~1 nM). Structural studies with E-76 complexed with FVIIa 
showed the mechanism of inhibition to be a conformational change in the activation 
loops (the 140s loop) of FVIIa  It has also been postulated that E-76 also disrupts the 
hydrogen bond conformation at the oxyanion hole, which is important for stabilization 
of the transition state of the substrate during catalysis. 
In another anticoagulant design strategy, the A and E series peptides were covalently 
linked together to make fusion peptides (Roberge et al., 2002). The A-linker-E 
bifunctional peptides are potent anticoagulants that specifically inhibit of TF-FVIIa 
catalyzed activation of FX.  
Cyclic peptide inhibitor 
Another peptidic inhibitor, the cyclic pentapeptide Cys-Gln-Gln-Tyr-Cys was derived 
from a tripeptide motif within the second EGF domain of FVII (Orning et al., 2002). 
This peptide is a specific and non-competitive inhibitor of TF-FVIIa complex, 
although in comparison to the exosite binding peptides its inhibitory potency is low.  
 FVa and FVIIa inhibitors  
Recombinant APC (drotrecogin alfa) mediates anticoagulant activity by inactivating 
FVa and FVIIIa (Bernard et al., 2001). Another anticoagulant targeting FVa and 
FVIIIa is soluble thrombomodulin (Kearon et al., 2005). Soluble thrombomodulin 
binds to thrombin and induces a conformational change in the active site of the 
enzyme that renders it a potent activator of protein C. A recombinant analog of the 
extracellular portion of soluble thrombomodulin, which has a half-life of 2 to 3 days 




Antibody to FIX 
Using phage display strategy, an antibody (10C12), was generated that specifically 
binds to the Gla domain of FIX. In addition to inhibiting platelet-dependent intrinsic 
tenase activity, 10C12 inhibited FIX activation by FXIa and by the extrinsic tenase 
complex (Refino et al., 2002). In vivo, 10C12 exerted antithrombotic activities in 
guinea pig and rat models, with effects on normal hemostasis. However, its efficacy is 
still to be evaluated in further clinical trials.  
Nitrophorin 2 
Nitrophorin 2 also known as prolixin-S, is a protein isolated from the saliva of blood-
sucking insect Rhodnius prolixus (Sun et al., 1996;Isawa et al., 2000). It inhibits free 




These include fondaparinux (Samama and Gerotziafas, 2003) and idraparinux 
(Herbert et al., 1998). These inhibitors are synthetic analogs of the unique 
pentasaccharide sequence that mediates the interaction of heparin with antithrombin 
(Rezaie, 2001). Once the pentasaccharide/antithrombin complex binds FXa, the 
pentasaccharide dissociates from antithrombin/Xa complex and can be reutilized. 
DX 9065A 
DX-9065a is a nonpeptidic arginine derivative that binds to the active site of FXa. 
Compared to standard heparin, DX 9065A exhibited a favorable 
antithrombotic/bleeding ratio, therefore showing that it might be considered as a 
promising compound in the treatment and prevention of various thrombotic diseases 
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(Dyke et al., 2002). Razaxaban, another synthetic active site inhibitor of FXa has 
shown promise as an anti-thrombotic agent (Wong et al., 2007). 
Inhibitors from tick  
Tick anticoagulant peptide (TAP), a 60 amino acid residue polypeptide isolated from 
the soft tick Ornithodoras moubata is one of the well studied tick-derived FXa 
inhibitor (Waxman et al., 1990).  It is a slow-binding reversible inhibitor of free FXa 
(Ki = 0.5 nM) and prothrombinase assembled FXa (Ki = 5.3 pM) (Vlasuk, 1993). 
Other tick-derived FXa inhibitors include Salp14 from Ixodes scapularis  
(Narasimhan et al., 2002) and factor Xa Inhibitor (fXaI) from Ornithodoros savignyi 
(Gaspar et al., 1996). 
Inhibitors from leech 
Antistasin, a 119 amino acid residue protein isolated from the salivary glands of the 
Mexican leech Haementeria officinalis (Han et al., 1989), is one of the most well 
studied leech derived FXa inhibitor. It is a tight-binding, reversible inhibitor of FXa 
(Ki = 0.31-0.62 nM) (Mao et al., 1998). Other FXa inhibitors from leech include 
lefaxin from Haementeria depressa (Faria et al., 1999), ghilanten from Haementeria 
ghilianii (Blankenship et al., 1990;Brankamp et al., 1991) and therostasin from 
Theromyzon tessulatum (Chopin et al., 2000). 
Nematode Anticoagulant protein 5 (NAP5) 
NAP5, a 77 amino acid residue protein from canine hookworm Ancylostoma caninum 
inhibits both free FXa (Ki ~ 43 pM) and prothrombinase assembled FXa 
(Ki ~ 144 pM) (Stassens et al., 1996). NAP6 from Ancylostoma caninum (Stassens et 
al., 1996) and AceAP1 from Ancylostoma ceylanicum (Harrison et al., 2002) are the 





It is a 411 amino acid containing glycoprotein isolated from vampire bat Desmodus 
rotundus (Apitz-Castro et al., 1995). Draculin is a tight binding non-competitive 
inhibitor of FXa. It also inhibits FIXa to some extent (Fernandez et al., 1999). 
 
Thrombin inhibitors 
Inhibitors from leech 
Hirudin is the most well studied anticoagulant belonging to this group. It is a 65 
amino-acid polypeptide originally isolated from the salivary glands of medicinal leech 
Hirudo medicinalis (Scharf et al., 1989;Markwardt, 1994). It is now produced using 
recombinant DNA technology, with the recombinant form lacking a sulfate at 
tyrosine-63 (Winant et al., 1991). Recombinant hirudin has a high affinity for 
thrombin and binds to both the active center and exosite 1 on thrombin, forming a 
slowly reversible complex with the enzyme. Two forms of hirudin have been 
produced for commercial use: Refludan (leprudin, Hoechst-Marion Roussel, Kansas 
City, MO, USA); and Desirudin (Revasc, GCP39393, Novartis, Basle, Switzerland). 
Other thrombin inhibitors from leech include hirullin (bufrudin) (Connolly et al., 
1992) from Hirudinaria manillensis, theromin (Salzet et al., 2000) from Theromyzon 
tessulatum and haemadin (hemadin) (Strube et al., 1993) from Haemadipsa sylvestris. 
Hirudin derivatives 
A dodecapeptide made up of residues 53 to 64 of the carboxyterminal region of 
hirudin designated as hirugen, is a weak inhibitor of thrombin activity (Glusa, 1994). 
Hirugen, by the addition of the peptide derived from the fibrinogen cleavage region of 
thrombin (D-Phe-Pro-Agr-Pro(Gly)4), has been converted into a potent inhibitor of 
thrombin. The chimeric peptide known as hirulog (Maraganore et al., 1990) 
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(Maraganore and Adelman, 1996), binds to both the active site and exosite I on 
thrombin. Hirulog was developed as bivalirudin by Biogen (Cambridge, MA, USA) 
(Nawarskas and Anderson, 2001). Unlike hirudin, bivalirudin can be given in weight-
adjusted doses and does not require careful laboratory monitoring.  
Inhibitors from tick 
Numerous thrombin inhibitors have been isolated from ticks. Ornithodorin is the most 
well studied of the tick-thrombin inhibitors. It is a 119 amino acid residue protein 
from the blood sucking soft tick Ornithodoros moubata, which inhibits thrombin with 
high specificity (Ki ~ 10-12 M). The crystal structure of the complex between 
ornithodorin and thrombin has been solved at 2.8 Å resolution (van de et al., 1996). 
Other tick-derived thrombin inhibitors include madanin (two isoforms) from 
Haemaphysalis longicornis (Iwanaga et al., 2003), boophilin from Boophilus 
microplus (cattle tick) (Lai et al., 2004), americanin from Amblyomma americanum 
(lone star tick) (Zhu et al., 1997), savignin from Ornithodoros savignyi (Nienaber et 
al., 1999) and nymphal thrombin inhibitor (NTI) from Hyalomma dromedarii (camel 
tick) (Ibrahim et al., 2001).  
Inhibitors from other arthopods 
Anophelin is the most studied protein belonging to this group. It is a cysteine less 
peptide containing 62 residues, isolated from the salivary glands of the mosquito 
Anopheles albimanus, which inhibits thrombin with high specificity (Ki ~ 2 nM) 
(Valenzuela et al., 1999). Others include, dipetalogastin from Dipetalogaster 
maximus (Mende et al., 1999), thrombostasin from Haematobia irritans irritans (horn 
fly) (Zhang et al., 2002) and TTI from Glossina morsitans morsitans (Tsetse fly) 




Low molecular weight thrombin inhibitors 
Several low-molecular-weight direct thrombin inhibitors have been produced. These 
agents bind to the active site of thrombin and are available in two classes: noncovalent 
and reversible covalent inhibitors. Argatroban (Novastan, Texas Biotechnology, 
Houston, TX, USA) (Walenga, 2002), napsagatran (Roche, Basle, Switzerland) (Roux 
et al., 1996), inogatran (Astra Zeneca, London, UK) (Gustafsson et al., 1996), and 
melagatran (Astra Zeneca, London, UK) (Koestenberger et al., 2005) are some of the 
well known non covalent inhibitors. An example of a reversible covalent inhibitor of 
thrombin is efegatran (Eli Lilly, Indianapolis, IN) (Klootwijk et al., 1999), which is 
currently undergoing clinical trials. Other reversible covalent inhibitors, including 
DNA aptamers (Macaya et al., 1993), are in various stages of development.  
FXIIIa inhibitors 
FXIIIa cross links α and λ chains of fibrinogen to fibrin to form polymers and dimers 
respectively, therefore of inhibition of FXIIIa has the potential to increase the 
susceptibility of the thrombus to lysis. Tridegin, peptide isolated from Haementeria 
ghilianti is a specific inhibitor of FXIIIa and enhances fibrinolysis in vitro (Finney et 
al., 1997). Other fibrinolytic agents that have exhibited promise are destabilase from 
leech (Arocha-Pinango et al., 1999) and desmoteplase from Desmodus rotundus 
(Stewart et al., 1998).   
 “The search should be on” – The above discussed anticoagulants target specific 
steps in coagulation. Initiation of coagulation can be inhibited by agents that target the 
TF-FVIIa complex, whereas propagation of coagulation can be blocked by drugs that 
target FIXa or FXa or by inactivation of FVa or FVIIIa. Thrombin inhibitors prevent 
fibrin formation and block thrombin-mediated feedback activation of FV, FVIII, and 
FXI. However, to gain acceptance for prophylaxis and treatment of 
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thromboembolism, new anticoagulants must have a high benefit-to-risk ratio, which is 
not always the case. Therefore, the search for novel anticoagulants and 




    Snake Venom Anticoagulant Proteins 
There's a patient (a guy I'll call Doug)
On an anticoagulant drug.
When he's cut he can't clot,
And he bleeds quite a lot,
So to catch it he carries a jug.
- A limerick by Chris Doyle
Snake venoms§ are complex mixtures 
of proteins and peptides possessing a 
diverse variety of physiological 
activities. Proteins and peptides 
comprise about 90 ± 95% of the dry 
weight of the venom. Other 
components in the venom are 
metallic cations (Na+, Ca2+ etc.), 
carbohydrates (in the form of 
glycoproteins), nucleosides, biogenic amines and very low levels of free amino acids 
and lipids (Russell, 1980). Snake venoms possess a whole host of enzymatic activities 
including, but not limited to, phospholipase A2 (PLA2), phosphodiesterase, 
phosphomonoesterase, L-amino acid oxidase, acetylcholinesterase, serine protease, 
metalloprotease, arginine esterase, 5'-nucleotidase, hyaluronidase and NAD 
nucleosidase (Russell, 1980). Not all these enzymes are present in all venoms. The 
peptides in snake venoms primarily consist of neurotoxins, cytotoxins, myotoxins, 
and disintegrins (Stocker, 1990). 
Although, the poisonous effect of snake bite is known since antiquity, it was 
Macfarlane’s work that first highlighted the effect of snake venoms on blood 
coagulation. He milked 20 assorted species of snakes and tested the crude venoms on 
hemophilic blood in vitro. The one “which stood out” was Russell’s viper venom 
                                                 
§ “You know, you can touch a stick of dynamite, but if you touch a venomous snake it'll turn 
around and bite you and kill you so fast it's not even funny” - Steve Irwin - The Crocodile Hunter 
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(RVV) (Macfarlane 1967 p. 441). Macfarlane showed that RVV reacted with FX in 
the presence of FV and phospholipid (Macfarlane, 1961).  
Over the years, a number of snake-venom components capable of interfering in the 
hemostatic process have been described, which can be broadly categorized into 
procoagulant or anticoagulant proteins, on the basis of their ability to shorten or 
prolong the clotting process. Procoagulant proteins are either serine proteases or 
metalloproteases. Their sizes vary between 24 kDa and 300 kDa. They induce clotting 
either by specifically activating zymogen, of one of the blood coagulation factors, or 
by directly converting soluble fibrinogen into an insoluble fibrin clot. Structure-
function relationship of these proteins have been studied intensively (For details refer 
to the review (Rosing and Tans, 1992;Kini et al., 2001;Morita, 2005;Kini, 2005b).  
Anticoagulant snake venom components are proteins or glycoproteins with molecular 
masses ranging from 6 kDa to 350 kDa. The first anticoagulant protein was purified 
from Trimeresurus gramineus snake venom by Shiau and Ouyang in 1965. This 
protein had an estimated molecular weight of 19.5 kDa (pI 4.5). It markedly inhibited 
prothrombin activation (Ouyang and Yang, 1975). Since then, numerous 
anticoagulant proteins have been characterized. 
Based on their mechanism, snake venom anticoagulant proteins can be classified 
broadly into two categories; ones that impair formation of blood clot by 
proteolytically cleaving one or more of the components that are critical part of the 
coagulation machinery and others that bind to activated factors and block their 
coagulant activity or that bind to non-activated factors and block the formation of 
clotting complexes such as tenase or prothrombinase. In the former group we have 
enzymes such as PLA2, serine proteases, metalloproteases and L-amino acid oxidase 
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(LAO). The latter group consists of non-enzymatic proteins such as C-type-lectin-
related-proteins and three-finger toxins.   
Anticoagulant Phospholipase A2 (PLA2) enzymes 
PLA2 enzymes are one of the imperative components of snake venoms. These 
enzymes hydrolyze glycerophospholipids at the sn-2 position of the glycerol 
backbone, liberating lysophospholipid and fatty acid. They can be divided into four 
distinct groups, two of which include all venom PLA2s from snake venoms (Dennis, 
1994). Most of the PLA2s purified from Elapidae and Hydrophidae belong to group I, 
while those purified from Viperidae venoms belong to group II. Both group I and II 
PLA2s, however share certain structural characteristics: low molecular mass (14 to 18 
kDa), five to eight disulfide bridges, and Ca2+-dependent catalytic activity. They 
exhibit a typical fold, having a core of three α-helices, a distinctive backbone loop 
that binds catalytically important calcium ion, and a β-wing that consists of a single 
loop of antiparallel β-sheet. The COOH-terminal segment forms a semi-circular 
banister, around the Ca2+-binding loop (Arni and Ward, 1996;Kini, 2003;Kini, 2005a) 
(Figure 1.7A). Venom PLA2s exhibit a wide array of biological activities, including 
neurotoxic, cardiotoxic, myotoxic, hemolytic, convulsive, anticoagulant, antiplatelet, 
edema inducing and tissue damaging effects (Kini, 2003). 
Anticoagulant venom PLA2s primarily mediate their effect by the hydrolysis of 
procoagulant phospholipids or by binding to them (Boffa and Boffa, 1976;Markland, 
1998;Mounier et al., 2001). Several strongly anticoagulant PLA2s have been 
described, such as those isolated from Vipera berus, Deboia russelli, Bitis caudalis, 
and Trimeresurus mucrosquamatus. These molecules’ activities are related to their 
capacity for binding to phospholipids, where they compete with coagulation factors 
(Ouyang et al., 1981;Babu and Gowda, 1994), or they may hydrolyze these 
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phospholipids (Kini and Evans, 1989). Weakly anticoagulant PLA2s such as superbins 
I and II or CM-I and CM-II from Austrelaps supererbus and Naja nigicollis 
respectively inhibit the extrinsic tenase complex (Stefansson et al., 1989;Subburaju 
and Kini, 1997). The anticoagulant activities of CM-I and CM-II were shown to be 
dependent on the presence of phospholipids (Stefansson et al., 1989). The PLA2 from 
B. lanceolatus was shown to inhibit FX activation in a phospholipid-dependent 
manner (Lobo et al., 2001). 
Interestingly, PLA2s also mediate anticoagulant activity by binding to coagulation 
factors. Stefansson et al. purified and characterized three isoenzymes from Naja 
nigricollis venom. The more basic PLA2, CM-IV inhibited the prothrombinase 
activity independently from the presence of phospholipids, whereas the weakly 
anticoagulant enzymes (CM-I and CM-II) required phospholipids (Stefansson et al., 
1990). In addition, an enzymatically inactivated CM-IV was able to inhibit the 
prothrombinase complex, although it failed to inhibit the tenase complex (Stefansson 
et al., 1990;Kini and Evans, 1995). In fact, CM-IV was shown to bind to FX (Kd = 
500 nM, with a stoichiometry of 1.3) and compete for its interaction with FV during 
formation of the prothrombinase complex (Kerns et al., 1999;Mounier et al., 2001) 
(Figure 1.7B). 
Notably, the anticoagulant activity of this PLA2 is not due to its basic nature, because 
other basic PLA2s such as notexin from Notechis scutatus scutatus, CM-III from Naja 
mossambica, and pseudexin B from P. porphyriacus do not exhibit this activity 
(Kerns et al., 1999;Mounier et al., 2000). Also, anticoagulant snake venom PLA2s, 
such as the basic subunit CB of crotoxin, PLA2 from Vipera berus and the 
catalytically inactive basic PLA2 from Bitis asper are thought to mediate their activity 








































Figure 1.7 (A) The predicted anticoagulant region of anticoagulant PLA2 enzymes. The 
ribbon model of N. naja PLA2 was generated from the PDB file (#1POA). The predicted 
anticoagulant region (highlighted in red) is fully exposed on the surface and easily accessible 
for interaction. Tryptophan residues are shown in yellow. (B) Mechanism of anticoagulant 
activity of PLA2. (i) Formation of regular prothrombinase complex on the negatively charged 
surface of a cell.(ii) The mechanism of anticoagulant action of PLA2 is based on its 
interaction with factor Xa and blockage of the interaction of factor Xa with factor Va for the 
formation of prothrombinase complex (A). (PT, prothrombin; FVa, activated factor V; FXa, 




Based on a systematic comparison of the amino acid sequences of strongly, weakly, 
and non-anticoagulant PLA2s, Kini and Evans (1987) proposed an anticoagulant 
region that lies between residues 54 and 77. This region is positively charged in 
strongly anticoagulant PLA2s, where a pair of lysine residues is present at both ends, 
but not in weak or non- anticoagulant PLA2s (Kini and Evans, 1987). All the chemical 
modification studies and site-directed mutagenesis experiments support this prediction 
(Kini and Evans, 1987;Inada et al., 1994;Mounier et al., 2000). 
L-amino acid oxidase (LAO) 
LAOs are hemorrhagic toxins in snake venoms, that catalyze oxidative deamination of 
L-amino acids with the generation of hydrogen peroxide. LAOs can alter platelet 
function (Sakurai et al., 2001). Recently, it was shown that M-LAO i.e. LAO isolated 
from Agkistrodon halys blomhoffii venom possesses anticoagulant activity (Sakurai et 
al., 2003). The enzyme prolongs clotting in activated partial thromboplastin time in a 
dose-dependent manner but does not affect prothrombin time, indicating that its 
principal activity is mediated via the intrinsic pathway. Later, M-LAO was found to 
specifically inhibit FIX in a dose-dependent manner, supporting the fact that it 
impairs the intrinsic clotting pathway. Interestingly, no interaction between M-LAO 
and FIX could be detected in surface plasmon resonance studies. On the contrary, it 
seems that the inhibition is dependent on the formation of hydrogen peroxide (Sakurai 
et al., 2003); indicating that, in this case, the enzymatic activity is required for 
inhibition. 
Serine proteases 
Snake venom serine proteases affecting coagulation, like human serine proteases, 
belong to the trypsin like subfamily of proteases. They are abundant in Viperidae and 
Crotalidae venoms. They are composed of approximately 235 amino acids and 
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contain six conserved disulfide bridges (Markland, 1998). These enzymes are not 
lethal by themselves and primarily facilitate the digestion of the prey, but they also 
contribute to the toxic effect of the venom when associated with other proteins.  
Serine proteases mediate anticoagulant effect by the activation of protein C, thereby 
promoting the degradation of FVa and FVIIIa. Stocker et al. characterized a protein C 
activator from southern copperhead (Agkistrodon contortrix contortrix) venom 
(Stocker et al., 1987). This protein C activator is called protac and is a serine protease 
of molecular weight 37 kDa. The enzyme is a single chain glycoprotein possessing 16 
± 20% carbohydrate (Murakami and Arni, 2005). Similar protein C activators have 
been isolated from the venoms of snake species belonging to the genus Agkistrodon 
(Klein and Walker, 1986;Stocker et al., 1986;Kisiel et al., 1987;McMullen et al., 
1989;Bakker et al., 1993).  
Another group of anticoagulant serine proteases are designated as thrombin like 
enzymes (TLE). They are widely distributed within several pit viper genera 
(Agkistrodon, Bothrops, Crotalus, Lachesis and Trimeresurus), as well as some true 
vipers (Bitis and Cerastes) and the colubrid, Dispholidus typus. TLEs convert 
fibrinogen into fibrin by cleaving fibrinopeptides A and/or B (Aronson, 1976;Bell, Jr., 
1997). As this activity resembles the most well known activity of thrombin, these 
venom components are generally termed ‘thrombin-like’ enzymes. However, the 
fibrin monomers generated by TLEs undergo limited polymerization, since only one 
fibrinopeptide is cleaved and also because these enzymes do not activate 
transglutaminase FXIII, to generate FXIIIa. Therefore, clot formation is hampered as 
cross-linking of fibrin monomers does not take place. TLEs have been isolated and 
characterized from numerous snake venoms. Because of their unique property they 
are widely used as defibrinogenating agents, ancrod [Arvin®; from Calloselasma 
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rhodostoma (the Malayan pit viper)] (Sherman, 2002) and batroxobin [Defibrase®; 
from Bothrops moojeni (the Brazilian lancehead snake)] (Huang et al., 1992) are 
some of the well-known ones.  
Snake Vemom Metalloproteases (SVMP) 
SVMPs belong to the M12 subfamily of metalloproteases also known as reprolysins. 
Based on domain architecture SVMPs are classified into PI (SVMPs having only a 
metalloprotease domain); PII (SVMPs being synthesized with metalloprotease domain 
and disintegrin domain); PIII (SVMPs as being synthesized with metalloprotease 
domain, disintegrin-like domain and cysteine-rich domain) and PIV (SVMPs having 
the PIII domain structure plus lectin-like domains connected by disulfide bonds) 
(Bjarnason and Fox, 1995;Jia et al., 1996;Fox and Serrano, 2005). Zn2+ ions are pre-
requisite for optimal catalytic activity of SVMPs. The zinc-binding site has a common 
amino acid sequence in the different metalloproteases, HEBXHXBGBXHZ, where H 
is histidine, E is glutamic acid, G is glycine, B is a bulky hydrophobic residue, X is 
any amino acid, and Z is differernt in all four subfamilies but is conserved in any 
given subfamily. SVMPs exhibit haemorrhagic, pro-coagulant, anticoagulant and 
antiplatelet effects  (Fox and Serrano, 2005).  
Anticoagulant SVMPs are fibrinogenases. Based on their cleavage specificity of the 
fibrinogen chain they are classified as either α- or β-chain fibrinogenases (Ouyang 
and Teng, 1976). Interestingly, no reports of a fibrinogenolytic snake venom enzyme 
with cleavage specificity directed solely to the γ-chain of fibrinogen are known. 
Specificity for the α- or β-chains is not absolute since there is substantial degradation 
of the alternate chain with increasing time. These enzymes differ significantly from 
plasmin which is a serine protease and is readily inactivated by plasma serine protease 
inhibitors (SERPINS). Further, plasmin cleaves peptide bonds at the COOH-terminal 
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side of lysine residues in the α-, β- and γ-chains of fibrinogen, sites distinctively 
different from the ones cleaved by the venom fibrinogenolytic enzymes (Fox and 
Serrano, 2005). 
Anticoagulant C-type-lectin-related-proteins 
Proteins belonging to this group are structurally homologous with true C-type lectins, 
but apparently they are unable to bind to carbohydrate (Ebner et al., 2003). 
Anticoagulant proteins belonging to this group can be discussed broadly under 
FIX/FX binding proteins and thrombin and prothrombin binding proteins. 
FIX/FX binding proteins 
Based on their ligand recognition specificity, these proteins can be further classified 
into three distinct groups: FIX/FX-binding proteins, such as those purified from T. 
flavoviridis (Atoda and Morita, 1989;Atoda et al., 1991), B. jararaca (Sekiya et al., 
1993), Echis carinatus leucogaster (Chen and Tsai, 1996), and A. halys brevicaudus 
(Koo et al., 2002) snake venoms; FIX-binding proteins, purified from T. flavoviridis 
(Atoda et al., 1995), T. stejnegri (Xu et al., 1999), and A. halys pallas (Zang et al., 
2003) venoms; and coagulation FX-binding proteins, purified from Deinagkistrodon 
acutus (Cox, 1993;Atoda et al., 1998) and A. acutus (Xu et al., 2000)  venoms. 
These proteins have a molecular mass of ~30 kDa and are αβ-heterodimers linked by 
a single disulfide bridge. The only exception is halyxin, from A.h. brevicaudus, which 
contains three chains (Koo et al., 2002). The structures of FIX/FX-binding protein 
(Mizuno et al., 1997) and FIX-binding protein (Mizuno et al., 1999) isolated from T. 
flavoviridis have been solved (Figure 1.8A and B). Interestingly, these two proteins 
possess same β subunit but different α subunits, which differ at only 19 (15%) of the 
total 129 amino acids. Each subunit of these molecules consists of a globular unit with 
an extended loop that contributes to a tight interface with the other subunit. The dimer 
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forms a concave interface, which is supposedly the binding site for coagulation 
factors’ Gla-domain (Figure 1.8A and B). The amino acid residues that differ between 
these proteins are concentrated in part of the concave surface (Mizuno et al., 1999). 
More recently, the structures of FX- and FIX-binding proteins complexed with the 
respective Gla domains of FX and FIX were solved (Mizuno et al., 2001;Shikamoto 
et al., 2003). Ca2+ is essential for the activity of the proteins since binding to FX is 
lost when Ca2+ is replaced by another ion such as terbium.  
These proteins prolong clotting in prothrombin time assay and inhibit FXa-induced 
clotting. Binding studies show that they bind specifically to FX/FXa or FIX/FIXa and 
the stoichiometry of binding is 1:1 for both factors. However, both FIX and FX 
binding proteins are unable to bind with Gla-domainless factors. This shows that they 
bind specifically (and tightly) to the Gla domain of FIX and FX but not with the Gla-
domain present in prothrombin, FVII, protein C, or protein S. However, the FIX/FX-
binding protein isolated from B. jararaca protein is an exception since it also binds to 
protein S although with a lower binding affinity. Structural data obtained from X-ray 
crystal structures have revealed that the formation of these complexes blocks the 
interaction of the Gla domain (Figure 1.8C) with membrane, which is essential for 
augmentation of the coagulation process. 
Thrombin and Prothrombin Binding Proteins 
Bothrojaracin from Bothrops jararaca (Zingali et al., 1993) and salmorin from 
Agkistrodon halys brevicaudus (Koh et al., 2000) are the most well studied proteins 
belonging to this group.  These are acidic proteins with a molecular weight of ~30 
kDa (Zingali et al., 1993;Koh et al., 2000). They consist of two distinct but 
homologous chains linked together by disulfide bridges. 
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Figure 1.8 (A) Overall structure of FX-bp and FXGD1-44 complex. Stereoview of ribbon 
model viewed perpendicular to the pseudodyad of the molecule, showing the interface 
between FX-bp and FXGD1-44. The subunits A and B of FX-bp are magenta and green. 
FXGD1-44 is white. The side chain of Gla residues and disulfide bonds are displayed. The 
bound Ca2+ ions are denoted by blue spheres. (B) FIX binding protein. The subunits A and B 
of FIX-bp are magenta and green. FIXGD1–46 is in white, and the interchain disulfide bond 
is shown in yellow. The bound Mg2+ and Ca2+ ions are drawn as orange and blue spheres, 
respectively. (Kindly provided by Dr. Takashi Morita) (C) Anticoagulant mechanism of 
factor IX/X-binding protein. (i) Formation of regular tenase complex. (ii) Binding of factor 
IX/X-binding protein with the Gla domain of factor IX/IXa or X/Xa leads to blockage of the 














































Figure 1.9 Anticoagulant mechanism of bothrojaracin. (A) Formation of regular 
prothrombinase complex. (B) Mechanism 1 of bothrojaracin inhibition is based on its binding 
to thrombin exosite I and consequent inhibition of its activities. (C) Mechanism 2 is based on 
the inhibition of prothrombin activation through interaction with prothrombin proexosite I. 





Bothrojaracin has only 11 of the 13 amino acid residues that are important for the 
carbohydrate recognition domain (CRD) and, thus lacks the capability to bind to 
carbohydrates (Arocas et al., 1997). Ca2+ is not important for its function unlike the 
FIX/FX binding proteins. Bothrojaracin-like proteins have been detected by biological 
and immunoblotting assays in other snake venoms from Brazilian snakes and purified 
to homogeneity (Castro et al., 1999).  
Bothrojaracin binds to thrombin (Figure 1.9), forming a stable 1:1 complex (Zingali et 
al., 1993). The calculated Kd for immobilized bothrojaracin was 0.6 nM (Arocas et 
al., 1996). Interestingly, bothrojaracin displaces all thrombin exosite I ligands, such as 
fibrin, hirudin, and thrombomodulin, indicating that it interacts with thrombin through 
exosite I. In addition, bothrojaracin inhibits the activation of FV by thrombin and is, 
therefore, a potent inhibitor of the feedback activation of the clotting cascade (Arocas 
et al., 1998). It also binds to γ -thrombin, a proteolytic product of α-thrombin in which 
exosite I is disrupted, indicating that bothrojaracin also binds to the thrombin exosite 
II, although with lesser affinity (Arocas et al., 1996). Bothrojaracin has also been 
shown to displace thrombin that is bound to the clot (Zingali et al., 2001). Assays 
show that even when all activities of thrombin are blocked by bothrojaracin, the 
catalytic activity of thrombin toward chromogenic substrates is not inhibited (Zingali 
et al., 1993). It has been observed that bothrojaracin produces two different structural 
changes in the thrombin catalytic site depending on whether it interacts with exosite 
II, as for γ -thrombin, or with exosite I, as observed for α-thrombin (Zingali et al., 
2005). Binding to α-thrombin increases its activity towards certain chromogenic 
substrates, while its binding to γ -thrombin inhibits it. This shows that bothrojaracin 
does not bind to the active site of thrombin. Intriguingly, bothrojaracin binds with 
high specificity to prothrombin (Arocas et al., 1996), with a dissociation constant of 
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100 nM, indicating a ∼100-fold lower binding affinity than that for thrombin. 
Although the mechanism of action of bothrojaracin is known in considerable detail, 
its structure-function relationship is yet to be elucidated.  
Salmorin shares certain functional similarities with bothrojaracin. It inhibits hirudin 
interaction with thrombin, increases fibrinogen clotting time (induced by thrombin), 
and forms a 1:1 complex with prothrombin (Koh et al., 2000). But unlike 
bothrojaracin, salmorin inhibits prothrombin activation by FXa independently from 
the presence of FV.  
Anticoagulant three-finger toxins 
Three-finger toxins are non-enzymatic polypeptides containing 60 to 74 amino acid 
residues (Kini, 2002). These proteins are abundant in elapid (cobras, kraits and 
mambas) and hydrophid (sea snakes) venoms. Recently, they have also been 
identified in colubrid venoms (Pawlak et al., 2006). Although there is no report of a 
three-finger toxin from viper venom, but recently three-finger protein scaffolds have 
been noted in vipers as well (Junqueira-de-Azevedo et al., 2006). These proteins 
contain four or five disulphide bridges. Of these four are found to be conserved in all 
the members. All proteins belonging to this family show an analogous pattern of 
folding, in which three β-stranded loops extend from a central core containing the four 
conserved disulphide bridges (Kini, 2002). Because of this appearance, this family of 
proteins is called the three-finger toxin family. Despite the overall similarity in 
structure they differ from each other in their biological activities. Anticoagulant 
effects of three-finger toxins were first identified in cardiotoxins purifed from Naja 
nigricollis crawshawii (spitting cobra) venom (Kini et al., 1988). Very recently our 
lab showed that anticoagulant activity of one of these proteins is mediated by the 




Snake venoms contain serine protease inhibitors that are able to inhibit the activity of 
blood coagulation factors, and thus these proteins are potential antiocoagulants. These 
proteins contain 57 to 60 amino acid residues with three disulfide bonds and belong to 
the Kunitz-pancreatic inhibitor family (Hollecker and Creighton, 1983). 
The first report of protease inhibitors was from the venom of Russell's viper (Vipera 
russelli), in which two proteins were isolated from the venom of the snake which 
were able to inhibit the activity of bovine plasma kallikrein, trypsin, plasmin, and α-
chymotrypsin (Takahashi et al., 1974a;Takahashi et al., 1974b;Iwanaga et al., 1976). 
Presence of protease inhibitors in the venom of Hemachatus haemachatus and Naja 
nivea were also reported (Hokama et al., 1976).  
The best studied of these proteins is textilinin (txln). This protein is a 59-amino-acid 
polypeptide, isolated from the venom of Pseudonaja textilis.  The protein has two 
distinct isoforms of molecular weights 6688 and 6692 Daltons respectively. Txln 1 
and 2 are inhibitors of plasmin though the former binds very tightly with a Ki of 
approximately 10-11 mol/l while the latter bound less tightly with a Ki of 
approximately 10-9 mol/l (Masci et al., 2000). Recently, the structure of txln 1 has 
been solved (Millers et al., 2006). Txln-1 shares only 47% amino-acid identity to 
aprotinin; however, six cysteine residues in the two peptides are in conserved 
locations. The overall fold of these molecules though similar, but they have 
contrasting surface features. Lately, α-chymotrypsin inhibitors have also been 
reported from the venom of Ophiophagus hannah (Chang et al., 2001) and Bungarus 




The anticoagulant proteins discussed here are potential leads for the development of 
antithrombotic agents. These proteins can also be used as molecular probes**, to 
facilitate our understanding of the basic biology of hemostasis. To search for new lead 
molecules we and others have been focusing on isolating and characterizing 
pharmacologically active proteins from snake venoms that affect blood coagulation 
and platelet aggregation. Recently, we purified and characterized an anticoagulant 
protein belonging to the three-finger family†† from an elapid snake Hemachatus 
haemachatus (African Ringhals cobra). Individually, this protein has mild 
anticoagulant activity; however, its synergistic interaction with a second three-finger 
toxin enhances its anticoagulant potency. The anticoagulant protein and its complex 




                                                 
** “But when we reach the limits of vivisection we have other means of going deeper and dealing 
with the elementary parts of organisms where the elementary properties of vital phenomena have 
their seat. We may introduce poisons into the circulation, which carry their specific action to one 
or another histological unit. . . Poisons are veritable reagents of life, extremely delicate 
instruments, which dissect vital units”.   - Claude Bernard (1813 – 1878) 
 





















Do, or do not. There is no 'try'. 
       ---Yoda ('The Empire Strikes Back')
 Aim and Scope 
“When I first took up fishing, I always used an enormous hook... [it is] more 
exciting not to catch a big fish than not to catch a small one... Now I have 
reduced the size of my hook." 


























   
 
 57
 Aim and Scope 
Nature’s defensive molecules, the venom peptides, have long been useful as 
molecular probes, therapeutic agents, as well as lead molecules for drug discovery. 
Their usefulness, however, has centered, not only on their unique intrinsic 
pharmacological properties but, also, on what and how much we know about them1. 
Proteins/toxins from snake venoms have inspired the design and development of a 
number of therapeutic agents or lead molecules, particularly for cardiovascular 
diseases. For example, a family of inhibitors of angiotensin converting enzyme were 
developed based on bradykinin potentiating peptides from South American snake 
venoms. Inhibitors of platelet aggregation, such as eptifibatide and tirofiban, were 
designed based on disintegrins, a large family of platelet aggregation inhibitors found 
in viperid and crotalid snake venoms. Ancrod extracted from the venom of Malayan 
pit viper reduces the blood fibrinogen levels and has been successfully tested in a 
variety of ischaemic conditions including stroke.  
In this study, I have reported the purification and characterization of a three-finger 
toxin, hemextin A, that mediates anticoagulant activity from the venom of the elapid 
snake Hemachatus haemachatus (African Ringhals cobra). Although it has mild 
anticoagulant activity, its synergistic interaction with the second three-finger toxin, 
hemextin B, enhances its anticoagulant potency. Hemextin A and its complex, 
hemextin AB complex, inhibit the activation of FX by the TF-FVIIa, by binding 
specifically to FVIIa. Hemextin AB complex is also the only known tetrameric 
complex, exclusively formed between three-finger toxins. Therefore, the molecular 
interactions participating in the formation of the complex were studied. Further, the 
particular domain in FVIIa, to which the anticoagulant protein and its complex bind to 
mediate anticoagulant activity, was identified. Therefore, in summary, this thesis 
                                                 
1 “That which we know is little, what we do not know is immense” 
     ---- Pierre-Simon de Laplace 
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describes a unique anticoagulant protein complex from snake venom. This new 
anticoagulant may help us develop different strategies and therapeutic agents to 
inhibit the initiation step in blood coagulation. 
 Specifically, the objectives2 of the study were: 
1. To isolate the anticoagulant protein and its synergistic partner from the 
crude venom of H. haemachatus and purify them to homogeneity, 
followed by the determination of their complete amino acid sequence. 
2. To determine the specific step in the coagulation cascade where the 
anticoagulant protein and the synergistic complex act to mediate the 
anticoagulant activity; followed by the determination of the specific 
coagulation serine protease to which the proteins bind to mediate their 
anticoagulant action.  
3. To biophysically characterize the complex formation between the 
anticoagulant protein and its synergistic partner.  
4. To identify the specific domain of the target enzyme to which the 
anticoagulant protein and the synergistic complex bind in order to mediate 
their anticoagulant function. 
5. To identify the condition(s) where the anticoagulant protein hemextin A 





                                                 
2 “Plan backwards as well as forward. Set objectives and trace back to see how to achieve them. You may find that 
no path can get you there. Plan forward to see where your steps will take you, which may not be clear or intuitive.” 
     ---- Donald Rumsfeld (American Secretary of Defense) 
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“Every enzyme or protein requires a specific method for its purification. Our 
present methods of purifying both enzymes and proteins are crude and 
unsatisfactory for the most part. It is fairly certain that better methods will be 
discovered in the near future.” 








Purification of the 
anticoagulant protein 
Purification of the Anticoagulant Protein 
Chromatography: from colour writing to separation science 
“An infinite variety of complicated mixtures can be separated by chromatography, 
giving detailed insights into our biochemistry, our environment and even our history. 
Tutankhamen's wine residues, the stratosphere of Saturn's moon Titan, dyes from ancient 
Navarro textiles, mine drainage samples, herrings' gas bubbles, vodka and earwax are just 
a few substances recently analysed by chromatography. Single, active components can be 
isolated from mixtures; or hundreds of metabolites in a cell extract can be unscrambled in 
a single two-dimensional chromatography run. Primary school children can perform 
successful separations with coloured solutions on paper. At the other extreme, analytical 
chemists and molecular biologists use sophisticated, high-resolution instruments coupled 
with state-of-the-art detectors and databases. Chromatography underpins so much and 
seems so intuitive now — but it is a surprisingly recent invention. 
 
There are 19th Century contenders, including Goppelsršder at the University of 
Basel, who found relationships between how high a solution rises in paper and its 
chemical composition1. However, the accolade for the first chromatography run usually 
goes to Mikhail Semenovich Tswett, a Russian botanist, in 19032. Tswett crushed leaves 
in alcohol. Drops of the alcohol solutions were layered on top of tubes filled with 
powdered chalk. When he washed the chalk columns with petroleum-based solvents, the 
pigments moved down the chalk and separated into coloured bands. Immediately, the 
admixture of blues and yellows within every plant green was revealed. And red blossoms 
were found to contain hidden tints of green. These separated pigments inspired the name 
‘chromatography’, literally ‘colour writing’. The name also links to the man, for Tswett 
in Russian means ‘colour’ or ‘a flower’. 
 
Tswett's observations led him to conclude that pigments with an adsorptive 
attraction for the chalk stationary phase were being retarded, whereas those that did not 
interact so well were flushed through the system more rapidly. Varying the solid and 
liquid phases facilitated separation of different mixtures. But despite its success in his 
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hands, Tswett's adsorption chromatography was slow to catch on: though he worked in 
Switzerland and Poland he published in Russian, limiting the readership of his papers. 
There were also professional rivalries. Those who did attempt to repeat his experiments 
ran into trouble by not following his protocols precisely, particularly his warning that 
certain solids would “decompose the pigments adsorbed on them”. So chromatography 
was used only rarely until the 1930s, after L.S. Palmer in the USA had used Tswett's 
techniques on various natural products3. Then, Edgar Lederer and Richard Kuhn in 
Heidelberg obtained a translation of Tswett's paper from Kuhn's mentor, Richard 
WillstŠtter, and used chromatography to discover that lutein from egg yolk is a mixture 
of closely related carotenoids (published as a series of papers, including one in 19314). 
The publicity surrounding their work gave chromatography a boost, and by the beginning 
of the 1940s, numerous vitamins, fatty acids, steroids and botanical compounds had been 
purified by adsorption chromatography, greatly accelerating the development of modern 
biochemistry.” 
--- Professor Carol MacKintosh, MRC 
Protein Phosphorylation Unit, University 
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Purification of the Anticoagulant Protein 
A single venom is a cocktail of well over a few hundred different proteins and 
peptides. Purification of these proteins to (relative) homogeneity1 can, therefore, be a 
formidable challenge.  However all these proteins (at least the more abundant ones) fall 
into a very small number of superfamilies. These can be translated into molecular mass 
ranges: for example, (in the case of several elapid venoms), >40 kDa (mainly enzymes), 
12 -15 kDa (phospholipases A2) and 6-8 kDa (three-finger toxins, proteinase inhibitors, 
etc.). Hence, gel-filtration or size-exclusion chromatography (SEC) also referred to as 
“molecular sieving”, which separates proteins solely on the basis of differences in 
molecular size, is an excellent initial fractionation step. Separation in (SEC) is achieved 
using a porous matrix to which the molecules, for steric reasons, have different degrees of 
access (smaller molecules have greater access and larger molecules less). The next, step 
is usually ion exchange chromatography that separates proteins on the basis of charge 
characteristics. Charged groups on the surface of a protein interact with oppositely 
charged groups immobilized on the ion-exchange medium, followed by their elution 
using a step gradient of increasing salt concentration. Reversed-phase high-pressure 
liquid chromatography (RP-HPLC) is usually the final step, separating the proteins on the 
basis of their hydrophobicity and yielding them in de-salted form. Implicit in the 
statement that only a few protein superfamilies exist in venom containing large numbers 
of different proteins, is the fact that there are numerous closely-related isoforms within 
each family, in the venom. Separation of these isoforms constitutes a significant 
challenge: parameters at the ion exchange and RP-HPLC steps, such as the choice of 
column, pH of buffers and the slope of the eluting gradient, need to be optimized for their 
                                                 
1 Although it may seem a paradox, all exact science is dominated by the idea of approximation. 
         - Bertand Russell 
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efficient separation. The use of RP-HPLC often necessitates exposing the proteins to high 
concentrations of organic solvent (acetonitrile, ACN). This may cause protein 
denaturation, evidenced by a loss in activity. Fortunately, the highly disulfide-linked 
nature of the three-finger toxins renders them fairly resistant to denaturation and 
proteolyis. Nonetheless, it is prudent to perform the purification as speedily as possible, 
preferably at 4ºC, to avoid proteolytic degradation. It is also vital to ensure that the 
purified protein being screened for biological activity does not contain contaminants that 
could mask the effects of protein. Hence, an accurate assessment of homogeneity, 
preferably using analytical RP-HPLC that can achieve high resolution and sensitivity to 
the nanomolar level is important. The primary structure of the protein is then established 
by the determination of its amino acid sequence and the assignment of the disulfide bonds 
(if any). 
This chapter details the purification and NH2-terminal sequence determination of 
the anticoagulant proteins. In addition, it also shows the importance of fold of the 
proteins for mediating anticoagulant activity. As mentioned in chapter 1, the 
anticoagulant protein forms a complex with another protein, and the resultant complex 
exhibits potent anticoagulant activity. The formation of complex between the two 
proteins has also been investigated using gel-filtration.  
MATERIALS AND METHODS 
Materials 
Lyophilized Hemachatus haemachatus venom was obtained from African Reptiles and 
Venoms (Gauteng, South Africa). The pre-packed chromatography columns were 
purchased from the following indicated sources: Superdex 30  and Superdex 75 (1.6 × 60 
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cm) (GE Healthcare BioSciences AB, Uppsala, Sweden), UNO S6 column (6-ml column 
volume; Bio-Rad, CA, USA), Jupiter C18 columns of dimensions (1 × 25 cm) and  (4.6 × 
250 mm) (Phenomenex, CA, USA) and PepMap column (narrowbore; LC Packings, CA, 
USA) Thromboplastin with calcium (for prothrombin time assays), and 4-vinylpyridine 
were purchased from Sigma. The following chemicals were purchased from the sources 
indicated: reagents for NH2-terminal sequencing (Applied Biosystem, Foster City, CA, 
USA), acetonitrile (Fisher Scientific, Fair Lawn, NJ, USA), trifluoroacetic acid (Fluka 
Chemika-Biochemika, Buchs Switzerland) and β-Mercaptoethanol (Nacalai Tesque, 
Kyoto, Japan). Human plasma was donated by healthy volunteers. All other chemicals 
and reagents used were of the highest purity available. 
Purification of Anticoagulant Protein 
Hemachatus haemachatus crude venom (100 mg in 1 ml of distilled water) was applied 
to a Superdex 30 gel-filtration column (1.6 × 60 cm) equilibrated with 50 mM Tris-HCl 
buffer (pH 7.4) and eluted with the same buffer using an ĀKTA purifier system (GE 
Healthcare BioSciences AB AB, Uppsala, Sweden). Individual fractions were assayed for 
anticoagulant activity using prothrombin time (see below). Fractions with potent 
anticoagulant activity were pooled and sub-fractionated on a cation-exchange column 
using the same chromatography system. The anticoagulant fraction was pooled and 
loaded onto a UNO S6 column (6-ml column volume) equilibrated with 50 mM Tris-HCl 
buffer (pH 7.5). Bound proteins were eluted with a linear gradient of 1 M NaCl in the 
same buffer. Fractions collected were assayed for anticoagulant activity. The 
anticoagulant peaks obtained from cation-exchange chromatography were applied to a 
Jupiter C18 column (1 × 25 cm) equilibrated with 0.1% trifluoroacetic acid. The bound 
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proteins were eluted using a linear gradient of 80% acetonitrile in 0.1% trifluoroacetic 
acid. Individual peaks were collected, lyophilized, examined for anticoagulant activity, 
and subsequently rechromatographed on a narrow bore PepMap column using a 
Chromeleon microliquid chromatography system. 
Electrospray Ionization Mass Spectrometry 
The homogeneity and mass of the anticoagulant proteins were determined by electrospray 
ionization (ESI) mass spectrometry using a PerkinElmer Life Sciences API-300 liquid 
chromatography/tandem mass spectrometry system. Typically, reverse-phase HPLC 
fractions were directly used for analysis. Ion spray, orifice, and ring voltages were set at 
4600, 50, and 350 V, respectively. Nitrogen was used as a nebulizer and curtain gas with 
a flow rate of 0.6 l/min. The spectrum was recorded in the 1000-3000 mass-to-charge 
(m/z) range, in steps of 0.1 amu, with 2 ms dwell time. A Shimadzu LC-10AD pump was 
used for solvent delivery (40% acetonitrile in 0.1% trifluoroacetic acid) at a flow rate of 
50 µl/min. BioMultiview software (PerkinElmer Life Sciences, USA) was used to 
analyze and de-convolute raw mass spectra. 
Reduction and Pyridylethylation 
Purified proteins were reduced and pyridylethylated using procedures described 
previously. Briefly, proteins (0.5 mg) were dissolved in 500 µl of denaturant buffer (6 M 
guanidine hydrochloride, 0.25 M Tris-HCl, and 1 mM EDTA (pH 8.5)). After the 
addition of 10 µl of β-mercaptoethanol, the mixture was incubated under vacuum for 2 h 
at 37 °C. 4-Vinylpyridine (50 µl) was added to the mixture and kept at room temperature 
for 2 h. Pyridylethylated proteins were purified on an analytical Jupiter C18 column (4.6 
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× 250 mm) using a gradient of acetonitrile in 0.1% (v/v) trifluoroacetic acid at a flow rate 
of 0.5 ml/min. 
NH2-terminal Sequencing 
Samples were loaded onto a glass filter pre-coated with Biobrene resin (Applied 
Biosystem, Foster City, CA, USA) dried off under argon and introduced into sequencer. 
NH2-terminal sequencing of the native and S-pyridylethylated proteins was performed by 
automated Edman degradation using a PerkinElmer Life Sciences Model 494 pulsed 
liquid-phase sequencer (Procise) with an on-line Model 785A phenylthiohydantoin-
derivative analyzer. 
Circular Dichroism (CD) Spectroscopy 
Far-UV CD spectra (260–190 nm) were recorded using a Jasco J-810 spectropolarimeter 
(Jasco, MD, USA). All measurements were carried out at room temperature using 0.1-cm 
path length stoppered cuvettes. The instrument optics was flushed with 30 liters of 
nitrogen gas/min. The spectra were recorded using a scan speed of 50 nm/min, a 
resolution of 0.2 nm, and a bandwidth of 2 nm. A total of four scans were recorded and 
averaged for each spectrum, and the base line was subtracted. The CD spectra of the 
anticoagulant proteins and their S-pyridylethylated forms were recorded in 50 mM Tris-
HCl buffer (pH 7.4). 
Reconstitution of the Anticoagulant Complex 
Preliminary studies indicated that the active anticoagulant protein interacted with another 
venom protein, forming a synergistic complex. We reconstituted the complex for various 
in vitro experiments immediately prior to the experiments by incubating equimolar 
 67
Purification of the Anticoagulant Protein 
concentrations of the two proteins (unless mentioned otherwise) at 37 °C for 5 min in 50 
mM Tris-buffer (pH 7.4). 
Anticoagulant Activity using re-calcification and prothrombin time assays 
Recalcification Time – The recalcification times were determined according to the 
method of Langdell et al. (LANGDELL et al., 1953). 50 mM Tris-HCl buffer (pH 7.4; 
100 µl), plasma (100 µl), and various concentrations of venom or its fraction (50 µl) were 
preincubated for 2 min at 37 °C. Clotting was initiated by the addition of 50 µl of 50 mM 
CaCl2. 
Prothrombin Time – The prothrombin times were measured according to the 
method of Quick (Quick, 1973). 100 µl of 50 mM Tris-HCl buffer (pH 7.4), 100 µl of 
plasma, and 50 µl of venom or its fractions were preincubated for 2 min at 37 °C. 
Clotting was initiated by the addition of 150 µl of thromboplastin with calcium reagent. 
Complex Formation Studies with Size-exclusion Chromatography 
The formation of a complex between anticoagulant proteins was examined by gel-
filtration chromatography on a Superdex 75 gel-filtration column (1.6 x 60 cm) using an 
ĀKTA purifier. The column was equilibrated with 50 mM Tris-HCl buffer (pH 7.4) at a 
flow rate of 1 ml/min. Individual proteins and an equimolar mixture of anticoagulant 
proteins (native or pyridylethylated) were incubated for 30 min at 37 °C and then loaded 
onto the column and eluted in the same buffer. Elution was followed at 280 nm. 
 
RESULTS 
Purification of the Anticoagulant Protein – Crude venom of H. haemachatus exhibited 
potent anticoagulant activity in both recalcification and prothrombin time assays (Figure 
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Figure 2.1. Anticoagulant activity of the crude venom. Shown are the effects of the 
crude venom on recalcification time (A) and prothrombin time (B). Note that the venom 
exhibited potent anticoagulant activity in both assays. Each data point represents the 
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2.1, A and B). To purify the anticoagulant protein, the crude venom was size-fractionated 
by gel-filtration chromatography (Figure 2.2). Fractions corresponding to peaks 2 and 3 
contained anticoagulant proteins as determined by prothrombin time assays. Peak 2 
corresponded to proteins mostly containing phospholipase A2 that have been 
characterized previously (Condrea et al., 1981). However, this peak had milder 
anticoagulant activity compared with peak 3 (Figure 2.2, inset), so we focused on 
isolating the anticoagulant protein from peak 3, which was fractionated further by cation-
exchange chromatography on a UNO S6 column (Figure 2.3). Only peak A (labeled 
Hemextin A) exhibited mild anticoagulant activity. During our preliminary studies, we 
found that the anticoagulant activity of peak A was potentiated by peak B (labeled 
Hemextin B; see below). Because this anticoagulant complex specifically inhibited the 
extrinsic tenase complex (described in Chapter 3), we named it the hemextin AB complex 
(Hemachatus extrinsic tenase inhibitor) and the individual proteins hemextins A and B, 
respectively. Fractions corresponding to both hemextins A and B were pooled separately 
and purified by reverse-phase HPLC (Figure 2.4A and B) and capillary liquid 
chromatography (Figure 2.5A and B). The homogeneity and mass of the individual 
proteins were determined by electrospray ionization mass spectrometry. The mass spectra 
of hemextins A and B showed three peaks with mass/charge ratios ranging from 3 to 6 
charges (data not shown) and their calculated molecular masses as 6835.00 ± 0.52 and 
6792.56 ± 0.32 Da, respectively (Figure 2.6A and B). 
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Figure 2.2 Size-exclusion chromatography (SEC) of Hemachatus haemachatus crude 
venom using a Superdex 30 column. SEC of venom on a Superdex 30 (1.6 × 60 cm)column 
with Tris-hydrochloride buffer (50mM; pH 7.4; flow rate 1.5 ml/min) a eluent. Fractions 
constituting peak 3 (indicated by horaizontal bar) were pool and subjected to cation exchange 
chromatography. Elution of proteins monitored at 280 nm is shown. Inset, anticoagulant activity 
of peaks 2 and 3. 
Figure 2.3 Cation exchange of peak 3 from SEC. Cation-exchange chromatography of peak 3 
using a UNO S6 column (Bed volume 6 ml). Only peak A (labeled Hemextin A) exhibited mild 
anticoagulant activity. During our preliminary studies, we found that the anticoagulant activity of 
peak A was potentiated by peak B (labeled Hemextin B). Elution of proteins monitored at 280 nm 
is shown 
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Figure 2.4 RP-HPLC profiles of hemextin A and hemextin B. A and B, Reverse-phase HPLC 
profiles of cation-exchange fractions containing hemextins A and B, respectively, using a Jupiter 
C18 semipreparative column using a linear gradient (28-55%, over 85 min for hemextin A;. 28-
55%, over 85 min for hemextin B) of buffer B (80% acetonitirle in 0.1% TFA) at a flow rate of 1 
ml/min. Elution of proteins monitored at 215 nm is shown. 
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Figure 2.5 Rechromatography of hemextin A and B. A and B, Reverse-phase HPLC profiles 
of cation-exchange fractions containing hemextins A and B, respectively, using a Jupiter C18 
semipreparative column using a linear gradient (28-55%, over 85 min for hemextin A;. 28-55%, 
over 85 min for hemextin B) of buffer B (80% acetonitirle in 0.1% TFA) at a flow rate of 1 
ml/min. Elution of proteins monitored at 215 nm is shown. 
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Figure 2.6 ESI-MS of hemextins A and B. ESI-MS spectra for (A) Hemextin A (B) Hemextin 
B. The spectra show a series of multiply charged ions. The insets show the determined MW.  
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NH2-terminal Sequence Determination - We determined the complete amino acid 
sequence of hemextins A and B by Edman degradation (Figure 2.7). The locations of the 
cysteine residues in the proteins were confirmed by sequencing the pyridylethylated 
proteins. Hemextin A and hemextin B have 61 and 60 amino acid residues respectively. 
The calculated masses of the proteins were 6835.34 Da for hemextin A and 6792.7 Da for 
hemextin B and coincides well with the estimated molecular masses of 6835 Da for 
hemextin A and 6792.56 for hemextin B.  
The amino acid sequences of the proteins were subjected to a similarity search using 
BLAST (Altschul et al., 1997). Multiple sequence alignment was carried out. The 
sequence data of the homologus proteins were obtained from SWISS-PROT (Swiss 
Institute of Bioinformatics), EMBL (Europen Bioinformatics Institute), PRF (Protein 
Research Foundation), PIR (Protein Information Resource), GENEBANK (National 
Center for Biotechnology Information) and PDB (Protein Data Bank) databases. The 
I.P.U.A.C (International Union of Pure and Applied Chemistry) one letter notation for 
amino acids is used throughout (1968). Both proteins show similarity to cardiotoxins, 
postsynaptic neurotoxins, fasciculin, and other members of the three-finger toxin family 
(Figure 2.7). Thus, hemextins A and B belong to three-finger toxin family 
CD Spectroscopy – Both hemextins A and B exhibited negative minima at 215 nm and 
positive maxima at 194 nm. Thus, similar to other three-finger toxins, both hemextins A 
and B exhibited a predominantly β-sheet structure (Figure 2.8). However, the S-
pyridylethylated forms of hemextins A and B displayed negative minima at 195 nm, i.e. a  
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Hemextin A   LKCHNKLVPFLSKT..CPEGKNL..CYKMTMLKMPKIPIKRG.CTDACPKSSLLVKVV.CCNKDK.CN
Hemextin B  LKCHNKVVPFLK....CKNKVVPFLCYKMTLKKVPKIPIKRG.CTDACPKSSLLNVM..CCKTDK.CN 
Cytotoxin 1   LKCHNKVVPFLSKT..CPEGKNL..CYKMTLKKVPKIPIKRG.CTDACPKSSLLVNVM.CCKTDK.CN 
Cytotoxin 2   LKCHNKLVPFLSKT..CPDGKNL..CYKMSMEVTPMIPIKRG.CTDTCPKSSLLVKVV.CCKTDK.CN 
Toxin 9B   LICHNRPLPFLHKT..CPEGQNI..CYKMTLKKTPMKLSVKRGCAATCPSERPLVQVE.CCKTDK.CNW
Weak toxin CM-1B  LECYQKSKVVT.....CQPEQKF..CYSDTMTFFPNHPVYLSGCTF.CRTDESGER...CCTTDR.CNK
Weak toxin CM-1C  FTCFTTPSDTSET...CPIGNNI..CYEKRWSGHGMQIEKG..CVASCPSFESHYKFLLCCRIEN.CNQ
Toxin II   LECHNQQSSQPPTTKSCPGDTN...CYNKRWRDHRGTIIERG.CG..CPTVKPGINLK.CCTTDR.CNN
Toxin IV   LECHNQQSSQTPTTQTCPGETN...CYKKQWSDHRGSRTERG.CG..CPTVKPGIKLK.CCTTDR.CNK
Cardiotoxin γ   LKCNQLIPPFWKT...CPKGKNL..CYKMTMRAAPMVPVKRG.CIDVCPKSSLLIKYM.CCNTDK.CN
Cardiotoxin A3  LKCNKLVPLFYKT...CPAGKNL..CYKMFMVATPKVPVKRG.CIDVCPKSSLLVKYV.CCNTDR.CN
Fasciculin   TMCYSHTTTSRAILTNCGENS....CYRKSRRHPPKMVLGRG.CG..CPPGDDYLEVK.CCTSPDKCNY
Mambin   RICYNHLGTKPPTTETCQEDS....CYKNIWTFDNIIRRG...CG..CFTPRGDMPGPYCCESDK.CNL
Calciseptin   RICYIHKASLPRATKTCVENT....CYKMFIRTQREYISERG.CG..CPTAMWPYQTE.CCKGDR.CNK
Muscarinic toxin 2  LTCVTTKSIGGVTTEDCPAGQNV..CFKRWHYVTPKNYDIIKGCAATCPKVDNNDPIR.CCGTDK.CND
Erabutoxin b   RICFNHQSSQPQTTKTCSPGESS..CYHKQWSDFRGTIIERG.CG..CPTVKPGIKLS.CCESEV.CNN
Loop I Loop II Loop III
Figure 2.7 Comparison of amino acid sequence of hemextin A and hemextin B with other 
sequences of the three-finger toxin family. The conserved cysteine residues are indicated in 
black. The four conserved disulfide linkages and the segments contributing to the three loops are 
outlined. Comparison were made with the following sequences: cytotoxin 1, cytotoxin 2, toxin 
9B, weak toxin CM-1B, weak toxin CM-1C, toxin II, toxin IV are from Hemachatus 
haemachatus (African Ringhals Cobra); carditoxin γ from N. nigricollis (Black spitting 
cobra); carditoxin A3 from Naja atra (Taiwan cobra); fasciculin from Dendroaspis 
angusticeps; mambin from Dendroaspis jamesoni; calciseptin from Dendrosaspis 
















































Figure 2.8 CD spectra. CD spectra of native (---) and S-pyridylethylated (—) (A) 
hemextinA and (B) hemextin B. Note, the native proteins exhibit a typical β-sheet 
structure, as observed in the other members of the three-finger toxin family. In the S-
pyridylethylated the di-sulfide bonds are destroyed as a result of which the proteins loose 
their characteristic β-sheet fold.  
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predominantly random-coil structure (Figure 2.8). Thus, reduction and pyridylethylation 
result in the loss of folding and three-dimensional structure in hemextins A and B. 
Anticoagulant Activity of Hemextins – The anticoagulant activity of hemextins A and B 
was determined by the prothrombin time assay (Figure 2.9). Hemextin A prolonged the 
clotting time and exhibited mild anticoagulant activity, whereas hemextin B did not show 
any significant effect on the clotting time even at higher concentrations. Interestingly, an 
equimolar mixture of hemextins A and B exhibited more potent anticoagulant activity, 
indicating synergism between these proteins (Figure 2.9). Such an increase in the 
anticoagulant effect could be due either to the inhibition of two separate steps in the 
coagulation cascade or to the formation of a complex between them. Because hemextin B 
by itself has no significant effect on prothrombin time, it does not inhibit a separate step; 
instead, it is likely that hemextins A and B form a complex. 
Complex Formation between Hemextins A and B – To investigate the formation of a 
complex between the two proteins, we employed a titration experiment in the 
prothrombin time assay. In this experiment, the concentration of hemextin A was kept 
constant at 4.4 µM, and its anticoagulant activity was monitored with increasing hemextin 
B concentrations (Figure 2.10). The anticoagulant activity increased with increasing 
concentrations of hemextin B until the ratio reached 1:1. Further addition did not increase 
the anticoagulant effect. The results indicate that hemextins A and B form a 1:1 complex 
and that complex formation is crucial for potent anticoagulant activity. Complex 
formation between hemextins A and B was further confirmed by gel-filtration  
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Figure 2.9 Effects of hemextins A and B on prothrombin time. A, shown are the effects of 
hemextin A ( ), hemextin B ( ), and the probable hemextin AB complex ( ) on prothrombin 
time. Note that the anticoagulant potency of hemextin A increased in the presence of hemextin B. 






















Figure 2.10 Complex formation between hemextins A and B is illustrated by their effect on 
prothrombin time. Note as the concentration of hemextin B increases there is an increase in 
anticoagulant activity; the curve plateaus out when the stoichiometric ratio of the two proteins 
becomes 1:1. 
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Figure 2.11 Gel filtration studies on the formation of hemextin AB complex. Note the elution 
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chromatography. As shown in Fig. 2.11, the retention time of individual hemextins A and 
B was ~70 min. However, the reconstituted complex eluted as a major peak with a 
retention time of ~40 min and as a minor peak with a retention time of ~70 min. The 
appearance of the major peak with a reduced retention time corresponding to ~27 kDa is 
consistent with the formation of a tetrameric complex with two molecules each of 
hemextins A and B (Figure 2.11). 
Importance of fold – Importance of fold for anticoagulant activity and complex formation 
were examined by S-pyridylethylated using samples. S-pyridylethylated hemextins did 
not exhibit any anticoagulant activity. An equimolar mixture of S-pyridylethylated 
hemextins A and B also failed to display any anticoagulant effect (Figure 2.12). Thus, 
proper folding is important for the interaction between hemextins A and B and their 
anticoagulant activity. 
We also reconstituted the hemextin AB complex with S-pyridylethylated forms of the 
native proteins. However, no change in the retention time of the mixture was observed 
compared with those of the individual S-pyridylethylated proteins (Figure 2.13). These 
results indicate that proper folding is essential for the formation of the hemextin AB 
complex. 
DISCUSSION 
In this chapter the isolation and preliminary characterization of two proteins, hemextins A 
and B, from the venom of H. haemachatus was reported. These proteins synergistically 
induce potent anticoagulant activity. Individually, only hemextin A exhibited mild 
anticoagulant activity, whereas hemextin B had no anticoagulant activity (Figure 2.9). 
The increase in the anticoagulant potency of hemextin A in the presence of hemextin B 
(Figure 2.9) indicated probable complex formation between the two proteins. We have  
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Figure 2.13 Importance of fold in the formation of hemextin AB 
complex. Note that the mixture of S-pyridylethylated hemextins A and B 
are unable to form a complex.  
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shown that 1:1 complex formation is important for potent anticoagulant activity using the 
prothrombin time assay (Figure 2.10). Complex formation was further confirmed by gel-
filtration chromatography (Figure 2.11). 
Both hemextins A and B belong to the three-finger family of snake venom proteins 
(Figure 2.7.) and not to the family of snake venom serine protease inhibitors. Proteins 
belonging to this group exhibit a characteristic β-sheet structure (Figure 2.14), also 
observed in the CD studies (Figure 2.8). It is a well known fact that disulfide bonds 
associated with cysteine residues are essential structural units in proteins (Debarbieux and 
Beckwith, 1999). To evaluate the importance of the three-finger fold in both complex 
formation and anticoagulant activity, we used reduced and subsequently pyridylethylated 
hemextins A and B. Upon pyridylethylation, they lost their native three-finger fold, as 
observed in the CD studies (Figure 2.8). The S-pyridylethylated hemextins were 
functionally inactive (Figure 2.12) and were unable to bind to each other to form the 
complex, as evident from the gel-filtration studies (Figure 2.13). This shows that proper 
folding of the proteins is important not only for function, but also for complex formation. 
Synergism2 among snake venom toxins is fairly well characterized, particularly among 
presynaptic neurotoxins. For example, crotoxin isolated from Crotalus durissus terrificus 
venom contains two subunits; the basic subunit is a phospholipase A2 enzyme, whereas 
the acidic subunit is catalytically inactive (although it is derived from a phospholipase A2-
like protein) (Habermann and Breithaupt, 1978). Individually, only the basic subunit is 
slightly toxic, whereas the complex exhibits potent toxicity. The acidic subunit appears to  
                                                 
2 Synergism is the simultaneous actions of separate entities which together have greater total effect than the 
sum of their individual effects. 
   --- Buchholz and Roth 
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Figure 2.14 Three-dimensional structural similarity among three-finger toxins from snake 
venoms. (A) Erabutoxin a (1QKD); (B) α-bungarotoxin (2ABX); (C) cardiotoxin V4 (1CDT); (d) 
κ-bungarotoxin (1KBA); (E) candoxin (1JGK); (F) fasciculin 2 (1FAS); (G) muscarinic toxin 
MT-2 (1FF4; R Menez et al., pers. comm., 2002); (H) FS2 toxin (1TFS). Note all these ‘sibling’ 
toxins share a similar structural fold; three β-sheeted ‘fingers’ start from the core. These β-
sheeted loops are numbered right to left as loop I, II and III, respectively. However, these toxins 
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act as a chaperone and enhances the specific binding of the basic subunit to the 
presynaptic site. Similarly, other presynaptic neurotoxins, such as taipoxin from 
Oxyuranus scutellatus (Doorty et al., 1997) and textilotoxin from Pseudonaja textilis (Su 
et al., 1983) venoms, contain three and four subunits, respectively. All the subunits are 
structurally similar to phospholipase A2 enzymes. The noncovalent interactions between 
the subunits of these toxins are important for their potent toxicity. Thus, a number of 
snake venom presynaptic toxins are protein complexes with phospholipase A2 as an 
integral part. Taicatoxin, another protein complex isolated from O. scutellatus venom, 
blocks calcium channels and has phospholipase A2, proteinase inhibitor, and neurotoxin 
(a three-finger toxin) subunits (Possani et al., 1992). There are only a few noncovalent 
protein complexes in snake venoms that do not contain phospholipase A2 as an integral 
part. For example, rhodocetin, an antiplatelet protein complex from Calloselasma 
rhodostoma venom, contains two subunits showing structural similarity to C-type lectins 
(Wang et al., 1999). Group C prothrombin activators from Australian snakes are 
procoagulant protein complexes that are structurally and functionally similar to 
mammalian blood coagulation FXa·FVa complexes (Rao and Kini, 2002;Rao et al., 
2003;Rao et al., 2004). Thus, hemextin AB complex is a unique snake venom protein 
complex formed by the interaction between two three-finger toxins, in which the 
anticoagulant activity of hemextin A is potentiated by its synergistic interaction with 





“Keep your eyes open for the odd or unexpected and never dismiss it simply because 
it does not fit within your program. If chance offers you a clue, follow the trail. You 
may not discover what you were looking for, but what you discover may be more 
interesting than what you were looking for.” 
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“The effect of a competitive inhibitor on the rate of an enzyme-catalysed reaction can be 
appreciated using a modified form of the Michaelis–Menten equation, in which the Km 
term in the denominator of   is multiplied by the factor 1 + (i/Ki), where i and Ki represent 
the concentration of inhibitor and its dissociation constant from the enzyme– inhibitor 
complex respectively. The resulting Km (app) can then be used to calculate Ki, using 
appropriate plots at various inhibitor concentrations. A simple graphical method that 
simplifies this task and permits the direct calculation of Ki without the need for tedious 
secondary plots was published in 1953 by Malcom Dixon4 (yes, the same M. Dixon, co-
author with M.C. Webb, of the best-seller Enzymes5). The Dixon plot for linear 
















11        (eq 4) 
The plot of 1/v against i at constant s generates a straight line. Measurements at a 
different substrate concentration give another straight line that intersects the previous one 
at a point whose abscissa co-ordinate equals –Ki. Even though this method cannot 
distinguish between competitive and mixed inhibition, and does not provide the value of 
the dissociation constant of the EIS complex for mixed and uncompetitive inhibitors, it is 
highly appreciated and widely used (3926 citations until September 2005, of which 262 
were between 2000 and 2005). The Dixon plot was the first graphical method specifically 
dedicated to enzyme inhibition and its popularity must be related to its simplicity. One 
can also easily get rid of the above-mentioned deficiencies by the concomitant use of a 
similarly conceived graphical method6. This is one of several kinetic inventions published 
                                                 
1 The above excerpt has been taken from the excellent article titled “Enzyme kinetics: the velocity of 
reactions” by Prof. Antonio Baici published in the Biochemical Journal (2006). The article highlights the 
basics of enzyme kinetics, and also tells the reader about the people who have contributed to its 
development. I chose this particular part of the article “Dedicated to inhibitors”, since by using similar 
principles we were able to predict the nature of inhibition mediated by the anticoagulant hemextin AB 
complex and calculate the Ki of inhibition as well. As the reader will note, the author has very succinctly 
defined the principles based on which one identifies the mechanism of inhibition and calculates the 
inhibition constants, briefly touching on their merits and demerits as well.    
The references cited in the excerpt are in the same order as cited in the original article and have not been 
modified. 
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in the Biochemical Journal by Athel Cornish-Bowden, the inexhaustible enzyme kinetic 
volcano, well known for his Fundamentals of Enzyme Kinetics7. When used together, the 
two plots complement each other and permit identification of the mechanisms of 
inhibition and calculation the inhibition constants.” 
 
--- Professor Antonio Baici, Department of 
Biochemistry, University of Zurich 




4. Dixon, M. (1953) The determination of enzyme inhibitor constants. Biochem. J. 55, 
170–171 
5. Dixon, M. and Webb, E.C. (1979) In Enzymes 3rd edn, Longman, London 
6. Cornish-Bowden, A. (1974) A simple graphical method for determining the inhibition 
constants of mixed, uncompetitive and noncompetitive inhibitors. Biochem. J. 137, 
143–144 
7. Cornish-Bowden, A. (2004) Fundamentals of enzyme kinetics 3rd edn, Portland Press, 
London In  
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“Mechanism of action” refers to the specific biochemical interaction through which a 
substance (which in most cases is a drug or a drug lead) produces its pharmacological 
effect. Snake venoms form a rich source of bioactive molecules, such as peptides, 
proteins and enzymes with important pharmacological activities. The protein components 
constitute a highly evolved and organized arsenal of biomolecules that attack, often with 
precision and coordinated synergism, a wide variety of molecular targets vital for the 
physiological process. While this would well suit the despicable intentions of the snake’s 
venom, it also offers boundless opportunities for the study of novel biomolecules of 
therapeutic interest2. For example, a family of inhibitors of angiotensin converting 
enzyme were developed based on bradykinin potentiating peptides from South American 
snake venoms (Higuchi et al., 1999). Inhibitors of platelet aggregation, such as 
eptifibatide and tirofiban, were designed based on disintegrins, a large family of platelet 
aggregation inhibitors found in viperid and crotalid snake venoms (McClellan and Goa, 
1998;O'Shea and Tcheng, 2002;Kondo and Umemura, 2002;Plosker and Ibbotson, 
2003;Huang and Hong, 2004;Marcinkiewicz, 2005). But prior to the use of a molecule 
for therapeutic purposes one has to find out the mechanism by which it acts3 and more 
precisely how specific it is towards its molecular target.  
In the previous chapter, we have seen that hemextin A has mild anticoagulant activity, 
whereas hemextin B is inactive. However, the 1:1 complex of the two proteins (hemextin 
                                                 
2 It will be an interesting paradox if it transpires that the venomous creatures that have so long been reviled 
by the human race turn out to provide key lessons for revolutions in medicine and science which prolong 
and enhance human existence. 
   ---Mark J. Dufton, Kill and cure: the promising future for venom research. 
            Endeavour, 17:3, 138-140 (1993) 
3 The most exciting phrase to hear in science, the one that heralds the most discoveries, is not "Eureka!" (I 
found it!) but, "That's funny..."   
---Isaac Asimov 
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AB complex) exhibits potent anticoagulant activity. The blood coagulation cascade 
consists of many steps. Therefore, identification of the site of activity is important in the 
understanding of the mechanism of anticoagulation, mediated by hemextin A and 
hemextin AB complex.  In this chapter we have identified the specific site in the 
coagulation cascade where hemextin A and hemextin AB complex act to mediate 
anticoagulation, followed by the identification of the specific coagulation factor which is 
inhibited by these anticoagulant proteins.  
Several techniques, including clot based tests, chromogenic or color assays, direct 
chemical measurements, and ELISAs, are used for identifying the mechanism of activity 
of an identified anticoagulant (Breddin et al., 1994;Walenga and Hoppensteadt, 2004). In 
order to identify the mechanism of anticoagulant activity we used clot based and 
chromogenic assays.  
For our studies we employed three clot based assays namely, prothrombin time, stypven 
time and thrombin time. Using these three assays we designed a simple “Dissection 
Approach” (Figure 3.1) (Kini and Banerjee, 2005), to identify the specific stage in the 
extrinsic coagulation pathway where hemextin A and hemextin AB complex mediate 
their activity. In prothrombin time, thromboplastin reagent containing TF and calcium is 
added to citrated plasma. Formation of extrinsic tenase results in rapid fibrin formation 
via extrinsic and common pathways. Therefore, this clotting assay measures the effect of 
an anticoagulant on the extrinsic tenase and prothrombinase complexes and the 
conversion of fibrinogen to fibrin clot. In Stypven time, Russell's viper venom activates 
FX directly, and clot formation proceeds via the common pathway. Thus, Stypven time 
circumvents the extrinsic tenase complex and monitors the effect of an anticoagulant on 
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Figure 3.1 Dissection Approach. Schematic representation showing the selective activation of 
the extrinsic coagulation pathway by the prothrombin, Stypven and the thrombin time clotting 
assays. In the prothrombin time, clotting is initiated at the tenase complex by the addition of Ca2+ 
and thromboplastin, which contains tissue factor and phospholipids (TF-PL). In the Stypven time, 
clotting is initiated at the prothrombinase complex by the addition of dilute Russell’s viper 
venom, which activates factor FX and factor FV by specific proteases. FXa and FVa form the 
prothrombinase complex on the PL surfaces with the addition of Ca2+. In thrombin time, clotting 
is initiated by the addition of thrombin, which converts soluble fibrinogen to a fibrin clot. 
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the prothrombinase complex and the conversion of fibrinogen to fibrin. In thrombin time, 
thrombin is added to citrated plasma and directly converts fibrinogen to fibrin. Thrombin 
time therefore, depicts the effect of an anticoagulant on the conversion of fibrinogen to 
fibrin only. A systematic analysis of the effect of an anticoagulant on these three clotting 
times would therefore help in identifying the stage of coagulation in the extrinsic 
coagulation cascade. Thus, the anticoagulant action of the individual proteins and their 
complex can be localized to certain activation step(s) in the cascade.  
Chromogenic assays are based on the utilization of enzyme specific substrate onto which 
a chromophore has been linked. The enzyme cleaves the chromogenic substrate, releasing 
a colored compound that can be detected with a spectrophotometer (Walenga and 
Hoppensteadt, 2004). The general methodology involving such an assay, is to incubate 
predetermined amount of a specific coagulation enzyme with a given amount of the 
anticoagulant. After incubation, residual enzymatic activity is determined by the addition 
of a selective chromogenic substrate. These assays are therefore best suited for 
identifying the mechanism of inhibition, the inhibitory constants and specificity of 
inhibition of an anticoagulant. Therefore, by the combined use of dissection approach 
(which involves the clotting assays) and chromogenic assays we were able to identify the 
specific blood coagulation factor to which the anticoagulant protein and its synergistic 
complex bind to mediate anticoagulation. 
MATERIALS AND METHODS 
Reagents – Thromboplastin with calcium (for prothrombin time assays), Russell's viper 
venom (RVV) (for Stypven time assays) and thrombin reagent (for thrombin time assays) 
were purchased from Sigma (St. Louis, MO, USA). The chromogenic substrates H-D-Ile-
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Pro-Arg-p-nitroanilide (pNA) dihydrochloride (2HCl), (S-2288), pyro-Glu-Pro-Arg-
pNA·HCl (S-2366), H-D-Phe-Pip-Arg-pNA·2HCl (S-2238), H-D-Pro-Phe-Arg-
pNA·2HCl (S-2302), Z-D-Arg-Gly-Arg-pNA·2HCl (S-2765), pyro-Glu-Gly-Arg-
pNA·HCl (S-2444), benzoyl-Ile-Glu(GluγOMe)-Gly-Arg-pNA·HCl (S-2222), H-D-Val-
Leu-Lys-pNA·2HCl (S-2251), H-D-Val-Leu-Arg-pNA·2HCl (S-2266) and MeO-Suc-
Arg-Pro-Tyr-pNA·HCl (S-2586) were from Chromogenix AB, Stockholm, Sweden. 
Spectrozyme®FIXa (H-D-Leu-Ph’Gly-Arg-pNA.2AcOH) was obtained from American 
Dignostica Inc., Stamford, CT, USA. All substrates were reconstituted in deionized water 
prior to use. Recombinant human tissue factor (Innovin) was purchased from Dade 
Behring, Marburg, Germany. Human plasma was donated by healthy volunteers. All 
other chemicals and reagents used were of highest purity available. 
Proteins - Human plasma derived FVIIa and FX and FXa was a gift from factor VII’s 
group (Kazuhiko Tomokiyo, Yasushi Nakatomi, Teruhisa Nakashima and Soutatou 
Gokudan) of Kaketsuken, which were purified as described earlier (Wildgoose and 
Kisiel, 1989;Nakagaki et al., 1991). Recombinant human soluble TF (residues 1-218; 
sTF) was a gift from Dr. Toshiyuki Miyata, National Cardiovascular Center, Suita, Japan 
and it was prepared as described earlier (Stone et al., 1995). Human plasma-derived 
thrombin, activated protein C, and factor IXa were gifts from Hiroshi Kaetsu, Shinji 
Nakahira, and Takayoshi Hamamoto, from Kaketsuken, respectively as described 
(Okajima et al., 1990;Nakagaki et al., 1991;Kaetsu et al., 1998). We also thank Dr. 
Mitsuhiro Ohta, Kobe Pharmaceutical University for providing three cardiotoxins (CM-
14, CM-17, CM-18 Naja Naja Atra).  Plasma kallikrein and plasmin were purchased 
from Enzyme Research Laboratories Inc, South Bend, IN, USA. Factor XIa and factor 
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XIIa were purchased from Haemtech, Essex junction, VT, USA. Proteins t-PA and u-PA 
were purchased from American Dignostica Inc., Stamford, CT, USA. α – chymotrypsin 
and trypsin were obtained from Worthington Biochemical Corporation, Lakewood, NJ, 
USA. 
Reconstitution of the anticoagulant complex – Studies described in the previous chapter 
indicated that the hemextin A interacted with hemextin B forming a synergistic complex. 
We reconstituted the complex for various in vitro experiments immediately prior to the 
experiment by incubating equimolar concentration of the two proteins (unless mentioned 
otherwise) at 37˚ C for a period of 5 min in 50 mM Tris-buffer (pH 7.4). 
Anticoagulant activity – For our studies we used four coagulation tests which were 
conducted using a BBL fibrometer: 
1. Recalcification time: The recalcification times were determined according to 
the method of Langdell et al. (LANGDELL et al., 1953). 50 mM Tris-HCl 
buffer (pH 7.4) (100 µL), plasma (100 µL) and various concentrations of 
venom or its fraction (50 µL) were preincubated for 2 min at 37˚C. Clotting 
was initiated by the addition of 50 µL of 50 mM CaCl2. 
2. Prothrombin time: The prothrombin times were measured according to the 
method of Quick (Quick, 1973). 100 µL of 50 mM Tris-HCl buffer (pH 7.4), 
100 µL of plasma and 50 µL of venom or its fractions were preincubated for 2 
min at 37˚C  Clotting was initiated by the addition of thromboplastin with 
calcium reagent (150 µL).  
3. Stypven time: Stypven time measurements were determined according to the 
method of Hougie (Hougie, 1956). Plasma (100 µL), 50 mM Tris-HCl buffer 
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(pH 7.4) (100 µL) and RVV (0.01 µg in 100 µL) and individual proteins or 
the reconstituted complex (50 µL) were preincubated for 2 min at 37˚C. 
Clotting was initiated by the addition of 50 mM CaCl2 (50 µL). 
4. Thrombin time: Thrombin time was determined according to the method of 
Jim (JIM, 1957). Individual proteins or the reconstituted complex were 
incubated with 100 µL of plasma and 100 µL of 50 mM Tris-HCl buffer (pH 
7.4) for 2 min at 37˚C in a total volume 250 µL. Clotting was initiated by the 
addition of standard thrombin reagent (0.01 NIH units in 50 µl). 
Reconstitution of the extrinsic tenase complex – TF-FVIIa complex was reconstituted by 
incubating 10 pM FVIIa with 70 nM of recombinant human TF (Innovin) in Buffer A (20 
mM HEPES, 150 mM NaCl, 10 mM CaCl2 and 1% BSA, pH 7.4) for 10 min at 37˚ C. 
Then FX was added to the mixture to obtain a final concentration of 30 nM. The 
activation was stopped by the addition 50 µL of stop buffer (20 mM HEPES, 150 mM 
NaCl, 50 mM EDTA and 1% BSA, pH 7.4) to 50 µL aliquots of the reaction mixture 
after 15 min incubation. FXa formed was measured by the hydrolysis 1 mM of S-2222 in 
Buffer A in a microtiter plate reader at 405 nm. The inhibitory effect on extrinsic tenase 
activity was determined by adding the individual proteins or the anticoagulant complex 
15 min prior to FX addition. 
Serine protease specificity –  The selectivity profile of anticoagulant proteins and their 
complex was examined against 12 serine proteases - procoagulant serine proteases (FIXa, 
FXa, FXIa, FXIIa, plasma kallikrein and thrombin), anticoagulant serine protease 
activated protein C (APC), fibrinolytic serine proteases (urokinase, t-PA and plasmin) 
and classical serine proteases (trypsin and chymotrypsin). Various concentrations of the 
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purified individual proteins or the reconstituted anticoagulant complex were preincubated 
with each of the enzymes for a period of five minutes at a temperature of 37ºC, followed 
by the addition of appropriate chromogenic substrate.  
In a total volume of 200 µl in the individual wells of the microtiter plate, final 
concentrations of FVIIa (300 nM)/S-2288 ,FVIIa-sTF (30 nM)/S-2288, FXa (0.75 nM)/S-
2765, α-thrombin (0.66 nM)/S-2238, plasmin (2 nM)/S-2251,   FIXa (3 
µM)/spectrozyme®fIXa, FXIa (0.34 nM)/S-2366, FXIIa (0.4 nM)/S-2302, recombinant 
tissue plasminogen activator (80 nM)/S-2288, APC (0.34 nM)/S-2366, urokinase /S-
2444, plasma kallikrein (0.4 nM)/S-2302, trypsin (2.17 nM)/S-2222 and chymotrypsin 
(0.4 nM)/S-2586. The kinetic rate of substrate hydrolysis (mOD/min) was measured over 
5 min. 
Kinetics of inhibition – All studies were performed in assay buffer containing 50 mM 
Tris-HCl, pH 7.4, containing 150 mM NaCl, 10 mM CaCl2, and 1% BSA at 37ºC. The 
kinetics of hydrolysis of the chromogenic substrate S-2288 by FVIIa-sTF was measured 
prior to examining the inhibitory effects of the individual proteins and the reconstituted 
anticoagulant complex. Reactions were initiated by the addition of S-2288 (0 – 5 mM) to 
the individual wells of a 96-well plate containing FVIIa (30 nM) in complex with sTF 
(100 nM) in a final volume of 180 µl. Initial reaction velocities were measured as a linear 
increase in the absorbance at 405 nm (A405 nm) over 5 min, with a SPECTRAmax plus® 
temperature-controlled microplate spectrophotometer (Molecular Devices, Sunnyvale, 
CA, USA).  
The inhibitory potency of anticoagulant complex was measured over a range of substrate 
concentrations. Reactions were initiated by the addition of S-2288 to premixed enzyme-
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cofactor and inhibitor in the wells of a microtiter plate. Reactions with FVIIa-sTF 
contained 0.025 to 0.1 µM of inhibitor complex and 0 to 3 mM of S-2288. The initial 
velocities were measured over 5 min under steady-state conditions and were fit by 
reiterative nonlinear regression to Equation 1, describing a classical non-competitive 






















............ (Eq.1)  
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RESULTS 
Site of anticoagulant activity – As observed in the studies depicted in the previous 
chapter, hemextin A and hemextin AB complex prolong clotting in prothrombin time 
clotting assays. To identify the specific stage in the extrinsic coagulation pathway, we 
used a simple "dissection approach" (Figure 3.1) (see above for details).  
Hemextin A exhibited a mild anticoagulant activity by prolonging the clotting time in the 
prothrombin time assay, but did not prolong Stypven time and thrombin time (Figure 
3.2A). As expected, hemextin B did not prolong clotting times in prothrombin time, 
Stypven time and thrombin time assays (Figure 3.2B). The hemextin AB complex 
exhibited a potent anticoagulant activity by prolonging the clotting time in prothrombin 
time assay. However, the clotting times in the other two assays were not affected (Figure 
3.2C). These results indicate that hemextin A and hemextin AB complex affect only the 
extrinsic tenase complex, but not the prothrombinase complex or conversion of 
fibrinogen to fibrin clot. 
To confirm the site of inhibition, we examined the effects of hemextins A and B and their 
complex on the reconstituted TF-FVIIa complex (Figure 3.3). Hemextin A exhibited mild 
inhibitory activity at higher concentrations. Hemextin B, on the other hand, did not 
mediate any inhibitory activity on the enzymatic action of the extrinsic tenase complex. 
However, hemextin AB complex completely inhibited extrinsic tenase activity (Figure 
3.3) with an IC50 value (concentration of the inhibitor which inhibits 50% of the activity) 
of 100 nM. Neither the individual proteins nor the complex mediated any inhibitory 
effect on FXa amidolytic activity (described below). The effect of the individual 
hemextins and the hemextin AB complex was also assessed on the intrinsic pathway 
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Figure 3.2 Localization of the step of activity. Eﬀect of hemextin A (A) hemextin B (B) and 
hemextin AB complex complex (C) on the prothrombin time (∆); Stypven time (●) and thrombin 
time (■) clotting assays(see text for details). Each data point represents the average ± SD. 
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Figure 3.3 Inhibition of TF-FVIIa activity.  The inhibitory potency of hemextin A and hemextin AB 




Figure 3.4 Complex formation 
demonstrated by the Inhibition of 
TF-FVIIa activity. Formation of 
hemextin AB complex (●) between 
hemextin A (■) and hemextin B is 
illustrated by their effect on TF-
FVIIa enzymatic activity. To 
determine the stoichiometry of 
complex formation, the 
concentration of hemextin A was 
kept low so that 100% TF-FVIIa 
activity is not inhibited upon 
complex formation. (The experiment 
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Figure 3.5 Effect of phospholipids on the inhibitory activity of hemextins A and B and hemextin AB 
complex. The inhibitory potency of hemextin A and hemextin AB complex for the inhibition of (A) FVIIa and 
(B) FVIIa-sTF amidolytic activity. (Note the absence of phospholipids do not affect the inhibitory potency of the 
protein(s) and the reconstituted complex; hemextin B did not exhibit any inhibitory activity in these assays). (The 
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using recalcification time assays. No anticoagulant activity was observed on the intrinsic 
pathway (data not shown). 
Further the effects of other three-finger toxins, particularly cardiotoxins/cytotoxins, 
which are structurally similar to hemextin A and B was also monitored on the TF-FVIIa 
proteolytic activity. CM - 14, CM – 17 and CM - 18 from Naja naja atra did not inhibit 
FXa formation by TF-FVIIa complex (data not shown). To determine the importance of 
hemextin AB complex formation for the inhibition of TF-FVIIa complex, we performed a 
similar titration experiment. The concentration of hemextin A was kept constant at 50 
µM so that only 70% activity of TF-FVIIa complex is inhibited, and its inhibitory activity 
on extrinsic tenase activity was evaluated in the presence of increasing concentrations of 
hemextin B. Higher concentrations of hemextin A was not used since it would not have 
been possible to monitor the stoichiometry of complex formation. As shown in (Figure 
3.4), the inhibitory activity of hemextin A increases with the increasing concentrations of 
hemextin B until the ratio reached 1:1. Further addition did not increase the anticoagulant 
effect. The results indicated that hemextins A and B form a 1:1 complex and the complex 
formation is crucial for the potent anticoagulant activity. No further increase in the 
inhibitory activity was observed after equimolar ratios of hemextins A and B. These 
observations further confirmed the importance of complex formation between hemextins 
A and B.  
To understand the effect of phospholipids, the inhibitory activity of hemextin A and 
hemextin AB complex was monitored on FVIIa amidolytic activity either in the presence 
or absence of sTF. In both the cases we observed potent inhibitory activity (Figure 3.5A 
and B) in a dose-dependant manner.  
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Figure 3.6 Serine protease specificity. Effect of hemextin A, hemextin B and the hemextin 
complex on the amidolytic activity of (A) FIXa, (B) FXa, (C) FXIa, (D) FXIIa, (E) plasma 
kallikrein, (F) thrombin, (G) trypsin, (H) chymotrypsin, (I) urokinase, (J) plasmin, (K) APC and 
(L) tPA. Benzamidine(■) was used as a positive control in all the experiments except in case of 
plasmin and chymotrypsin where aprotinin was used. The inhibitory potency of the proteins and 
the reconstituted complex was measure with respect to the blank (□), assay mixture containing 
assay buffer in place of the proteins.  Note both hemextin A and hemextin complex, but not 
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Figure 3.7 Inhibition of plasma kallikrein amidolytic activity and comparison of potency 
with FVIIa inhibition. (A) The inhibitory potency of hemextin A , hemextin B  and hemextin 
AB complex for the inhibition of plasma kallikrein amidolytic activity. (B) The inhibitory 
potency of hemextin A and hemextin AB complex for coagulation FVIIa. (Note that the IC50 is ~ 
5 µM for the inhibition of plasma kallikrein activity in comparison to 100 nM as observed in the 
case of FVIIa, indicating that both the protein and its complex are potent inhibitors of FVIIa) 
(The experiment was carried out on two separate days). 
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Specificity of inhibition – To determine the specificity of inhibition, hemextins A and B 
and their complex were screened against 12 serine proteases (Figure 3.6). No inhibitory 
activity was observed against any of the serine protease with the exception of FVIIa and 
plasma kallikrein. As with FVIIa, hemextins A and hemextin AB complex inhibit plasma 
kallikrein in a dose-dependant manner (Figure 3.7). Hemextin B did not inhibit 
kallikrein’s protease activity. However, the inhibitory potency towards FVIIa (either in 
the absence or presence of sTF) was at least 50 times higher than towards plasma 
kallikrein (Figure 3.7). 
Kinetics of inhibition – To determine the mechanism of inhibition, we examined the 
inhibitory kinetics of hemextin AB complex on amidolytic activity of sTF-FVIIa 
complex on S-2288. Kinetic studies revealed that hemextin inhibited FVIIa-sTF activity 
non-competitively. Lineweaver-Burk plots showed that Km remained unaltered where as 
Vmax decreased with increasing concentrations of inhibitor (Figure 3.8A) a characteristic 
of a non-competitive inhibitor. The Ki value for inhibition was determined to be 25 nM 
(Figure 3.8B). We also calculated the turnover number (Kcat) (number of moles of 
substrate converted to product per mole of enzyme per min) at different concentrations of 
the inhibitor. As observed in the case of classical non-competitive inhibitors Kcat 
decreased with increasing concentrations of hemextin AB complex (data not shown). 
Since the amidolytic activity of FVIIa alone is very weak (Maun et al., 2005), we did not 
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Figure 3.8 Nature of Inhibition. (A) Double reciprocal (Lineweaver-Burk) plots for the kinetic 
activity of FVIIa-sTF in the presence of 50 nM (□) (2Ki), 25 nM (○) (Ki), 12.5 nM (■) (1/2 Ki) of 
reconstituted hemextin AB complex. (●) represents the kinetic activity FVIIa-sTF in the absence 
of hemextin AB complex. Note that the Vmax decreases with increase in the inhibitor 
concentration where as the Km remains unchanged, a classical phenomenon observed in non-
competitive inhibitors. (B) Corresponding secondary plot depicting the Ki for the inhibition. (The 
experiment was carried out on two separate days) 
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DISCUSSION 
It is a well known fact that formation of unwanted clots has detrimental or debilitating 
effects and hence the need for anticoagulant therapies. Current anticoagulants used for 
treating these disorders, are non-specific and have a narrow therapeutic range 
necessitating careful laboratory monitoring to achieve optimal efficacy and minimize 
bleeding (Goolsby, 2002). This is further complicated by other factors such as dietary 
intake. Therefore, novel anticoagulant and antiplatelet agents are being sought after. 
Since the FVIIa is the key initiator of blood coagulation and is present in the plasma 
milieu at very low concentrations, it beckons to be an attractive drug target for the design 
and development of anticoagulants. So far, only two proteins are known that specifically 
inhibit the TF-FVIIa complex have been well characterized, namely, tissue factor 
pathway inhibitor (TFPI) and nematode anticoagulant peptide c2 (NAPc2). TFPI is an 
endogenous inhibitor of this complex, whereas NAPc2 is an exogenous inhibitor isolated 
from canine hookworm, Ancylostoma caninum and now expressed in yeast. The 
anticoagulation mechanism of each of these anticoagulants has been dealt in detail in the 
introductory chapters of the thesis. But most importantly, both the anticoagulants use FXa 
and TF as scaffold to bind to FVIIa. In other words they inhibit both coagulation serine 
proteases FVIIa and FXa. This limitation has prompted the design of specific inhibitors 
targeting FVIIa (the details of which are provided in the introductory chapter). However, 
this presents a formidable challenge since the domain architecture of FVIIa is very 
similar to the other coagulation serine proteases. To suffice to this necessity, we and 
others have been focusing on isolating and characterizing pharmacologically active 
proteins from snake venoms that affect blood coagulation and platelet aggregation.  
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Hemextin A and its synergistic complex with hemextin B prolong clotting in prothrombin 
time assays. Using the “dissection approach” we identified the site of anticoagulant 
action of hemextin A and its synergistic complex. Both hemextin A and hemextin AB 
complex inhibit the extrinsic tenase complex but not other steps in the extrinsic pathway. 
These results were further confirmed by studying the effect of hemextin A and its 
complex on the reconstituted TF-FVIIa complex. Both hemextin A and hemextin AB 
complex inhibit the FXa formation by the reconstituted extrinsic tenase complex (Figure 
3.3). Further, hemextin A and hemextin AB complex inhibit the amidolytic activity of 
FVIIa both in the presence and in the absence of sTF (Figure 3.5). Hemextin AB complex 
inhibits with IC50 values of ~ 100 nM and ~105 nM respectively. Similar IC50 values may 
be indicative of the fact that hemextin A and hemextin AB complex do not bind to the 
cofactor binding site of FVIIa. The inhibitory activity of hemextin A and hemextin AB 
complex may not be due to nonspecific interaction of hemextin A or its complex with the 
phospholipids in the extrinsic tenase complex, as indicated by their inability to prolong 
the Stypven time, since they failed to inhibit the prothrombinase complex, which is also 
formed on the phospholipid surfaces. This was further confirmed by determining the 
inhibitory activity of hemextin A and hemextin AB complex on the amidolytic of 
reconstituted extrinsic tenase complex using sTF and FVIIa. Further, hemextin A and 
hemextin AB complex inhibited amidolytic activity of FVIIa. Hemextin B, however, did 
not exhibit any inhibitory activity in the absence of hemextin A. To further characterize 
the inhibitory properties and determine the specificity of inhibition, we screened 
hemextins A and B and hemextin AB complex against 12 serine proteases. In addition to 
FVIIa and its complexes, hemextin A and hemextin AB complex inhibited the amidolytic 
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activity of only kallikrein in a dose-dependant manner (Figure 3.7). However, the IC50 for 
the inhibition of kallikrein was ~ 5 µM, in contrast to that of FVIIa/TF-FVIIa/sTF-FVIIa 
which was ~ 100 nM.  
Kinetic studies revealed that hemextin AB complex is a non-competitive inhibitor of 
FVIIa-sTF complex with a Ki of 25 nM. Thus these data strongly indicate that hemextin 
AB complex is a highly specific inhibitor of FVIIa.  
Some other anticoagulants from snake venoms also inhibit extrinsic tenase complex.  
However, they are not as specific.  For example, CM IV, a strongly anticoagulant 
phospholipase A2 (PLA2) from Naja nigricollis venom prolongs coagulation by inhibiting 
two successive steps in the coagulation cascade. It inhibits the TF-FVIIa complex by both 
enzymatic and nonenzymatic mechanisms, whereas it inhibits the prothrombinase 
complex by only nonenzymatic mechanism (Stefansson et al., 1990;Kerns et al., 1999). 
Hemextin A and its synergistic complex are the first reported specific inhibitors of FVIIa 
isolated from snake venom. 
Similar dose-dependent inhibition of TF-FVIIa complex and FVIIa indicates that 
hemextin AB complex neither requires TF for its inhibitory activity nor interferes in the 
binding of TF to FVIIa. Unlike TFPI and NAPC2, it also does not use FXa as a scaffold 
to bind to FVIIa and thus does not require FX or FXa to inhibit FVIIa. Further, TFPI and 
NAPC2 bind to the active site of FVIIa.  In contrast, as shown by the kinetic studies 
(Figure 3.8) hemextin AB complex is a noncompetitive inhibitor, unlike competitive 
inhibitors which bind to the active site. Therefore, hemextin A and hemextin AB complex 
are novel inhibitors of FVIIa and TF-FVIIa complex.  
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These inhibitors will help us develop different strategies and therapeutic agents to inhibit 







                                                 
4 If it was so, it might be; and if it were so, it would be; but as it isn't, it ain't. That's logic. -- Lewis Carroll 
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“The invention of deliberately oversimplified theories is one of the major techniques of 
science, particularly of the ‘exact' sciences, which make extensive use of mathematical 
analysis. If a biophysicist can usefully employ simplified models of the cell and the 
cosmologist simplified models of the universe then we can reasonably expect that 
simplified games may prove to be useful models for more complicated conflicts.” 
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A Short History of the Thermodynamics of Enzyme-catalyzed 
Reactions1
“The first and second laws of thermodynamics were known before Gibbs wrote his 
great paper "Equilibrium of Heterogeneous Substances" that was published in the 
Transactions of the Connecticut Academy in 1876 (1), but he completely changed the 
character of thermodynamics by showing it obeyed all the rules of calculus and 
introducing the chemical potential µ and what we now call the Gibbs energy, G. 
Obeying the rules of calculus means that there are many relationships between various 
thermodynamic properties. The introduction of the chemical potential made it possible 
to treat chemical reactions. The first law introduces the internal energy U that 
provides the criterion for spontaneous change and equilibrium at constant volume V 
and entropy S. The enthalpy H is defined by: 
H = U + PV…….(Eq.1) 
and it provides the criterion for spontaneous change and equilibrium at constant 
pressure and entropy. The Helmholtz energy A is defined by: 
A = U – TS…………(Eq.2) 
 
and it provides the criterion for spontaneous change and equilibrium at constant 
volume and temperature. This is beginning to look useful in the laboratory except that 
chemistry is usually carried out at constant pressure and temperature. Gibbs defined 
the property G, which we now call the Gibbs energy, as follows: 
  
G = H – TS…………….(Eq.3) 
The Gibbs energy provides the criterion for spontaneous change and equilibrium at 
constant temperature and pressure. These three definitions are what we now refer to as 
 
1  I have taken this excerpt form Professor Robert A Alberty’s reflections published in the journal of 
biological chemistry. The above excerpt is the introductory section of the excellent article and 
comprehensively pin points the key concepts in thermodynamics that form the basis for any chemical 
reaction, protein-protein interaction included. In this chapter, I have used isothermal titration 
calorimetry to study the thermodynamics of hemextin AB assembly, and the first three equations form 
the basis of the study. I hope the reader will feel the same. 
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Legendre transforms. Legendre transforms are the most significant concept in this 
short history. Note that Equations 1, 2, 3 each involve a product of conjugate variables 
that yields energy. Everybody knows that the variables in an equation can be changed 
by simply substituting an equation for one of the variables in terms of a new variable. 
Not everybody knows that a derivative can be introduced as a new variable, but Gibbs 
did. I wrote a review on Legendre transforms in 1994 (2), and later I chaired an 
IUPAC Committee that wrote a Technical Report on Legendre transforms (3). Two 
more Legendre transforms will be used in these Reflections. 
Before going further, we must be clear about what thermodynamics can tell us about a 
reaction system. Callen (4) has written: "Prediction of the new equilibrium state is the 
central problem of thermodynamics." Thermodynamic measurements on systems at 
equilibrium can be used to calculate properties that can be used to predict whether 
reactions in a system will go to the right or the left under a given set of conditions in 
addition to making it possible to calculate the equilibrium composition. It is not 
necessary to have measurements on the actual reactions in the system to do this 
because other pathways can be used to calculate the equilibrium composition. Rather 
than tabulating equilibrium constants of chemical reactions, chemists recognized a 
long time ago that the most efficient way to store thermodynamic information on 
chemical reactions was to make tables of the standard Gibbs energies of formation, 
fG0, standard enthalpies of formation, fH0, and standard molar entropies, Sm, of 
species (5).”  
--- Professor Robert A. Alberty, 
Department of Chemistry; Massachusetts 
Institute of Technology. Reflections, J. Biol. 
Chem., Vol. 279, Issue 27, 27831-27836, July 2, 
2004 
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M., Churney, K. L., and Nutall, R. L. (1982) J. Phys. Chem. Ref. Data 11, Suppl. 2, 
1–392 
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Proteins play a wide variety of functional roles in biological systems, including 
catalysis, transport, regulation, defense, and maintenance of cell architecture. All of 
these functions depend on specific interactions between proteins and other molecules. 
These interactions must be characterized in structural and energetic terms to 
understand the functions of proteins in a cellular context. An initial goal might be 
merely to demonstrate that a particular protein interacts with a particular ligand and 
perhaps explore the specificity of this interaction by surveying a range of other 
potential ligands. If an interaction is demonstrated, the high-resolution structural 
methods of X-ray crystallography or nuclear magnetic resonance (NMR) could be 
used to provide atomic-level structural information about the interaction. However, a 
second, and perhaps more important, goal is to explore the energetics of the 
interaction, in both thermodynamic and kinetic terms, and for this, a range of other 
methods can be employed. 
A principal challenge involved in studying non-covalent protein-protein interactions, 
is their rapid detection. In recent years, mass spectrometry (MS) is an important tool 
used in the detection of formation of protein-protein complexes. Detection of protein-
protein complexes in physiological buffer solutions is also done using dynamic light 
scattering (DLS). Various biophysical techniques are available to characterize binding 
and assembly of macromolecules in solution, including calorimetry, fluorescence 
spectroscopy, UV spectroscopy, stopped-flow kinetics, circular dichroism, mass 
spectrometry and NMR. 
Calorimetry specifically isothermal titration calorimetry (ITC) permits the study of 
macromolecular interactions in solution, and is the only technique that can resolve the 
enthalpic (∆H) and entropic components (∆S) of binding affinity and hence the 
difference in the Gibbs free energy (∆G) between the initial and final states.  
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CD in the far ultraviolet region (178–260 nm) arises from the amides of the protein 
backbone and is sensitive to the conformation of the protein. Thus CD can determine 
whether there are changes in the conformation of proteins when they interact. CD 
bands in the near ultraviolet (350–260 nm) and visible regions arise from aromatic 
and prosthetic groups. There are also changes in these regions when proteins bind to 
each other. Because CD is a quantitative technique, changes in CD spectra are directly 
proportional to the amount of the protein–protein complexes formed, and these 
changes can be used to estimate binding constants. Changes in the stability of the 
protein complexes as a function of temperature or added denaturants, compared to the 
isolated proteins, can also be used to determine binding constants.  
NMR gives information about the dynamic structural changes that take place in the 
macromolecules upon interaction. Thus, a combination of these methods can provide 
the accurate quantitative information about the binding affinity between the 
interacting partners in a protein complex. They also allow us to explore the interaction 
on the molecular level and obtain parameters such as the order of the binding kinetics, 
the kinetic rate constants and the thermodynamics of the interactions (including 
independent measurements of ∆G, ∆S and ∆H).  
Hemextin AB complex specifically and non-competitively inhibits the TF-FVIIa 
complex with a Ki of 25 nM. Further, it inhibits FVIIa in the absence of TF and FX 
(Banerjee et al., 2005c;Banerjee et al., 2005d). Thus, unlike TFPI and NAPc2, this 
unique complex neither requires FX scaffold nor does it bind to the active site of 
FVIIa. Also, it is the only known snake venom hetero-tetrameric protein complex 
formed by the interaction between two three-finger toxins. Thus, hemextin AB 
complex is both structurally and functionally unique. In this chapter, we have 
investigated the molecular interactions involved in the assembly of this unique 
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anticoagulant complex. In particular, the role of electrostatic and hydrophobic 
interactions in complex formation has been examined. The anticoagulant complex has 
identical molecular diameter in both gas and solution phases. ITC studies reveal that 
complex formation is entropically unfavored, which indicates the reduced structural 
flexibility of the complex.  Hemextin AB assembly is an enthalpically driven process, 
with some conformational changes accompanying the complex formation. The 
tetrameric complex behaves differently in buffers of higher ionic strength. It is also 
sensitive to the presence of glycerol in the buffer solution. Thus, a complex interplay 
of electrostatic and hydrophobic interactions drives the formation and stabilization of 
this novel anticoagulant protein complex. Based on our observations, we propose a 
model for the assembly of hemextin AB complex.  
MATERIALS AND METHODS 
CD spectroscopic studies – Far UV CD spectra (260-190 nm) were recorded using a 
Jasco J-810 spectropolarimeter (Jasco Corporation, Tokyo, Japan). All measurements 
were carried out at room temperature using 0.1 cm path-length stoppered cuvettes. 
The instrument optics was flushed with 30 l/min of nitrogen gas. The spectra were 
recorded using a scan speed of 50 nm /min, resolution 0.2 nm, and band width 2 nm. 
For each spectrum, a total of six scans were recorded, averaged and baseline 
subtracted. Conformation of hemextin A and hemextin B at different concentrations 
were monitored in 50 mM Tris-HCl buffer (pH 7.4). To study the complex formation, 
titration experiments were carried out by keeping the concentration of the hemextin A 
constant at 0.5 mM, and varying the concentrations of hemextin B. 
 Determination of molecular diameters – The apparent molecular diameters of the 
hemextin AB complex and the individual hemextins were determined in both the gas 
and solution phases.   
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(A) Gas Phase Electrophoretic Mobility Macromolecule Analyzer (GEMMA) – The 
molecular diameters in the gas phase were determined with GEMMA (Loo et al., 
2005) using a nano-differential mobility analyzer, model 3980 (TSI, St Paul, MN, 
USA), and a standard condensation particle counter type 3025 (TSI, St Paul, MN, 
USA). Since GEMMA is a considerably new technique for studying protein-protein 
interaction, a comprehensive sketch on the technique is provided below. 
 GEMMA works on the principles of aerosol physics of nanometer-sized particles 
(Knutson EO and Whitby KT, 1973a;Knutson EO and Whitby KT, 1973b). In this 
technique, protein molecules are treated as nearly spherical particles and their 
electrophoretic mobility (EM) in air is measured. Using the Millikan’s equation, 
which establishes a correlation between the analyte diameters to the singly charged 
particle mobility in air (Tammet H., 1995), a spectrum of particle concentration 
versus an equivalent EM diameter is plotted. In order to measure the EMs in a laminar 
stream of air, protein molecules are first transferred into the gas phase at atmospheric 
pressure. Charged droplets are produced by an electrospray process from an aqueous 
buffer containing the sample. The electrospray conditions are selected in such a way 
that the mean number of protein molecules per generated charged aerosol droplet is 
below unity. The mono disperse droplets are ‘dried’ and charge-reduced to produce 
singly charged positive or negative molecular ions. These ions are separated 
according to their electrophoretic mobilites (EMs), by a differential mobility analyzer 
(DMA).(Kousaka Y et al., 1985) Depending on the applied air flow rate and voltage, 
ions with certain mobility leave the DMA and are detected by a condensation particle 
counter (CPC). Finally, the number of detected ions is plotted against the inverse EM 
of ions. A schematic representation of the system is depicted in Figure 4.1. 
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Figure 4.1 Schematic representation of different parts of GEMMA 
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In this study the instrument was operated in the ‘cone jet’ mode with an operating 
voltage between 2.5 and 3.0 kV, resulting in currents from 200 to 300 nA. Filtered 
ambient air at 2 l/min and a concentric sheath gas flow of filtered CO2 at 0.1 l/min 
was used to stabilize the electrospray against corona discharge. Sample solutions of 
hemextin A (4 ng/ml) and hemextin B (4 ng/ml) were prepared in 20 mM ammonium 
acetate (pH 7.4) immediately prior to the experiment. Hemextin AB complex (4.5 
ng/ml) was reconstituted in the above buffer and was incubated at 37˚C for 10 min. 
Another three-finger protein, toxin C isolated and purified from the same venom was 
used as a control in the GEMMA experiments. The samples were infused into the 
electrospray chamber with an inlet flow rate of 100 nl/min. Twenty scans over the 
whole EM diameter range (0 to 25 nm) were recorded and averaged to obtain a 
GEMMA spectrum. No smoothing algorithm was applied for the data presentation. 
(B) DLS – Complex formation studies with DLS were carried out at 25 °C using a 
BI200SM instrument (Brookhaven Instruments Corporation, Holstvile, NY, USA). A 
vertically polarized argon ion laser (514.2 nm, 75 mW; NEC model GLG-3112) was 
used as the light source. Sample solutions of hemextin A (4 mM), hemextin B (4.1 
mM) and hemextin AB complex (4.6 mM) in 50 mM Tris-HCl buffer (pH 7.4), were 
prepared immediately prior to the experiment. The hydrodynamic diameter for the 
hemextin AB complex and the individual hemextins were recorded at 25 ºC in 
solutions of different ionic strengths and at different glycerol concentrations. The 
ionic strengths were varied by the addition of NaCl. From the measured translational 
diffusion coefficient (DT), the hydrodynamic radius (RH) can be calculated using the 
Stokes-Einstein relation:  
DT = kBT/6πηRH…………………….. (Eq. 1), 
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where, kB is the Boltzmann constant, T is the temperature in Kelvin and η being the 
viscosity of the solvent. The intensity-intensity time correlation functions were 
obtained with a BI-9000 digital correlator equipped with the instrument. The particle 
size and size distribution were obtained by analyzing the field correlation function 
│g(1)(τ)│using constrained regularized CONTIN method (Provencher, 1976). 
Thermodynamics of hemextin AB complex formation – ITC experiments were 
performed using a Microcal VP-ITC calorimeter (Microcal LLC, Northampton, MA) 
to study the thermodynamics of the formation of hemextin AB complex. Unless 
otherwise noted, all experiments were performed in 50 mM Tris-HCl buffer (pH 7.4). 
Both the proteins were dissolved in the same buffers, filtered and degassed prior to 
titration. Hemextin A (0.1 mM) was kept in the sample cell and hemextin B (1 mM) 
was loaded into the syringe. The syringe stirring speed was set to 300 rpm. Data were 
collected in high feedback mode, with a filter period of 3 s. For each experiment, a 
control titration was performed by injecting hemextin B into the appropriate buffer. 
Finally, the control data were subtracted from the raw data to obtain an isotherm 
corrected for heats of dilution. The first injections presented defects in the baseline 
and these data points were not included in the fitting process. The calorimetric data 
were processed and fitted to the single set of identical sites model using Microcal 
Origin (Version 7.0) data analysis software supplied with the instrument. The 
expression for the heat released per injection, ∆Q(i), is given by 
 
∆Q(i) = Q(i) + dVi /2V0[Q(i) + Q(i-1)] – Q(i- 1)...............(Eq. 2), 
where Q(i) is the total heat content, dVi is the volume injected at the ith injection, and 
V0 is the cell volume. The total heat content Q of the solution (determined relative to 
zero for the un-liganded species) contained in the V0, was calculated according to 
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Equation 3, where KA is the binding affinity constant, n is the number of sites, ∆H is 
the enthalpy of ligand binding, Mt and Xt is the bulk concentration of macromolecule 




























0 ................(Eq. 3) 
The change in heat (∆Q) measured between the completions of two consecutive 
injections is corrected for dilution of the protein and ligand in the cell according to 
standard Marquardt method (Levenberg, 1944;Marquardt, 1963). The free energy 
change (∆G) during the interaction was calculated using the relationship: (∆G = ∆H – 
T∆S = - RT ln Ka). All the experiments were performed at 37 °C unless otherwise 
indicated.   
The role of electrostatic interactions in the complex formation was evaluated by 
performing ITC experiments in 50 mM Tris-HCl buffer of various ionic strengths. 
The ionic strengths of the buffers were altered by adding sodium chloride (NaCl) (35 
mM to 150 mM). To study the role of hydrophobic interactions in the complex 
formation, experiments were performed in 50 mM Tris-HCl buffer (pH 7.4) 
containing various concentrations of glycerol (125 mM to 250 mM). Glycerol has 
been shown to form hydration layer around proteins, nullifying the hydrophobic 
interactions (Liu et al., 2004b). To study the effects of protonation on complex 
formation; additional calorimetric experiments were performed in PBS (pH 7.4) or in 
10 mM MOPS (pH 7.4).  
Size-exclusion chromatography (SEC) studies – All SEC experiments were carried out 
at room temperature on a pre-packed Superdex 75 gel filtration column (1.6 × 60 cm) 
using a ÄKTA Purifier system (Amersham Biosciences, Uppsala, Sweden). The 
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column was eluted with 50 mM Tris-HCl buffer (pH 7.4) or the specified elution 
buffer, at a flow rate of 1 ml/min. The sample volume applied to the column was 4 ml. 
The column was calibrated using ovomucoid (28 kDa) ribonuclease (15.6 kDa), 
cytochrome C (12 kDa), apoprotinin (7 kDa) and pelovaterin (4 kDa) 
(Lakshminarayanan et al., 2005) as molecular weight markers. The void volume was 
determined by running Blue Dextran. The column was equilibrated with at least two 
bed volumes of the elution buffer prior to each run. Electrostatic contributions in the 
hemextin AB complex formation were studied by monitoring its elution in 50 mM 
Tris-HCl buffer (pH 7.4) with different concentrations of NaCl (75 mM and 150 
mM). Hydrophobic contributions for the complex formation were determined by 
recording the elution of hemextin AB complex in 50 mM Tris-HCl buffer (pH 7.4) 
with different concentrations of glycerol (125 mM and 250 mM). In both the studies, 
the column was first equilibrated with the desired buffer prior to the application of the 
reconstituted hemextin AB complex in the respective buffer to the column.  The 
protein elution was monitored by recording absorbance at 280 nm. 
Anticoagulant activity – The anticoagulant activity of individual hemextins and 
hemextin AB complex were determined using prothrombin time clotting assay (Quick 
AJ., 1935). The anticoagulant activity of a specific concentration of hemextin A (4.4 
µM), hemextin B (4.4 µM) and hemextin AB complex (0.22 µM) was monitored in 
50 mM Tris-HCl (pH 7.4) containing different concentrations of NaCl (35 mM to 150 
mM for studying the role of electrostatic interactions) and glycerol (125 mM to 250 
mM for studying the role of hydrophobic interactions). The concentrations of 
hemextin A and hemextin AB complex were chosen in a way such that in the absence 
of salt/glycerol the recorded clotting times are similar. Control experiments were 
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performed without the addition of the anticoagulant proteins to evaluate the effect of 
salt and glycerol on clotting. 
1D-NMR spectroscopy – One-dimensional proton NMR experiments were carried out 
using Bruker 700 MHz spectrometer, equipped with a modern cryo-probe, and 
electronic variable temperature unit. The spectra were acquired using Topspin 
software (Bruker) interfaced to the spectrometer.  Hemextin A (0.5 mM) and hemextin 
B (0.5 mM) were prepared in 50 mM Tris-HCl buffer (pH 7) and transferred to a 5 
mm diameter Willmad NMR tube. All deuterated solvents were purchased from 
Aldrich Laboratories with 99.9% isotopic purity. The spectral width was set to 11,202 
Hz for all NMR experiments. The huge resonance due to the water protons was 
suppressed by the WATERGATE pulse sequence (Piotto et al., 1992). Typically, 512 
scans were averaged for each FID before apodization and then performing the Fourier 
transformation. 1H chemical shifts were referenced to a sodium 2,2-dimethyl-2-
silapentane-5-sulfonate solution (DSS).  
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RESULTS AND DISCUSSION
Conformational changes during complex formation – In chapter 3, it was shown using 
clotting and kinetic assays that, hemextin A and hemextin B interact with each other 
and form a 1:1 heterotetrameric complex and this complex formation is important for 
its ability to inhibit FVIIa and clot initiation.  
To study the conformational changes associated with the hemextin AB complex 
formation we used far UV-CD. First, we recorded the CD spectra of individual 
hemextins A and B (Figure 4.2, A and B). Their CD spectra display negative minima 
at 217 nm and  positive maxima at 196 nm, which are due to the n to π∗ transition and 
the π to π∗ transition of the amide chromophore, respectively, typical of a β-sheet 
structure (Figure 4.2, A and B).  
Next, a titration CD experiment was performed in order to study the complex 
formation between the two proteins. In this experiment, the concentration of hemextin 
A was kept constant at 0.5 mM and the conformational changes in hemextin A in the 
presence of various concentrations of hemextin B were recorded. The shape of the CD 
spectrum upon addition of hemextin B to hemextin A did not change significantly 
(Figure 4.2C). However, the CD intensity at 217 nm increases with the incremental 
addition of hemextin B and reaches maximum at the 1:1 molar ratio suggesting 
stoichiometric binding of hemextin B to hemextin A (Figure 4.2D). The difference 
spectrum obtained by subtracting the CD spectrum of 1:1 complex from the sum of 
the CD spectra of hemextin A and hemextin B indicates the formation of additional β-
sheet structure or the stabilization of β-sheet structure during the complex formation 
(Figure 4.3).  
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40 Hemextin A 1 mM
Hemextin B 1 mM[A] constant 0.5 mM
Hemextin B 0.25 mM
Hemextin B 0.3 mM
Hemextin B 0.4 mM
Hemextin B 0.5 mM
Hemextin B 0.7 mM


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.2 Conformational changes associated with the formation of hemextin AB 
complex.   CD spectra of (A) hemextin A and (B) hemextin B at various protein 
concentrations are shown. The conformational changes due to the aggregation at higher 
concentrations are marked with arrows. (C) Conformational changes in hemextin A with 
increasing concentrations of hemextin B. (D) CD change in hemextin A at 217 nm with 
increasing concentrations of hemextin B. No significant changes in CD spectra were observed 
with further addition of hemextin A after the ratio of hemextin A to hemextin B reached 1:1 

















































Figure 4.3 Conservation of β-sheet after complex formation. The difference spectrum 
obtained by subtracting the CD spectrum of 1:1 complex from the sum of the CD spectrum of 
hemextin A and hemextin B. (Note the conservation of β-sheet structure in the complex, 
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Changes in molecular diameters during the complex formation – The diameter of the 
individual hemextins and hemextin AB complex were determined in both gas and 
solution phases.   
In the gas phase analysis using GEMMA, hemextin A and hemextin B showed the 
apparent molecular diameters of 10.20 ± 0.38 nm and 8.82 ± 0.42 nm, respectively 
(Figure 4.4). Hemextin AB complex exhibited a larger diameter of 16.30 ± 0.43 nm. 
To further confirm on the GEMMA results, we examined the effect of toxin C, 
another three-finger toxin isolated from the venom of H. haemachatus, on the 
molecular diameters of hemextins A and B, to determine the specificity of interaction. 
Toxin C did not affect the anticoagulant activity of hemextin A in prothrombin time 
clotting assay (data not shown) and did not form a complex with hemextin A. At 
equimolar concentration of toxin C, the molecular diameter of hemextin A or 
hemextin B remains unaffected (Figure 4.3).  
The solution phase studies with DLS also confirmed the increase in molecular 
diameter associated with the complex formation. Single scattering populations 
(unimodal distribution) for hemextin A, hemextin B and hemextin AB complex were 
observed in DLS suggesting the homogeneity of the sample preparations with 
hydrodynamic diameters of 10.3 nm, 9.9 nm and 16.8 nm, respectively (Figure 4.5). 
The narrow size distribution of a single monodisperse species for 1:1 mixture of 
hemextin A and hemextin B suggests the formation of a well-defined complex. It is 
important to note that the tetrameric hemextin AB complex and individual hemextins 
exhibited comparable molecular diameters in both gas and solution phases. The 
apparent molecular dimensions are significantly larger than the theoretical diameter 
estimated for a native protein and much smaller than the estimated length of the 
proteins in completely “extended conformation” (Lu et al., 1998;Wilkins et al., 1999).  
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Figure 4.4 Measurement of molecular diameter during Hemextin AB complex formation 
using GEMMA. The molecular diameters of the individual hemextins and the hemextin AB 
complex are calculated based on their electrophoretic mobility. The formation of hemextin 
AB complex leads to an increase in the molecular diameter. Addition of equimolar toxin C 
does not show any significant increase in the molecular diameters of hemextin A and 
hemextin B validating the obtained data. 
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Figure 4.5 Determination of hydrodynamic diameter using DLS. A. CONTIN analysis hemextin A, hemextin 
B and hemextin AB complex in 50 mM Tris-HCl  buffer. Note the formation of the hemextin AB complex leads 
to an increase in the hydrodynamic diameter. 
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Such an anomaly could be due to the non-globular conformation of the proteins 
(Longhi et al., 2003).  The molecular diameter of hemextin AB complex is, however, 
much smaller compared to the estimated size of a tetramer indicating that the four 
monomers are compactly packed. 
Thermodynamics of hemextin AB complex formation — ITC was used to study the 
thermodynamics of hemextin AB complex formation. Each injection gave rise to 
negative (exothermic) heat of reaction (Figure 4.6). The binding isotherm fits to a 
single set of binding sites model, suggesting an equimolar binding between hemextin 
A and hemextin B. The interaction between them is thermodynamically allowed (as 
indicated by negative ∆G) (Table 4.1). A favorable negative ∆H but unfavorable 
negative ∆S changes indicate that the complex formation is enthalpically driven and, 
van der Waals interactions and hydrogen bonds may play an important role in the 
complex formation. Also, the formation of a less dynamic complex is entropically 
disfavored, as has been observed in the studies pertaining to the dimerization of 
insulin (Tidor and Karplus, 1994). Thus the recorded negative entropic change (∆S) 
indicates the formation of a less flexible or less disordered hemextin AB complex. 
The binding constant (KA) for the formation of hemextin AB complex was 2.23 x 106 
M-1 and it falls within the KA values for protein-protein interactions in biologically 
relevant processes that range from 104 to 1016 M-1 (Stites, 1997b). 
The effect of temperature on the complex formation — To further understand 
energetics of the complex formation, complete temperature profile of the 
thermodynamic parameters associated with the binding of hemextin A to hemextin B 
was studied over the temperature range of 25-45 °C. The temperature dependence of  
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Figure 4.6 Interaction studies between hemextin A and B using ITC. (A) Raw ITC data 
showing heat release upon injections of 1 M hemextin B into a 1.4-ml cell containing 0.1 mM 
of hemextin A; (B) Integration of the raw ITC data yields the heat/mol versus molar ratio. The 
best values of the fitting parameters are 1.04 for N, 2.23 × 106 M-1 for Ka and -11.68 kcal.M-1 

















Effect of temperature on hemextin A-hemextin B interaction 
 
ITC experiments KA × 106 (M-1)  ∆H (kcal/mole)  ∆S (cal/deg.mole)  ∆G (kcal/mole)  
At different temperatures 
(°C)     
25 2.07  -9.928  -4.435  -8.606  
37 2.23  -11.68 -8.645  -9.225  
45 1.97 -13.127  -12.49  -9.001  
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∆H is shown in Figure 4.7A and Table 4.1. The temperature dependence of ∆H over a 
narrow temperature range is given by the equation: 
∆H = ∆H0 + ∆Cp(T-T0)..........................(Eq. 4) 
 
where, ∆H0  is the binding enthalpy at an arbitrary reference temperature and ∆Cp is 
the heat capacity change of binding. The ∆Cp obtained from the slope (∆Cp = δ∆H 
/δT) (Figure 4.7A), is -163 cal/K-1mol-1. Negative ∆Cp indicates a reduction in the 
nonpolar solvent-accessible surface area, as explained by the following equation 
(Murphy and Freire, 1992), 
∆Cp = 0.45(∆ASAnonpol) – 0.26 (∆ASApol) cal /molK ..............(Eq. 5) 
where, ∆ASApol and ∆ASAnonpol are the change in the polar- and non-polar-accessible 
surface areas, respectively. Thus, hemextin AB complex formation is associated with 
the burial of hydrophobic surface area.    
Figure 4.7B, shows the plot of ∆G and ∆H as a function of T∆S. It is clear that the ∆G 
of binding remained temperature independent and is a result of linear dependence of 
∆H on T∆S. This strongly suggests the enthalpy-entropy compensation for the binding 
of hemextin A to hemextin B.  This phenomenon is a universal feature for protein-
peptide interactions, where weak molecular interactions undergo constant 
rearrangements to realize a lower free energy of binding (Schwarz et al., 1995;Sharma 
et al., 2002;Perozzo et al., 2004;Prabhu and Sharp, 2005). The co-relation between 
entropy and enthalpy for a range of interacting protein-protein systems was 
determined (r2 = 0.956). The data for hemextin AB complex falls well along this 
correlation line (Figure 4.8). 
The negative ∆Cp indicates the net thermodynamic driving force for the association to 
shift from entropic to enthaplic with increasing temperature. At the intersection point 
of both lines ∆G = ∆H = -8.4 kCal.mol-1 (Figure 4.7B), which corresponds to a
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Figure 4.7 Thermodynamics of hemextin A-hemextin B interaction. (A) Effect of 
temperature on the energetics of hemextin A-hemextin B interaction: enthalpy change (∆H), 
change in entropy term (T∆S) and free energy change (∆G). (B) Enthalpy-entropy 
compensation in complex formation. (Note: Point of intersection of lines corresponding to ∆H 
and ∆G corresponds to Ts) 
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Figure 4.8 Enthalpy-entropy compensation. Enthalpy-entropy compensation in various 
protein-protein interactions described in the literature (O) (Data were taken from Ye and Wu 
(Ye and Wu, 2000), McNemar et al. (McNemar et al., 1997) and references sited in the 
review by Stites (Stites, 1997a)  and hemextin A-hemextin B (●) interactions (this chapter) 
are shown. Inset shows the enthalpy-entropy compensation in hemextin A-hemextin B 
interaction. 
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temperature Ts (Temperature at which the contribution from entropy is zero (von 
Hippel, 1994;Spolar and Record, Jr., 1994). At Ts the contribution from entropy 
changes from favorable to unfavorable. From Figure 5A, ∆H = -8.4 kCal.mol-1 is 
connected with a Ts of 16 °C (289 °K).  
The negative ∆Cp for the hemextin AB complex formation further suggests that the 
observed entropy change upon binding must include significant contribution from the 
hydrophobic effect in the physiological temperature range. Therefore, for protein-
protein/ligand interaction(s) the net entropy of association is given by the 
equation:               
∆S assoc =  ∆SHE + ∆ Srt +  ∆ Sother ........................(Eq. 6) 
where, ∆SHE,  ∆Srt, and ∆Sother are the entropy changes due to hydrophobic effect, 
reduction of rotational and translational degree of freedom, and from other sources, 
respectively.  
At Ts, the overall entropy of association is zero and the above equation becomes:  
∆S assoc=  ∆SHE (Ts) + ∆Srt +  ∆Sother = 0 ........................(Eq. 7)  
In the absence of crystallographic data, the ∆SHE(Ts) was estimated from the equation,   
∆SHE(Ts) = 1.35 ∆Cp ln(Ts/386)...........................................(Eq. 8) 
and found to be 64 cal deg-1 mol -1. It has been shown that protein-protein interaction 
∆Srt is nearly equal to -50 cal deg-1 mol-1 (Janin and Chothia, 1978;Finkelstein and 
Janin, 1989). Thus the ∆Sother is calculated to be -14 cal deg-1 mol-1. The non-zero 
value of ∆Sother suggests that the hemextin AB complex formation is not a rigid-body-
association but formed through local unfolding and refolding during binding 
interaction. Again, Ψ = ∆Sother/ -5.6 cal deg-1 mol-1, where Ψ designates the number  
amino acid residues involved in the folding transition (Hilpert et al., 2003). Therefore, 
approximately three residues are involved in the folding transition. Also, From Figure 
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4.7B, the enthalpic counterpart of TS, namely TH, the temperature at which the 
enthalpic contribution to the Gibbs free energy of binding changes from favorable to 
unfavorable is calculated to be 244 °K. Therefore, below -29 °C the binding process is 
entropically driven and only in the interval between TS and TH (i.e., between -29 °C 
and 16°C), both the entropic and enthalpic part of the Gibbs free energy of binding are 
favorable. 
The effect of buffer ionization on the complex formation — The observed calorimetric 
enthalpy is a result of the binding event in addition to all the associated events (water 
a(di)ssociation, ionization of the components, heats of dilution, heats of mixing, etc). 
To facilitate binding, residues at the interface may be protonated or deprotonated, 
resulting in the exchange of protons with the buffer. Under such circumstances, as 
calorimetric enthalpy is dependent on the buffer ionization enthalpy, calorimetric 
titrations were also performed in phosphate and MOPS buffers at pH 7.4. An increase 
in the enthalpy change (∆Hobs) was observed with an increase in the change of buffer 
ionization enthalpy (∆Hion) on the complex formation. A plot of calorimetric enthalpy  
against ionization enthalpy yielded the number of protons (nH+) involved in the 
interaction, and the binding enthalpy was corrected for protonation effects (∆Hbin) 
according to the following relationship: 
∆Hobs = ∆Hbin + nH+.∆Hion ..................(Eq. 9) 
A positive slope indicates propensity for the uptake of protons from the buffer, 
whereas a negative value indicates propensity for the release of protons into the buffer. 
The plot (Figure 6A) yielded an nH+ value of – 0.57 and a binding enthalpy (∆Hbin) of 
–3.638 kcal/mole for the complex formation. Thus, hemextin AB complex formation 
is associated with a net release of protons into the buffer. 
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Figure 4.9 Effect of buffer ionization on the enthalpy for hemextin AB complex 
formation. All experiments were performed at pH 7.4. Ionization enthalpy changes used for 
buffers were 0.71 kcal/mol for phosphate, 5.27 kcal/mol for MOPS, and 11.3 kcal/mol for 
Tris (Katragadda et al., 2004) 
 139
Biophysical characterization of hemextin AB complex 
 
Oligomerization states of the anticoagulant complex and individual hemextins – As 
highlighted in Chapters 2 and 3, hemextin AB complex exists as a tetramer and the 
complex formation is pivotal for its potent anticoagulant activity (Banerjee et al., 
2005a). Therefore, we evaluated the role of both electrostatic and hydrophobic 
interactions in complex formation. 
(A) Electrostatic interactions in hemextin AB complex formation – Firstly, the binding 
constant for hemextin AB complex formation was determined by ITC in buffers of 
increasing ionic strength. The log KA values for the complex formation decreased 
linearly with the increasing NaCl concentration (Figure 4.10B, Table 4.2), illustrating 
the participation of electrostatic interactions in complex formation.  Secondly, the 
effect of buffer ionic strength on the assembly of hemextin AB complex was 
examined with the help of SEC. In the absence of salt, the complex eluted as a 
tetramer and the individual hemextins as monomers (Figure 4.11A). In the presence of 
75 mM NaCl the tetramer started dissociating into dimer (Figure 4.11B). With further 
increase in ionic strength of the buffer (NaCl 150 mM) the complex eluted mostly as a 
dimer and monomer(s). ESI-MS and HPLC analyses of the dimer peak indicated that 
it contains both hemextins A and B (data not shown). This observation again 
reconfirms the importance of electrostatic interactions in hemextin AB assembly. 
Interestingly, an additional protein peak eluted slower than the monomers indicating 
hemextin A and/or hemextin B was undergoing a conformational change in buffers of 
high ionic strength. Therefore, we monitored the elution profiles of individual 
hemextins in buffers of high ionic strength. Hemextin A at 75 mM NaCl 
concentration showed two peaks; a second protein peak eluted slower than the 
monomer (Figure 4.11B). With further increase in the ionic strength (NaCl 150 mM)  
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Figure 4.10 ITC studies in buffer of high ionic strength. (A) Representative thermogram of 
hemextin A – hemextin B interaction with corresponding binding isotherm in 50 mM Tris-
HCl buffer (pH 7.4) containing 150 mM NaCl. (B) Dependence of KA on the ionic 
strength of the buffer. The binding affinity decreases with the increase in buffer ionic 
strength indicating the importance of electrostatic interactions. 
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Effect of increasing ionic-strength on hemextin A-hemextin B interaction 
 
ITC experiments KA × 106 (M-1)  ∆H (kcal/mole)  ∆S (cal/deg.mole)  ∆G (kcal/mole)  
At different salt 
concentrations (mM)     
0.00 2.23 -11.7 -8.645 -9.0 
35 0.63  -10.5  -7.2  -8.2 
75 0.33 -9.32 -4.8 -7.8 
100 0.02  -7.31 -3.82  -6.12  
150 0.002 -5.01  -1.2  -4.6  



















Figure 4.11 SEC studies of Hemextin AB complex in buffer of high ionic strength. A. 
Elution profiles of hemextin AB complex in Tris-HCl buffer. Effect various concentrations of 
NaCl (B) on hemextin AB complex. The tetrameric complex (peak denoted by 4) dissociates 
into dimer and monomer (peaks denoted by 2 and 1, respectively) with the increase in salt. 
Asterisk denotes the peak containing conformationally altered hemextin A. (C) Calibration of 
the column using the following proteins as molecular weight markers – ovomucoid (28 kDa), 
ribonuclease (15.6 kDa), cytochrome C (12 kDa), apoprotinin (7 kDa) and pelovaterin (4 
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hemextin A eluted mostly in the second peak. ESI-MS and HPLC analyses of this 
second peak show that it is structurally intact hemextin A (data not shown). Thus, the 
change in the elution profile of hemextin A in buffers of higher ionic strength hinted a 
conformational change in the protein, which was further confirmed by 1D NMR 
studies (see below). Increased ionic strength of buffer did not have any effect on the 
elution of hemextin B (Figure 4.11A and B).  
We also determined the hydrodynamic diameters of hemextin AB complex and 
individual hemextins in buffer solutions of high ionic strength using DLS (Figure 
4.12). (As GEMMA works on the principle of nano-ESI, we did not determine the 
molecular diameters in buffers containing high salt using this technique.). At high salt 
concentrations, the hemextin AB complex exhibits a high polydispersity indicating 
the presence of different species. At 75 mM NaCl, there are three different 
populations. In addition to the monomer(s) and the tetramer, there is an additional 
population with an apparent molecular diameter of 12.4 nm. Based on our SEC results 
(Figure 4.11B), we suggest that the 12.4 nm species could be the dimeric hemextin 
AB complex. As expected, the population of 12.4 nm species increases when the 
concentration of NaCl is increased to 150 mM (Figure 4.12). Thus DLS data also 
suggests the dissociation of the tetrameric complex to a dimer. As expected, 
polydispersity was also observed with hemextin A in buffers of high ionic strength 
(Figure 4.12).  An additional population of 11.57 nm sized particle, in addition to its 
native size of 10.4 nm is observed. Based on the SEC (Figure 11B) and 1D-NMR (see 
below), we suggest that the 11.57 nm species represents the conformationally altered 
form of hemextin A. No change in the hydrodynamic diameter of hemextin B was 
observed with the increase in buffer ionic strength (Figure 4.12).   
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Figure 4.12 Determination of hydrodynamic diameter using DLS. CONTIN analysis 
hemextin A, hemextin B and hemextin AB complex in 50 mM Tris-HCl buffer and at 
different NaCl concentrations. The calculated hydrodynamic diameters for each molecular 
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To understand the implications of the change in conformation of hemextin A and the 
breakdown of tetrameric complex, we monitored the anticoagulant activity of the 
complex and individual hemextins in buffers of high ionic strengths. Higher 
concentration of NaCl did not affect the anticoagulant activity of hemextin A (Figure 
4.13). Thus despite the change(s) in conformation (see below), hemextin A retains its 
anticoagulant activity. The anticoagulant activity of hemextin AB complex, in 
contrast, decreased with the increase in ionic strength up to 100 mM NaCl (Figure 
4.13). However, further increase in the salt concentration did not significantly affect 
the anticoagulant activity. At 150 mM NaCl the complex exists as a mixture of a 
dimer, monomer(s) and conformationally altered hemextin A as is evident from the 
SEC experiments (Figure 4.11B). Therefore, the remaining anticoagulant activity 
observed at 150 mM or higher NaCl concentration is due to the presence of 
monomeric hemextin A and not due to dimeric hemextin AB complex. Hence, it can 
be concluded that the dimer formed at high salt concentrations does not have any 
significant anticoagulant activity.  
Thus, these studies in buffers of high ionic strength strongly suggest that electrostatic 
interactions play crucial role in the assembly of hemextin AB complex. As hemextin 
A undergoes conformational change(s) in the presence of salt (see below), the 
dissociation of tetramer in a buffer of high ionic strength may not only be due to the 
disruption of electrostatic interaction but also due to conformational change(s) in 
hemextin A. Further, high salt concentration leads to the formation of a dimer which 
is functionally inert (in terms of lack of synergic increase in anticoagulant activity). 
Based on the obtained results, we hypothesize that the dimer assembled at 150 mM 
NaCl concentration is probably formed by the interplay of predominantly 
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Figure 4.13 Effect of buffer ionic strength on anticoagulant activity. Effect various 
concentrations of  NaCl on the anticoagulant activity of hemextin A (O), hemextin B (•), 
hemextin AB complex (▲). The anticoagulant activity of hemextin AB complex decreases 
with the increase in concentrations of NaCl and glycerol. The arrow inside the plot indicates 
the concentrations of NaCl where the anticoagulant complex exists mostly as a mixture of 
dimer and monomers (see text for details). (■) denotes the anticoagulant activity recorded in 
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hydrophobic interactions. Therefore, successive experiments were carried out to 
evaluate the importance of hydrophobic interactions in the complex formation.  
(B) Hydrophobic interactions in the hemextin AB complex formation – We carried 
out ITC experiments in buffers containing increasing concentrations of glycerol. 
Glycerol has been shown to form a ‘hydration’ layer around the proteins, thereby 
inhibiting hydrophobic interactions (Liu et al., 2004c). This behavior of glycerol is 
evident because of the fact that it increases the osmotic second virial co-efficient 
(B22).  B22, formally defined by: 
∫ Ω−∆−−= dkTGMWB er )1)(exp(16 1 int2222 π , where 
∆Ginter represents the interaction energy (potential of mean force) acting between two 
protein molecules in solution, MW is the molecular weight of the protein(s), and the 
dΩ indicates that the integral is carried out over all possible relative orientations of 
the two.  A positive or an increase in B22 reflects overall repulsive forces between 
protein molecules, where protein solutions are stable; a negative or a decrease B22, on 
the other hand indicates overall interprotein attraction that favors fluid-fluid phase 
separation. These observations have been made in case of the studies depicting the 
effect of monohydric and polyhydric alcohols including glycerol on the self 
interaction of hen-egg lysozyme (Liu et al., 2004a).  
A decrease in the association constant was observed with the increase in glycerol 
concentration (Figure 4.14 and Table 4.3), showing the importance of hydrophobic 
interactions in the complex formation. We monitored the elution of hemextin AB 
complex in buffers containing glycerol on a Superdex 75 column (Figure 4.15B). In 
buffers containing high glycerol concentration the tetramer dissociates into dimer and 
monomers. ESI-MS and HPLC analyses of the dimer peak indicate that it contains 
both hemextins A and B (data not shown). However, no additional peak 
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Figure 4.14 ITC studies in buffer of high glycerol concentration. (A) Representative 
thermogram of hemextin A – hemextin B interaction with corresponding binding isotherm in 
50 mM Tris-HCl buffer (pH 7.4) containing 250 mM glycerol. (B) Dependence of Ka on the 
glycerol concentration. The binding affinity decreases with the increase in glycerol 
concentration indicating the importance of hydrophobic interactions 
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Effect of increasing glycerol concentrations on hemextin A-hemextin B interaction  
 
ITC experiments KA × 106 (M-1)  ∆H (kcal/mole)  ∆S (cal/deg.mole)  ∆G (kcal/mole)  
At different glycerol 
concentrations (mM)     
0.00 2.23 -11.7 -8.645 -9.0 
125 0.32  -10.8  -11.01  -7.6 
175 0.2 -10.5 -10.6 -7.2 
250 0.05  -9.4 -10.0  -6.4  

















Figure 4.15 SEC studies of Hemextin AB complex in buffer containing different 
concentrations of glycerol. A. Elution profiles of hemextin AB complex in Tris-HCl buffer. 
Effect various concentrations of glycerol (B) on hemextin AB complex. The tetrameric 
complex (peak denoted by 4) dissociates into dimer and monomer (peaks denoted by 2 and 1, 
respectively) with the increase in glycerol. (C) Calibration of the column using the following 
proteins as molecular weight markers – ovomucoid (28 kDa), ribonuclease (15.6 kDa), 
cytochrome C (12 kDa), apoprotinin (7 kDa) and pelovaterin (4 kDa). The molecular weights 
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Figure 4.16 Determination of hydrodynamic diameter using DLS. CONTIN analysis 
hemextin A, hemextin B and hemextin AB complex in 50 mM Tris-HCl  buffer and at 
different glycerol concentrations. The calculated hydrodynamic diameters for each molecular 
species are shown.  
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corresponding to altered conformation of hemextin A was observed. The elution of 
individual hemextins remained unaltered in the presence of glycerol (Figure 4.15B). 
The breakdown of hemextin AB complex in the presence of glycerol was also 
observed in the DLS studies (Figure 4.16). At 125 mM glycerol concentration, an 
additional population of 12.8 nm-sized species was observed in addition to the 
monomers and the tetrameric complex. Based on SEC studies, we propose that the 
12.8 nm species is a dimer. The 12.8 nm species increases with the increase in 
glycerol concentration (Figure 4.16). It is important to note that the apparent 
molecular diameter of this dimer is different from the dimer formed in buffers of high 
ionic strength (12.8 nm versus 12.4 nm; Figure 4.16 and 4.12). (As GEMMA works 
on the principle of nano-ESI, we did not determine the molecular diameters in buffers 
containing glycerol using this technique.). No polydispersity was observed in the case 
of individual hemextins in the presence of glycerol (Figure 4.16).  
To further understand the implication of the breakdown of hemextin AB complex in 
glycerol, we monitored its anticoagulant activity and that of the individual hemextins 
in buffers containing different concentrations of glycerol.  The anticoagulant activity 
of hemextin AB complex decreased with the increase in glycerol concentration 
(Figure 4.17). At 125 mM glycerol concentration there is no decrease in the 
anticoagulant activity. However, at 250 mM glycerol concentration (at which 
hemextin AB complex exists as a mixture of dimer and monomers; Figure 4.15B) 
there is a decrease in the anticoagulant activity. But this activity is higher than that of 
the anticoagulant effect of hemextin A alone. Therefore, we conclude that the dimer 
observed at 250 mM glycerol concentration exhibits the anticoagulant activity higher 
than hemextin A alone but lower than that of the tetramer. In other words, dimer 
formed in the presence of glycerol is different from the dimer formed in salt; the  
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Figure 4.17 Effect of glycerol on anticoagulant activity. Effect various concentrations of 
glycerol on the anticoagulant activity of hemextin A (O), hemextin B (•), hemextin AB 
complex (▲). The anticoagulant activity of hemextin AB complex decreases with the 
increase in the glycerol concentration. The arrows indicate the concentrations of glycerol 
where the anticoagulant complex exists mostly as a mixture of dimer and monomers (see text 
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former dimer exhibiting an increased anticoagulant activity compared to hemextin A 
alone, whereas the latter not doing so. Glycerol, however, did not affect the 
anticoagulant activity of individual hemextins (Figure 4.17). The dissociation of the 
tetramer into dimer and monomers in the presence of glycerol indicates the 
importance of hydrophobic interactions in the tetrameric complex formation. This is 
further supported by the negative ∆Cp change observed during the formation of 
hemextin AB complex. 
Our data strongly suggests that both electrostatic and hydrophobic interactions are 
important for the formation of tetrameric hemextin AB complex. To confirm that 
decrease in binding affinity between the monomers observed in salt and glycerol is 
not a solute osmotic effect, the KA recorded in salt and glycerol was plotted against 
osmotic pressure (Figure 4.18). At similar osmolality of salt and glycerol decrease in 
binding affinity was more pronounced in salt than glycerol. This indicates that fall 
binding affinity is due to disruption of either electrostatic (for salt) or hydrophobic 
(for glycerol) interactions. 
The effect of buffer conditions on the conformation of hemextins – Earlier 
studies using SEC (Figure 4.11B) and DLS (Figure 4.12) indicated that hemextin A 
undergoes conformational changes in the presence of salt. We conducted 1D-NMR 
analysis to study the conformation of hemextins A and B under different buffer 
conditions (Figure 4.19). In the presence of NaCl, there is a decrease in the number of 
Hα resonance peaks between 4.8 ppm and 6 ppm in the case of hemextin A (Figure 
19A). These chemical shifts contribute to the inter-residue NOE cross peaks between 
Hα of different amino acid residues forming anti-parallel β-sheet structure typically 
observed in all three-finger toxins. Thus a decrease in the β-sheet content of hemextin 
A is observed in the presence of NaCl. In addition, there are several changes in the  
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Figure 4.18 Evaluation of solute osmotic effect on binding affinity. The effect of solute 
osmolality (for NaCl and glycerol) on the binding affinity between the hemextin A and 
hemextin B was evaluated. Note that at similar osmolality of NaCl and glycerol, effect on 
binding affinity decreases more in the presence of NaCl than glycerol. This indicates that the 




































































































































































































































































































































































































































































































































































































































































































Biophysical characterization of hemextin AB complex 
 
chemical shifts of side chains. A notable change is a highly shielded methyl peak 
which appears at the negative chemical shift value (−0.38 ppm) in the presence of salt. 
These observations strongly support conformational changes in hemextin A in the 
presence of NaCl. The overall dispersion of 1D proton NMR spectra of hemextin A in 
the presence of glycerol (deuterated) remains the same with the subtle changes in the 
amide region (Figure 4.19A). Thus, hemextin A did not undergo any significant 
conformational change upon the addition of glycerol. Similar studies with hemextin B 
show that it did not undergo any significant conformational changes in the presence of 
NaCl or glycerol (Figure 4.19B) since there is almost one to one match for the 
spectral frequencies.  
Model for hemextin AB complex – Based on our studies we propose a model for the 
assembly of hemextin AB complex (Figure 4.20). Two molecules each of hemextin A 
and B form the tetrameric complex in Tris-HCl buffer (Figure 4.20A). The formation 
of this compact, synergistic complex is important for its anticoagulant activity. As 
illustrated earlier, hemextin AB dimer in high salt is different from the dimer formed 
in the presence of glycerol (Figure 4.20C). The former dimer has an apparent 
molecular diameter of 12.4 nm and lacks anticoagulant activity, whereas the latter has 
an apparent molecular diameter of 12.8 nm and exhibits slightly higher anticoagulant 
effects (Figure 4.20C). Thus, the breakdown of tetramer to dimer probably occurs in 
two different interfaces of interaction between hemextin A and B. One interface is 
sensitive to the ionic strength of its surroundings while the other is sensitive to 
glycerol (Figure 4.20C).  Further, in the presence of salt, hemextin A undergoes 
conformational changes (Figure 4.20B) which may interfere in the tetramer formation. 
The dimer formed under high ionic conditions lacks the complete synergistic 
anticoagulant site (marked by a dotted semicircle in Figure 4.20C). In contrast,  
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Figure 4.20 A proposed model of hemextin AB complex. A. Schematic diagram depicting 
the formation of hemextin AB complex. Hemextins A and B, two structurally similar three-
finger toxins, form a compact and rigid tetrameric complex with 1:1 stoichiometry. B 
(Banerjee et al., 2005b;Banerjee et al., 2005d). Schematic diagram showing the effect of salt 
and glycerol on conformations of hemextins A and B. Hemextin A undergoes a 
conformational change in the presence of salt. C. Dissociation of the tetrameric hemextin AB 
complex in the presence of salt and glycerol. The dissociation probably occurs in two 
different planes. Thus the hemextin AB dimer in high salt is different from the dimer formed 
in the presence of glycerol. Two putative anticoagulant sites are shown with dotted 
semicircles (See text for details). 
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hydrophobic interactions are predominant in the second interface. Therefore, glycerol 
dissociates the tetramer into dimers. However, in this case only minor changes occur 
in the synergistic anticoagulant site of the complex (as shown in Figure 4.20C) and 
hence the resultant dimer is active. We propose that the tetramer formation most 
likely stabilizes the anticoagulant site of hemextin A. The binding between hemextin 
AB complex/ hemextin A and FVIIa has been characterized to validate the proposed 
model, the details of which are provided in Chapter 5.  
CONCLUDING REMARKS 
Hemextin AB complex is the first synergistic anticoagulant complex isolated from 
snake venom comprising solely of two three-finger toxins – hemextin A and hemextin 
B. The complex formation is a pre-requisite for the synergistic inhibition of FVIIa. 
The complex exists as a tetramer; where as individual hemextins are monomers. The 
complex formation is an enthalpically driven process. Unfavorable entropic change 
associated with the complex formation, and identical apparent molecular diameters 
recorded in the gas and solution phases indicate that the complex has lesser structural 
flexibility in comparison to the monomers. The complex formation is associated with 
protein unfolding and refolding. Both electrostatic and hydrophobic interactions are 
important for the assembly of the tetramer. Based on our results we proposed that the 
tetramer formation takes place by the participation of two interfaces. One of the 
interfaces is sensitive to the buffer ionic strength, indicating that electrostatic 
interactions are predominantly active in that interface. The other being sensitive to B22 
of the solution indicates the participation of mostly hydrophobic interactions. The 
proposed model may help in a better understanding of the structure-function 
relationship of this novel anticoagulant complex. 
------------------------------------------------------------------------------------------------------- 
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Thank you note, 
 
The work described in this chapter is currently under consideration in the 
Biophysical Journal. During revision of the paper, the reviewers wanted me to show, 
that dissociation of the tetramer into dimer in salt/glycerol is not due to solute 
osmotic effect, but due to disruption of electrostatic (for salt) or hydrophobic (for 
glycerol) interactions. For the calculation of osmotic pressure, for a given 
concentration of salt or glycerol, the reviewers kindly proposed a website which was 
supposed to have the conversion tables. Unfortunately, the site was experiencing 
technical problems. Since the revised version of a manuscript is to be submitted 
within a stipulated period, I had no other means2, but to write to some of the 
scientists who are studying the effect of solute osmolality on biological molecules, for 
the conversion tables. Before I proceed to the next chapter, I will like to thank Dr. 
Jörg Rösgen (University of Texas Medical Branch), and Dr. Nina Sidorova and Dr. 
Donald Rau (NIH/NICHD/LPSB) for kindly providing me with the conversion 
tables, and also for helpful discussions on how the data should be analyzed. Because 
of their help, I was able to submit the revised version of the manuscript and also 
include the data on osmotic effect in this chapter.     
 






2 “The end does not justify the means, but justifiable means that bring about a fair and necessary 
conclusion are not to be dismissed”.   
   --- Joel Converse in Robert Ludlum’s The Aquitaine Progression (Pg 185) 
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“The scientific accomplishment of the Twentieth Century that I admire most is the 
revealing of the multifaceted capabilities of proteins and of their structures that 
make these capabilities possible.” 
--- Paul D. Boyer (“A Research Journey with ATP Synthase”J. Biol. Chem., 
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Molecular Interactions with FVIIa 
 Targeting proteases: successes, failures and future prospects1
--- Professor Boris Turk, Department of Biochemistry and Molecular 
Biology at Jozef Stefan Institute, Ljubljana, Slovenia. Nature 
Reviews Drug Discovery 5, 785–799 (September 2006)
Protease inhibitors approved for clinical use 
 
                                                 
1 The above table is taken from the excellent review article “Targeting proteases: successes, failures and 
future prospects” by Professor Boris Turk published in Nature Reviews Drug Discovery, in September 
2006. The table shows the current protease inhibitory drugs approved for clinical use, anticoagulants 
included (under the section of thrombosis). I will like to highlight to the reader that the current 
anticoagulants approved for clinical use, target FX and thrombin, which are downstream proteases in the 
clotting cascade. Therefore, hemextin AB complex which is a specific inhibitor of FVIIa, provides a new 
paradigm in our search for anticoagulants targeting clot initiation (in spite of its large size), though there is 
a long way to go before its clinical viability can be evaluated.
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Understanding the molecular interaction between the inhibitor and its target enzyme is 
the key to drug design. As illustrated in the introductory section of the thesis FVIIa is the 
key to initiation of the coagulation cascade.  In Chapter 3, we have seen that hemextin A 
hemextin AB complex specifically inhibit FVIIa activity to mediate anticoagulation. In 
this chapter we investigate the molecular interactions involved in the formation of 
hemextin AB-FVIIa complex and hemextin A-FVIIa complex.  Effect of the presence of 
co-factor on the binding between FVIIa and the anticoagulant proteins has also been 
studied. Since, the anticoagulant protein and its complex inhibit FVIIa non-competitively 
(as illustrated in Chapter 3), their binding to active site occupied FVIIa was also studied. 
Lastly, binding site of hemextin AB complex and hemextin A on the FVIIa molecule was 
identified. For these studies, we primarily use isothermal titration calorimetry (ITC) and 
size-exclusion chromatography (SEC). 
 
MATERIALS AND METHODS 
Materials –The chromogenic substrate H-D-Ile-Pro-Arg-p-nitroanilide (pNA) 
dihydrochloride (2HCl), (S-2288) was from Chromogenix AB, Stockholm, Sweden and 
was reconstituted in deionized water prior to D-Phe-L-Phe-L-Arg chloromethyl ketone 
(FFR-ck) was purchased from Bachem (King of Prussia, PA, USA). All other chemicals 
and reagents used were of highest purity available. 
Proteins – Hemextin A and hemextin B was purified similarly as described in Chapter 2.  
Human plasma-derived FVIIa was kindly provided by Factor VII Group (Kazuhiko 
Tomokiyo, Yasushi Nakatomi, Teruhisa Nakashima, and Soutatou Gokudan) of 
KAKETSUKEN and were purified as described (Nakagaki et al., 1991). Recombinant 
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human soluble TF (sTF; residues 1–218) was a gift from Dr. Toshiyuki Miyata (National 
Cardiovascular Center, Suita, Japan), and it was prepared as described (Stone et al., 
1995). 
Reconstitution of the anticoagulant complex –We reconstituted the complex for various 
in vitro experiments immediately prior to the experiment by incubating equimolar 
concentration of hemextin A with hemextin B (unless mentioned otherwise) at 37˚ C for a 
period of 5 min in 50 mM Tris-buffer (pH 7.4).  
Reconstitution of the sTF-FVIIa complex – sTF-FVIIa complex was reconstituted by 
incubating 30 nM FVIIa with 100 nM of sTF in 50 mM Tris-HCl buffer (pH 
7.4), containing 10 mM CaCl2, and 1% BSA for 10 min at 37˚ C. The kinetics of 
hydrolysis of the chromogenic substrate S-2288 by sTF-FVIIa was measured prior to the 
binding studies to ensure proper complex formation. 
Preparation of active site inhibited FVIIa – Active site inhibitor FFR-ck was used for the 
studies. For the preparation, FVIIa was treated with 2-fold molar excess of FFR-ck. 
Unreacted FFR-ck was separated from active site blocked FVIIa by size-exclusion 
chromatography on a Superdex 200 gel filtration column (1.0 × 30 cm) using an ÄKTA 
Purifier system (Figure 5.1). The residual FVIIa activity, of active site inhibited FVIIa 
was measured in an FVIIa-specific amidolytic assay using S-2288 as the substrate.  
FVIIa-specific amidolytic assay – The assay was performed in assay buffer containing 
50 mM Tris-HCl, pH 7.4, containing 10 mM CaCl2, and 1% BSA at 37ºC. In a total 
volume of 200 µl in the individual wells of the microtiter plate, final concentrations of 
FVIIa/active site inhibited FVIIa was 300 nM. Reactions were initiated by the addition of 
S-2288 (1 mM). Initial reaction velocities were measured as a linear increase in the 
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Figure 5.1 Elution profile of active site inhibited FVIIa (FFRck-FVIIa). Note the eluted peak 
had a retention volume of 16.1 ml corresponding to a mass of ~50 kDa. Fractions corresponding 
to the peak were pooled and checked for FVIIa activity. The pooled fractions had less <XX% 

















Molecular Interactions with FVIIa 
absorbance at 405 nm over 5 min, with a SPECTRAmax plus® temperature-controlled 
microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). FFRck-FVIIa 
had 5% residual activity (Figure 5.1, inset) as measured in the assay. 
Separation of light and heavy chains of FVIIa – Partially reduced FVIIa was separated 
under the conditions described in the legend (Figure 5.2A). Both the chains were treated 
with 10 mM iodoacetamide for 20 min in ice water, in the dark.  Homogeneity and 
molecular weight of the chains were determined by eluting each of them in TBS on a pre-
packed Superdex 200 gel filtration column (1.0 × 30 cm) using the same chromatography 
system (Figure 5.2B to C) and also on SDS-PAGE (Figure 5.2A inset).  
Preparation of light chain of FVIIa under non-reduced conditions – The FVIIa light 
chain (residues 1-144 plus 248-266) was isolated as described in (Persson and Petersen, 
1995). 
Circular dichroism (CD) spectroscopy – Conformational changes in FVIIa, associated 
with binding to hemextin AB complex were monitored using CD. Far UV CD spectra 
(260-190 nm) were recorded using a Jasco J-810 spectropolarimeter (Jasco Corporation, 
Tokyo, Japan). All measurements were carried out at room temperature using 0.1 cm path 
length stoppered cuvettes. The instrument optics was flushed with 40 l/min of nitrogen 
gas. The spectra were recorded using a scan speed of 50 nm /min, resolution 0.2 nm, and 
band width 2 nm. For each spectrum, a total of 4 scans were recorded, averaged and 
baseline subtracted. 
Isothermal Titration Calorimetric (ITC) studies – The thermodynamics of binding of 
individual hemextins and the reconstituted anticoagulant complex with FVIIa and its 
different derivatives were monitored using a VP-ITC titration calorimetric system 
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Figure 5.2 Separation of light and heavy chains derived from FVIIa. Human FVIIa (3.5 mg) 
was incubated with 0.5 M 2-mercaptoethanol in 1.1 ml of TBS at. 20˚C for 30 min. The sample 
was applied to a column (6 ml) of DEAE-Sepharose CL-6B column. equilibrated with TBS 
containing 0.5 M 2-mercaptoethanol. The flow rate was 2 ml/min. After washing the column with 
20 ml of the equilibration buffer, the heavy chain of FVIIa was eluted with 35 ml of TBS 
containing 6.0 M urea and 0.5 M 2-mercaptorthanol. Then the column was washed with 20 ml of 
TBS and a linear gradient from 0.1 to 0.6 M NaCl in 50 mM Tris-HCI. pH 8.0 was performed to 
elute the light chain of FVIIa. The separated heavy and light chains were rerun in TBS on a pre-
packed Superdex 200 gel filtration column (1.0 × 30 cm) (data not shown). The patterns of 
the isolated light and heavy chains on SDS-PAGE are shown in the inset: HC, heavy chain of 
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(MicroCal, LLC, Northampton, MA). FVIIa or its derivatives were taken in 50 mM Tris-
HCl buffer (pH 7.4) in the calorimetric cell and were titrated with individual hemextins or 
the reconstituted anticoagulant complex dissolved in the same buffer in a 250-µl injection 
syringe with continual stirring at 300 rpm at 37 °C. All protein solutions were filtered and 
degassed prior to titration. The first injections presented defects in the base line, and these 
data were not included in the fitting process. Additional experiments were performed 
with FVIIa in 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl or 250 mM 
glycerol at 37 °C. The calorimetric data were processed and fitted to the single set of 
identical sites in the same way as described in Chapter 4. 
Size-exclusion chromatographic (SEC) studies – Binding studies with FVIIa and its 
derivatives were also carried out using SEC. All SEC experiments were carried out at 
room temperature on a pre-packed Superdex 200 gel filtration column (1.0 × 30 cm) 
using the ÄKTA Purifier system. The column was equilibrated with 50 mM Tris-HCl 
buffer (pH 7.4) or the specified elution buffer, at a flow rate of 0.5 ml/min. The sample 
volume applied to the column was 0.4 ml. The column was calibrated using catalase 
(232-kDa), lactate dehydrogenase (140-kDa), bovine serum albumin (67-kDa), 
ovalbumin (43-kDa), chymotrypsinogen A (25-kDa) and ribonuclease A (13.7-kDa) as 
molecular weight markers. The void volume was determined by running Blue Dextran. 
The column was equilibrated with at least three bed volumes of the elution buffer prior to 
each run. Protein elution was monitored by recording absorbance at 280 nm. 
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RESULTS AND DISCUSSION 
Binding of FVIIa to hemextin AB complex – The binding between hemextin AB complex 
and FVIIa was studied in Tris buffer (pH 7.4) using ITC (Figure 5.3A, Table 5.1), as 
under these conditions the complex exists as a heterotetramer (Chapter 4). Interestingly, 
two kinetic phases were associated with each injection. Immediately following injection, 
an initial exothermic phase (negative numbers) which was followed by a smaller and 
slower endothermic phase (positive numbers), suggesting that a slow conformational 
rearrangement takes place after binding. Similar kind of thermogram has also been 
observed in the binding of FXa with human secretory phospholipase A2, where a 
conformational rearrangement takes place on binding (Mounier et al., 1998). The binding 
is enthalpically driven with 1:1 stoichiometry (Table 5.1). SEC studies show that the 
estimated molecular weight of the tetrameric hemextin AB complex-FVIIa complex is 
~88,000 Da (Figure 5.3B). Both these studies indicate that only one FVIIa binds to 
tetrameric hemextin AB complex.  In the proposed model for hemextin AB complex 
assembly (Chapter 4), the tetramer possesses two identical anticoagulant sites and 
therefore could bind two molecules of FVIIa. However, both ITC and SEC studies show 
that hemextin AB complex binds to only one molecule of FVIIa (Figures 5.3). This could 
be due to either steric hindrance or negative cooperativity. The two FVIIa binding sites on 
the tetramer juxtaposed very closely, as a result the binding of the first FVIIa molecule 
precludes the binding of the second FVIIa molecule. Such steric interference in protein-
protein interactions is well documented (Lewicki and Gallagher, 2002;Pfleger and Eidne, 
2006). Alternatively, the binding of the first FVIIa rapidly induces structural changes in 
the other binding site destroying the adjacent binding site resulting in negative  
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Figure 5.3 Binding of hemextin AB complex to FVIIa. (A) ITC studies. Thermogram with the 
corresponding binding isotherm for the binding of hemextin AB complex to FVIIa in 50 mM Tris 
buffer (pH 7.4). (B) SEC studies Elution profiles of the complex of FVIIa with hemextin AB 



















Molecular Interactions with FVIIa 
cooperativity (Kim et al., 2001). The larger size of FVIIa and fairly stable conformation 
of hemextin AB complex supports the steric hindrance.  
The effect of temperature on hemextin AB-FVIIa complex formation — Since, hemextin 
AB complex is the only known natural and specific inhibitor of FVIIa, the energetics of 
complex formation between the two molecules was investigated in detail. Complete 
temperature profile of the thermodynamic parameters associated with the binding of 
hemextin AB complex to FVIIa was studied over the temperature range of 25-45 °C 
(298-318 °K). The temperature dependence of ∆H is shown in Figure 5.4A and Table 5.1. 
The temperature dependence of ∆H over a narrow temperature range is given by the 
equation: 
∆H = ∆H0 + ∆Cp(T-T0)..........................(Eq. 1) 
where, ∆H0  is the binding enthalpy at an arbitrary reference temperature and ∆Cp is the 
heat capacity change of binding. The ∆Cp obtained from the slope (∆Cp = δ∆H /δT) 
(Figure XA), is -121.43 cal/K-1mol-1. Negative ∆Cp indicate a reduction in the nonpolar 
solvent-accessible surface area, as explained by the following equation (Murphy and 
Freire, 1992), 
∆Cp = 0.45(∆ASAnonpol) – 0.26 (∆ASApol) cal /molK …………….. (Eq. 2) 
where, ∆ASApol and ∆ASAnonpol are the change in the polar- and non-polar-accessible 
surface areas respectively.  
Figure 5.4B, shows the plot of ∆G and ∆H as a function of T∆S. It is clear that the ∆G of 
binding remained temperature independent and is a result of linear dependence of ∆H on 
T∆S. This strongly suggests the enthalpy-entropy compensation for the binding of 
hemextin A to hemextin B.  This phenomenon is a universal feature for protein-peptide  
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Figure 5.4 Thermodynamics of FVIIa-hemextin AB complex formation. (A) Effect of 
temperature on the energetics of FVIIa-hemextin AB complex interaction: enthalpy change (∆H), 
change in entropy term (T∆S) and free energy change (∆G). (B) Enthalpy-entropy compensation 
in complex formation. (Note: Point of intersection of lines corresponding to ∆H and ∆G 















Thermodynamic analysis of FVIIa binding to hemextin AB complex at different 
temperatures 
 
Binding to FVIIa KA × 105 (M-1) ∆H (kcal/mole) ∆S (cal/deg.mole) ∆G (kcal/mole) 
Number of binding 
sites (N) 
At different temperatures (˚C)      
25 3.84 -6.56 3.322 -7.61 0.97 
37 4.11 -7.931 -1.112 -7.586 1.01 
45 1.55 -9.0010 -4.55 -7.548 1.08 
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interactions, where weak molecular interactions undergo constant rearrangements to 
realize a lower free energy of binding. 
The negative ∆Cp also indicates the net thermodynamic driving force for the association 
to shift from entropic to enthaplic with increasing temperature. At the intersection point 
of both lines ∆G = ∆H = -7.5 kCal.mol-1 (Figure 5.4B), which corresponds to a 
temperature Ts (Temperature at which the contribution from entropy is zero. At Ts the 
contribution from entropy changes from favorable to unfavorable. From Figure 5.4A, ∆H 
= -7.5 kCal.mol-1 is connected with a Ts of 33.3 °C (306.3 °K). A positive entropy 
change observed at 25ºC (298 K) that is lower than Ts, further confirms this finding. 
The negative ∆Cp for the hemextin AB complex formation further suggests that the 
observed entropy change upon binding must include significant contribution from the 
hydrophobic effect in the physiological temperature range. Therefore, for protein-
protein/ligand interaction(s) the net entropy of association is given by the equation:  
∆S assoc =  ∆SHE + ∆ Srt +  ∆ Sother ........................(Eq. 3) 
where, ∆SHE,  ∆Srt, and ∆Sother are the entropy changes due to hydrophobic effect, 
reduction of rotational and translational degree of freedom, and from other sources, 
respectively.  
At Ts, the overall entropy of association is zero and the above equation becomes:  
∆S assoc=  ∆SHE (Ts) + ∆Srt +  ∆Sother = 0 ........................(Eq. 4) 
 In the absence of crystallographic data, the ∆SHE(Ts) was estimated from the equation, 
∆SHE(Ts) = 1.35 ∆Cp ln(Ts/386)......................................(Eq. 5) 
and found to be 37.86 cal deg-1 mol -1. It has been shown that protein-protein interaction 
∆Srt is nearly equal to -50 cal deg-1 mol-1  
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Figure 5.5 Conformational changes associated with the formation of hemextin AB-FVIIa 
complex. Individual spectra of hemextin AB complex, FVIIa are also shown for comparison. As 
shown in the figure complex formation leads to an increase in the 310-helix structure.  
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(Janin and Chothia, 1978;Finkelstein and Janin, 1989). Thus the ∆Sother is calculated to be 
-12.14 cal deg-1 mol-1. The non-zero value of ∆Sother suggests that the FVIIa-hemextin AB 
complex formation, is not a rigid-body-association but formed through local unfolding 
and refolding during binding interaction. 
Conformational changes associated with hemextin AB-FVIIa complex formation – The 
above analysis of the thermodynamic parameters indicated a plausible conformational 
change associated with complex formation between FVIIa and hemextin AB complex. 
Circular dichroism is a useful technique to monitor the conformational changes for a 
moderately week to strong protein-protein interactions (Kd ~1 mM to 1 µM). Figure 5.5 
shows the CD spectra of hemextin AB complex, FVIIA, and hemextin AB-FVIIA 
complex. The CD spectra of hemextin AB complex exhibits dominant presence of β-
sheet structure (Figure 5.5). The CD of FVII exhibits a strong double minimum at 207 
nm and 222 nm, and a weak positive maxima around 195 nm indicating the presence of a 
right-handed helical structure. However, the ratio of [θ222]/ [θ207] is 0.7 indicates the 
interconverting populations of the presence of both 310- and a-helical structure 
(Millhauser, 1995). The hemextin AB-FVIIa complex exhibited a slight increase in θ222 
indicating an increase in 310-helix structure upon complexation.  The result suggests 
considerable unfolding upon complex formation. Since CD was recorded at room 
temperature much below Ts, the complex formation is driven by favourable entropy 
changes. Thus, CD difference spectra of hemextin-FVIIa complex studies support the 
thermodynamic data obtained from ITC. 
Binding of FVIIa to hemextin A – The binding between hemextin A and FVIIa was also 
investigated. ITC studies revealed that the binding is predominantly exothermic with 1:1  
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Figure 5.6 Binding of hemextin A to FVIIa. (A) ITC studies. Thermogram with the 
corresponding binding isotherm for the binding of hemextin A complex to FVIIa in 50 mM Tris 
buffer (pH 7.4).; Note the presence of only one kineric phase, unlike two as observed in the case 
of hemextin AB-FVIIa formation (B) SEC studies. Elution profiles of the complex of FVIIa with 
hemextin AB complex in 50 mM Tris buffer (pH 7.4); Note on complex formation there is a 



























































Figure 5.7 Conformational changes associated with the formation of hemextin A-FVIIa 
complex. Individual spectra of hemextin A, FVIIa are also shown for comparison.  
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stoichiometry (Figure 5.6A). Unlike, the thermogram of hemextin AB-FVIIa complex 
formation (Figure 5.3A) which has two kinetic phases, hemextin A-FVIIa complex had 
only one kinetic phase. The binding affinity (80 µM) was also lower than that observed 
for the binding between tetrameric hemextin AB complex and FVIIa (Table 5.1), 
explaining the lower anticoagulant potency of hemextin A. The estimated molecular 
weight of the hemextin A- FVIIa complex from SEC studies was ~57000 Daltons (Figure 
5.6B) validating 1:1 stoichiometry of complex formation. Since hemextin AB complex 
on binding to FVIIa, induces a conformational change in the FVIIa molecule, a similar 
study was conducted with hemextin A (Figure 5.7). CD studies with hemextin A and 
FVIIa showed that, hemextin A-FVIIa complex has a predominantly β−sheeted structure. 
Binding of hemextin AB complex dimer to FVIIa – In chapter 4, we have seen that the 
anticoagulant complex exists as a tetramer. However, in the presence of glycerol (250 
mM) and NaCl (150 mM), it dissociates and predominantly exists as a dimer. 
Prothrombin time assay indicate that the dimer in glycerol is active where as that in NaCl 
has no anticoagulant activity. We studied the binding between hemextin AB complex 
dimer (formed in both salt and glycerol) and FVIIa using ITC and SEC and compared it 
to the binding between FVIIa and hemextin A. 
To determine whether the dimer formed in glycerol binds to FVIIa, we studied the 
interaction of hemextin AB complex with FVIIa in the presence of glycerol (250 mM). 
ITC experiments show that the interaction of dimeric hemextin AB complex with FVIIa 
is predominantly exothermic with 1:1 stoichiometry (Figure 5.8A). This was further 
confirmed using SEC, where the estimated molecular weight of the complex between 
dimeric hemextin AB complex and FVIIa complex was ~64000 Daltons. However, the 
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 Figure 5.8 Binding of hemextin AB complex or hemextin A binding to FVIIa in 50 mM 
Tris buffer (pH 7.4) containing 250 mM glycerol. Thermograms with the corresponding 
binding isotherm for the binding of (A) hemextin AB complex (B) hemextin A to FVIIa. in  Tris 
buffer containing 250 mM glycerol; (C) Elution profiles of hemextin AB complex or hemextin A 
with FVIIa in Tris-HCl buffer containing 250 mM glycerol. 
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Thermodynamics of binding of hemextin AB complex/hemextin A to FVIIa in different 
buffer solutions 
 
Binding to FVIIa  KA × 105 (M-1) ∆H (kcal/mole) ∆S (cal/deg.mole) ∆G (kcal/mole) 
Number of Binding 
Sites  (N) 
Hemextin AB complex 
Tetramer  in Tris-HCl 
Buffer 4.11 -7.931 -1.112 -7.586 1.01 
Dimer in glycerol 1.77 -3.933 -1.1 -3.62 1.05 
Dimer in salt 0.119 -2.994 -1.66 -2.54 0.89 
Hemextin A 
In Tris-HCl buffer 0.125 -3.005 -1.7 -2.5 1.00 
In glycerol 0.118 -2.821 -1.74 -2.3 0.97 
In salt 0.121 -3.042 -1.56 -2.6 1.03 
Note: All experiments were carried at 37˚C 
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binding affinity for FVIIa was lower than that of the tetrameric hemextin AB complex 
but higher than that of hemextin A, alone (Table 5.2).  
Binding between hemextin A and FVIIa in the presence of glycerol was predominantly 
exothermic (Figure 5.8B). The 1:1 stoichiometry of complex formation was confirmed by 
ITC (Figure 5.8B) and SEC (Figure 5.8C).  The estimated molecular weight of hemextin 
A–FVIIa complex in glycerol was ~57000 Daltons (Figure 5.8C). No significant 
difference in the binding affinity of hemextin A for FVIIa was observed in the presence 
or absence of glycerol (Table 5.2). However, binding affinity of hemextin A for FVIIa 
was lower than that of the tetramer and dimeric hemextin AB complex in the presence of 
glycerol (Table 5.2).  
Hemextin AB complex predominantly exists as a dimer in the presence of 150 mM NaCl. 
The dimer in salt has lower anticoagulant potency than that in glycerol and the 
anticoagulant potency of the dimer is same as that of hemextin A. To determine if the 
dimer in salt binds to FVIIa, ITC studies were conducted in 150 mM NaCl. Figure 5.9A 
and Table 5.2; show that the binding is predominantly exothermic with 1:1 stoichiometry. 
The estimated molecular weight of the dimeric hemextin AB- FVIIa complex from the 
SEC experiments was ~57000 Daltons (Figure 5.9C). Interestingly, the binding affinity of 
the dimer in salt for FVIIa was lower than that of the tetramer and the dimer in glycerol, 
but was almost identical that observed for hemextin A (in all the three conditions) (Table 
5.2).  
We also studied the binding of hemextin A to FVIIa in the presence of salt and glycerol. 
In salt hemextin A complexed with FVIIa with a 1:1 stoichiometry (Figure 5.9B) and the 
binding was predominantly exothermic. The estimated molecular weight of 
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Figure 5.9 Binding of hemextin AB complex or hemextin A binding to FVIIa in 50 mM 
Tris buffer (pH 7.4) containing 150 mM salt. Thermograms with the corresponding binding 
isotherm for the binding of (A) hemextin AB complex (B) hemextin A to FVIIa. in  Tris buffer 
containing 150 mM NaCl; (C) Elution profiles of hemextin AB complex or hemextin A with 
FVIIa in Tris-HCl buffer containing 150 mM NaCl.  
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the hemextin A- FVIIa complex in salt was ~57000 Daltons (Figure 5.9C), confirming 
the stoichiometry of complex formation. The binding affinity of hemextin A for FVIIa in 
the presence of salt was almost identical to that observed in the other two conditions 
(Table 5.2). This shows that the conformational change occurring in hemextin A in the 
presence of salt does not alter its affinity for FVIIa. However, the observed binding 
affinity of hemextin A for FVIIa was lower than that observed for tetrameric hemextin 
AB complex and dimeric hemextin AB complex (formed in glycerol) (Table 5.2). 
Interestingly, the observed binding affinity of hemextin A for FVIIa was nearly the same 
as that of dimeric hemextin AB complex (formed in the presence of salt). 
The dimeric hemextin AB complex formed in the presence of glycerol binds to FVIIa 
with a higher affinity than hemextin A and hemextin AB complex dimer formed in salt. 
Again, the dimer formed in salt has the same binding affinity for FVIIa as that of 
hemextin A (Table 5.2). From these observations it can be concluded that the dimer 
formed in glycerol is different from the dimer formed in salt and dissociation of the 
tetramer into a dimer can take place in two different planes depending on buffer condition 
(which validates the proposed model). The reason for the higher anticoagulant potency of 
the dimer formed in glycerol is probably because one of the anticoagulant sites of the 
tetramer is conserved in this type of dimer. This observation also corroborates well with 
the proposed model. However, the lower anticoagulant potency of dimer formed in 
glycerol over that of the tetramer may be because of the fact that dimer formation 
destabilizes the anticoagulant site. Thus, although the stoichiometry remains the same, 
the binding affinity for FVIIa is diminished. The dimer in salt has similar binding affinity 
as hemextin A in the presence of salt (Table 5.2), albeit slightly lower. Under these  
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Figure 5.10 Binding of hemextin A/hemextin AB complex to sTF-FVIIa. (A) Elution profiles 
of the complex of sTF-FVIIa with hemextin AB complex/hemextin A. Thermograms with the 
corresponding binding isotherm for the binding of (B) hemextin A and (C) hemextin AB complex 
to sTF-FVIIa. (Note, the presence of sTF does not affect the binding between FVIIa and the 
anticoagulant protein or its complex.). 
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Table 5.3.
 
Thermodynamic analysis of binding to FVIIa and its derivatives to hemextin AB 
complex/hemextin A 
 
Binding to FVIIa and its derivatives KA × 105 (M-1) ∆H (kcal/mole) ∆S (cal/deg.mole) ∆G (kcal/mole) 
Number of 
binding site (N) 
Hemextin AB complex      
FVIIa 4.11 -7.931 -1.112 -7.586 1.01 
sTF-FVIIa 4.06 -7.84 -1.13 -7.49 1.16 
FVIIa-Heavy chain 5.2 -7.82 -0.5 -7.67 0.921 
FFRck-FVIIa 0.33 -5.01 -3.7 -4.74 1.08 
Hemextin A      
FVIIa 0.125 -3.005 -1.7 -2.5 1.00 
sTF-FVIIa 0.127 -3.1 -1.5 -2.69 1.07 
FVIIa-Heavy chain 0.798 -4.1 -1.2 -3.7 0.96 
FFRck-FVIIa 0.065 -2.3 -1.2 -1.3 0.94 
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conditions only hemextin A forms a complex with FVIIa and the molecular weight is 
~57000 Daltons.  
Effect of sTF on the binding of anticoagulant proteins to FVIIa – In Chapter 3, we have 
seen that hemextin AB complex exhibits similar IC50 values (~100 nM) for inhibition of 
both FVIIa and sTF-FVIIa. Therefore, we investigated the binding of the anticoagulant 
protein and its synergistic complex with sTF-FVIIa, and compared it to the binding to 
FVIIa alone.  Hemextin A binds to sTF-FVIIa with 1:1 stoichiometry (Figure 5.10B), the 
estimated molecular weight of the sTF-FVIIa-hemextin A complex being 77,000 Da 
(Figure 5.10A). Hemextin AB complex also binds to sTF-FVIIa in 1:1 stoichiometry, 
though its binding affinity towards the procoagulant complex is higher than hemextin A 
(Figure 5.10C) (Table 5.3). The estimated molecular weight of the FVIIa-sTF-hemextin 
AB complex was estimated to be 116,000 Da (Figure 5.10A).  
Interestingly, no significant change was observed in the recorded binding affinity 
between FVIIa and the anticoagulant proteins, in the presence of sTF (Table 5.3). 
According to the X-ray crystallographic structure of sTF-FVIIa solved by Banner et al. at 
2.0 Å resolution (PDB code 1DAN) (Banner et al., 1996), the two fibronectin domains of 
sTF have extensive contact with the γ−carboxyglutamic acid (Gla) and the first epidermal 
growth factor (EGF1) like domains of FVIIa. This observation is also supported by 
mutational data. However, minor contact regions do exist between sTF and the second 
EGF and protease domains of FVIIa. Since, sTF does not affect the binding affinity 
between FVIIa and hemextin A/hemextin AB complex, the regions of FVIIa participating 
in complex formation with sTF are not involved in binding with the anticoagulant protein 
or its complex.  
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Interaction with individual FVIIa chains – FVIIa consists of an NH2-derived light chain 
(relative molecular mass, 20,000) consisting of 152 amino acid residues and a COOH 
terminal–derived heavy chain (relative molecular mass, 30,000) consisting of 254 amino 
acid residues linked via a single disulfide bond (Cys135 to Cys262). The light chain 
contains the membrane-binding Gla domain and two EGF domains (EGF1 and EGF2), 
while the heavy chain contains the catalytic protease domain (Kranjc et al., 2005). Above 
studies with sTF showed that the binding site of the anticoagulant protein and its complex 
can not be localized in the Gla and EGF1 domains of FVIIa light chain. Therefore, we 
studied the interaction of the individual separated chains of FVIIa with hemextin A and 
hemextin AB complex. 
Light chain of FVIIa showed no binding to either hemextin A or hemextin AB complex. 
This may not be due to the conformational change(s) in the light chain isolated under 
reducing conditions since light chain produced under non-reducing conditions did not 
exhibit any binding as well. This observation ruled out EGF2 domain of FVIIa as a 
binding site for the anticoagulant protein and its complex. The separated heavy chain of 
FVIIa exhibited binding to both hemextin A and hemextin AB complex (Figure 5.11). 
Interestingly, the recorded binding affinity of the anticoagulant protein and its complex 
for the heavy chain was slightly higher than that recorded for FVIIa (Table 3). This may 
be due to better exposure of the anticoagulant binding site in the absence of the light 
chain. Thus, the binding site of hemextin A and hemextin AB complex is localized in the 
heavy chain of FVIIa. 
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Figure 5.11 Binding of hemextin A/hemextin AB complex to the heavy chain of FVIIa. 
Thermograms with the corresponding binding isotherm for the binding of (A) hemextin A and (B) 
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Interaction with active site inhibited FVIIa – Previous studies show that hemextin AB 
complex is a non-competitive inhibitor of sTF-FVIIa (Ki = 25 nM). Therefore, occupation 
of the active site of FVIIa will not inhibit complex formation between FVIIa and 
anticoagulant protein/complex. We investigated the complex formation of FFRck-FVIIa 
with hemextin A and hemextin AB complex. SEC studies showed that FFRck-FVIIa 
retains complex formation ability with hemextin A and hemextin AB complex (Figure 
5.12). The estimated molecular weight of FFRck-FVIIa-hemextin A complex and FFRck-
FVIIa-hemextin AB complex was 57,000 Da and 88,000 Da respectively. No, significant 
change in the molecular weight was observed over that of the corresponding complexes 
of the anticoagulant proteins with FVIIa. This may be because; the molecular weight of 
FFRck is negligible and therefore adds little to the molecular weight of FVIIa. Binding 
was further confirmed using ITC. The binding is exothermic and takes in 1:1 
stoichiometry (Figure 5.12B and C). However, the recorded binding affinity showed that 
the anticoagulant protein and its complex bind with lower affinity to FFRck-FVIIa than 
FVIIa (Table 3). This may be because of the conformational changes involved at the S2 
sub-site (According to the nomenclature of Schecter and Berger (Schechter and Berger, 
1967)) originating from the active site; taking place on the binding of FFRck to FVIIa 
(Kemball-Cook et al., 1999). This observation again highlights the binding site of the 
anticoagulant protein and its complex to be localized in the heavy chain of FVIIa, but 
away from the active site. 
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Figure 5.13 Binding of hemextin A/hemextin AB complex to active site blocked FVIIa 
(FFRck-FVIIa). (A) Elution profiles of the complex of FFRck-FVIIa with hemextin AB 
complex/hemextin A. Thermograms with the corresponding binding isotherm for the binding of 
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CONCLUDING REMARKS 
Hemextin A and hemextin AB complex bind to the heavy chain of FVIIa. Binding to 
FVIIa takes place with equal affinity irrespective of the presence or absence of co-factor. 
However, further studies with exosite binding peptides will help us to identify the 
particular region of the FVIIa heavy chain that participates in the binding process. 
Binding also takes place even when the active site of FVIIa is blocked; this highlights the 
non-competitive nature of inhibition both for the anticoagulant protein and its complex, 
which is also supported by enzyme kinetic studies (Chapter 3). This study therefore 
facilitates our understanding of the inhibitory mechanism of the hemextin A and 
hemextin AB complex, and therefore will help in devising novel anticoagulation 
strategies targeting the heavy chain of FVIIa. 
------------------------------------------------------------------------------------------------------------ 
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Thank you note, 
 
The work narrated in chapter 5 is currently under consideration in the Journal of 
Biological Chemistry. After, finding out that hemextin AB complex/hemextin A 
specifically binds to FVIIa, I was intrigued to find out the exact chain of FVIIa to which 
the anticoagulant proteins bind. For these studies, I needed an in depth knowledge of 
the structure & function of FVIIa, and many a times I had to write to the stalwarts in the 
field of FVIIa biochemistry for their suggestions. Two of them had always answered my 
questions and without their help I would not have been able to complete some of the 
experiments detailed in the chapter. Before I proceed to the next chapter, I will like to 
thank Dr James H. Morrissey (Department of Biochemistry, University of Illinois 
College of Medicine, Urbana-Champaign) and Dr Robert A. Lazarus (Department of 
Protein Engineering, Genentech, Inc.) for helpful discussions.  






“When I am working on a problem I never think about beauty. I only think about 
how to solve the problem. But when I have finished, if the solution is not beautiful, I 






   
Chapter 61  
Structural Characterization 
of Anticoagulant Protein 
Hemextin A 
                                                 
1This picture shows three stages in solving a biological structure by X-ray crystallography. The 
background is a diffraction image, which we can observe on a X-ray sensitive detector when 
illuminating a crystal with X-rays. The spots of varying intensity carry the structural information we 
are interested in. The foreground is electron density and the interpretation of it, the atomic model 
(shown as space-filling model). (Adapted with kind permission from the lab page of Dr. Karsten W. 
Theis, University of Massachusetts Amherst) 
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The Future of X-Ray Analysis 
The number of papers on crystal structure rose rapidly until 1933, then fluctuated 
about a mean. This date may be taken as the end of the heroic age of X-ray analysis. 
It was then realized that the new structures would be essentially like the old ones, 
and interest was directed towards new and more complex phenomena... Beyond the 
ordinary compounds of organic chemistry there lies the wide range of complicated 
biological molecules of which the proteins are the best known but by no means the 
only type...The structure of the proteins, fundamental to the understanding of living 
processes, will not yield to X-ray analysis alone; the attack must be combined with 
biochemical, electrophoretic, electron microscope and other methods, but there is no 
doubt that X-rays will play a crucial part in verifying all hypothetical structures put 
forward on any other basis.  
 --- Prof. J.D. Bernal, FRS, Birkbeck College, London; Nature, June 1945. 
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Much of our understanding of protein function at the atomic level originates from 
studying protein structures. Several technologies are employed to study the three-
dimensional structures of proteins. The two techniques that have been widely used to 
elucidate protein structure are: single-crystal X-ray diffraction and nuclear magnetic 
resonance (NMR) spectroscopy2.  
For the proteins that form suitable crystals, X-ray crystallography represents a mature and 
rapid approach. Since, this technique was used for determining the structure of hemextin 
A, the methodology will be discussed in a greater detail (see below). 
Soluble proteins that do not crystallize readily can only be studied by solution state NMR 
spectroscopy. For proteins larger than around 15 kDa, however, this method is relatively 
slow compared to crystallography, and isotope labeling is required. But, NMR has a 
number of important uses that are complementary to crystallography. It is particularly 
good at studying relatively small proteins or domains, which are often difficult to 
crystallize. It can also be used to help with the "phase" problem, by providing structural 
information about domains within a larger protein. It can also identify flexible regions in 
a protein that may be causing problems with crystallization or difficulties with chain 
tracing. NMR has a unique ability to study unfolded proteins at the atomic level and it 
can play a significant role as an analytical tool - defining the purity and stability of 
                                                 
2“If biology were a car, structural biologists would be looking under the bonnet to find out how the engine works. Put more 
prosaically, structural biology aims to understand how biology works at the molecular level. Much information is gleaned by 
studying at atomic resolution the three-dimensional structures of molecules that make up living organisms, and the 
interactions of these molecules with one another. But, just as a photograph of a car engine doesn’t tell us how that engine 
actually works, static biological structures alone may not suffice for us to work out the functional mechanisms of biomolecules. 
Instead, a video of the structural dynamics — analogous to observations of a running car engine made from inside and out — 
would be much more revealing.”  
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protein preparations. It can also be used to identify the relative flexibility of domains in a 
multi-domain protein (Ulmer et al., 2002).  
Electron microscopy (EM) can be utilized in protein structural analyses. However, EM is 
not extensively utilized for the determination of three-dimensional structure of proteins, 
but for solving the structures of large supramolecular assemblies.  Although mainly 
aiming at molecular resolution (10-30 Å), electron microscopy can provide near-atomic 
resolution e.g., tubulin (Nogales et al., 1998), aquaporin (Murata et al., 2000), light-
harvesting complex (Kuhlbrandt et al., 1994), and bacteriorhodopsin (Henderson et al., 
1990). Time-resolved techniques offer the possibility of studying conformations that are 
inaccessible to X-ray crystallography. For example, the activated state of the nicotinic 
acetylcholine receptor, which has a lifetime of 10 ms, was studied at 4.6-9 Å resolution, 
using three-dimensional helical reconstruction of tubular membrane crystals (Unwin, 
1995;Miyazawa et al., 1999). Another means of imaging biological samples with 
molecular resolution is by atomic force microscopy (AFM). In addition to providing 
topographical images of surfaces with nanometer- to angstrom-scale resolution, forces 
between single molecules and mechanical properties of biological samples can be 
investigated. Other lesser used approaches for studying protein structure include 
correlative microscopy, multi-color labeling/cluster analysis and electron tomography.  
X-ray crystallography 
X-ray diffraction analysis of crystal structures is quite analogous to using a very high-
power microscope that can see molecular shapes. The wavelength of the light used is 
usually in the vicinity of 1.5 Å, about the length of a single carbon-carbon bond, and the 
use of X-rays with this wavelength permits, in theory, resolution of individual atoms.  
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In this technique, the intensities of the diffracted X-rays from the single crystal together 
with some additional data described below, allows one to compute the three dimensional 
structure of the protein (present in the crystal). The crystal acts as a three-dimensional 
diffraction grating and scatters the incident beam of X-rays only in certain directions. But 
all the molecules in the crystal scatter together in these directions, and since there are 
>1015 molecules, at least in most crystals, this enables the scattered signal to be recorded 
before the specimen is destroyed by radiation damage. 
It can be demonstrated that this diffraction is the vector sum of the diffraction by the 
individual atoms of the unit cell, each having amplitude that is related to the number of 
electrons and the size of the atom as well as a phase that is derived from the position of 
the atom within the unit cell. The sum of these individual contributions is a vector with 
an amplitude |F(h)| and a phase α(h) where h is equal to (hkl) and h, k, and l are the 
Miller indices that define the diffraction maxima. 
F(h), designated as the structure factor (because it depends only on the structure of the 
scatterer), can be expressed in terms of the fj, the individual scattering factors for the j 
atoms in the unit cell, and the atomic coordinates xj.  
)(exp)()x.(2exp)( j hihFhifhF j απ == ∑ ……….. (Eq.1) 
By rotating the crystal relative to the X-ray beam, it is possible to record and measure the 
complete diffraction pattern of the crystal. |F(h)| can directly be measured since it is 
related to the intensities of the diffraction maxima, but the phase angle α(h), cannot be 
measured experimentally. These lost phases are recovered by mainly using three 
methods, two of which (multiple isomorphous replacement (Green et al., 1964) and 
 199
Structural Characterization of hemextin A 
anomalous scattering (Yang et al., 1990)) involve heavy atoms, while the third uses a 
procedure called molecular replacement. When both the amplitudes and the phases of the 
scattered X rays are known, they can be combined to produce an electron-density map of 
the contents of the unit cell, the repeating unit of the crystal. The electron density (ρ) at 
any position xyz in the unit cell of the crystal is represented by the following equation 
(with i equal to the square root of –1). 
( ) ∑ ++−= hkl lzkyhxihklilkhFzyx )(2exp)(exp),,(,, παρ ………….. (Eq.2) 
The resolution of the electron density map depends on the angular extent to which the 
intensity data have been measured. This is related to the spacing, d, of lattice planes 
within the unit cell according to Bragg's Law:  
θλ sin2d= ............... (Eq.3) 
where, λ is the wavelength of the diffracted X rays and θ is the diffraction angle 
Resolution in a protein structure is usually defined as the value of the dmin corresponding 
to the θmax of the data set. For highly ordered small-molecule crystals that can diffract to 
the limit allowed by the wavelength of the X rays used i.e., to θ max = 90°, the resolution 
would be l /2 Å. Proteins have not yet been observed to attain this resolution.  
After an electron density of good resolution is obtained, the polypeptide sequence of the 
protein is fitted to this map to generate the initial model of the protein. The initial model 
of the protein will contain significant errors resulting from the imperfect phasing of the 
experimental electron-density map. This model is therefore improved, a procedure called 
refinement. The aim of refinement is to minimize differences between the calculated and 
experimental structure factors while at the same time optimizing the stereochemistry. 
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There are a variety of software packages available for refinement, listed in Westhof and 
Dumas (Westhof and Dumas, 1996). The progress of the refinement can be indicated 










co ..................... (Eq.4) 
R factor can vary from 0.4 to 0.5 (or from 40% to 50%, if expressed as a percentage) for 
an essentially correct but unrefined structure, to values as low as 0.12 (12%) for an 
exceptionally well-refined structure. Most well-refined structures produce R values <0.2 
(20%).  
After the initial structure of the protein is obtained, it is assessed for errors using the 
Ramachandran plot (RAMACHANDRAN et al., 1963). The Ramachandran plot is used 
by structural biologist to verify the stereochemistry of the determined structure. Recently, 
Brunger (Sutton et al., 1998) has proposed a cross-validation procedure that involves 
omitting a certain percentage (approximately 10%) of the reflections in the refinement 
but using them to calculate an Rfree, which will then provide an independent check of the 
validity of the structure. 
Structure of hemextin A 
As discussed in the previous chapters, hemextin AB complex is the only known 
heterotetrameric complex of three-finger toxins. It is also the only known natural 
inhibitor of FVIIa, which unlike the other known natural inhibitors (TFPI and NAPc2) 
does not use FX or TF to bind to FVIIa. Of the two proteins that participate in the 
formation of hemextin AB complex, hemextin A individually exhibits mild anticoagulant 
activity where as hemextin B is inactive. Using X-ray crystallography, we have solved 
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the three-dimensional structure of hemextin A. In this chapter, we discuss the 
crystallization, data collection and structure determination of hemextin A, the active 
component participating in the formation of hemextin AB complex.  
 
MATERIALS AND METHODS 
Proteins and Reagents – Hemextin A, was isolated from the crude venom of H. 
haemachatus in the same way as detailed in Chapter 2. Crystallization Screens (I & II), 
crystallization trays and grease were purchased from Hampton Research 
34 Journey, Aliso Viejo, CA, USA. All other reagents were of the highest analytical 
grade. 
Crystallization of hemextin A – Two of the most commonly used methods for protein 
crystallization3 fall under the category of vapor diffusion. These are known as the 
hanging drop and sitting drop methods. Both entail a droplet containing purified protein, 
buffer, and precipitant being allowed to equilibrate with a larger reservoir containing 
similar buffers and precipitants in higher concentrations. Initially, the droplet of protein 
solution contains an insufficient concentration of precipitant for crystallization, but as 
water vaporizes from the drop and transfers to the reservoir, the precipitant concentration 
increases to a level optimal for crystallization. Since the system is in equilibrium, these 
optimum conditions are maintained until the crystallization is complete (McPherson, 
1990).  
                                                 
3 The protein crystallization process is still empiric and a biggest part of the success is hided (hidden) in the hand and 
experience of the scientist who performed the protein crystallization and pure luck. 
   - Rhodes, Gale. “Crystallography Made Crystal Clear”. San Diego: Academic Press, 1993 
 
 202
Structural Characterization of hemextin A 
The hanging drop method differs from the sitting drop method in the vertical 
orientation of the protein solution drop within the system. It is important to mention that 
both methods require a closed system, that is, the system must be sealed off from the 
outside using an airtight container or high-vacuum grease between glass surfaces. 
Crystallization trials for hemextin A were conducted using the hanging drop vapor 
diffusion method and a wide range of conditions were tested using the Hampton Research 
Screens (I & II). In either case, the protein concentration was kept approximately 30 
mg/ml and the drops were prepared by mixing equal volumes (1 µl) of protein solution 
and the crystallizing solution. The initial screening identified the crystallization 
conditions for hemextin A with polyethyleneglycol (PEG) 4000 as a precipitating agent. 
By systematic optimization around the preliminary condition, we obtained diffraction 
quality crystals for hemextin A. The crystals of hemextin A were obtained from  0.2 M 
ammonium acetate, 0.1 M sodium acetate trihydrate, 30% (w/v) PEG 4000 (pH 4.6) and 
appeared 12 to 15 days after they were set up. The crystals were rod-shaped and belonged 
to the orthorhombic crystal system (Figure. 6.1). 
Data Collection – One complete native data set for hemextin A was collected. Prior to 
data collection, crystals of the protein were briefly soaked in a cryo-protectant solution 
consisting of mother liquor supplemented with 25% (w/v) glycerol. Crystals were picked 
by a nylon cryo-loop, and frozen at 100 K in nitrogen (gas) cold stream (Cryostream 
cooler; Oxford Cryosystems, Oxford, England). A complete data set was then measured 
both at R-Axis IV++ area detector mounted on a rotating anode X-ray generator (CuKα 
radiation) and at synchrotron beamline using Quantum 4-CCD detector, Brookhaven 
National Laboratory. 
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Figure 6.1 Crystal of hemextin A. Diffraction quality crystals for hemextin A. were 
obtained from  0.2 M ammonium acetate, 0.1 M sodium acetate trihydrate, 30% (w/v) 
PEG 4000 (pH 4.6) and appeared 12 to 15 days after they were set up. The crystals were 
rod-shaped and belonged to the orthorhombic crystal system 
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The data were indexed, integrated, and scaled using HKL2000 (Yeates, 1997). Hemextin 
A crystal belonged to the orthorhombic system, and diffracted up to 1.5 Å resolution. The 
space group was established as P212121, with a = 49.27, b = 49.51 and c = 57.87Å, Vm= 
2.92 Å3 Da-1, two molecules per asymmetric unit and corresponded to a solvent content of 
57.9%. 
Solution of structure and refinement – The structure of the hemextin A was 
determined by molecular replacement method using MolReP program. The coordinates of 
Naja nigricollis toxin-γ monomer structure (PDB code 1tgx) were used as a search 
model. Two hemextin A molecules were located in the asymmetric unit after rotation and 
translation function searches The rigid body refinement after determining the translation 
components gave a correlation coefficient of 0.63 and R = 0.51. The resultant electron-
density map obtained for hemextin A was of good quality. Several cycles of map fitting 
with the using O v7.0 (Jones et al., 1991), and refinement using the program CNS v.1.1. 
(Brunger et al., 1998) led to convergence. During the initial stage of refinement Non 
Crystallographic Symmetry (NCS) restrains were used. The crystallographic and 
refinement statistics were given in Table 6.1. 
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Table 6.1 Crystallographic data and refinement statistics* 
Data set Hemextin A 
Crystal  
Space Group P212121




Data collection  
Resolution range (Å) 50-1.50 
Wavelength (Å) 0.9795 
Observed reflections 287505 
Unique reflections 23374 
Completeness (%) 99.9 
Overall (I/σI) 10.5 
Redundancy 12 
Rsyma (%) 7.1 
Refinement and Quality  
Resolution range (Å)  I>σ(I) 20–1.50 
Rworkb 0.2276 
Rfreec 0.2577 
RMSD bond lengths (Å) 0.01 
RMSD bond angles(º) 1.9 
Average B-factors (Å2)  
Protein atoms (928 atoms) 14.41 
Water molecules (361 atoms) 36.88 
Ramachandran plot  
Most favored regions (%) 86.5 
Additional allowed regions 
(%) 11.6 
Generously allowed regions 
(%) 1.9 
Disallowed regions (%) 0 
 
* Statistics from the current model. a Rsym = |Ii -<I>|/ |Ii| where Ii is the intensity of the ith measurement, and <I> 
is  
the mean intensity for that reflection. 
               b Rwork = | Fobs - Fcalc|/ |Fobs| where Fcalc and Fobs are the calculated and observed 
structure factor amplitudes, respectively. 
              c Rfree = as for Rwork, but for 8.0% of the total reflections chosen at random and omitted from refinement. 
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Model Validation – The correctness of stereo-chemistry of the model was verified using 
PROCHECK. The calculations of r.m.s. deviations from ideality for bonds, angles, and 
dihedral and improper angles performed in CNS showed satisfactory stereochemistry. 
Ramachandran plot, showed approximately 87% of all residues within the most favored 
regions and no residues in the disallowed regions.  An example of the electron density 
from a simulated annealing omit map in the conserved region is presented in Figure 6.2.  
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RESULTS AND DISCUSSION 
Structure of hemextin A – The three-dimensional structure of hemextin A was determined 
at 1.5Å resolution. The crystal structure of hemextin A shows the general three-fingered 
folding and consists of six β-strands (β2↓β1↑β4↓β3↑β6↓β5↑) which forms two β-sheets 
(Figure 6.3). The fist β-sheet consists of two antiparallel β-strands β1 (Lys2-Lys6) and β2 
(Phe10-Thr14), while the second contains four antiparallel strands β3 (Leu21-Thr26), β4 
(Ile35-Thr40), β5 (Ala42-Ser47) and β6 (Lys51-Asn56).The overall structure of the 
protein is conserved with other members of the three-finger family. The fold of hemextin 
A is maintained by four disulfide bonds.  
As mentioned above, there are two molecules in the asymmetric unit. The overall 
dimensions of the dimeric hemextin A is approximately 36 × 22 × 22Å, with that of the 
monomer being 29 × 13 × 22Å. The two molecules of the asymmetric unit are held 
together by the hydrophobic interactions mediated by the side chains of Leu7, Tyr23, 
Met25, Leu27, Ile35, Pro44, Leu48, Leu49 and Val50 from both monomers. 
A search for topologically similar proteins within the PDB was performed with the 
program DALI (Holm and Sander, 1993). Significant structural similarity was found 
between the hemextin A and several three finger toxins. The highest structural similarity 
is observed between hemextin A and toxin-γ (Bilwes et al., 1994), a carditoxin from Naja 
nigricollis (PDB code 1tgx) yielding an RMSD of 1.7Å for 60 Cα atoms, with a Z score 
10.7. This is followed by bucandin (Torres et al., 2001), a presynaptic neurotoxin from 
Bungarus candidus (PDB code 1f94; RMSD of 2.3Å for 56 Cα atoms with a Z score 8.6 
and erabutoxin b (REF), a neurotxic protein binding to acetylcholine receptor from the 
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Figure 6.2 Electron density map. An example of the electron density from a simulated 




















Structural Characterization of hemextin A 
 
Figure 6.3 Overall structure of hemextin A.  Note, the three-fingered folding consisting of six 
β-strands (β2↓β1↑β4↓β3↑β6↓β5↑). Cysteine bonds are shown in yellow 
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Figure 6.4 Surface plot of hemextin A, showing electrostatic potential. The localization of 

















Structural Characterization of hemextin A 
 
Figure 6.5 Superimposition of hemextin A with three-finger proteins of highest structural 
similarity. Hemextin A (green) with toxin γ (PDB code 1tgx; yellow) and erabutoxin-b (PDB 
code 3ebx; green). 
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venom of the sea snake Laticauda semifasciata (PDB code 3ebx; RMSD of 2.5Å for 55 
Cα atoms; Z score = 7.2)(Low et al., 1976). These observations are consistent with an 
evolutionarily conserved structure for the three finger toxins. Figure 6.5 shows the 
superposition of hemextin A with topologically similar three-finger toxins. 
Concluding remarks 
In conclusion, the structure of hemextin A shows that it belongs to the three-
finger family of snake venom proteins. Proteins belonging to this family differ from each 
other in their biological activities (Kini, 2002). However, hemextin A is the only known 
three-finger protein that exhibits FVIIa inhibitory activity. Therefore, even a cautious 
guess4 about the critical residues required for the anticoagulant activity can not be made, 
and can only be identified either by site directed mutagenesis studies or by solving the 
FVIIa-hemextin A complex structure. The structure of hemextin A will help us in 
identifying the position of the active site residues and the conformation of the active site. 
This will in turn facilitate the design of anticoagulant peptides for the treatment of 
thromboembolic disorders. 
As evident from the other chapters in the thesis, hemextin A forms a complex with 
another three-finger toxin hemextin B. Currently, we have optimized the crystallization 
condition for hemextin AB complex and the structure of the complex will be solved using 
X-ray crystallography. Though the present structure of hemextin A does not shade light 
on the residues important for complex formation, it is pivotal in the understanding of the 
conformational changes which the protein undergoes upon complex formation. These 
                                                 
4 First you guess. Don’t laugh, this is the most important step. Then you compute the consequences. Compare 
the consequences to experience. If it disagrees with experience, the guess is wrong. In that simple statement is 
the key to science. It doesn’t matter how beautiful your guess is or how smart you are or what your name is. If it 
disagrees with experience, it’s wrong. That’s all there is to it. -----  Richard P. Feynman (US theoretical physicist) 
 
 213
Structural Characterization of hemextin A 
conformational restrains can be introduced into the molecule, which will help in 
improving the potency of anticoagulant activity of hemextin A. 
In, summary the structure of hemextin A is the first stepping stone in the path of 
understanding the structure-function relationship of the hemextin AB complex5.    
------------------------------------------------------------------------------------------------------------ 
 
                                                 
5 Just because something doesn’t do what you planned it to do doesn’t mean it’s useless. 
















A conclusion is the place where you got tired of thinking. 




A dissertation is never finished. It is abandoned at the least damaging point. 
     - Phil Race, How to get a good degree (1999) 
Conclusions 
 
This thesis reports the isolation and characterization of two proteins – hemextin A and 
hemextin B from the venom of H. haemachatus that synergistically induce potent 
anticoagulant activity. Individually, only hemextin A exhibited mild anticoagulant 
activity, whereas hemextin B has no anticoagulant activity. Hemextin A has 61 amino 
acid residues with a molecular weight of 6835 Da where as hemextin B consists of 60 
amino acid residues with a molecular weight of 6792 Da. The primary structure of both 
proteins show that the cysteine bonding pattern is conserved with the important members 
of the three-finger family of snake venom proteins, which shows that both the proteins 
are members of this family. 
The increase in the anticoagulant potency of hemextin A in the presence of hemextin B 
indicated probable complex formation between the two proteins. 1:1 complex formation 
was detected between hemextins A and B. This complex was designated as hemextin AB 
complex. Complex formation between the two proteins is pivotal for the potent 
anticoagulant activity.  
It is a well known fact that disulfide bonds (SS) associated with cysteine residues are 
essential structural units in proteins. Hemextins A and B consist of eight cysteine residues 
associated with four disulfide bonds. Proper folding of the proteins is a pre-requisite not 
only for the anticoagulant function but also for proper formation of hemextin AB 
complex. 
Using “dissection approach”, it was revealed that both hemextin A and hemextin AB 
complex inhibit the extrinsic tenase complex but not other steps in the extrinsic pathway. 
Further studies showed that hemextin A and hemextin AB complex inhibit the amidolytic 




the synergistic complex being higher than hemextin A, the IC50 of inhibition being ~100 
nM in both the assays. Similar IC50 values may be indicative of the fact that hemextin A 
and hemextin AB complex do not bind to the cofactor binding site of FVIIa. Specificity 
of hemextin A and the hemextin AB complex were screened against 12 serine proteases, 
which revealed that both hemextin A and the complex are specific and potent inhibitors 
of FVIIa. However, both hemextin A and hemextin AB complex also inhibited plasma 
kallikrein activity with lesser potency. Kinetic data showed that hemextin AB complex is 
a noncompetitive inhibitor of FVIIa-sTF complex with a Ki of 25 nM. 
Hemextin AB complex is only known heterotetrameric complex formed by two three-
finger toxins, and therefore molecular interactions participating in complex formation 
were characterized biophysically. Complex formation is enthalpically driven and 
indicates burial of hydrophobic surface area. Hemextin AB complex has a relatively 
larger molecular diameter than the individual hemextins in both gas and solution phases. 
Its formation is not a rigid-body-association, but the assembly takes place through local 
unfolding and refolding. Both electrostatic and hydrophobic interactions are important for 
the assembly of the tetramer. Based on our results we have proposed a model for the 
formation of the tetramer. This model predicts that complex formation takes place by the 
participation of two interfaces. One of the interfaces is sensitive to the buffer ionic 
strength, indicating that electrostatic interactions are predominantly active in that 
interface. The other being sensitive to the glycerol concentration of the solution indicates 
the participation of mostly hydrophobic interactions.  
The proposed model was further validated, in the studies where the particular binding site 




and hemextin AB complex bind specifically to the heavy chain of FVIIa. Interestingly, 
the binding affinity of both the anticoagulant protein and the complex for FVIIa is not 
affected by soluble tissue-factor (the co-factor for FVIIa). This highlights the fact that the 
anticoagulant binding site is distinct from the co-factor binding site. Since, hemextin AB 
complex is a non-competitive inhibitor of FVIIa, we also tested the binding of the 
anticoagulant for active site blocked FVIIa. Binding was detected, though there was fall 
in the binding affinity which can be attributed to the conformational change in the heavy 
chain that takes place when the active site of FVIIa is occupied. But the finding clearly 
highlights the fact that the anticoagulant site is distinct from the active site of FVIIa. 
Since hemextin A is the only known three-finger protein that exhibits FVIIa inhibitory 
activity, its structure was solved using X-ray crystallography at 1.5 Å resolution. 
Hemextin A, like all three-finger proteins has the characteristic three-finger fold and 
consists of six β-strands. Currently, the condition for crystallizing the tetrameric 
hemextin AB complex is being optimized and in the near future its structure will be 
solved. 
Thus, in summary this thesis details the isolation, purification and characterization of an 
anticoagulant three-finger protein and its synergistic complex with another protein 
belonging to the same family, that specifically inhibit clot initiation by inhibiting the 
activity of coagulation FVIIa. This study therefore provides a new paradigm in the search 






A PhD is about finding more and more about less and 
less, until one eventually knows everything about nothing 
Anon 
 
While the work ascribed to this thesis has addressed some fundamental issues pertaining 
to the structure and function of hemextin AB complex (a synergistic anticoagulant 
complex between two three-finger toxins hemextins A and B, from Ringhals venom), it 
has also given rise to some pertinent questions1 that could open up new and interesting 
avenues of research. 
1. Why does hemextin A undergo conformational change in salt, and hemextin 
B does not? 
Both the proteins belong to the three-finger toxin family and share 84% sequence 
identity. But it is hemextin A that is sensitive to the ionic strength of its surroundings 
and not hemextin B. Therefore, it will be interesting to study the molecular dynamics 
of both the proteins, especially hemextin A in solutions of different ionic strength(s) 
using NMR spectroscopy. This study also has great potential in a broader sense, since 
it may shade light on the effect of electrostatics on protein folding.  
2. How will the 3D-structure of tetrameric hemextin AB complex look like? 
Hemextin AB complex is the only known tetrameric complex between two three-
finger toxins. This thesis describes the crystallization and structure of hemextin A. 
The next step would be to solve the structure of the synergistic complex. The 
individual structure of hemextin B can then be solved using MR. A comparison of the 
                                                 
1 “Science is wonderfully equipped to answer the question "How?" but it gets terribly confused when you 
ask the question "Why?"” 





structures will show the conformational changes that both proteins undergo on 
complex formation. More importantly, it will tell how hemextin B potentiates the 
anticoagulant activity of hemextin A, and the key residues in the proteins involved in 
complex formation.   
3. Which part(s) of the heavy chain of FVIIa is involved in binding to the 
anticoagulant complex? 
In this thesis it has been shown that hemextin AB complex binds to the heavy chain 
of FVIIa. However, the specific part of the heavy chain involved in interaction still 
remains to be elucidated. The heavy chain of FVIIa has two distinct exosites (Banner 
et al., 1996). Peptides have been identified that bind to these exosites (Dennis et al., 
2000). Competition binding experiments can be conducted with these peptides to 
confirm if these exosites of the heavy chain are involved the binding process.  
Further, H-D exchange studies, between isolated FVIIa heavy chain and hemextin AB 
complex can be carried out to identify the particular segment of heavy chain that is 
involved in the binding process. 
4. How will the 3D-structure of FVIIa-hemextin AB complex /sTF-FVIIa-
hemextin AB complex look like? 
Hemextin AB complex can be co-crystallized with coagulation FVIIa or reconstituted 
sTF-FVIIa complex, followed by the determination of 3D-structure using MR, since 
the individual structures of both sTF-FVIIa (Banner et al., 1996) and FVIIa 
(Kemball-Cook et al., 1999) are known. If solved, this structure will provide valuable 




and inhibitor. The principal challenge however, will be to optimize the conditions for 
the proper growth of enzyme-inhibitor complex. 
5. How to design2 an anticoagulant? 
Hemextin A and its synergistic complex with hemextin B, inhibit clot initiation by 
binding specifically to coagulation FVIIa. Hemextin A is the active protein. Before 
designing an anticoagulant one needs to identify the specific residues that are 
important for anticoagulant activity. Site directed mutagenesis can achieve that aim. 
A point to keep note of in this step is the correct fold of the mutants, since the work in 
this thesis shows that β-sheet fold of hemextin A is important for its anticoagulant 
activity. 
After the residues important for anticoagulant activity have been identified, we can 
mimic this activity in a protein scaffold that has a three-finger fold, but is itself inert 
and has lesser amino acid residues compared to hemextin A. Following the successful 
identification of the protein scaffold, using the combinatorial search algorithm 
(Looger et al., 2003) one will be able to identify the particular region of the scaffold 
that satisfies the constraints, where the active residues (identified from mutagenesis 
studies) can be inserted. Since the anticoagulant activity of hemextin A is potentiated 
by hemextin B, it can be concluded that a particular conformation of the protein has 
potent anticoagulant activity, and the protein attains this conformation upon binding 
to hemextin B. Biophysical studies have shown that on complex formation there is 
stabilization of β-sheet in hemextin A. Therefore, various conformers of the scaffold 
                                                 
2 “A common mistake that people make when trying to design something completely foolproof is to 
underestimate the ingenuity of complete fools.” 




with the active residues (SAR) can be synthesized using iterative higherarchial 
approach algorithm (Hellinga and Richards, 1991). The SAR conformer with the 
highest anticoagulant activity is to be selected. Further optimization of the 
anticoagulant site in SAR can be done using the RD algorithm (Dwyer et al., 2004). 
The binding affinity of this binding site optimized SAR for FVIIa is to be determined. 
Next, by using PARE (Predicting Association Rate Enhancement) algorithm 
(Schreiber and Fersht, 1996), further increase in the kon between FVIIa and SAR can 
be made, and can be experimentally evaluated using Biacore. The final version of SAR 
then can be directed for evolution by random mutagenesis (Dwyer et al., 2004). The 
final version of the rationally designed SAR can then be evaluated for anticoagulant 










Thank you note, 
 
The part on future prospect depicts some of my ideas that can be pursued to answer 
some of the questions which I feel pertinent regarding the project. Out of all the 
questions the final one of designing an anticoagulant, came to my mind while reading 
an excellent paper published in Science titled “Computational design of a 
biologically active enzyme” by Professor Hellinga and his colleagues. However, I 
got some help in the understanding of the algorithms, since this aspect of science 
was completely new to me. For this I will like to thank Prof. Gideon Schreiber 
(Department of Biological Chemistry, Weizmann Institute of Science), who not 
only answered my questions but also sent me all the material on PARE algorithm 
(which is designed by him), including a complete book chapter. If the reader 
however, finds any flaw in the sequence of experimental design(s), it is I who is 
to be blamed solely. 







“The point is that you can and should find many more examples by reading the 
literature yourself. If you read things at face value and don’t wise up to the hidden 
meanings in paper-speak, you might miss an opportunity to extend your own 
research. Worse, you might even get a left behind if your field is one that moves on 
rapidly. Use every opportunity to consult experienced and trusted collegues on what 
they think the authors mean, when they use a particular word or phrase. This way 
you’ll also learn another great leasson: different people interpret the same passage 
in different ways. So much for scientific papers being unambiguous and crystal 
clear!” 
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What the caterpillar calls the end of the world, the master calls a butterfly 





Snakes, particularly the venomous ones, have always been creatures of the 
myth. For example in Egyptian history, the snake plays an important role, 
with the Nile cobra adorning the crown of the pharaoh in ancient times. 
Similarly, in Greek mythology snakes are often associated with deadly and 
dangerous antagonists. The nine headed Hydra Hercules defeated and the 
three Gorgon sisters are literary examples. Interestingly, two medical 
symbols involving snakes are still used today – “Bowl of Hygieia”, symbolizing 
pharmacy, and the “Caduceus and Rod of Asclepius”, which are symbols 
denoting medicine in general. Present day Hollywood movie captions like “It 
will take your breath away” (on the poster of the movie Anaconda) and “Sit 
back. Relax. Enjoy the fright” (on the poster of the movie Snakes on a Plane), 
still heighten our fear and curiosity about these wonderful creatures. But 
some of us rather than giving snakes of all descriptions a wide berth, seek 
them out. They are as you might have rightly guessed, snake charmers and 
snake venom researchers. While charming of snakes is outside the scopes of 
this thesis, the study of venom is its substance. But in order to maintain the 
flow of the thesis, it was not possible for me to elucidate on the different 
varieties of venomous snakes, different families of snake venom proteins and 
also on the different types of spitting cobras (one of which have made this 
study possible by generously providing me with its venom), in the actual 
chapters. In the following pages, brief overviews of the above mentioned 
topics are given, to provide the reader with preliminary information about 





Table 1. Classification of venomous snakes 
Family Number of 
Species 
Examples Distribution Characteristics 




Small head, short 
and fixed fangs. 







fangs on the 
maxillary bone. 
Crotalidae (Folding fang) 40 Pit vipers Americas, Parts of 
Southeast Asia, 
Southeast Europe 
Similar to the 
family Viperdae, 
but they possess 
heat-sensitive pits 
on head 








50 Sea snakes Asia and 
Australasia 
Nostrils dorsally on 
head, flattened 
tail. 
From: Harris J.B. (1991) In: Snake toxins (Ed Harvey, A.L.) 
There are about 3200 species of snakes. Approximately 1300 species are 
venomous. Avoid them all! 
Venomous snakes are usually defined as those which possess venom glands 
and specialized venom-conducting fangs, which enable then to inflict serious 
bites upon there victims. In general there are five families of venomous 
snakes recognized: the Colubridae, which possess small rear fangs; the 
front-fanged Elapidae and Hydrophidae; and the viper group, which consists 
of the Viperdae and Crotalidae. Venomous snakes are widespread throughout 
the world. However they do not occur in several islands, New Zealand, 










Enzymatic anticoagulant proteins 
Inhibits activation 


















to FXa and 




















Weaker soft clot 



























Deplete  fibrinogen 
in the plasma 
Releases either 
fibrinopeptide A 
or B;  fibrin 
clots are 
removed leading 









L-Amino acid oxidase Inhibits FIX activity Mechanism not 
known 
Non-enzymatic anticoagulant proteins 






Bind to the Gla 
domain of FIX 
and FX, and 










Inhibit activity of 
thrombin 
Bind to α−thrombin 
at both exosite-




Act on the extrinsic 






















Table 3. Snake venom protein families 
 









118 – 130 residues; 7 
disulfide bonds; His is the 
active site residue; Ca2+-
dependent activity 
 
Pre- and post-synaptic 
neurotoxicity, myotoxicity, 
cardiotoxicity, convulsant 
effect, hypotensive effect, 
platelet aggregation induction 
and inhibition, hemolysis, 






~235 residues; 6 disulfide 
bonds; His, Ser, Asp form 









~200 residues; 3 – 4 
disulfides; 4 -domains 
(Domain A – 
metalloprotease– 
disintegrin– Cys-rich); 
various protein substrates 
Hemorrhage, anti -platelet 






~545 residues; monomers, 
dimers or tetramers; 3 
disulfide bonds; His, Ser, 
Glu form active site triad 
Not Known 
Acetylcholinesterase 





80 – 140 Kd; two subunits; 
flavoproteins 
Platelet aggregation,  





58 – 75 residues; 4 – 5 
disulfide bonds; typical 
three finger-like loops 
with disulfide-rich core 
Post-synaptic neurotoxicity, 
cardiotoxicity, cytolysis, 
platelet aggregation inhibition, 
analgesic effect, ion channel 











58 – 65 residues; 3 
disulfide bonds; bovine 
pancreatic trypsin inhibitor 
family 
Proteinase inhibition; potassium 




Long, medium or short 
chain; 48 – 85 residues; 4–
7 disulfides; precursor 
contains metalloproteinase 
domain 





 19 – 24 kDa; Cys-rich C-
terminal; homology with 
helothermine and Cys rich 
secretory proteins from 
testes 
Blocking of cyclic nucleotide-







~50 residues, 5 disulfide 
bonds, similar domain 
architecture like Whey 
Acidic Proteins 




Dimers, trimers or 
tetramers; Similar or 
different subunits held by 
disulfide bonds; ~130 
residues; 3 intrachain and 
1 interchain disulfide bond 
Induction or inhibition of 










This group of snakes refers to any one of several species of cobras that 
have the ability to spit or eject venom from their mouth when defending 
themselves against predators. 
The spit venom is far diluted 
than the one that is secreted 
and is harmless to intact skin. 
However it can cause permanent 
blindness if introduced to the 
eye causing chemosis and corneal 
swelling. 
The venom is not actually spitted 
but sprayed. Spraying is carried 
out using muscular contractions 
upon the venom glands. The 
muscles squeeze the glands and 
force the venom out the forward 
facing holes at the tip of the fang. Upon leaving the fang tip a large gust of 
air is expelled from the lung. The venom is propelled forward, mist-like, in 
the form of droplets. Four out of seven species of cobras found in Africa 
and seven out of nine species found in Asia can spit to varying degrees. 
While spitting is typically their primary form of defense, all spitting cobras 
are also capable of delivering venom through a bite as well. A brief 
description of some of the spitting cobras including the one, the venom of 
which has been used in this study is given below. 
 
 










Hemachatus haemachatus (African Ringhals Cobra) 
Ringhals cobras are generally dull grey, grey brown or black and have white 
bars on the neck. The number of bars varies between one and 3 but is usually 
2.  They have keeled 
scales and are 
ovoviviparous, which 
make them unique 
among elapids. Unlike 
cobras, they have light 
bars on dark ventral 
scales, whereas the 
cobras have dark bars 
on lighter scales. The 
ventral scales of this 
species are normally 
dark grey to light grey, 
but white in juveniles.  
They are found in Southern Africa. However, isolated populations also exist 
in Zimbabwe and Mozambique. In South Africa ringhals are primarily 
distributed in the south cape through Swaziland, Orange free state, Natal, 
Tranbskei, Lesotho and southern Transvaal.  
Ringhals cobra is only a small snake, adults have a average length of 100 cm 
but large ones may grow up to 150 cm. Their preferred habitat is grassland 
and moist savanna. But they also live in rocky areas as well. They are also 
known to live close to permanent water holes and scrub.  In the wild ringhals 
mostly eat toads but also small rodents, birds, lizards and even snakes. As 
mentioned above ringhals is ovoviviparous. In the wild the females give birth 
to 20-35 young, but as many as 65 babies have been recorded. The babies 
have an average length of 17 cm.  
Ringhals’ bites are not common but can be potentially lethal. The average 
yield of venom per milking is around 80-120 mg and approximately 30-40mg 




Photograph reproduced with kind permission from Mr. Mark M Lucas 
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Naja Pallida (Red Spitting Cobra) 
 
 
Red spitting cobra 
ranges in length 
between 70 to120 cm, 
with a maximum of 
150 cm. It has a long 
tail which can be (15–
19) % of the total 
body length. It is a 
relatively small cobra 
that is quite slender 
in body proportions. 
It has a small head 
(some specimens 
however, can have big 
heads with huge swollen venom glands clearly seen at the side of the head) 
with large eyes, with a round pupil. The tail is long and the body is cylindrical 
in shape.  
The colour of this cobra can be variable depending on the origin of the snake. 
The specimens from southern Kenya and northern Tanzania have an orange 
red colour, with a broad steel blue or black throat band. In some specimens 
from East Africa two or three throat bands has also been observed. The 
ventral side of the snake is also reddish in colour with sometimes a crèmes 
white throat. Specimens from other areas can be yellow, pinkish, pink-grey, 
pale red or steel grey which can be mistaken for dark green, most of them 
will have the throat band, but this throat band will fade or even sometimes 
disappear in larger adults. The true red specimens will become red-brown 
with increase in their size.  
These cobras prefer grassland semi desserts and savannah. They are often 
found near water holes where they hunt on frogs and other amphibians which 
is their main food. They are also known to be cannibalistic, this could be the 
reason that the juveniles and smaller specimens are day active while adult 
are preferred nocturnal. 
The venom spat by red spitting cobras has been analyzed to document 
variations in protein composition occurring over short temporal periods (less 
than 5 min). These cobras exhibited distinct control of venom flow with spits 
averaging 1.7% of the volume of the venom gland, thus enabling the cobras to 
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rapidly expel over 40 consecutive spits. Variations in the low and high 
molecular weight proteins were observed when comparing the 1st, 20th and 
40th spits produced by the same specimens. The first few spits were 
characterized by a distinctive 9 kDa protein which was never observed 
beyond the 7th spit; but was present in milked venom and was present when 
the spitting behavior was preceded by a 5 min period of induced defensive 
behaviors. 
 











Naja nigricollis nigricollis (Black-necked Spitting Cobra) 
 
This species is recognized in three subspecies black-necked spitting cobra 
(Naja nigricollis nigricollis), black Spitting cobra (Naja nigricollis woodi), 
western barred spitting 
cobra (Naja nigricollis 
nigricincta). Adults 
snake reach an average 
length of 1 m (maximum 
1.5 m). 
It is a long, slender, 
pitch black snake. It is 
more agile and thinner 
than a black mole snake 
and when threatened, it 
will spread the 
characteristic cobra 
hood. 
This is an arid-adapted snake found in some of the harshest areas of the 
Northern and Western Cape provinces in Africa. It is a generalist and will 
eat most reptiles, amphibians and rodents. It is alert and agile and can 
normally evade danger by spreading a hood in an attempt to get an attacker 
to back off and then by rapidly retreating to a place of safety under a rock 
or down a hole. If escape is hindered, it will spit venom profusely at its 
attacker and take advantage of any hesitation this may cause to affect its 
escape. It is a good spitter and can spit venom several meters. If molested 
further, it will bite. The venom is neurotoxic and a bite from this species 
may cause death if not treated. If venom is sprayed in the eyes of a mammal, 
it may cause blindness if not washed out immediately with a neutral solvent 
such as water. 
 
Photograph reproduced with kind permission from Mr. Mark M Lucas 
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Naja Siamensis (Golden Spitting Cobra) 
 
Also known as Isan spitting cobra; Naja (naja) isanensis. However, it is often 
mislabeled as Naja 
sputatrix . The latter 
does not have a black 
and white pattern.  
The identification 
pattern of this species 
is highly variable. 
Specimens from 
northern and eastern 
Thailand tend to be 
uniformly light brown, 
olive, sometimes 
distinctly greenish, 
often with a somewhat 
faded appearance. Specimens from central Thailand are highly variable. 
Some have a very contrasting black-and-white pattern, with or without 
speckling and cross-banding, and a light venter with or without broad dark 
cross-bands, others are some shade of brown or greyish brown, with or 
without lighter cross-bands on dorsum, often with several broad dark bands 
across belly, others, especially from the west, are uniformly black. Hood 
mark in northern, eastern and southeastern Thailand V, U, or, most 
commonly, spectacle-shaped, but often very indistinct or absent altogether; 
in central Thailand, H-shaped hood marks are also common, but hood marks 
are often absent altogether.  
This species have 25-31 scale rows around hood, 19-21 just ahead of 
midbody; 153-174 ventrals, 45-54 subcaudals, basal pairs sometimes 
undivided. They are usually 90-120 cm in length with a maximum of 160 cm. 
This species is widely distributed in Thailand (except on Malayan Peninsula), 
western Laos, Cambodia, southern Vietnam.  
 
   
 
 














Naja Sputatrix (Javan Spitting Cobra) 
 
This species is also known 
as south Indonesian 
spitting cobra or Malayan 
spitting cobra. 
Specimens from Java are 
usually uniform yellowish, 
brown or blackish; 
juveniles often have 
throat band and lateral 
throat spots, sometimes 
a hood mark, which is 
most often chevron-
shaped, rarely mask-, 
spectacle-, horseshoe- or O-shaped; specimens from the Lesser Sunda 
Islands usually medium or light brown, with lighter scale bases; throat band 
and heart-shaped hood mark persist into adulthood.  
This species possess 19-28 scale rows around hood, 18-21 just ahead of 
midbody; Javan specimens have more scale rows than Lesser Sunda 
specimens; 162-183 ventrals, 42-54 subcaudals, normally all divided. An adult 
snake is up to 150 cm, rarely more.  
The species is widely distributed in Southern Indonesia: Java, Bali, Lombok, 
Sumbawa, Komodo, Flores, Lomblen, Alor, possibly other islands in the group. 
However, the occurrence of this species on Timor and Sulawesi requires 
confirmation.  
 
   































This is a new species of spitting cobra described from north-eastern Africa. 
The distinctiveness of the new species has been confirmed by multivariate 
analysis of pattern and 
scalation data. Phylogenetic 
analysis of mitochondrial 
DNA sequences reveals the 
new species to be the sister 
taxon of N. pallida, but with 
considerable levels of 
sequence divergence 
relative to that species. 
The populations concerned had previously been assigned to N. pallida. The 
new species differs from N. pallida principally in having more than one dark 
band across the neck and under the throat, as well as a pair of spots under 
the throat. It occupies a disjunct range across Egypt, the Sudan, Chad, 
Niger and Eritrea, where it seems to occupy primarily relatively mesic 
habitats. Naja mossambica is more closely related to N. nigricollis than to N. 
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of the step of action of anticoagulant agents in the blood
coagulation cascade1
R . M. K IN I and Y . BANER JEE*
*Protein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore 117 543,
Singapore; and Department of Biochemistry and Molecular Biophysics, Medical College of Virginia, Virginia Commonwealth University,
Richmond, VA 13298, USA
To cite this article: Kini RM, Banerjee Y. Dissection approach: a simple strategy for the identification of the step of action of anticoagulant agents in
the blood coagulation cascade. J Thromb Haemost 2005; 3: 170–1.
Thromboembolic disorders, such as phlebitis, phelebothrom-
bosis, deep vein thrombosis and pulmonary embolism, are
important problems in the aging population worldwide.
Anticoagulant agents are used for the effective prophylaxis
and treatment of thrombosis. Identifying the site at which the
anticoagulants affect the blood coagulation cascade and
understanding the mechanism are essential steps in the
characterization of novel and efﬁcacious anticoagulants. We
designed a simple approach [1] to determine the particular step
at which an anticoagulant interferes in the extrinsic pathway.
This dissection approach is rapid, cost effective and employs
three commonly used clotting assays, namely prothrombin
time [2], Stypven time [3] and thrombin time [4]. It is based on
the simple principle that initiating the cascade upstream from
the inhibited step will result in elevated clotting times, while
initiating the cascade downstream from the inhibited step will
not affect the clotting time [1] (Fig. 1A).
Prothrombin time [2] measures the effect of an anticoagulant
on the extrinsic tenase and prothrombinase complexes and the
conversion of ﬁbrinogen to ﬁbrin clot. Stypven time [3]
circumvents the extrinsic tenase complex and monitors its
effect on the prothrombinase complex and the conversion of
ﬁbrinogen to ﬁbrin. Thrombin time [4] depicts its effect on the
conversion of ﬁbrinogen to ﬁbrin only. A systematic analysis of
the effect of an anticoagulant on these three clotting times
would help in identifying the stage of coagulation in the
extrinsic coagulation cascade.
We successfully used this approach to localize the site of
action of three anticoagulant proteins in the extrinsic pathway:
a weak anticoagulant (CM-I), a strong anticoagulant (CM-IV)
phospholipase A2 enzyme puriﬁed from the venom of Naja
nigricollis [1,2 5], and a three ﬁnger toxin (protein A) puriﬁed
from the venom of Hemachatus haemachatus. All three
proteins delay prothrombin time showing that they interfere
in the extrinsic pathway (Fig. 1B–D). CM-I and protein A did
not prolong clotting in Stypven and thrombin time assays
(Fig. 1B,C), showing that they inhibit only the extrinsic tenase
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Fig. 1. (A) Schematic representation showing the selective activation of
the extrinsic coagulation pathway by the prothrombin, Stypven and the
thrombin time clotting assays. In the prothrombin time, clotting is initiated
at the tenase complex by the addition of Ca2+ and thromboplastin,
which contains tissue factor and phospholipids (TF-PL). In the Stypven
time, clotting is initiated at the prothrombinase complex by the addition of
dilute Russell’s viper venom, which activates factor (F)X and factor
(F)V by speciﬁc proteases. FXa and FVa form the prothrombinase
complex on the PL surfaces with the addition of Ca2+. In thrombin time,
clotting is initiated by the addition of thrombin, which converts soluble
ﬁbrinogen to a ﬁbrin clot. Eﬀect of weakly anticoagulant phospholipase
A2 (CM-I) (B), a three ﬁnger toxin, protein A (C) and strongly antico-
agulant phospholipase A2 (CM-IV) (D) on the prothrombin time (D),
Stypven time (d)3 and thrombin time (j)4 clotting assays. Each point
represents the average ± SD.
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complex. On the other hand, CM-IV prolonged the Stypven
time, but did not prolong the thrombin time (Fig. 1D). Thus,
CM-IV has no effect on the conversion of ﬁbrinogen to ﬁbrin,
but it may affect either the prothrombinase complex alone or
both the extrinsic tenase and prothrombinase complexes.
Subsequent studies using reconstituted complexes have
conﬁrmed these conclusions. CM-I [6] and protein B
(Y. Banerjee and R. M. Kini, unpublished observations)
inhibit only the extrinsic tenase complex, whereas CM-IV
inhibits both the extrinsic tenase and prothrombinase com-
plexes [5,7,8].
Currently, to identify the steps, the anticoagulant is screened
serially with either the coagulation factors involved in the
extrinsic pathway or those that are plasma deﬁcient in speciﬁc
coagulation factors, making the procedure cumbersome and
costly. The dissection approach allows us to identify the speciﬁc
site of anticoagulant activity in the extrinsic pathway rapidly
and in a cost-effective manner. Therefore, this simple approach
will be useful in characterizing the potential anticoagulants and
in developing lead compounds for the prevention/treatment of
thromboembolic disorders.
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Factor XIII—circulating levels and Val34Leu polymorphism in
relatives of South Asian patients with ischemic stroke1
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Academic Unit of Molecular Vascular Medicine, University of Leeds, Leeds, UK
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Epidemiological studies demonstrate an association of coagu-
lation factors with a family history of stroke. The aim of this
study was to investigate whether there was an association of
factor (F)XIII measures and FXIIIVal34Leu genotype with a
family history of stroke in South Asians. One hundred and
forty-three South Asian ﬁrst-degree relatives of conﬁrmed
stroke patients were compared with 146 control subjects [1]. All
the subjects gave written informed consent according to a
protocol approved by Local Research Ethics Committee.
Blood samples were taken under optimum conditions and the
biochemical, coagulation and ﬁbrinolytic assays were per-
formed by standard techniques. FXIII activity was determined
by biotin incorporation microtiter plate-based assay using
ﬁbrinogen and 5-(biotinamido) pentylamine as substrates,
based on a modiﬁed method described by Song et al. [2].
FXIII B-subunit antigen levels were determined by sandwich-
ELISA and A2B2 was measured by ELISA based on an
anti-B/anti-A sandwich.
TheVal34Leu polymorphismwas determined by polymerase
chain reaction using forward 5¢-ACC CAG AGT GGT GGG
GAA G-3¢ and reverse 5¢-GAC CTT GTA AAG TCA AAA
ATG TC-3¢ primers. Statistical analyses were performed with
SPSS forWindows Version 8.0 (SPSS Inc., Chicago, IL, USA).
Trendlines were calculated with linear regression analysis.
The general and metabolic characteristics of South Asian
relatives and controls are given in Table 1. FXIII B-subunit
antigen signiﬁcantly correlated positively with triglycerides
(r ¼ 0.20/0.25) in both groups and negatively with HDL-
cholesterol in controls (r ¼ ) 0.14). FXIII B-subunit antigen
correlated with ﬁbrinogen (r ¼ 0.31/0.44), factor (F)VII anti-
gen (r ¼ 0.20/0.30) in both groups, plasminogen activator
inhibitor (PAI)-1 antigen (r ¼ 0.20) and vonWillebrand factor
(VWF) (r ¼ 0.21) in relatives only. FXIII B had no correlation
with FXIII cross-linking activity.
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Hemextin AB complex, a unique anticoagulant protein
complex fromHemachatus haemachatus (African
Ringhals cobra) venom that inhibits clot initiation and
factor VIIa activity.
Yajnavalka Banerjee, Jun Mizuguchi, Sadaaki Iwanaga, and R. Manjunatha Kini
We inadvertently reported wrong concentrations of hemextin AB
complex in the experiments examining the anticoagulant activity; factor
VIIa-TF, factor VIIa, and factor VIIa-sTF inhibitory activity; kinetics of
inhibition; and isothermal titration calorimetric studies. Because the
complex formed had a ratio of 1:1 between hemextin A and hemextin B,
it was assumed that the complex exists as a dimer. The gel filtration data
that were included during the revision of the manuscript showed that
the complex is a tetramer. However, we did not recalculate the molar
concentrations of the hemextin AB complex to reflect the tetramer
situation instead of the original assumption of a dimer. Therefore, the
concentrations of the hemextin AB complex should be half that
depicted in the article. This error, however, does not affect our main
conclusions as depicted in the paper.
The following corrected statements should be incorporated.
PAGE 42603:
The second sentence in the second paragraph under the subheading
“Kinetics of Inhibition” should read: “contained 0.0125–0.05 M inhib-
itor complex . . . ”
The second sentence in the first paragraph under the subheading
“Isothermal Titration Calorimetry (ITC)” should read: “reconstituted
anticoagulant complex (0.2 mM) . . . ”
PAGE 42607:
In the first full paragraph in the left column, line 8, the IC50 for
inhibition should appear as “100 nM” instead of 200 nM.
PAGE 42608:
In the left column, the last line of the figure legend for Fig. 8, the IC50
for inhibition should appear as “5 M” instead of 10 M.
In the first full paragraph in the right-hand column, the last two
sentences should read: “The binding was exothermic, with H 
7.931 kcalM1,G7.543 kcalM1, andS1.25 calM1. The
calculated K for the binding was 4.11 105 M1.” The calculated con-
centration affects the molar ratio in Fig. 10; the modified Fig. 10 and its
corresponding legend are shown following.
PAGE 42609:
In the first paragraph in the right-hand column, the sentence begin-
ning in line 4 should read: “The hemextin AB complex inhibited with
IC50 values of100 and105 nM, respectively.”
Also, in the same paragraph, lines 24–27 should read: “However, the
IC50 for the inhibition of kallikrein was 5 M, in contrast to that of
FVIIa/TF-FVIIa/sTF-FVIIa, which was 100 nM. Kinetic studies
revealed that the hemextin AB complex is a noncompetitive inhibitor of
the sTF-FVIIa complex, with a Ki of 25 nM.”
FIGURE 10. ITC studies on the formation of a complex between the
hemextin AB complex and FVIIa. A, raw data in cal/s versus time showing
heat release upon injections of 0.2 mM reconstituted hemextin AB complex
intoa1.4-ml cell containing10MFVIIa.B, integrationof the rawdata yielding
theheat/mol versusmolar ratio. Thebest valuesof the fittingparameterswere
4.11 105 M1 for K,7.931 kcalM1 for H, and1.25 calM1 for S.
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VOLUME 280 (2005) 36848–36856
A single aromatic amino acid at the carboxyl terminus of Helicobacter pylori1,3/4 fucosyltransferase determines
substrate specificity.
Bing Ma, Leon H. Lau, Monica M. Palcic, Bart Hazes, and Diane E. Taylor
PAGE 36848:
In theAbstract, lines 19–21, this sentence should read: “Thesemutations did not decrease1,3 activity but reduced the1,4 activity to 66.9, 55.6,
and 3.1% of wild type level, respectively.”
PAGE 36850:
In the right-hand column, lines 11–13, this sentence should read: “However, the 1,4 activities were reduced to 66.9, 55.6, and 3.1% of the WT
level, and their 1,4/1,3 ratios were at 55.6, 65.2, and 1.8% of the WT level, respectively (Fig. 1).”
Additions and Corrections
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Hemextin AB Complex, a Unique Anticoagulant Protein
Complex from Hemachatus haemachatus (African Ringhals
Cobra) Venom That Inhibits Clot Initiation and
Factor VIIa Activity*
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During injury or trauma, blood coagulation is initiated by the
interaction of factor VIIa (FVIIa) in the blood with freshly exposed
tissue factor (TF) to form the TFFVIIa complex. However,
unwanted clot formation can lead to death and debilitation due to
vascular occlusion, and hence, anticoagulants are important for the
treatment of thromboembolic disorders. Here, we report the isola-
tion and characterization of two synergistically acting anticoagu-
lant proteins, hemextins A and B, from the venom of Hemachatus
haemachatus (African Ringhals cobra). N-terminal sequences and
CDspectra of the native proteins indicate that these proteins belong
to the three-finger toxin family. Hemextin A (but not hemextin B)
exhibits mild anticoagulant activity. However, hemextin B forms a
complex (hemextin AB complex) with hemextin A and synergisti-
cally enhances its anticoagulant potency. Prothrombin time assay
showed that these two proteins form a 1:1 complex. Complex for-
mation was supported by size-exclusion chromatography. Using a
“dissection approach,” we determined that hemextin A and the
hemextin AB complex prolong clotting by inhibiting TFFVIIa
activity. The site of anticoagulant effects was supported by their
inhibitory effect on the reconstituted TFFVIIa complex. Further-
more, we demonstrated their specificity of inhibition by studying
their effects on 12 serine proteases; the hemextin AB complex
potently inhibited the amidolytic activity of FVIIa in the presence
andabsenceof solubleTF.Kinetic studies showed that thehemextin
AB complex is a noncompetitive inhibitor of soluble TFFVIIa
amidolytic activity, with a Ki of 50 nM. Isothermal titration calori-
metric studies showed that the hemextinAB complex binds directly
to FVIIa with a binding constant of 1.62  105 M1. The hemextin
AB complex is the first reported natural inhibitor of FVIIa that does
not require a scaffold to mediate its inhibitory activity. Molecular
interactions of the hemextin AB complex with FVIIa/TFFVIIa will
provide a newparadigm in the search for anticoagulants that inhibit
the initiation of blood coagulation.
Blood coagulation is an innate response to vascular injury that results
from a series of amplified reactions in which zymogens of serine pro-
teases circulating in the plasma are sequentially activated by limited
proteolysis, leading to the formation of blood clot, thereby preventing
the loss of blood (1–3). It is initiated through the extrinsic pathway (4).
Membrane-bound tissue factor (TF),3 exposed during vascular injury,
interacts with factor VIIa (FVIIa), which preexists in the plasma (at
1–2% of total factor VII) (5, 6), and forms the extrinsic tenase complex.
This complex activates FX to FXa. In association with its cofactor FVa,
FXa performs a proteolytic cleavage of prothrombin to thrombin.
Thrombin cleaves fibrinogen to fibrin, promoting the formation of a
fibrin clot, and activates platelets for inclusion in the clot. The TFFVIIa
complex can also activate FIX to FIXa, thus helping in the propagation
of the coagulation cascade through the intrinsic pathway. The coagula-
tion cascade is under tight regulation. Any imbalance in its regulation
could lead to either unclottable blood, resulting in excessive bleeding
during injuries, or unwanted clot formation, resulting in death and
debilitation due to vascular occlusion with the consequence of myocar-
dial infarction, stroke, pulmonary embolism, or venous thrombosis (3).
Therefore, there is an urgent need for the prophylaxis and treatment of
thromboembolic disorders.
Anticoagulants are pivotal for the prevention and treatment of
thromboembolic disorders, and 0.7% of the western population
receives oral anticoagulant treatment (7). Coumarins and heparin are
the most well known clinically used anticoagulants. Coumarins inhibit
the activity of all vitamin K-dependent proteins, including procoagu-
lants (thrombin, FXa, FIXa, and FVIIa) and anticoagulants (activated
protein C and protein S), whereas heparin mediates its anticoagulant
activity by enhancing the inhibition of thrombin and FXa by antithrom-
bin III (8, 9). The nonspecific mode of action of these anticoagulants
accounts for their therapeutic limitations in maintaining a balance
between thrombosis and hemostasis (10). These limitations have pro-
vided the impetus for the development of new anticoagulants that target
specific coagulation enzymes or a particular step in the clotting process
(11, 12). Because of its relatively low concentrations in blood (10 nM)
and its pivotal role in the initiation of the coagulation cascade (13),
FVII/FVIIa is an attractive drug target for the development of novel and
specific anticoagulant agents.
Proteins/toxins from snake venoms have inspired the design and
development of a number of therapeutic agents or lead molecules, par-
ticularly for cardiovascular diseases (14). For example, a family of inhib-* This work was supported in part by the Biomedical Research Council, Agency for Sci-
ence and Technology, Singapore. The costs of publication of this article were
defrayed in part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
1 Recipient of a National University of Singapore research scholarship.
2 Towhomcorrespondence shouldbeaddressed. Tel.: 65-6874-5235; Fax: 65-6779-2486;
E-mail: dbskinim@nus.edu.sg.
3 The abbreviations used are: TF, tissue factor; FVIIa, factor VIIa; pNA, p-nitroanilide; 2HCl,
dihydrochloride;Glu, pyroglutamic acid; sTF, soluble tissue factor; HPLC, high pres-
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itors of angiotensin-converting enzyme was developed based on brady-
kinin-potentiating peptides from South American snake venoms (15).
Inhibitors of platelet aggregation, such as eptifibatide and tirofiban,
were designed based on disintegrins, a large family of platelet aggrega-
tion inhibitors found in viperid and crotalid snake venoms (16–21).
Ancrod (extracted from the venom of the Malayan pit viper) reduces
blood fibrinogen levels and has been successfully tested in a variety of
ischemic conditions, including stroke (22). To search for new lead mol-
ecules, we and others have been focusing on isolating and characterizing
pharmacologically active proteins from snake venoms that affect blood
coagulation and platelet aggregation. In this study, we report the puri-
fication and characterization of a three-finger toxin that mediates anti-
coagulant activity from the venom of the elapid snake Hemachatus
haemachatus (African Ringhals cobra). Although it has mild anticoag-
ulant activity, its synergistic interaction with the second three-finger
toxin enhances its anticoagulant potency. The anticoagulant protein
and its complex specifically inhibit the activation of FX by the TFFVIIa
complex by noncompetitively inhibiting the enzymatic activity of FVIIa.
This is the first report of a naturally occurring FVIIa inhibitor that does
not require a scaffold to mediate its inhibitory activity.
EXPERIMENTAL PROCEDURES
Materials
LyophilizedH. haemachatus venomwas obtained from African Rep-
tiles and Venoms (Gauteng, South Africa). Thromboplastin with cal-
cium (for prothrombin time assays), Russell’s viper venom (for Stypven
time assays), thrombin reagent (for thrombin time assays), benzamidine
hydrochloride, and 4-vinylpyridine were purchased from Sigma.
-Mercaptoethanol was purchased from Nacalai Tesque (Kyoto,
Japan). The chromogenic substrates H-D-Ile-Pro-Arg-p-nitroanilide
(pNA) dihydrochloride (2HCl) (S-2288), Glu-Pro-Arg-pNAHCl
(S-2366), H-D-Phe-pipecolyl-Arg-pNA2HCl (S-2238), H-D-Pro-Phe-
Arg-pNA2HCl (S-2302), Z-D-Arg-Gly-Arg-pNA2HCl (S-2765),
Glu-Gly-Arg-pNAHCl (S-2444), benzoyl-Ile-Glu(Glu--methoxy)-
Gly-Arg-pNAHCl (S-2222), H-D-Val-Leu-Lys-pNA2HCl (S-2251),
H-D-Val-Leu-Arg-pNA2HCl (S-2266), and methoxysuccinyl-Arg-
Pro-Tyr-pNAHCl (S-2586) were from Chromogenix AB (Stockholm,
Sweden). Spectrozyme FIXa (H-D-Leu-phenylalanyl-Gly-Arg-pNA2-
AcOH) was obtained from American Diagnostica Inc. (Stamford, CT).
All substrates were reconstituted in deionized water prior to use. Rec-
ombinant human TF (Innovin) was purchased from Dade Behring (M-
arburg, Germany). Human plasma was donated by healthy volunteers.
All other chemicals and reagents used were of the highest purity
available.
Proteins
Human plasma-derived FVIIa, FX, and FXa were a gift from the Fac-
tor VII Group (Kazuhiko Tomokiyo, Yasushi Nakatomi, Teruhisa
Nakashima, and Soutatou Gokudan) of KAKETSUKEN and were puri-
fied as described (23, 24). Recombinant human soluble TF (sTF; resi-
dues 1–218) was a gift from Dr. Toshiyuki Miyata (National Cardiovas-
cular Center, Suita, Japan), and it was prepared as described (25).
Human plasma-derived thrombin, activated protein C, and FIXa were
gifts from Hiroshi Kaetsu, Shinji Nakahira, and Takayoshi Hamamoto
(KAKETSUKEN), respectively, and prepared as described (23, 26, 27).
Three cardiotoxins (CM-14, CM-17, and CM-18 from Naja naja atra)
were obtained from Dr. Mitsuhiro Ohta (Kobe Pharmaceutical Univer-
sity). Plasma kallikrein and plasmin were purchased from Enzyme
Research Laboratories (South Bend, IN). FXIa and FXIIa were pur-
chased from Haemtech (Essex Junction, VT). Tissue plasminogen acti-
vator and urokinase-type plasminogen activator were purchased from
American Diagnostica Inc. -Chymotrypsin and trypsin were obtained
fromWorthington.
Purification of Anticoagulant Protein
H. haemachatus crude venom (100 mg in 1 ml of distilled water) was
applied to a Superdex 30 gel-filtration column (1.6  60 cm) equili-
brated with 50 mM Tris-HCl buffer (pH 7.4) and eluted with the same
buffer using an KTA purifier system (Amersham Biosciences AB,
Uppsala, Sweden). Individual fractions were assayed for anticoagulant
activity using prothrombin time (see below). Fractions with potent anti-
coagulant activity were pooled and subfractionated on a cation-ex-
change column using the same chromatography system. The anticoag-
ulant fraction was pooled and loaded onto a UNO S6 column (6-ml
column volume; Bio-Rad) equilibrated with 50mMTris-HCl buffer (pH
7.5). Boundproteinswere elutedwith a linear gradient of 1MNaCl in the
same buffer. Fractions collected were assayed for anticoagulant activity.
The anticoagulant peaks obtained from cation-exchange chromatogra-
phy were applied to a Jupiter C18 column (1 25 cm) equilibrated with
0.1% trifluoroacetic acid. The bound proteins were eluted using a linear
gradient of 80% acetonitrile in 0.1% trifluoroacetic acid. Individual peaks
were collected, lyophilized, examined for anticoagulant activity, and
subsequently rechromatographed on a narrow bore PepMap column
using a Chromeleonmicroliquid chromatography system (LCPackings,
San Francisco, CA).
Electrospray IonizationMass Spectrometry
The homogeneity andmass of the anticoagulant proteins were deter-
mined by electrospray ionization mass spectrometry using a
PerkinElmer Life Sciences API-300 liquid chromatography/tandem
mass spectrometry system. Typically, reverse-phase HPLC fractions
were directly used for analysis. Ion spray, orifice, and ring voltages were
set at 4600, 50, and 350 V, respectively. Nitrogenwas used as a nebulizer
and curtain gas. A ShimadzuLC-10ADpumpwas used for solvent deliv-
ery (40% acetonitrile in 0.1% trifluoroacetic acid) at a flow rate of 50
l/min. BioMultiview software (PerkinElmer Life Sciences) was used to
analyze and deconvolute raw mass spectra.
Reduction and Pyridylethylation
Purified proteins were reduced and pyridylethylated using proce-
dures described previously (28). Briefly, proteins (0.5mg)were dissolved
in 500 l of denaturant buffer (6 M guanidine hydrochloride, 0.25 M
Tris-HCl, and 1 mM EDTA (pH 8.5)). After the addition of 10 l of
-mercaptoethanol, themixture was incubated under vacuum for 2 h at
37 °C. 4-Vinylpyridine (50 l) was added to the mixture and kept at
room temperature for 2 h. Pyridylethylated proteins were purified on an
analytical Jupiter C18 column (4.6  250 mm) using a gradient of ace-
tonitrile in 0.1% (v/v) trifluoroacetic acid at a flow rate of 0.5 ml/min.
N-terminal Sequencing
N-terminal sequencing of the native and S-pyridylethylated proteins
was performed by automated Edman degradation using a PerkinElmer
Life Sciences Model 494 pulsed liquid-phase sequencer (Procise) with
an on-line Model 785A phenylthiohydantoin-derivative analyzer.
CD Spectroscopy
Far-UV CD spectra (260–190 nm) were recorded using a Jasco J-810
spectropolarimeter. All measurements were carried out at room tem-
perature using 0.1-cm path length stoppered cuvettes. The instrument
optics was flushed with 30 liters of nitrogen gas/min. The spectra were
Factor VIIa Inhibitor from Snake Venom
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recorded using a scan speed of 50 nm/min, a resolution of 0.2 nm, and a
bandwidth of 2 nm.A total of four scans were recorded and averaged for
each spectrum, and the base line was subtracted. The CD spectra of the
anticoagulant proteins and their S-pyridylethylated forms were
recorded in 50 mM Tris-HCl buffer (pH 7.4).
Reconstitution of the Anticoagulant Complex
Preliminary studies indicated that the active anticoagulant protein
interacted with another venom protein, forming a synergistic complex.
We reconstituted the complex for various in vitro experiments imme-
diately prior to the experiments by incubating equimolar concentra-
tions of the two proteins (unless mentioned otherwise) at 37 °C for 5
min in 50 mM Tris-buffer (pH 7.4).
Anticoagulant Activity
The anticoagulant activities of H. haemachatus venom and its frac-
tions were determined by four coagulation tests using a BBL
Fibrometer.
Recalcification Time—The recalcification times were determined
according to the method of Langdell et al. (29). 50 mM Tris-HCl buffer
(pH 7.4; 100 l), plasma (100 l), and various concentrations of venom
or its fraction (50l) were preincubated for 2min at 37 °C. Clotting was
initiated by the addition of 50 l of 50 mM CaCl2.
Prothrombin Time—The prothrombin times were measured accord-
ing to the method of Quick (30). 100 l of 50 mM Tris-HCl buffer (pH
7.4), 100 l of plasma, and 50 l of venom or its fractions were prein-
cubated for 2 min at 37 °C. Clotting was initiated by the addition of 150
l of thromboplastin with calcium reagent.
Stypven Time—The Stypven times were measured according to the
method ofHougie (31). Plasma (100l), 50mMTris-HCl buffer (pH 7.4;
100 l), Russell’s viper venom (0.01 g in 100 l), and individual pro-
teins or the reconstituted complex (50 l) were preincubated for 2 min
at 37 °C. Clotting was initiated by the addition of 50 l of 50 mM CaCl2.
ThrombinTime—The thrombin timeswere determined according to
the method of Jim (32). Individual proteins or the reconstituted com-
plex was incubated with 100l of plasma and 100l of 50mMTris-HCl
buffer (pH 7.4) for 2 min at 37 °C in a total volume of 250 l. Clotting
was initiated by the addition of standard thrombin reagent (0.01 NIH
unit in 50 l).
Complex Formation Studies with Size-exclusion Chromatography
The formation of a complex between anticoagulant proteins was
examined by gel-filtration chromatography on a Superdex 30 gel-filtra-
tion column (1.6  60 cm) using an KTA purifier. The column was
equilibrated with 50 mM Tris-HCl buffer (pH 7.4) at a flow rate of 1
ml/min. Individual proteins and an equimolar mixture of anticoagulant
proteins (native or pyridylethylated) were incubated for 30 min at 37 °C
and then loaded onto the column and eluted in the same buffer. Elution
was followed at 280 nm.
Reconstitution of the Extrinsic Tenase Complex
The TFFVIIa complex was reconstituted by incubating 10 pM FVIIa
with 70 pM recombinant human TF (Innovin) in Buffer A (20 mM
HEPES, 150mMNaCl, 10mMCaCl2, and 1% bovine serum albumin (pH
7.4)) for 10 min at 37 °C. FX was added to the mixture to obtain a final
concentration of 30 nM. The activation was stopped by the addition 50
l of stop buffer (20 mM HEPES, 150 mM NaCl, 50 mM EDTA, and 1%
bovine serum albumin (pH 7.4)) to 50-l aliquots of the reaction mix-
ture after 15 min of incubation. FXa formed was measured by the
hydrolysis of 1 mM S-2222 in Buffer A in amicrotiter plate reader at 405
nm. The inhibitory effect on extrinsic tenase activity was determined by
adding the individual proteins or the anticoagulant complex 15 min
prior to FX addition.
Serine Protease Specificity
The selectivity profile of anticoagulant proteins and their complex
was examined against 12 serine proteases: procoagulant serine pro-
teases (FIXa, FXa, FXIa, FXIIa, plasma kallikrein, and thrombin), anti-
coagulant serine protease activated protein C, fibrinolytic serine pro-
teases (urokinase, tissue plasminogen activator, and plasmin), and
classical serine proteases (trypsin and chymotrypsin). Various concen-
trations of the purified individual proteins or the reconstituted antico-
agulant complex were preincubated with each of the enzymes for 5 min
at 37 °C, followed by the addition of the appropriate chromogenic
substrate.
In a total volume of 200 l in the individual wells of the microtiter
plate, the final concentrations were as follows: FVIIa (300 nM)/S-2288,
sTFFVIIa (30 nM)/S-2288, FXa (0.75 nM)/S-2765, -thrombin (0.66
nM)/S-2238, plasmin (2 nM)/S-2251, FIXa (3 M)/Spectrozyme FIXa,
FXIa (0.34 nM)/S-2366, FXIIa (0.4 nM)/S-2302, recombinant tissue plas-
minogen activator (80 nM)/S-2288, activated protein C (0.34 nM)/S-
2366, urokinase/S-2444, plasma kallikrein (0.4 nM)/S-2302, trypsin (2.17
nM)/S-2222, and chymotrypsin (0.4 nM)/S-2586. The kinetic rate of sub-
strate hydrolysis (mOD/min) was measured over 5 min.
Kinetics of Inhibition
All studies were performed in 50 mM Tris-HCl buffer (pH 7.4) con-
taining 150 mM NaCl, 10 mM CaCl2, and 1% bovine serum albumin at
37 °C. The kinetics of hydrolysis of the chromogenic substrate S-2288 by
sTFFVIIa wasmeasured prior to examining the inhibitory effects of the
individual proteins and the reconstituted anticoagulant complex. Reac-
tionswere initiated by the addition of S-2288 (0–5mM) to the individual
wells of a 96-well plate containing FVIIa (30 nM) in complex with sTF
(100 nM) in a final volume of 180 l. Initial reaction velocities were
measured as a linear increase in the absorbance at 405 nm over 5 min
with a SpectraMax Plus temperature-controlled microplate spectro-
photometer (Molecular Devices Corp., Sunnyvale, CA).
The inhibitory potency of the anticoagulant complex was measured
over a range of substrate concentrations. Reactions were initiated by the
addition of S-2288 to premixed cofactorenzyme and inhibitor in the
wells of a microtiter plate. Reactions with sTFFVIIa contained 0.025–
0.1 M inhibitor complex and 0–3 mM S-2288. The initial velocities
weremeasured over 5min under steady-state conditions andwere fit by
reiterative nonlinear regression to Equation 1, describing a classical
noncompetitive inhibitor, to derive the Ki value.
1/V  Km/Vmax1 I/Ki1/S 1/Vmax1 I/Ki
(Eq. 1)
Isothermal Titration Calorimetry (ITC)
The interaction of the reconstituted anticoagulant complex with
FVIIa was monitored with a VP-ITC titration calorimetric system
(MicroCal, LLC, Northampton, MA). The instrument was calibrated
using the built-in electrical calibration check. FVIIa (10 M) in 50 mM
Tris-HCl buffer and 10 mM CaCl2 (pH 7.4) in the calorimetric cell was
titrated with the reconstituted anticoagulant complex (0.4 mM) dis-
solved in the same buffer in a 250-l injection syringe with continual
stirring at 300 rpm at 37 °C. All protein solutions were filtered and
degassed prior to titration. The first injections presented defects in the
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base line, and these data were not included in the fitting process. The
calorimetric data were processed and fitted to the single set of identical
sites model using MicroCal Origin (Version 7.0) data analysis software
supplied with the instrument. The total heat content (Q) of the solution
(determined relative to zero for the unliganded species) contained in the
active cell volume (V0) was calculated according to Equation 2,
Q 
nMtHV0
2 1  XtnMt  1nKuMt






where K is the binding affinity constant; n is the number of sites; H is
the enthalpy of ligand binding; and Mt and Xt are the bulk concentra-
tions of macromolecule and ligand, respectively, for the binding X	M
7 XM. The change in heat (H) measured between the completions of
two consecutive injections is corrected for dilution of the protein and
ligand in the cell according to standard Marquardt methods. The free
energy change (G) during the interaction was calculated using the
relationship G 
 H  TS 
 RT ln Ka, where T is the absolute
temperature and R is the universal gas constant.
RESULTS
Purification of the Anticoagulant Protein—Crude venom of H.
haemachatus exhibited potent anticoagulant activity in both recalcifi-
cation and prothrombin time assays (Fig. 1, A and B). To purify the
anticoagulant protein, the crude venom was size-fractionated by gel-
filtration chromatography (Fig. 2A). Fractions corresponding to peaks 2
and 3 contained anticoagulant proteins as determined by prothrombin
time assays. Peak 2 corresponded to proteins mostly containing phos-
pholipase A2 that have been characterized previously (33). However,
this peak had milder anticoagulant activity compared with peak 3 (Fig.
2A, inset), so we focused on isolating the anticoagulant protein from
peak 3, which was fractionated further by cation-exchange chromatog-
raphy on aUNOS6 column (Fig. 2B). Only peakA (labeledHemextin A)
exhibited mild anticoagulant activity. During our preliminary studies,
we found that the anticoagulant activity of peak A was potentiated by
peak B (labeled Hemextin B; see below). Because this anticoagulant
complex specifically inhibited the extrinsic tenase complex (described
FIGURE 1. Anticoagulant activity of the crude venom. Shown are the effects of the
crude venom on recalcification time (A) and prothrombin time (B). Note that the venom
exhibited potent anticoagulant activity in both assays. Each data point represents the
mean S.D.
FIGURE 2. Purification of hemextins A and B. A, size-exclusion chromatography of H.
haemachatus crude venom using a Superdex 30 column. Inset, anticoagulant activity of
peaks 2 and 3. B, cation-exchange chromatography of peak 3 using a UNO S6 column. C
and D, reverse-phase HPLC profiles of fractions containing hemextins A and B, respec-
tively, using a Jupiter C18 semipreparative column. E and F, capillary liquid chromatog-
raphy profiles of hemextins A and B, respectively. The homogeneity andmass of hemex-
tins A and B were determined by electrospray ionization mass spectrometry. G and H,
reconstructed mass spectra of hemextins A and B, respectively. CPS, counts/s; amu,
atomic mass units.
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below), we named it the hemextin AB complex (Hemachatus extrinsic
tenase inhibitor) and the individual proteins hemextins A and B, respec-
tively. Fractions corresponding to both hemextins A and B were pooled
separately and purified by reverse-phase HPLC (Fig. 2, C and D) and
capillary liquid chromatography (Fig. 2, E and F). The homogeneity and
mass of the individual proteins were determined by electrospray ioni-
zation mass spectrometry. The mass spectra of hemextins A and B
showed three peaks withmass/charge ratios ranging from 3 to 6 charges
(data not shown) and their calculated molecular masses as 6835.00 
0.52 and 6792.56 0.32 Da, respectively (Fig. 2, G and H).
N-terminal Sequence Determination—We determined the sequence
of the first 25 amino acid residues of hemextins A and B by Edman
degradation (Fig. 3A). The locations of the cysteine residues in the pro-
teins were confirmed by sequencing the pyridylethylated proteins. Both
proteins show similarity to cardiotoxins, postsynaptic neurotoxins, fas-
ciculin, and othermembers of the three-finger toxin family (Fig. 3A), but
not to serine protease inhibitors isolated from snake venoms (34, 35).
Thus, hemextins A and B belong to three-finger toxin family.
CD Spectroscopy—Both hemextins A and B exhibited negative min-
ima at 215 nm and positive maxima at 194 nm. Thus, similar to other
three-finger toxins, both hemextins A and B exhibited a predominantly
-sheet structure (Fig. 3B). However, the S-pyridylethylated forms of
hemextins A and B displayed negative minima at 195 nm, i.e. a predom-
inantly random-coil structure (Fig. 3B). Thus, reduction and pyridyl-
ethylation result in the loss of folding and three-dimensional structure
in hemextins A and B.
Anticoagulant Activity of Hemextins—The anticoagulant activity of
hemextins A and Bwas determined by the prothrombin time assay (Fig.
4A). Hemextin A prolonged the clotting time and exhibited mild anti-
coagulant activity, whereas hemextin B did not show any significant
effect on the clotting time even at higher concentrations. Interestingly,
an equimolar mixture of hemextins A and B exhibited more potent
anticoagulant activity, indicating synergism between these proteins
(Fig. 4A). Such an increase in the anticoagulant effect could be due
either to the inhibition of two separate steps in the coagulation cascade
or to the formation of a complex between them. Because hemextin B by
itself has no significant effect on prothrombin time, it does not inhibit a
separate step; instead, it is likely that hemextinsA andB forma complex.
S-Pyridylethylated hemextins did not exhibit any anticoagulant activity.
An equimolar mixture of S-pyridylethylated hemextins A and B also
failed to display any anticoagulant effect (Fig. 4A, inset). Thus, proper
folding is important for the interaction between hemextins A and B and
their anticoagulant activity.
Complex Formation between Hemextins A and B—To investigate the
formation of a complex between the two proteins, we employed a titra-
tion experiment in the prothrombin time assay. In this experiment, the
concentration of hemextin A was kept constant at 4.4 M, and its anti-
coagulant activity was monitored with increasing hemextin B concen-
trations (Fig. 4B). The anticoagulant activity increased with increasing
concentrations of hemextin B until the ratio reached 1:1. Further addi-
tion did not increase the anticoagulant effect. The results indicate that
FIGURE 3.N-terminal sequences of hemextins A
andB.A, the first 25N-terminal residuesof hemex-
tins A and B were determined by Edman degrada-
tion. Conserved cysteine residues in the three-fin-
ger toxin family are indicated. B, shown are the CD
spectra of native and S-pyridylethylated hemex-
tins A and B.
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hemextins A and B form a 1:1 complex and that complex formation is
crucial for potent anticoagulant activity.
Complex formation between hemextins A and B was further con-
firmed by gel-filtration chromatography. As shown in Fig. 5, the reten-
tion time of individual hemextins A and B was70 min. However, the
reconstituted complex eluted as a major peak with a retention time of
40 min and as a minor peak with a retention time of 70 min. The
appearance of the major peak with a reduced retention time corre-
sponding to 27 kDa is consistent with the formation of a tetrameric
complexwith twomolecules each of hemextins A and B.We also recon-
stituted the hemextin AB complex with S-pyridylethylated forms of the
native proteins. However, no change in the retention time of the mix-
ture was observed compared with those of the individual S-pyridyleth-
ylated proteins (Fig. 5). These results indicate that proper folding is
essential for the formation of the hemextin AB complex.
It is important to note that hemextins A and B do not exist as a
complex in the crude venom. Complex formation is probably hindered
by the presence of high concentrations of citrate and other salts in the
venom. The reconstituted hemextin AB complex could be easily sepa-
rated into individual components on a cation-exchange column (data
not shown).
Site of Anticoagulant Activity—As shown above, hemextin A and its
complex with hemextin B prolonged prothrombin time (Fig. 4A). To
identify the specific stage in the extrinsic coagulation pathway, we used
a simple “dissection approach” (36, 37). We employed three commonly
used clotting time assays, viz. prothrombin time, Stypven time, and
thrombin time. This approach is based on the principle that initiating
the cascade “upstream” from the inhibited step will result in elevated
clotting times, whereas initiating the cascade “downstream” from the
inhibited step will not affect clotting times. Thus, the anticoagulant
action of the individual proteins and the complex can be localized to
certain activation step(s) in the cascade (for details, see Refs. 32 and 33).
Hemextin A exhibited mild anticoagulant activity by prolonging the
clotting time in the prothrombin time assay, but did not prolong
FIGURE 4. Effects of hemextinsA andBonprothrombin time.A, shown are the effects
of hemextin A (E), hemextin B (), and the probable hemextin AB complex (Œ) on
prothrombin time. Note that the anticoagulant potency of hemextin A increased in the
presenceof hemextin B. Eachdata point represents themean S.D. Inset, comparisonof
the anticoagulant activities of the control (C), S-pyridylethylated hemextin A (S-HA),
S-pyridylethylated hemextin B (S-HB), amixture of S-pyridylethylated hemextins A and B
(S-HAB), hemextin A (HA), hemextin B (HB), and the hemextin AB complex (HAB). B, com-
plex formation between hemextins A and B is illustrated by their effect on prothrombin
time.
FIGURE 5.Gel-filtration studies on the formation of the hemextin AB complex.Note
that the elution time of the hemextin AB complex was reduced to40 min compared
with that of the individual hemextins (70min). Also note that themixture of S-pyridyl-
ethylated hemextins A and B was unable to form a complex.
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Stypven time and thrombin time (data not shown). As expected, hemex-
tin B did not prolong clotting times in the prothrombin time, Stypven
time, and thrombin time assays. The hemextin AB complex exhibited
potent anticoagulant activity by prolonging the clotting time in the pro-
thrombin time assay. However, the clotting times in the other two
assays were not affected (data not shown). These results indicate that
hemextin A and the hemextin AB complex affect only the extrinsic
tenase complex, but not the prothrombinase complex or conversion of
fibrinogen to fibrin clots.
To confirm the site of inhibition, we examined the effects of hemex-
tins A and B and their complex on the reconstituted TFFVIIa complex
(Fig. 6A). Hemextin A exhibited mild inhibitory activity at higher con-
centrations. On the other hand, hemextin B did not mediate any inhib-
itory activity on the enzymatic action of the extrinsic tenase complex.
However, the hemextin AB complex completely inhibited extrinsic
tenase activity (Fig. 6A) with an IC50 (concentration of the inhibitor that
inhibits 50% of the activity) of 200 nM. Neither the individual proteins
nor the complexmediated any inhibitory effect on FXa amidolytic activ-
ity (described below). The effects of the individual hemextins and the
hemextin AB complex on the intrinsic pathwaywere also assessed using
recalcification time assays. No anticoagulant activity on the intrinsic
pathway was observed (data not shown). Furthermore, the effects of
other three-finger toxins, particularly cardiotoxins/cytotoxins, which
are structurally similar to hemextins A and B, on TFFVIIa proteolytic
activity were also monitored. CM-14, CM-17, and CM-18 fromN. naja
atra did not inhibit FXa formation by the TFFVIIa complex (data not
shown). To determine the importance of hemextin AB complex forma-
tion for the inhibition of the TFFVIIa complex, we performed a similar
titration experiment. The inhibitory activity of hemextin A at 50 M
(the concentration at which the hemextin AB complex inhibited only
70% of theTFFVIIa activity) was examined in the presence of increas-
ing concentrations of hemextin B. As shown in Fig. 6B, the inhibitory
activity of hemextin A increased with increasing concentrations of
hemextin B until the ratio reached 1:1. Further addition did not increase
the inhibition. The results indicate that hemextins A and B form a 1:1
complex and that complex formation is crucial for potent anticoagulant
activity. These observations further confirm the importance of complex
formation between hemextins A and B.
To understand the effect of phospholipids, the inhibitory activity of
hemextin A and the hemextin AB complex on FVIIa amidolytic activity
was monitored in the presence or absence of sTF. In both the cases, we
observed potent inhibitory activity in a dose-dependent manner (Fig. 7,
A and B).
Specificity of Inhibition—To determine the specificity of inhibition,
hemextins A and B and their complex were screened against 12 serine
proteases. No inhibitory activity was observed against any of the serine
proteases with the exception of FVIIa and plasma kallikrein. As with
FVIIa, hemextin A and the hemextin AB complex inhibited plasma
kallikrein in a dose-dependent manner (Fig. 8). Hemextin B did not
inhibit the protease activity of kallikrein. However, the inhibitory
potency for FVIIa (in the absence or presence of sTF) was at least 50
times higher than for plasma kallikrein.
Kinetics of Inhibition—To determine the mechanism of inhibition,
we examined the kinetics of hemextin AB complex inhibition of the
amidolytic activity of the sTFFVIIa complex in the presence of S-2288.
Kinetic studies revealed that hemextin inhibited sTFFVIIa activity non-
competitively. Lineweaver-Burk plots showed that Km values remained
FIGURE6. InhibitionofTFFVIIaactivity.A, shown is thehemextinA (Œ), hemextinB (f),
and hemextin AB complex (E) inhibitory potency on TFFVIIa activity. B, the formation of
the hemextin AB complex (●) between hemextin A (f) and hemextin B is illustrated by
their effect on TFFVIIa enzymatic activity. To determine the stoichiometry of complex
formation, the concentration of hemextin A was kept low so that 100% TFFVIIa activity
was not inhibited upon complex formation.
FIGURE 7. Effect of phospholipids on the inhibitory activity of hemextins A and B
and the hemextin AB complex. Shown is the hemextin A (●), hemextin B (Œ), and
hemextin AB complex (f) inhibitory potency on FVIIa (A) and sTFFVIIa (B) amidolytic
activity. Note that the absence of phospholipids did not affect the inhibitory potency of
the protein(s) and the reconstituted complex.
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unaltered, whereas Vmax values decreased with increasing concentra-
tions of the inhibitor (Fig. 9A), a characteristic of a noncompetitive
inhibitor. TheKi for inhibitionwas determined to be 50 nM (Fig. 9B).We
also calculated the turnover number (Kcat; moles of substrate converted
to product/mol/enzyme/min) at different concentrations of the inhibi-
tor. As observed in the case of classical noncompetitive inhibitors, the
Kcat decreasedwith increasing concentrations of the hemextin AB com-
plex (data not shown). Because the amidolytic activity of FVIIa alone is
very weak (38), we did not study the kinetics of the inhibition of FVIIa
amidolytic activity by the hemextin AB complex.
Binding of theHemextinABComplex to FVIIa—Westudied the inter-
action between the hemextin AB complex and FVIIa by ITC. We mon-
itored the thermodynamic changes associated with the binding of the
hemextin AB complex to FVIIa (Fig. 10). The binding was exothermic,
with H
5.445 kcalM1, G
4.121 kcalM1, and S
4.274
calM1. The calculated K for the binding was 1.62 105 M1.
DISCUSSION
Initiation of blood coagulation during injury or trauma is essential for
the survival of the organism. However, the formation of unwanted clots
has detrimental or debilitating effects and hence the need for anticoag-
ulant therapies. The current anticoagulants used for treating these dis-
orders are nonspecific and have a narrow therapeutic range, necessitat-
ing careful laboratory monitoring to achieve optimal efficacy and to
minimize bleeding. This is further complicated by other factors such as
dietary intake (39). Therefore, novel anticoagulant and antiplatelet
agents are being sought. Because FVIIa is the key initiator of blood
coagulation and is present in the plasma milieu at very low concentra-
tions, it is an attractive drug target for the design and development of
anticoagulants.
So far, only two proteins that specifically inhibit the TFFVIIa com-
plex have been well characterized, viz. tissue factor pathway inhibitor
(TFPI) and nematode anticoagulant peptide c2 (NAPc2). TFPI is an
endogenous inhibitor of this complex (40), whereas NAPc2 is an exog-
enous inhibitor isolated from canine hookworm (Ancylostoma cani-
num) (41). TFPI is a 42-kDa plasma glycoprotein consisting of three
tandem Kunitz-type domains. The first and second units inhibit
TFFVIIa and FXa, respectively. The thirdKunitz domain and theC-ter-
minal basic region of the molecule have heparin-binding sites (42). The
anticoagulant action of TFPI is a two-stage process. The second Kunitz
domain binds first to a molecule of FXa and deactivates it. The first
domain then rapidly binds to an adjacent TFFVIIa complex, preventing
further activation of FX (43–45). On the other hand, NAPc2 is an 8-kDa
FIGURE 9. Nature of inhibition. A, double-reciprocal (Lineweaver-Burk) plots for the
kinetic activity of sTFFVIIa in the presence of 100 nM (; 2Ki), 50 nM (E; Ki), and 25 nM (f;
1⁄2Ki) reconstituted hemextin AB complex. Also shown is the kinetic activity of sTFFVIIa
in the absence of the hemextin AB complex (●). Note that the Vmax decreased with
increasing inhibitor concentrations, whereas the Km remained unchanged, a classical
phenomenon observed in noncompetitive inhibitors. B, corresponding secondary plot
depicting the Ki for inhibition.mOD, milli-optical density.
FIGURE 10. ITC studies on the formation of a complex between the hemextin AB
complex and FVIIa. A, raw data in microcalories/s versus time showing heat release
upon injections of 0.4mM reconstituted hemextin AB complex into a 1.4-ml cell contain-
ing 10 M FVIIa; B, integration of the raw data yielding the heat/mol versus molar ratio.
The best values of the fitting parameters were 1.62 105 M1 for K,5.445 kcalM1 for
H, and4.274 calM1 for S.
FIGURE8. Inhibitionofplasmakallikreinamidolytic activity.Shown is thehemextinA
(Œ), hemextin B (●), and hemextin AB complex (f) inhibitory potency on plasma kal-
likrein amidolytic activity. Note that the IC50 for inhibition was10 M.
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short polypeptide. Its mechanism of action requires prerequisite bind-
ing to FXa or zymogen FX to form a binary complex prior to its inter-
action and inhibition of membrane-bound TFFVIIa (41). Therefore,
despite the structural differences, both inhibitors form a quaternary
complex with TFFVIIaFXa. However, in both complexes, the active
site of FVIIa is occupied by the respective inhibitors and is not
accessible.
Because of the lack of natural inhibitors that specifically interferewith
FVIIa activity, a number of artificial inhibitors have been designed and
developed. They include proteins that block the association of TF and
FVIIa, such as antibodies against TF and FVIIa, TFAA (a TF mutant
with reduced cofactor function for FX), FFR-VIIa (inactivated form of
FVIIa with 5-fold higher affinity for TF compared with native FVIIa),
and peptides derived fromTF and FVIIa (47–54). In addition, two series
of peptide exosite inhibitors were selected from phage display libraries
for their ability to bind to the TFFVIIa complex (47, 48). They bind to
two distinct exosites on the serine protease domain of FVIIa and exhibit
steric and allosteric inhibition (50). Although both peptide classes are
potent and selective inhibitors of the TFFVIIa complex, they fail to
inhibit 100% activity even at saturating concentrations. This is over-
come either by the fusion of the two peptides (51) or by using a protease
switch with substrate phage (49). A number of synthetic compounds
have also been designed as active-site inhibitors of FVIIa as well as the
TFFVIIa complex (52, 55–58). A number of naphthylamidines have
recently been reported to have FVIIa inhibitory activity (59). They were
synthesized by the coupling of amidinobenzaldehyde analogs to a poly-
styrene resin. However, apart from inhibiting FVIIa activity, these syn-
thetic compounds nonspecifically inhibit the activity of other blood
coagulation serine proteases (59).
Hemextin AB Complex Is a Novel Anticoagulant—We have reported
here the isolation and characterization of two proteins, hemextins A
and B, from the venom of H. haemachatus that synergistically induce
potent anticoagulant activity. Individually, only hemextin A exhibited
mild anticoagulant activity, whereas hemextin B had no anticoagulant
activity (Fig. 4A). The increase in the anticoagulant potency of hemextin
A in the presence of hemextin B (Fig. 4A) indicated probable complex
formation between the two proteins. We have shown that 1:1 complex
formation is important for potent anticoagulant activity using the pro-
thrombin time assay (Fig. 4B). Complex formation was further con-
firmed by gel-filtration chromatography (Fig. 5).
Both hemextins A and B belong to the three-finger family of snake
venom proteins (Fig. 3A) and not to the family of snake venom serine
protease inhibitors. Proteins belonging to this group exhibit a charac-
teristic -sheet structure (60), also observed in the CD studies (Fig. 3B).
It is a well known fact that disulfide bonds associated with cysteine
residues are essential structural units in proteins (61). To evaluate the
importance of the three-finger fold in both complex formation and
anticoagulant activity, we used reduced and subsequently pyridylethyl-
ated hemextins A and B. Upon pyridylethylation, they lost their native
three-finger fold, as observed in the CD studies (Fig. 3B). The S-pyridyl-
ethylated hemextins were functionally inactive (Fig. 4A, inset) and were
unable to bind to each other to form the complex, as evident from the
gel-filtration studies (Fig. 5). This shows that proper folding of the pro-
teins is important not only for function, but also for complex formation.
Using the dissection approach (36, 37), we identified the site of anti-
coagulant action of hemextin A and its synergistic complex. Both
hemextinA and the hemextinAB complex inhibited the extrinsic tenase
complex, but not other steps in the extrinsic pathway. These results
were further confirmed by studying the effect of hemextin A and its
complex on the reconstituted TFFVIIa complex. Both hemextin A and
the hemextin AB complex inhibited FXa formation by the reconstituted
extrinsic tenase complex (Fig. 6A). Furthermore, hemextin A and the
hemextin AB complex inhibited the amidolytic activity of FVIIa in both
the presence and absence of sTF (Fig. 7, A and B). The hemextin AB
complex inhibited with IC50 values of200 and210 nM, respectively.
Similar IC50 valuesmay be indicative of the fact that hemextin A and the
hemextin AB complex do not bind to the cofactor-binding site of FVIIa.
The inhibitory activity of hemextin A and the hemextin AB complex
may not be due to nonspecific interaction of hemextin A or its complex
with the phospholipids in the extrinsic tenase complex, as indicated by
their inability to prolong Stypven time, because they failed to inhibit the
prothrombinase complex, which is also formed on the phospholipid
surfaces. This was further confirmed by determining the inhibitory
activity of hemextin A and the hemextin AB complex on the amidolytic
activity of the reconstituted extrinsic tenase complex using sTF and
FVIIa (Fig. 7B). Furthermore, hemextin A and the hemextin AB com-
plex inhibited the amidolytic activity of FVIIa (Fig. 7A). However,
hemextin B did not exhibit any inhibitory activity in the absence of
hemextin A. To further characterize the inhibitory properties and to
determine the specificity of inhibition, we screened hemextins A and B
and the hemextinAB complex against 12 serine proteases. In addition to
FVIIa and its complexes, hemextin A and the hemextin AB complex
inhibited the amidolytic activity of only kallikrein in a dose-dependent
manner (Fig. 8). However, the IC50 for the inhibition of kallikrein was
10 M, in contrast to that of FVIIa/TFFVIIa/sTFFVIIa, which was
200 nM. Kinetic studies revealed that the hemextin AB complex is a
noncompetitive inhibitor of the sTFFVIIa complex, with a Ki of 50 nM.
Using ITC studies, we have shown that the hemextin AB complex
directly interacts with FVIIa (Fig. 10). The binding interaction between
FVIIa and the hemextin AB complex is associated with a negative
change in free energy, indicating that this complex formation is favored.
The negative change in entropy observed upon binding indicates the
formation of a tightly folded complex between the two moieties (62).
Thus, these data strongly indicate that the hemextin AB complex is a
highly specific inhibitor of FVIIa. To our knowledge, this is the first
natural inhibitor of FVIIa.
Someother anticoagulants from snake venoms also inhibit the extrin-
sic tenase complex. However, they are not as specific. For example,
CM-IV, a strongly anticoagulant phospholipaseA2 fromNaja nigricollis
venom, prolongs coagulation by inhibiting two successive steps in the
coagulation cascade. It inhibits the TFFVIIa complex by both enzy-
matic and nonenzymatic mechanisms (63), whereas it inhibits the pro-
thrombinase complex by only a nonenzymatic mechanism (64, 65).
Hemextin A and its synergistic complex are the first reported specific
inhibitors of FVIIa isolated from snake venom.
The similar dose-dependent inhibition of the TFFVIIa complex and
FVIIa indicates that the hemextin AB complex neither requires TF for
its inhibitory activity nor interferes in the binding of TF to FVIIa. Unlike
TFPI and NAPc2, it also does not use FXa as a scaffold to bind to FVIIa
and thus does not require FX or FXa to inhibit FVIIa. Furthermore,
TFPI and NAPc2 bind to the active site of FVIIa. In contrast, as shown
by the kinetic studies (Fig. 9), the hemextin AB complex is a noncom-
petitive inhibitor, unlike competitive inhibitors that bind to the active
site. Thus, the hemextin AB complex does not appear to bind to the
active site of FVIIa. Therefore, hemextin A and the hemextin AB com-
plex are novel inhibitors of FVIIa and the TFFVIIa complex.
Hemextin AB Complex Is a Unique Protein Complex—Synergism
among snake venom toxins is fairly well characterized, particularly
among presynaptic neurotoxins. For example, crotoxin isolated from
Crotalus durissus terrificus venom contains two subunits; the basic sub-
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unit is a phospholipase A2 enzyme, whereas the acidic subunit is cata-
lytically inactive (although it is derived from a phospholipase A2-like
protein) (66). Individually, only the basic subunit is slightly toxic,
whereas the complex exhibits potent toxicity. The acidic subunit
appears to act as a chaperone and enhances the specific binding of the
basic subunit to the presynaptic site. Similarly, other presynaptic neu-
rotoxins, such as taipoxin from Oxyuranus scutellatus (67) and textilo-
toxin from Pseudonaja textilis (68) venoms, contain three and four sub-
units, respectively. All the subunits are structurally similar to
phospholipase A2 enzymes. The noncovalent interactions between the
subunits of these toxins are important for their potent toxicity. Thus, a
number of snake venom presynaptic toxins are protein complexes with
phospholipase A2 as an integral part. Taicatoxin, another protein com-
plex isolated from O. scutellatus venom, blocks calcium channels and
has phospholipase A2, proteinase inhibitor, and neurotoxin (a three-
finger toxin) subunits (69). There are only a few noncovalent protein
complexes in snake venoms that do not contain phospholipase A2 as an
integral part. For example, rhodocetin, an antiplatelet protein complex
from Calloselasma rhodostoma venom, contains two subunits showing
structural similarity to C-type lectins (70). Group C prothrombin acti-
vators from Australian snakes are procoagulant protein complexes that
are structurally and functionally similar to mammalian blood coagula-
tion FXaFVa complexes (46, 71, 72). The hemextin AB complex is a
unique snake venom protein complex formed by the interaction
between two three-finger toxins, in which the anticoagulant activity of
hemextinA is potentiated by its synergistic interactionwith hemextin B.
It should be noted that crude snake venom does not contain the hemex-
tin AB complex. It is not clear when and how this complex is formed.
In summary, we have described a unique anticoagulant protein com-
plex from snake venom that specifically and noncompetitively inhibits
FVIIa activity.Our results strongly indicate that the interaction between
hemextins A and B is essential for potent anticoagulant activity. This
new anticoagulant may help us develop different strategies and thera-
peutic agents to inhibit the initiation step in blood coagulation.
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Hemextin AB complex from the venom of Hemachatus haemachatus is the first known natural 
anticoagulant that specifically inhibits the enzymatic activity of blood coagulation factor VIIa in 
the absence of factor Xa. It is also the only known heterotetrameric complex of two three-finger 
toxins (Banerjee, Y., Mizuguchi, J., Iwanaga, S., and Kini, R. M. (2005) J Biol.Chem 280, 
42601-42611). Individually only hemextin A has mild anticoagulant activity, whereas hemextin 
B is inactive. However, hemextin B synergistically enhances the anticoagulant activity of 
hemextin A and their complex exhibits potent anticoagulant activity. In this study we 
characterized the nature of molecular interactions leading to the complex formation. Circular 
 Biophys J BioFAST, published on August 17, 2007 as doi:10.1529/biophysj.106.100164
 Copyright 2007 by The Biophysical Society.
  
2
dichroism studies indicate the stabilization of β-sheet in the complex. Hemextin AB complex has 
an increased apparent molecular diameter in both gas and liquid phase techniques. The complex 
formation is enthalpically favorable and entropically unfavorable with a negative change in the 
heat capacity. Thus, the anticoagulant complex shows reduced structural flexibility than 
individual subunits. Both electrostatic and hydrophobic interactions are important for the 
complexation; the former driving the process and the latter helping in the stabilization of the 
tetramer. The tetramer dissociates into dimers and monomers with the increase in the ionic 
strength of the solution and also with increase in the glycerol concentration in the buffer. The 
two dimers formed under each of these conditions display distinct differences in their apparent 
molecular diameters and anticoagulant properties. Based on these results, we have proposed a 
model for this unique anticoagulant complex.   
 
Keywords: Protein-protein interaction, snake venom, anticoagulant, isothermal titration 




Blood coagulation is a physiological response to vascular injury that results in the formation of 
hemostatic plug which prevents blood loss (Davie et al., 1991;Davie, 1995). The process is 
initiated by tissue factor (TF), a cellular receptor for the activated coagulation factor VIIa 
(FVIIa), which is exposed after vascular injury (Nemerson, 1988). FVIIa bound to TF activates 
factor X (FX) and factor IX. Activated factor X (FXa) converts small amounts of prothrombin to 
thrombin (Yegneswaran et al., 2003). Thrombin in turn amplifies the coagulation cascade by 
activating the platelets (Kumar et al., 1995) and factors V (Myles et al., 2001) and VIII (Saenko 
et al., 1998;Curtis et al., 1994). Coagulation is propagated when factor IXa binds to factor VIIIa 
to form intrinsic tenase, a complex that efficiently activates FX. FXa then binds to factor Va to 
form prothrombinase, thereby increasing the rate of FXa–mediated conversion of prothrombin to 
thrombin by >300,000-fold (Mann et al., 2003). The resultant burst of thrombin rapidly converts 
fibrinogen to fibrin. Fibrin monomers polymerize to form the fibrin mesh that is stabilized and 
cross-linked by transglutaminase factor XIIIa (Higgins et al., 1983;Lewis et al., 1987). Thus the 
initial formation of TF-FVIIa complex is crucial for the clot initiation and is considered an ideal 
target for the treatment of thromboembolic disorders. Drugs that target this complex are potent 
inhibitors of coagulation and thus are highly sought after. Though, naturally occurring inhibitors 
of FVIIa have been identified, they are not specific. For example, dysinosin A isolated from the 
sponge family Dysideidae inhibits FVIIa with a Ki of 108 nM. However it also an inhibitor of 
thrombin (Hanessian et al., 2002;Carroll et al., 2002). Until recently only two natural 
anticoagulants targeting specifically the TF-FVIIa complex has been identified. They are tissue 
factor pathway inhibitor (TFPI) (Lindhout et al., 1995;Salemink et al., 1999) and nematode 
anticoagulant peptide (NAPc2) (Moons et al., 2003;Lee and Vlasuk, 2003). TFPI is a 42-kDa 
plasma glycoprotein consisting of three tandem Kunitz-type domains. The first and second 
domains inhibit TF-FVIIa and FXa, respectively. The third Kunitz domain and the C-terminal 
basic region of the molecule have heparin-binding sites. The anticoagulant action of TFPI is a 
two-stage process. The second Kunitz domain binds first to a molecule of FXa and deactivates it. 
The first domain then rapidly binds to an adjacent TF-FVIIa complex, preventing further 
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activation of FX (Baugh et al., 1998;Broze, Jr. and Miletich, 1987;Sanders et al., 1985). On the 
other hand, NAPc2 is an 8-kDa short polypeptide. It first binds to FXa or zymogen FX to form a 
binary complex prior to its interaction and inhibition of membrane-bound TF-FVIIa (Buddai et 
al., 2002). Therefore, despite the structural differences, both inhibitors form a quaternary 
complex with TF-FVIIa-FXa. Further, in both the complexes the active site of FVIIa is occupied 
by the respective inhibitors and is not accessible.   
Snake venoms are veritable gold mines of anticoagulant proteins (Kini, 2006). Recently, we 
isolated and characterized a novel anticoagulant protein complex (hemextin AB complex) from 
the venom of elapid snake Hemachatus haemachatus (African ringhals cobra) (Banerjee et al., 
2005a;Banerjee et al., 2005b). Hemextin AB complex specifically and non-competitively inhibits 
the TF-FVIIa complex with a Ki of 25 nM. Further, it inhibits FVIIa in the absence of TF and 
FX. Thus, unlike TFPI and NAPc2, this unique complex neither requires FX scaffold nor does it 
bind to the active site of FVIIa (Banerjee et al., 2005a).  
Structurally, hemextin AB complex consists of two proteins – hemextin A and hemextin B 
both of which belong to the three-finger toxin family of snake venom proteins. Individually, only 
hemextin A exhibits a mild anticoagulant activity, whereas hemextin B is inactive. However, 
hemextin B synergistically enhances the anticoagulant activity of hemextin A and their complex 
has potent anticoagulant activity. Thus, the formation of this unique synergistic complex of 
three-finger toxins is important for its ability to inhibit clot initiation (Banerjee et al., 2005a). 
There are only a few non-covalent protein complexes in snake venoms that do not contain 
phospholipase A2 as an integral part, such as rhodocetin (Wang et al., 1999;Paaventhan et al., 
2005) and pseutarin C (Rao and Kini, 2002). Hemextin AB complex is the only known snake 
venom protein complex formed by the interaction between two three-finger toxins and is the only 
known heterotetrameric complex of three-finger toxins.  
Since hemextin AB complex is both structurally and functionally unique, we have investigated 
the molecular interactions involved in the formation of this novel complex. In particular we have 
examined the role of electrostatic and hydrophobic interactions in the formation of tetrameric 
anticoagulant complex. Hemextin AB complex has identical molecular diameter in both gas and 
solution phases. Isothermal titration calorimetry (ITC) studies reveal that the complex formation 
is entropically unfavored, which indicates the reduced structural flexibility of the complex.  
Hemextin AB assembly is an enthalpically driven process with some conformational changes 
accompanying the complexation. The tetrameric complex behaves differently in buffers of higher 
ionic strength. It is also sensitive to the presence of glycerol in the buffer solution. Thus, a 
complex interplay of electrostatic and hydrophobic interactions drives the formation and 
stabilization of this novel anticoagulant protein complex. Based on our observations, we propose 
a model for the assembly of hemextin AB complex.  
 
MATERIALS AND METHODS 
 
Purification of hemextins A and B – Hemextin A and hemextin B were purified using the 
methods described earlier (Banerjee et al., 2005a). Briefly, H. haemachatus crude venom (100 
mg in 1 ml distilled water) was applied to a Superdex 30 gel filtration column (1.6 × 60 cm) 
equilibrated with 50 mM Tris-HCl buffer (pH 7.4) and eluted using the same buffer, using an 
ÄKTA Purifier system (Amersham Biosciences, Uppsala, Sweden). Fractions containing potent 
anticoagulant activity were pooled and sub-fractionated on a Uno S-6 (Bio-Rad, Hercules, CA, 
USA; column volume, 6 ml) cation-exchange column. The peaks containing hemextin A and 
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hemextin B were further purified using RP-HPLC on a Jupiter C18 (1× 25 cm) column. Both 
proteins were found to be homogeneous with molecular masses of 6835.00 ± 0.52 and 6792.56 ± 
0.32 Daltons respectively, as determined by electrospray ionization mass spectrometry (ESI-MS) 
(Banerjee et al., 2005a). 
 
Circular dichroism (CD) spectroscopic studies – Far UV CD spectra (260-190 nm) were 
recorded using a Jasco J-810 spectropolarimeter (Jasco Corporation, Tokyo, Japan). All 
measurements were carried out at room temperature (25 ºC) using 0.1 cm pathlength stoppered 
cuvettes. The instrument optics was flushed with 30 l/min of nitrogen gas. The spectra were 
recorded using a scan speed of 50 nm/min, resolution 0.2 nm, and band width 2 nm. For each 
spectrum, a total of six scans were recorded, averaged and baseline subtracted. The conformation 
of hemextin A and hemextin B at different concentrations were monitored in 50 mM Tris-HCl 
buffer (pH 7.4). To study the complex formation, titration experiments were carried out by 
keeping the concentration of hemextin A constant at 0.5 mM, and varying the concentration of 
hemextin B. 
Determination of molecular diameters – The apparent molecular diameters of the hemextin AB 
complex and the individual hemextins were determined in both the gas and solution phases using 
Gas Phase Electrophoretic Mobility Macromolecule Analyzer (GEMMA) and dynamic light 
scattering (DLS) respectively.  
(A) GEMMA – The molecular diameters in the gas phase were determined with GEMMA 
(Kaufman, 1995;Knutson and Whitby, 1975) using a nano-differential mobility analyzer, model 
3980 with a standard condensation particle counter type 3025 (TSI, St Paul, MN, USA). The 
instrument was operated in the ‘cone jet’ mode with an operating voltage between 2.5 and 3.0 
kV, resulting in currents from 200 to 300 nA. Filtered ambient air at 2 l/min and a concentric 
sheath gas flow of filtered CO2 at 0.1 l/min was used to stabilize the electrospray against corona 
discharge. Sample solutions of hemextin A (4 ng/ml) and hemextin B (4 ng/ml) were prepared in 
20 mM ammonium acetate (pH 7.4) immediately prior to the experiment. Hemextin AB complex 
(4.5 ng/ml) was reconstituted in the above buffer and was incubated at 37˚C for 10 min. Another 
three-finger protein, toxin C isolated and purified from the same venom was used as a control in 
the GEMMA experiments. The samples were infused into the electrospray chamber with an inlet 
flow rate of 100 nl/min. Twenty scans over the whole electrophoretic mobility (EM) diameter 
range (0 to 25 nm) were recorded and averaged to obtain a GEMMA spectrum. Data presentation 
was done without the application of any smoothing algorithm. 
(B) DLS – The complex formation studies with DLS were carried out at 25 °C using a 
BI200SM instrument (Brookhaven Instruments Corporation, Holstville, NY, USA). A vertically 
polarized argon ion laser (514.2 nm, 75 mW; NEC model GLG-3112) was used as the light 
source. Sample solutions of hemextin A (4 mM), hemextin B (4.1 mM) and hemextin AB 
complex (4.6 mM) in 50 mM Tris-HCl buffer (pH 7.4) were prepared immediately prior to the 
experiment. The hydrodynamic diameter for the hemextin AB complex and the individual 
hemextins were recorded at 25 ºC in solutions of different ionic strengths and at different 
glycerol concentrations. The ionic strengths were varied by the addition of NaCl. From the 
measured translational diffusion coefficient (DT), the hydrodynamic radius (RH) can be calculated 
using the Stokes-Einstein relation:  
 




where, kB is the Boltzmann constant, T is the temperature in Kelvin and  is the viscosity of the 
solvent. The intensity-intensity time correlation functions were obtained with a BI-9000 digital 
correlator. The particle size and size distribution were obtained by analyzing the field correlation 
function │g(1)(τ)│using constrained regularized CONTIN method (Provencher, 1976). 
  
 
Thermodynamics of hemextin AB complex formation – ITC experiments were performed using 
a Microcal VP-ITC calorimeter (Microcal LLC, Northampton, MA) to study the thermodynamics 
of the formation of hemextin AB complex. Unless otherwise noted, all experiments were 
performed in 50 mM Tris-HCl buffer (pH 7.4). Both the proteins were dissolved in the same 
buffers, filtered and degassed prior to titration. Hemextin A (0.1 mM) was kept in the sample cell 
and hemextin B (1 mM) was loaded into the syringe. The syringe stirring speed was set to 300 
rpm. Data were collected in high feedback mode, with a filter period of 3 s. For each experiment, 
a control titration was performed by injecting hemextin B into the appropriate buffer. Finally, the 
control data were subtracted from the raw data to obtain an isotherm corrected for heats of 
dilution. The first injections presented defects in the baseline and these data points were not 
included in the fitting process. The calorimetric data were processed and fitted to the single set of 
identical sites model using Microcal Origin (Version 7.0) data analysis software supplied with 
the instrument. The expression for the heat released per injection, ∆Q(i), is given by 
 
∆Q(i) = Q(i) + dVi /2V0[Q(i) + Q(i-1)] – Q(i- 1) …………(Eq. 2) 
 
where Q(i) is the total heat content, dVi is the volume injected at the ith injection, and V0 is the 
cell volume. The total heat content Q of the solution (determined relative to zero for the un-
liganded species) contained in the active cell volume, V0, was calculated according to Equation 
3, where KA is the binding affinity constant, n is the number of sites, ∆H is the enthalpy of ligand 
binding, Mt and Xt is the bulk concentration of macromolecule and ligand, respectively, for the 
binding X + M ↔ XM 
 
 
          ……………….. (Eq. 3) 
 
The change in heat (∆Q) measured between the completions of two consecutive injections is 
corrected for dilution of the protein and ligand in the cell according to standard Marquardt 
method (Levenberg, 1944;Marquardt, 1963). The free energy change (∆G) during the interaction 
was calculated using the relationship: (∆G = ∆H – T∆S = - RT ln Ka). All the experiments were 
performed at 37 °C unless otherwise indicated.   
The role of electrostatic interactions in the complex formation was evaluated by performing 
ITC experiments in 50 mM Tris-HCl buffer of various ionic strengths. The ionic strengths of the 
buffers were altered by adding sodium chloride (NaCl) (35 mM to 150 mM). To study the role of 
hydrophobic interactions in the complex formation, experiments were performed in 50 mM Tris-
HCl buffer (pH 7.4) containing various concentrations of glycerol (125 mM to 250 mM).  
 
Size-exclusion chromatography (SEC) studies – All SEC experiments were carried out at room 
temperature on a pre-packed Superdex 75 gel filtration column (1.6 × 60 cm) using a ÄKTA 
Purifier system (Amersham Biosciences, Uppsala, Sweden). The column was eluted with 50 mM 
2




t a t t a t t
nM HV X X X
Q
nM nKM nM nKM nM
 ∆   = + + − + + − 
   
  
6
Tris-HCl buffer (pH 7.4) or the specified elution buffer, at a flow rate of 1 ml/min. The sample 
volume applied to the column was 4 ml. The column was calibrated using ovomucoid (28 kDa) 
ribonuclease (15.6 kDa), cytochrome C (12 kDa), apoprotinin (7 kDa) and pelovaterin (4 kDa) 
(Lakshminarayanan et al., 2005) as molecular weight markers. The void volume was determined 
by running Blue Dextran. The column was equilibrated with at least two bed volumes of the 
elution buffer prior to each run. Electrostatic contributions in the hemextin AB complex 
formation were studied by monitoring its elution in 50 mM Tris-HCl buffer (pH 7.4) with 
different concentrations of NaCl (75 mM and 150 mM). Hydrophobic contributions for the 
complex formation were determined by recording the elution of hemextin AB complex in 50 mM 
Tris-HCl buffer (pH 7.4) with different concentrations of glycerol (125 mM and 250 mM). In 
both the studies, the column was first equilibrated with the desired buffer prior to the application 
of the reconstituted hemextin AB complex in the respective buffer to the column.  The protein 
elution was monitored by recording absorbance at 280 nm. 
 
Anticoagulant activity – The anticoagulant activity of individual hemextins and hemextin AB 
complex were determined using prothrombin time clotting assay (Quick AJ., 1935). The 
anticoagulant activity of a specific concentration of hemextin A (4.4 µM), hemextin B (4.4 µM) 
and hemextin AB complex (0.22 µM) was monitored in 50 mM Tris-HCl (pH 7.4) containing 
different concentrations of NaCl (35 mM to 150 mM for studying the role of electrostatic 
interactions) and glycerol (125 mM to 250 mM for studying the role of hydrophobic 
interactions). The concentrations of hemextin A and hemextin AB complex were chosen in a 
way such that in the absence of salt/glycerol the recorded clotting times are similar. Control 
experiments were performed without the addition of the anticoagulant proteins to evaluate the 
effect of salt and glycerol on clotting. 
 
1D-NMR spectroscopy – One-dimensional proton NMR experiments were carried out using 
Bruker 700 MHz spectrometer, equipped with a modern cryo-probe, and electronic variable 
temperature unit. The spectra were acquired using Topspin software (Bruker) interfaced to the 
spectrometer.  Hemextin A (0.5 mM) and hemextin B (0.5 mM) were prepared in 50 mM Tris-
HCl buffer (pH 7) and transferred to a 5 mm diameter Willmad NMR tube. All deuterated 
solvents were purchased from Aldrich Laboratories with 99.9% isotopic purity. The spectral 
width was set to 11,202 Hz for all NMR experiments. The huge resonance due to the water 
protons was suppressed by the WATERGATE pulse sequence (Piotto et al., 1992). Typically, 
512 scans were averaged for each FID before apodization and then performing the Fourier 
transformation. 1H chemical shifts were referenced to a sodium 2,2-dimethyl-2-silapentane-5-
sulfonate solution (DSS).  
 
RESULTS AND DISCUSSION 
 
Conformational changes during the complex formation – It has been shown previously that 
hemextin A and hemextin B interact with each other and form a 1:1 heterotetrameric complex 
and this complex formation is important for its ability to inhibit FVIIa and clot initiation 
(Banerjee et al., 2005a). To study the conformational changes associated with the hemextin AB 
complex formation we used far UV-CD. First, we recorded the CD spectra of individual 
hemextins A and B (Figure 1, A and B). Their CD spectra display negative minima at 217 nm 
and  positive maxima at 196 nm, which are due to the n to π∗ transition and the π to π∗ transition 
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of the amide chromophore, respectively, typical of a β -sheet structure (Figure 1, A and B). Next, 
a titration CD experiment was performed in order to study the complex formation between the 
two proteins. In this experiment, the concentration of hemextin A was kept constant at 0.5 mM 
and the conformational changes in hemextin A in the presence of various concentrations of 
hemextin B were recorded. The shape of the CD spectrum upon addition of hemextin B to 
hemextin A did not change significantly (Figure 1C). However, the CD intensity at 217 nm 
increases with the incremental addition of hemextin B and reaches maximum at the 1:1 molar 
ratio suggesting increase in β-sheet content and stoichiometric binding of hemextin B to 
hemextin A respectively (See supporting information- Figure S1A). The difference spectrum 
obtained by subtracting the CD spectrum of 1:1 complex from the sum of the CD spectra of 
hemextin A and hemextin B indicates the conservation of β-sheet structure in the complex, 
suggesting possible folding upon complex formation. ( See supporting information- Figure S1B). 
  
 
Changes in molecular diameters during the complex formation – The diameter of the 
individual hemextins and hemextin AB complex were determined in both gas and solution 
phases.  In the gas phase analyses using GEMMA, hemextin A and hemextin B showed the 
apparent molecular diameters of 10.20 ± 0.38 nm and 8.82 ± 0.42 nm, respectively (Figure 2). 
Hemextin AB complex exhibited a larger diameter of 16.30 ± 0.43 nm. To further confirm on the 
GEMMA results, we examined the effect of toxin C, another three-finger toxin isolated from the 
venom of H. haemachatus, on the molecular diameters of hemextins A and B, to determine the 
specificity of interaction. Toxin C did not affect the anticoagulant activity of hemextin A in 
prothrombin time clotting assay (data not shown) and did not form a complex with hemextin A. 
At equimolar concentration of toxin C, the molecular diameter of hemextin A or hemextin B 
remains unaffected (Figure 2). The solution phase studies with DLS also confirmed the increase 
in molecular diameter associated with the complex formation. Single scattering populations 
(unimodal distribution) for hemextin A, hemextin B and hemextin AB complex were observed in 
DLS suggesting the homogeneity of the sample preparations with hydrodynamic diameters of 
10.3 nm, 9.9 nm and 16.8 nm, respectively (Figure 3A). The narrow size distribution of a single 
monodisperse species for 1:1 mixture of hemextin A and hemextin B suggests the formation of a 
well-defined complex. It is important to note that the tetrameric hemextin AB complex and 
individual hemextins exhibited comparable molecular diameters in both gas and solution phases. 
The apparent molecular dimensions are significantly larger than the theoretical diameter 
estimated for a native protein and much smaller than the estimated length of the proteins in 
completely “extended conformation” (Wilkins et al., 1999;Lu et al., 1998). Such an anomaly 
could be due to the non-globular conformation of the proteins (Longhi et al., 2003).  The 
molecular diameter of hemextin AB complex is, however, much smaller compared to the 
estimated size of a tetramer indicating that the four monomers are compactly packed. 
 
Thermodynamics of the hemextin AB complex formation — ITC permits the study of 
macromolecular interactions in solution and is the only technique that can resolve the enthalpic 
and entropic components of binding affinity (Perozzo et al., 2004;Velazquez-Campoy et al., 
2004;Weber and Salemme, 2003). It was used to study the thermodynamics of hemextin AB 
complex formation. Each injection gave rise to negative (exothermic) heat of reaction (Figure 4). 
The binding isotherm fits to a single set of binding sites model, suggesting an equimolar binding 
between hemextin A and hemextin B. The interaction between them is thermodynamically 
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allowed (as indicated by negative ∆G) (Table 1). A favorable negative ∆H but unfavorable 
negative ∆S changes indicate that the complex formation is enthalpically driven and, van der 
Waals interactions and hydrogen bonds may play an important role in the complex formation 
(Katragadda et al., 2004). Also, the formation of a less dynamic complex is entropically 
disfavored, as has been observed in the studies pertaining to the dimerization of insulin (Tidor 
and Karplus, 1994). Thus the recorded negative entropic change (∆S) indicates the formation of a 
less flexible or less disordered hemextin AB complex. The binding constant (KA) for the 
formation of hemextin AB complex was 2.23 x 106 M-1 and it falls within the KA values for 
protein-protein interactions in biologically relevant processes that range from 104 to 1016 M-1 
(Stites, 1997). 
 
The effect of temperature on the hemextin AB complex formation — To further understand 
energetics of the complex formation, complete temperature profile of the thermodynamic 
parameters associated with the binding of hemextin A to hemextin B was studied over the 
temperature range of 25-45 °C. The temperature dependence of ∆H is shown in Figure 5A and 
Table 1. The temperature dependence of ∆H over a narrow temperature range is given by the 
equation:  
 
∆H = ∆H0 + ∆Cp(T-T0)..........................(Eq. 4) 
 
where, ∆H0  is the binding enthalpy at an arbitrary reference temperature and ∆Cp is the heat 
capacity change of binding. The ∆Cp obtained from the slope (∆Cp = δ∆H /δT) (Figure 5A), is -
163 cal/K-1mol-1. Negative ∆Cp indicates a reduction in the nonpolar solvent-accessible surface 
area, as explained by the following equation (Murphy and Freire, 1992), 
 
 
∆Cp = 0.45(∆ASAnonpol) – 0.26 (∆ASApol) cal /molK …………….. (Eq. 5) 
where, ∆ASApol and ∆ASAnonpol are the change in the polar- and non-polar-accessible surface 
areas, respectively. Thus, hemextin AB complex formation is associated with the burial of 
hydrophobic surface area.    
Figure 5B shows the plot of ∆G and ∆H as a function of T∆S. It is clear that the ∆G of binding 
remained temperature independent and is a result of linear dependence of ∆H on T∆S. This 
strongly suggests the enthalpy-entropy compensation for the binding of hemextin A to hemextin 
B.  This phenomenon is a universal feature for protein-peptide interactions, where weak 
molecular interactions undergo constant rearrangements to realize a lower free energy of binding 
(Cooper, 1999;Dunitz, 1995;Katragadda et al., 2004;Lumry, 2003). The co-relation between 
entropy and enthalpy for a range of interacting protein-protein systems was determined (r2 = 
0.956). The data for hemextin AB complex falls well along this correlation line (See supporting 
information- Figure S2). 
The negative ∆Cp indicates the net thermodynamic driving force for the association to shift 
from entropic to enthaplic with increasing temperature. At the intersection point of both lines ∆G 
= ∆H = -8.4 kCal.mol-1 (Figure 5B), which corresponds to a temperature Ts (Temperature at 
which the contribution from entropy is zero (Spolar and Record, Jr., 1994;von Hippel, 1994). At 
Ts the contribution from entropy changes from favorable to unfavorable. From Figure 5A, ∆H = -
8.4 kCal.mol-1 is connected with a Ts of 16 °C (289 °K).  
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The negative ∆Cp for the hemextin AB complex formation further suggests that the observed 
entropy change upon binding must include significant contribution from the hydrophobic effect 
in the physiological temperature range. Therefore, for protein-protein/ligand interaction(s) the 
net entropy of association is given by the equation:  
                     
∆S assoc =  ∆SHE + ∆ Srt +  ∆ Sother ........................(Eq. 6) 
  
where, ∆SHE,  ∆Srt, and ∆Sother are the entropy changes due to hydrophobic effect, reduction of 
rotational and translational degree of freedom, and from other sources, respectively.  
 
At Ts, the overall entropy of association is zero and the above equation becomes:  
  
∆S assoc=  ∆SHE (Ts) + ∆Srt +  ∆Sother = 0 ........................(Eq. 7) 
   
In the absence of crystallographic data, the ∆SHE(Ts) was estimated from the equation, 
   
∆SHE(Ts) = 1.35 ∆Cp ln(Ts/386)...........................................(Eq. 8) 
 
and found to be 64 cal deg-1 mol -1. It has been shown that protein-protein interaction ∆Srt is 
nearly equal to -50 cal deg-1 mol-1 (Finkelstein and Janin, 1989;Janin and Chothia, 1978). Thus 
the ∆Sother is calculated to be -14 cal deg-1 mol-1. Because of experimental uncertainties in the 
heat capacity change and the entropy of complex formation, as well as in the value of the 
rotational-translational entropy term, the analysis of coupled folding is typically not suitable for 
distinguishing small extents of folding from the rigid body case.   However, from the non-zero 
value of ∆Sother it can be concluded that that there is no evidence for large-scale coupled folding, 
during the formation of hemextin AB complex. Again, Ψ = ∆Sother/ -5.6 cal deg-1 mol-1, where Ψ 
designates the number amino acid residues involved in the folding transition (Hilpert et al., 
2003). Therefore, approximately three residues are involved in the folding transition. Also, From 
Figure 5B the enthalpic counterpart of TS, namely TH, the temperature at which the enthalpic 
contribution to the Gibbs free energy of binding changes from favorable to unfavorable is 
calculated to be 244 °K. Therefore, below -29 °C the binding process is entropically driven and 
only in the interval between TS and TH (i.e., between -29 °C and 16°C), both the entropic and 
enthalpic part of the Gibbs free energy of binding are favorable.  
 
Oligomerization states of the anticoagulant complex and individual hemextins – Hemextin AB 
complex exists as a tetramer and the complex formation is pivotal for its potent anticoagulant 
activity. Also as determined in prothrombin time and kinetic assays the stoichiometry of complex 
formation is 1:1  (Banerjee et al., 2005a). We evaluated the role of both electrostatic and 
hydrophobic interactions in complex formation. 
 
(A) Electrostatic interactions in hemextin AB complex formation – Firstly, the binding constant 
for hemextin AB complex formation was determined by ITC in buffers of increasing ionic 
strength. The log KA values for the complex formation decreased linearly with the increasing 
NaCl concentration (Figure 6A, Table 1), illustrating the participation of electrostatic 
interactions in complex formation.  Secondly, the effect of buffer ionic strength on the assembly 
of hemextin AB complex was examined with the help of SEC. In the absence of salt, the 
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complex eluted as a tetramer and the individual hemextins as monomers (Figure 7A). In the 
presence of 75 mM NaCl the tetramer started dissociating into dimer (Figure 7B). With further 
increase in ionic strength of the buffer (NaCl 150 mM) the complex eluted mostly as a dimer and 
monomer(s). ESI-MS and HPLC analyses of the dimer peak indicated that it contains both 
hemextins A and B (data not shown). This observation again reconfirms the importance of 
electrostatic interactions in hemextin AB assembly. Interestingly, an additional protein peak 
eluted slower than the monomers indicating hemextin A and/or hemextin B was undergoing a 
conformational change in buffers of high ionic strength. Therefore, we monitored the elution 
profiles of individual hemextins in buffers of high ionic strength. Hemextin A at 75 mM NaCl 
concentration showed two peaks; a second protein peak eluted slower than the monomer (Figure 
7B). With further increase in the ionic strength (NaCl 150 mM) hemextin A eluted mostly in the 
second peak. ESI-MS and HPLC analyses of this second peak show that it is structurally intact 
hemextin A (data not shown). Thus, the change in the elution profile of hemextin A in buffers of 
higher ionic strength hinted a conformational change in the protein, which was further confirmed 
by 1D NMR studies (see below). Increased ionic strength of buffer did not have any effect on the 
elution of hemextin B (Figure 7A and B).  
We also determined the hydrodynamic diameters of hemextin AB complex and individual 
hemextins in buffer solutions of high ionic strength using DLS (Figure 3B). (As GEMMA works 
on the principle of nano-ESI, we did not determine the molecular diameters in buffers containing 
high salt using this technique.). At high salt concentrations, the hemextin AB complex exhibits a 
high polydispersity indicating the presence of different species. At 75 mM NaCl, there are three 
different populations. In addition to the monomer(s) and the tetramer, there is an additional 
population with an apparent molecular diameter of 12.4 nm. Based on our SEC results (Figure 
7B), we suggest that the 12.4 nm species could be the dimeric hemextin AB complex. As 
expected, the population of 12.4 nm species increases when the concentration of NaCl is 
increased to 150 mM (Figure 3B). Thus DLS data also suggests the dissociation of the tetrameric 
complex to a dimer. As expected, polydispersity was also observed with hemextin A in buffers 
of high ionic strength (Figure 3B).  An additional population of 11.57 nm sized particle, in 
addition to its native size of 10.4 nm is observed. Based on the SEC (Figure 7B) and 1D-NMR 
(see below), we suggest that the 11.57 nm species represents the conformationally altered form 
of hemextin A. No change in the hydrodynamic diameter of hemextin B was observed with the 
increase in buffer ionic strength (Figure 3B).   
To understand the implications of the change in conformation of hemextin A and the 
breakdown of tetrameric complex, we monitored the anticoagulant activity of the complex and 
individual hemextins in buffers of high ionic strengths. Higher concentration of NaCl did not 
affect the anticoagulant activity of hemextin A (Figure 8A). Thus despite the change(s) in 
conformation (see below), hemextin A retains its anticoagulant activity. The anticoagulant 
activity of hemextin AB complex, in contrast, decreased with the increase in ionic strength up to 
100 mM NaCl (Figure 8A). However, further increase in the salt concentration did not 
significantly affect the anticoagulant activity. At 150 mM NaCl the complex exists as a mixture 
of a dimer, monomer(s) and conformationally altered hemextin A as is evident from the SEC 
experiments (Figure 7B). Therefore, the remaining anticoagulant activity observed at 150 mM or 
higher NaCl concentration is due to the presence of monomeric hemextin A and not due to 
dimeric hemextin AB complex. Hence, it can be concluded that the dimer formed at high salt 
concentrations does not have any significant anticoagulant activity.  
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Thus, these studies in buffers of high ionic strength strongly suggest that electrostatic 
interactions play crucial role in the assembly of hemextin AB complex. As hemextin A 
undergoes conformational change(s) in the presence of salt (see below), the dissociation of 
tetramer in a buffer of high ionic strength may not only be due to the disruption electrostatic 
interaction but also due to conformational change(s) in hemextin A. Further, high salt 
concentration leads to the formation of a dimer which is functionally inert (in terms of lack of 
synergic increase in anticoagulant activity). Based on the obtained results, we hypothesize that 
the dimer assembled at 150 mM NaCl concentration is probably formed by the interplay of 
predominantly hydrophobic interactions. Therefore, successive experiments were carried out to 
evaluate the importance of hydrophobic interactions in the complex formation.  
(B) Hydrophobic interactions in the hemextin AB complex formation – We carried out ITC 
experiments in buffers containing increasing concentrations of glycerol. Adsorption of glycerol 
to hydrophobic patches on the surface of proteins interferes in the hydrophobic interactions (Liu 
et al., 2004). A decrease in the association constant was observed with the increase in glycerol 
concentration (Figure 6B and Table 1), showing the importance of hydrophobic interactions in 
the complex formation. We monitored the elution of hemextin AB complex in buffers containing 
glycerol on a Superdex 75 column (Figure 7C). In buffers containing high glycerol concentration 
the tetramer dissociates into dimer and monomers. ESI-MS and HPLC analyses of the dimer 
peak indicate that it contains both hemextins A and B (data not shown). However, no additional 
peak corresponding to altered conformation of hemextin A was observed. The elution of 
individual hemextins remained unaltered in the presence of glycerol (Figure 7C). The breakdown 
of hemextin AB complex in the presence of glycerol was also observed in the DLS studies 
(Figure 3C). At 125 mM glycerol concentration, an additional population of 12.8 nm-sized 
species was observed in addition to the monomers and the tetrameric complex. Based on SEC 
studies, we propose that the 12.8 nm species is a dimer. The 12.8 nm species increases with the 
increase in glycerol concentration (Figure 3C). It is important to note that the apparent molecular 
diameter of this dimer is different from the dimer formed in buffers of high ionic strength (12.8 
nm versus 12.4 nm; Figure 3B and 3C). (As GEMMA works on the principle of nano-ESI, we 
did not determine the molecular diameters in buffers containing glycerol using this technique.). 
No polydispersity was observed in the case of individual hemextins in the presence of glycerol 
(Figure 3C).  
To further understand the implication of the breakdown of hemextin AB complex in glycerol, 
we monitored its anticoagulant activity and that of the individual hemextins in buffers containing 
different concentrations of glycerol.  The anticoagulant activity of hemextin AB complex 
decreased with the increase in glycerol concentration (Figure 8B). At 125 mM glycerol 
concentration there is no decrease in the anticoagulant activity. However, at 250 mM glycerol 
concentration (at which hemextin AB complex exists as a mixture of dimer and monomers; 
Figure 7C) there is a decrease in the anticoagulant activity. But this activity is higher than that of 
the anticoagulant effect of hemextin A alone. Therefore, we conclude that the dimer observed at 
250 mM glycerol concentration exhibits the anticoagulant activity higher than hemextin A alone 
but lower than that of the tetramer. In other words, dimer formed in the presence of glycerol is 
different from the dimer formed in salt; the former dimer exhibiting an increased anticoagulant 
activity compared to hemextin A alone, whereas the latter not doing so. Glycerol, however, did 
not affect the anticoagulant activity of individual hemextins (Figure 8B). 
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The dissociation of the tetramer into dimer and monomers in the presence of glycerol indicates 
the importance of hydrophobic interactions in the tetrameric complex formation. This role of 
hydrophic interaction is further supported by the negative ∆Cp change observed during the 
formation of hemextin AB complex. 
 
Our data strongly suggests that both electrostatic and hydrophobic interactions are important for 
the formation of tetrameric hemextin AB complex. To confirm that decrease in binding affinity 
between the monomers observed in salt and glycerol is not a solute osmotic effect, the KA 
recorded in salt and glycerol was plotted against osmotic pressure (See supporting information- 
Figure S3). At similar osmolality of salt and glycerol decrease in binding affinity was more 
pronounced in salt than glycerol. This indicates that fall binding affinity is due to disruption of 
either electrostatic (for salt) or hydrophobic (for glycerol) interactions. 
   The effect of buffer conditions on the conformation of hemextins – Earlier studies using SEC 
(Figure 7B) and DLS (Figure 3) indicated that hemextin A undergoes conformational changes in 
the presence of salt. We conducted 1D-NMR analysis to study the conformation of hemextins A 
and B under different buffer conditions (Figure 9). In the presence of NaCl, there is a decrease in 
the number of Hα resonance peaks between 4.8 ppm and 6 ppm in the case of hemextin A 
(Figure 9A). These chemical shifts contribute to the inter-residue NOE cross peaks between Hα 
of different amino acid residues forming anti-parallel β-sheet structure typically observed in all 
three-finger toxins (Kini, 2002). Thus a decrease in the β-sheet content of hemextin A is 
observed in the presence of NaCl. In addition, there are several changes in the chemical shifts of 
side chains. A notable change is a highly shielded methyl peak which appears at the negative 
chemical shift value (−0.38 ppm) in the presence of salt. These observations strongly support 
conformational changes in hemextin A in the presence of NaCl. The overall dispersion of 1D 
proton NMR spectra of hemextin A in the presence of glycerol (deuterated) remains the same 
with the subtle changes in the amide region (Figure 9A). Thus, hemextin A did not undergo any 
significant conformational change upon the addition of glycerol. Similar studies with hemextin B 
show that it did not undergo any significant conformational changes in the presence of NaCl or 
glycerol (Figure 9B) since there is almost one to one match for the spectral frequencies.  
 
Model for hemextin AB complex – Based on our studies we propose a model for the assembly 
of hemextin AB complex (Figure 10). Two molecules each of hemextin A and B form the 
tetrameric complex in Tris-HCl buffer (Figure 10A). The formation of this compact, synergistic 
complex is important for its anticoagulant activity. As illustrated earlier, hemextin AB dimer in 
high salt is different from the dimer formed in the presence of glycerol (Figure 10C). The former 
dimer has an apparent molecular diameter of 12.4 nm and lacks anticoagulant activity, whereas 
the latter has an apparent molecular diameter of 12.8 nm and exhibits slightly higher 
anticoagulant effects (Figure 10C). Thus, the breakdown of tetramer to dimer probably occurs in 
two different interfaces of interaction between hemextin A and B. One interface is sensitive to 
the ionic strength of its surroundings while the other is sensitive to glycerol (Figure 10C).  
Further, in the presence of salt, hemextin A undergoes conformational changes (Figure 10B) 
which may interfere in the tetramer formation. The dimer formed under high ionic conditions 
lacks the complete synergistic anticoagulant site (marked by a dotted semicircle in Figure 10C) 
and hence the resultant dimer is as active as hemextin A alone. (Figure 8). In contrast, 
hydrophobic interactions are predominant in the second interface. Therefore, glycerol dissociates 
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the tetramer into dimers. However, in this case only minor changes occur in the synergistic 
anticoagulant site of the complex (as shown in Figure 10C) and hence the resultant dimer is 
active (Figure 8). We propose that the tetramer formation most likely stabilizes the anticoagulant 
site of hemextin A. The binding between hemextin AB complex/ hemextin A and FVIIa has been 





Hemextin AB complex is the first synergistic anticoagulant complex isolated from snake venom 
comprising solely of two three-finger toxins – hemextin A and hemextin B (Banerjee et al., 
2005a). The tetrameric complex formation is a pre-requisite for the synergistic inhibition of 
FVIIa. This complex formation is an enthalpically driven process. The complex exhibits identical 
apparent molecular diameters in gas and solution phases. Thermodynamics of hemextin AB 
complex formation indicates the absence of large scale coupled folding. Both electrostatic and 
hydrophobic interactions are important for the assembly of the tetramer. Based on our results we 
propose that the tetramer formation takes place by the participation of two interfaces. One of the 
interfaces is predominantly sensitive to the buffer ionic strength, indicating that electrostatic 
interactions are predominantly active in that interface. The other being sensitive to glycerol 
concentration of the solution indicates the participation of mostly hydrophobic interactions. The 
proposed model may help in a better understanding of the structure-function relationship of this 
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Thermodynamic analysis of hemextin A-hemextin B interaction 
 
 
ITC experiments KA × 10
6 (M-1) ∆H (kcal/mole) ∆S (cal/deg.mole) ∆G (kcal/mole) 
At different temperatures (°C)  
25 2.07 
-9.92 
 -4.43 -8.6 
37 2.23 
-11.7 
 -8.645 -9 
45 1.97 
-13.12 
 -12.49 -9.15 
At different salt concentrations  
35 mM NaCl 0.63 -10.5 -7.2 -8.2 
75 mM NaCl 0.33 -9.32 -4.8 -7.8 
100 mM NaCl 0.02 -7.31 -3.82 -6.12 
150 mM NaCl 0.002 -5.01  -1.2 -4.6 
At different glycerol concentrations  
125 mM glycerol 0.32 -10.8 -11.01 -7.6 
175 mM glycerol 0.2 -10.5 -10.6 -7.2 










Figure 1: Conformational changes associated with the formation of hemextin complex.   CD 
spectra of (A) hemextin A (0.5 mM) and (B) hemextin B (0.5 mM). (C) Conformational changes 
in hemextin A with increasing concentrations of hemextin B: ▬ hemextin A 0.5 mM; ▬ 
hemextin A 0.5 mM plus hemextin B 0.25 mM; ▬ hemextin A 0.5 mM plus hemextin B 0.4 
mM; ▬ hemextin A 0.5 mM plus hemextin B 0.5 mM; ▬ hemextin A 0.5 mM plus hemextin B 
0.9 mM; inset, the observed change in the CD spectra around the 217 nm region. 
 Figure 2. Measurement of molecular diameter during the hemextin AB complex formation 
using GEMMA. The molecular diameters of the individual hemextins and the hemextin AB 
complex are calculated based on their electrophoretic mobility. The formation of hemextin AB 
complex leads to an increase in the molecular diameter. Addition of equimolar toxin C does not 
show any significant increase in the molecular diameters of hemextin A and hemextin B 
validating the obtained data. 
Figure 3. Determination of hydrodynamic diameter using DLS. A. CONTIN analysis hemextin A, 
hemextin B and hemextin AB complex in 50 mM Tris-HCl  buffer. Effect various concentrations 
of NaCl (B) and glycerol (C) on hemextin AB complex. The calculated hydrodynamic diameters 
for each molecular species are shown. (Note the dimer formed in glycerol has a different 
diameter than the one formed in salt) 
Figure 4. Interaction studies between hemextin A and B using ITC. (A) Raw ITC data 
showing heat release upon injections of 1 M hemextin B into a 1.4-ml cell containing 0.1 mM of 
hemextin A; (B) Integration of the raw ITC data yields the heat/mol versus molar ratio. The best 
values of the fitting parameters are 1.04 for N, 2.23 × 106 M-1 for KA and -11.68 kcal.M-1 for ∆H 
(Table 1). 
Figure 5. Thermodynamics of hemextin A-hemextin B interaction. (A) Effect of temperature 
on the energetics of hemextin A-hemextin B interaction: enthalpy change (∆H), change in 
entropy term (T∆S) and free energy change (∆G). (B) Enthalpy-entropy compensation in 
complex formation. (Note: Point of intersection of lines corresponding to ∆H and ∆G 
corresponds to Ts) 
Figure 6. Hemextin AB complex formation under different buffer conditions. (A) 
Dependence of KA on the ionic strength of the buffer. The binding affinity decreases with the 
increase in buffer ionic strength indicating the importance of electrostatic interactions. (B) 
Dependence of KA on the glycerol concentration. The binding affinity decreases with the increase 
in glycerol concentration indicating the importance of hydrophobic interactions. 
Figure 7. SEC studies of Hemextin AB complex in different buffer conditions. A. Elution 
profiles of hemextin AB complex in Tris-HCl buffer. Effect various concentrations of NaCl (B) 
and glycerol (C) on hemextin AB complex. The tetrameric complex (peak denoted by 4) 
dissociates into dimer and monomer (peaks denoted by 2 and 1, respectively) with the increase in 
salt or glycerol. Asterisk denotes the peak containing conformationally altered hemextin A. (D) 
Calibration of the column using the following proteins as molecular weight markers – 
ovomucoid (28 kDa), ribonuclease (15.6 kDa), cytochrome C (12 kDa), apoprotinin (7 kDa) and 
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pelovaterin (4 kDa). The molecular weights of the tetramer, dimer and monomers were 
calculated from the calibration curve. 
Figure 8. : Effect of buffer conditions on anticoagulant activity. Effect various concentrations 
of  NaCl (A) and glycerol (B) on the anticoagulant activity of hemextin A (O), hemextin B (M), 
hemextin AB complex (▲). The anticoagulant activity of hemextin AB complex decreases with 
the increase in concentrations of NaCl and glycerol. The arrows indicate the concentrations of 
(A) NaCl and (B) glycerol where the anticoagulant complex exists mostly as a mixture of dimer 
and monomers (see text for details). (■) denotes the anticoagulant activity recorded in the 
absence of the proteins. 
Figure 9: One-dimensional 
1
H NMR studies. Spectrum of (A) hemextin A and hemextin B 
under different buffer conditions. Note, in the presence of salt hemextin A undergoes a 
conformational change. Also, the peaks are sharp through out the spectrum. In addition, all 1D 
1H NMR spectra also exhibited a wide range of chemical shift dispersions (amide region 7 to 10 
ppm, Hα region 3.8  to 6 ppm and methyl region −0.4 –to 1.5 ppm) which is a characteristics of 
well folded proteins. Therefore, the observed structural change is not due to resonance 
broadening or aggregation (as no aggregation state was observed as mentioned) but it is only due 
to addition of NaCl to hemextin A. 
Figure 10: A proposed model of hemextin AB complex. A. Schematic diagram depicting the 
formation of hemextin AB complex. Hemextins A and B, two structurally similar three-finger 
toxins, form a compact and rigid tetrameric complex with 1:1 stoichiometry (Banerjee et al., 
2005a). B. Schematic diagram showing the effect of salt and glycerol on conformations of 
hemextins A and B. Hemextin A undergoes a conformational change in the presence of salt. C. 
Dissociation of the tetrameric hemextin AB complex in the presence of salt and glycerol. The 
dissociation probably occurs in two different planes. Thus the hemextin AB dimer in high salt is 
different from the dimer formed in the presence of glycerol. Two putative anticoagulant sites are 
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Hemextin A was isolated and purified from African Ringhals cobra
(Hemachatus haemachatus). It is a three-finger toxin that specifically inhibits
blood coagulation factor VIIa and clot formation and that also interacts with
hemextin B to form a unique anticoagulant complex. Hemextin A was
crystallized by the hanging-drop vapour-diffusion method by equilibration
against 0.2M ammonium acetate, 0.1M sodium acetate trihydrate pH 4.6 and
30% PEG 4000 as the precipitating agent. The crystals belong to space group
P212121, with unit-cell parameters a = 49.27, b = 49.51, c = 57.87 A˚ and two
molecules in the asymmetric unit. They diffracted to 1.5 A˚ resolution at
beamline X25 at BNL.
1. Introduction
Snake venoms are veritable gold mines of pharmacologically active
polypeptides and proteins (Kini, 2003; Koh et al., 2006; Marsh &
Williams, 2005). The venom from a single species of snake may
contain several hundred different proteins, which may however be
classified into a small number of superfamilies. The three-finger
family, a toxin superfamily, contains proteins with molecular weights
in the approximate range 6000–8000 Da and encompasses non-
enzymatic polypeptides containing 60–74 amino-acid residues that
confer lethality to Elapidae and Hydrophidae venoms (Kini, 2002).
Proteins belonging to this family contain four or five disulfide bridges,
of which four are conserved in all members. All proteins belonging to
this family show a similar pattern of protein folding; they adopt a leaf-
like shape comprising of three adjacent loops (‘fingers’) forming a
large and flat -pleated sheet that emerges from a small globular core
confined by four conserved disulfide bridges, hence their name.
Despite their similarity in structure, these proteins differ from each
other in their biological activities. Members of this family include
nicotinic and muscarinic toxins with selectivity towards distinct types
of nicotinic and muscarinic acetylcholine receptors, fasciculins that
inhibit acetylcholinesterase (Marchot, 1999; Taylor et al., 1995),
calciseptins that block the L-type calcium channels (Joseph et al.,
2004), cardiotoxins (cytotoxins) that exert their toxicity by forming
pores in cell membranes (Kumar et al., 1996; Menez et al., 1990) and
dendroaspins, which are antagonists of various cell-adhesion
processes (Williams et al., 1993).
Recently, we isolated and characterized a novel anticoagulant
protein complex (hemextin A and B) from the venom of the elapid
snakeHemachatus haemachatus (African Ringhals cobra; Banerjee et
al., 2005a,b). Hemextins A and B belong to the three-finger toxin
family of snake-venom proteins. Individually, hemextin A exhibits
mild anticoagulant activity, whereas hemextin B is inactive. However,
hemextin B synergistically enhances the anticoagulant activity of
hemextin A and their complex has potent anticoagulant activity.
Thus, the formation of this unique synergistic complex of three-finger
toxins is important for its ability to inhibit clot initiation. There are
only a few noncovalent protein complexes in snake venoms that do
not contain phospholipase A2 as an integral part, such as rhodocetin
(Wang et al., 1999) and pseutarin C (Rao et al., 2003). The hemextin
AB complex is the only known snake-venom protein complex formed
# 2007 International Union of Crystallography
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by the interaction between two three-finger toxins and is the only
known heterotetrameric complex of three-finger toxins. Here, we
report the crystallization and preliminary diffraction studies of
hemextin A, a unique anticoagulant protein, with the aim of under-
standing its structure and the function of this three-finger toxin in the
anticoagulant process.
2. Methods and results
2.1. Purification of hemextin A
Hemextin A was purified using previously described methods
(Banerjee et al., 2005b). Briefly, crude H. haemachatus venom
(100 mg in 1 ml distilled water) was applied onto a Superdex 30 gel-
filtration column (1.6  60 cm) equilibrated with 50 mM Tris–HCl
buffer pH 7.4 and eluted with the same buffer using an A¨KTA
Purifier system (Amersham Biosciences, Uppsala, Sweden). Fractions
containing potent anticoagulant activity were pooled and sub-
fractionated on a Uno S-6 (Bio-Rad, Hercules, CA, USA; 6 ml
column volume) cation-exchange column. The peaks containing
hemextin A were further purified using RP-HPLC on a Jupiter C18
(1  25 cm) column (Fig. 1a). The protein was found to be homo-
geneous, with a molecular weight of 6835.00  0.52 Da as determined
by electrospray ionization mass spectrometry (ESI–MS; Fig. 1c).
The presence of hemextin A was confirmed using size-exclusion
chromatography (SEC). All SEC experiments were carried out at
room temperature on a pre-packed Superdex 75 gel-filtration column
(1.6 60 cm) using the same A¨KTA Purifier system. The column was
eluted with 50 mM Tris–HCl buffer pH 7.4 at a flow rate of
1 ml min1. The sample volume applied onto the column was 4 ml.
The column was calibrated using ovomucoid (28 kDa), ribonuclease
(15.6 kDa), cytochrome c (12 kDa), apoprotinin (7 kDa) and pelo-
vaterin (4 kDa) as molecular-weight markers (Fig. 1b). The void
volume was determined by running Blue Dextran. The column was
equilibrated with at least two bed volumes of elution buffer prior to
each run.
2.2. Crystallization
Crystallization trials for hemaxtin A were conducted using the
hanging-drop vapour-diffusion method and a wide range of condi-
tions were tested using Hampton Research Crystal Screens I and II.
The protein concentration was kept at approximately 30 mg ml1 and
the drops were prepared by mixing equal volumes (1 ml) of protein
solution in 50 mM Tris buffer pH 7.4 and crystallization solution. The
screens were set up at 295 K using VDX plates from Hampton
Research. 500 ml reservoir solution was placed in each well. The
initial screen identified a PEG-based crystallization condition. By
systematic optimization around the preliminary condition, we
obtained diffraction-quality crystals of hemextin A. The best crystals
were from a condition consisting of 0.2M ammonium acetate, 0.1M
sodium acetate trihydrate, 30%(w/v) PEG 4000 pH 4.6. The rod-
shaped crystals appeared after 12–15 d (Fig. 2).
2.3. Data collection
We have collected a complete native data set for hemextin A. Prior
to data collection, crystals of hemaxtin A were briefly soaked in a
cryoprotectant solution consisting of reservoir solution supplemented
with 25%(w/v) glycerol, picked up with a nylon cryo-loop and frozen
at 100 K in a nitrogen-gas cold stream (Cryostream cooler; Oxford
Cryosystems, Oxford, England). Synchrotron data were collected at
beamline X25, NSLS, Brookhaven National Laboratory. Data sets
were collected using a Quantum 4 CCD detector and were processed
using HKL-2000 (Otwinowski & Minor, 1997; Table 1). The crystals
diffract to 1.5 A˚ resolution. The space group was P212121, with unit-
cell parameters a = 49.27, b = 49.51, c = 57.87 A˚. The Matthews
coefficient VM of 2.92 A˚
3 Da1 (Matthews, 1968) is within the
expected range for two monomers in the asymmetric unit and
corresponds to a solvent content of 57.89%.
3. Discussion
Hemextin A, a three-finger toxin, was successfully purified from
crude H. haemachatus venom. As shown in Fig. 1(a), hemextin A
exists as a monomer in solution. Hemextin A was crystallized using
crystallization communications
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Figure 1
(a) Size-exclusion chromatography elution profile of hemextin A. (b) Molecular-
weight standards. (c) Mass spectrum of hemextin A.
Figure 2
Crystal of hemextin A. Ten divisions of the scale is equivalent to 0.17 mm.
the hanging-drop vapour-diffusion method. The X-ray diffraction
data showed that the crystal belongs to the orthorhombic system,
space group P212121, with two molecules in the asymmetric unit.
Using a three-finger toxin homology structure (PDB code 1ug4) as a
search model, the rotation function gave two clear solutions corre-
sponding to two molecules in the asymmetric unit. The translation
function calculated in the resolution range 8–4 A˚ using the program
AMoRe (Navaza, 1994) had two peaks that were significantly above
the background and were of nearly equal height. The translation
function confirmed that each of these peaks corresponded to an
orientation of one of the two molecules in the asymmetric unit. Rigid-
body refinement performed with AMoRe after combining the two
solutions gave a correlation coefficient of 0.62 and an R factor of 0.40.
We are now in the process of building the model and refining the
structure. The structure of hemextin A will help in detailed under-
standing of its anticoagulant activity.
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Table 1
Data-collection statistics for hemextin A.
Values in parentheses are for the highest resolution shell.
Beamline X25, NSLS, BNL
Wavelength (A˚) 0.97950






Resolution limits (A˚) 50–1.5 (1.55–1.50)




Completeness (%) 100 (100)
Overall I/(I) 10.5
Rsym† (%) 0.071 (0.26)
† Rsym =
P jIi  hIij=
P jIij, where Ii is the intensity of the ith measurement and hIi is the
mean intensity of the reflection.
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Hemextin AB complex from Hemachatus haemachatus venom is the only known natural 
anticoagulant that specifically inhibits factor VIIa (FVIIa) enzymatic activity in the absence of 
factor Xa (Banerjee, Y., Mizuguchi, J., Iwanaga, S., and Kini, R. M. (2005) J Biol.Chem 280, 
42601-42611). It is also the only known hetero-tetrameric complex of two three-finger proteins. 
Recently, we elucidated the molecular interactions involved in hemextin AB complex formation, 
proposing a model for its assembly. Here, we biophysically characterize the binding of hemextin 
AB complex and hemextin A with FVIIa, and localize their binding site in the enzyme. Binding 
of the anticoagulants with FVIIa was studied using isothermal titration calorimetry (ITC) and 
size-exclusion chromatography (SEC), in buffers of high ionic strength and that containing 
glycerol. Hemextin AB complex binds to FVIIa under both conditions with variable affinities. 
The results from these studies also validated our earlier proposed model of hemextin AB 
complex assembly. Conformational changes associated with the binding of anticoagulant 
complex with FVIIa were studied using circular dichroism spectroscopy. The hemextin AB-
FVIIa complex exhibited a slight increase in E222 indicating an increase in 310-helix structure 
upon complex formation. Binding studies using ITC and SEC indicate that both hemextin A and 
hemextin AB complex bind to FVIIa in the presence of soluble tissue factor, suggesting that their 
binding site in FVIIa is distinct from the cofactor binding site. The anticoagulant proteins also 
exhibited binding with active site blocked FVIIa, confirming their non-competitive nature of 
inhibition. Further binding studies with the anticoagulant proteins were conducted using 
separated light and heavy chains of FVIIa. Both hemextin A and hemextin AB complex bind to 
FVIIa heavy chain with high affinity, but not to light chain indicating the binding site is localized 
in this chain.  
Page 2 of 37































































Blood coagulation following vascular injury is initiated  by exposure of factor VII (FVII) and 
factor VIIa (FVIIa) to the membrane bound cofactor, tissue factor (TF, resulting in production of 
Factor FXa (FXa) and more FVIIa (1-4). The process is propagated upon production of factor 
IXa (FIXa) (5) and more FXa (6) that, upon binding to their respective cofactors FVIIIa and FVa, 
form platelet bound complexes, ultimately resulting in the formation of thrombin. Thrombin 
cleaves fibrinogen to fibrin and the polymerized fibrin is cross-linked by transglutaminase 
FXIIIa (7) to form the fibrin clot staunching the flow of blood thereby preventing blood loss. The 
initiation and subsequent regulation of coagulation is understandably complex since maintenance 
of hemostasis is crucial for survival. Abnormal/unwanted blood clot formation, also known as 
thrombosis, can lead to death and debilitation due to myocardial infarction, acute coronary 
syndrome, acute ischemic stroke, and pulmonary embolism. Thus, anticoagulants are central for 
the treatment and prevention of thrombosis (8). Coumarin and heparin are the classical 
anticoagulants (9;10). However, due to the non-specific mode of action of these anticoagulants, 
they have a very narrow therapeutic window (11). This limitation has provided the impetus for 
the design/development of novel anticoagulants targeting specific coagulation enzymes or steps 
in the coagulation pathway.  
There is increasing enthusiasm in the inhibition of FVIIa as a target to achieve therapeutic 
anticoagulation because of its ‘central’ and ‘upstream’ position in the coagulation process and 
also because of its minute concentrations in the plasma milieu. Snake venoms are veritable 
goldmines of anticoagulant proteins (12), a number of which have inspired the design and 
development of therapeutic agents or lead molecules for cardiovascular diseases (13-16). 
Previously, we reported the purification and characterization of a three-finger toxin, hemextin A, 
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4from the venom of an elapid snake Hemachatus haemachatus (African Ringhals cobra) that 
mediates anticoagulant activity (17;18). Although, individually it has mild anticoagulant activity, 
its 1:1 complex with a second three-finger toxin, hemextin B, enhances its anticoagulant potency. 
Hemextin A and its synergistic complex – hemextin AB complex, specifically inhibit the 
enzymatic activity of FVIIa with a Ki of 25 nM. Further, it inhibits FVIIa in the absence of TF 
and FX. Thus, it is the first and only known natural inhibitor of FVIIa which does not use FXa 
scaffold (17). Two molecules each of hemextin A and B form the tetrameric complex in Tris-
HCl buffer (Figure 1A) (19). Complex formation leads to the stabilization of -sheet structure. 
The formation of this compact, synergistic complex is enthalpically driven and is important for 
its anticoagulant activity. The tetramer dissociates into dimer in the presence of salt as well as 
glycerol. Dimer formed in the presence of salt appears to be different from that formed in 
glycerol; hemextin AB dimer in high salt has an apparent molecular diameter of 12.4 nm and 
shows anticoagulant activity of hemextin A alone, whereas the dimer formed in the presence of 
glycerol has an apparent molecular diameter of 12.8 nm and exhibits higher anticoagulant effects 
than hemextin A alone (Figure 1C). Thus, the breakdown of tetramer to dimers probably occurs 
at two different interfaces between hemextin A and B. One interface is sensitive to the ionic 
strength of its surroundings while the other is sensitive to glycerol (Figure 1C).  The dissociation 
of the complex in the presence of salt is probably due to the conformational change in hemextin 
A as well as electrostatic interactions (Figure 1B). The dimer formed under high ionic conditions 
lacks the complete synergistic anticoagulant site (marked by a dotted semicircle in Figure 1C). 
This could explain its anticoagulant activity similar to that of hemextin A alone. In contrast, 
hydrophobic interactions are predominant in the second interface. Therefore, glycerol dissociates 
the tetramer into dimers. However, in this case only minor changes occur in the synergistic 
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5anticoagulant site of the complex (as shown in Figure 1C) and the resultant dimer is active. 
Based on these observations we proposed a model for hemextin AB complex (Figure 1) (19), and 
the tetramer formation most likely stabilizes the anticoagulant site of hemextin AB complex.  
In this study, we have attempted to understand the interactions between hemextin AB 
complex/hemextin A and FVIIa and to identify the anticoagulant binding site in the enzyme. 
Binding between hemextinA/hemextin AB complex and FVIIa was studied using isothermal 
titration calorimetry (ITC) and size-exclusion chromatography (SEC) in buffers of different ionic 
strengths and containing different concentrations of glycerol. The results of these studies 
validated our previously proposed model (19). Further, interactions of the anticoagulant protein 
and its complex with FVIIa were investigated in the presence of soluble tissue factor (sTF) and 
active site inhibitor D-Phe-L-Phe-L-Arg chloromethyl ketone (FFRck). The results indicate that 
the anticoagulant binding site is probably different from the cofactor binding site and the active 
site. We also examined the binding of individual heavy and light chains of FVIIa to the 
anticoagulant proteins. The results indicated that the binding site of hemextin AB complex and 
hemextin A is localized in the heavy chain of FVIIa. Based on the obtained results we propose a 
model depicting the mechanism of hemextin AB complex activity. 
Experimental Procedures
Materials – Lyophilized H. haemachatus venom was obtained from African Reptiles and 
Venoms, Gauteng, South Africa. The chromogenic substrate H-D-Ile-Pro-Arg-p-nitroanilide 
(pNA) dihydrochloride (2HCl), (S-2288) was from Chromogenix AB, Stockholm, Sweden and 
was reconstituted in deionized water prior to experiment. FFRck was purchased from Bachem 
(King of Prussia, PA, USA). All other chemicals and reagents used were of highest purity 
available. 
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6Proteins – Hemextin A and hemextin B was purified using the methods described earlier 
(17;18). Briefly, H. haemachatus crude venom (100 mg in 1 ml distilled water) was applied to a 
Superdex 30 gel filtration column (1.6 × 60 cm) equilibrated with 50 mM Tris-HCl buffer (pH 
7.4) and eluted using the same buffer, using an ÄKTA Purifier system (Amersham Biosciences, 
Uppsala, Sweden). Fractions containing potent anticoagulant activity were pooled and sub-
fractionated on a Uno S-6 (Bio-Rad, Hercules, CA, USA; column volume, 6 ml) cation-exchange 
column. The peaks containing hemextin A and hemextin B were further purified using RP-HPLC 
on a Jupiter C18 (1× 25 cm) column. Both proteins were found to be homogeneous with 
molecular masses of 6835.00 ± 0.52 and 6792.56 ± 0.32 Daltons respectively, as determined by 
electrospray ionization mass spectrometry (ESI-MS) (17). 
Human plasma-derived FVIIa was kindly provided by Factor VII Group (Kazuhiko Tomokiyo, 
Yasushi Nakatomi, Teruhisa Nakashima, and Soutatou Gokudan) of KAKETSUKEN and were 
purified as described (20). Recombinant human soluble TF (sTF; residues 1–218) was a gift from 
Dr. Toshiyuki Miyata (National Cardiovascular Center, Suita, Japan), and it was prepared as 
described (21). 
Reconstitution of the anticoagulant complex – We reconstituted hemextin AB complex for 
various in vitro experiments immediately prior to the experiment by incubating equimolar 
concentration of hemextin A with hemextin B at 37U C for a period of 5 min in 50 mM Tris-
buffer (pH 7.4).  
Reconstitution of the sTF-FVIIa complex – sTF-FVIIa complex was reconstituted by incubating 
30 nM FVIIa with 100 nM of sTF in 50 mM Tris-HCl buffer (pH 7.4), containing 10 mM CaCl2,
and 1% BSA for 10 min at 37U C. The kinetics of hydrolysis of the chromogenic substrate S-
2288 by sTF-FVIIa was measured prior to the studies. 
Page 6 of 37






























































7Preparation of active site inhibited FVIIa – Active site inhibitor FFR-ck was used for the study. 
For the preparation, FVIIa was treated with and 2-fold molar excess of FFR-ck. Unreacted FFR-
ck was separated from active site blocked FVIIa by size-exclusion on Superdex 200 gel filtration 
column (1.0 × 30 cm) chromatography using the same ÄKTA Purifier system. The residual 
FVIIa activity of active site inhibited FVIIa was measured in an FVIIa-specific amidolytic assay 
using S-2288 as the substrate.  
FVIIa-specific amidolytic assay – The assay was performed in assay buffer containing 50 mM 
Tris-HCl, pH 7.4, containing 10 mM CaCl2, and 1% BSA at 37 ºC. In a total volume of 200 µl in 
the individual wells of the microtiter plate, final concentrations of FVIIa/active site inhibited 
FVIIa was 300 nM. Reactions were initiated by the addition of S-2288 (1 mM). Initial reaction 
velocities were measured as a linear increase in the absorbance at 405 nm over 5 min, with a 
SPECTRAmax plus® temperature-controlled microplate spectrophotometer (Molecular Devices, 
Sunnyvale, CA, USA). FFRck-FVIIa had <5% residual activity (Figure 9A, inset) as measured in 
the assay. 
Separation of light and heavy chains of FVIIa – Human FVIIa (3.5 mg) was incubated with 0.5 
M 2-mercaptoethanol in 1.1 ml of  tris-buffered saline (100 mM Tris-HCl, pH 7.5 + 0.9% NaCl) 
(TBS) at 20 ºC for 30 min. The mixture was applied to a column (6 ml) of DEAE-Sepharose CL-
6B equilibrated with TBS containing 0.5 M 2-mercaptoethanol. After washing the column with 
20 ml of the equilibration buffer, the heavy chain of FVIIa was eluted with 35 ml of TBS 
containing 6.0 M urea and 0.5 M 2-mercaptoethanol. Then the column was washed with 20 ml of 
TBS and the light chain of FVIIa was eluted using a linear gradient from 0.1 to 0.6 M NaCl in 50 
mM Tris-HCI, pH 8.0. Both the chains were treated with 10 mM iodoacetamide for 20 min in ice 
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8water, in the dark.  Homogeneity and molecular weight of the chains were determined on SDS-
PAGE. 
Preparation of light chain of FVIIa under non-reduced conditions – The FVIIa light chain 
(residues 1-144 plus 248-266) was isolated as described in (22). 
Circular dichroism (CD) spectroscopy – Conformational changes in FVIIa, associated with 
binding to hemextin AB complex were monitored using CD. Far UV CD spectra (260-190 nm) 
were recorded using a Jasco J-810 spectropolarimeter (Jasco Corporation, Tokyo, Japan). All 
measurements were carried out at room temperature using 0.1 cm pathlength stoppered cuvettes. 
The instrument optics was flushed with 40 l/min of nitrogen gas. The spectra were recorded 
using a scan speed of 50 nm /min, resolution 0.2 nm, and band width 2 nm. For each spectrum, a 
total of 4 scans were recorded, averaged and baseline subtracted.  
Isothermal Titration Calorimetric (ITC) studies – The thermodynamics of binding of individual 
hemextins and the reconstituted anticoagulant complex with FVIIa and its derivatives was 
monitored using a VP-ITC titration calorimetric system (MicroCal, LLC, Northampton, MA). 
The instrument was calibrated using the built-in electrical calibration check. FVIIa or its 
derivatives was taken in 50 mM Tris-HCl buffer (pH 7.4) in the calorimetric cell and was titrated 
with individual hemextins or the reconstituted anticoagulant complex dissolved in the same 
buffer in a 250-\l injection syringe with continual stirring at 300 rpm at 37 °C. All protein 
solutions were filtered and degassed prior to titration. The first injections presented defects in the 
base line, and these data were not included in the fitting process. Additional experiments were 
performed with FVIIa in 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl or 250 mM 
glycerol at 37 °C.         
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9The calorimetric data were processed and fitted to the single set of identical sites model using 
MicroCal Origin (Version 7.0) data analysis software supplied with the instrument. The 
expression for the heat released per injection, 2Q(i), is given by 
2Q(i) = Q(i) + dVi /2V0[Q(i) + Q(i-1)] – Q(i- 1) …………(Eq. 1) 
where, Q(i) is the total heat content, dVi is the volume injected at the ith injection, and V0 is the 
cell volume. The total heat content Q of the solution (determined relative to zero for the un-







































…………… (Eq. 2) 
where, Ka is the binding affinity constant, n is the number of sites, 2H is the enthalpy of ligand 
binding, Mt and Xt is the bulk concentration of macromolecule and ligand, respectively, for the 
binding X + M> XM.  
 The change in heat (2Q) measured between the completions of two consecutive injections is 
corrected for dilution of the protein and ligand in the cell according to standard Marquardt 
method (23;24). The free energy change (2G) during the interaction was calculated using the 
relationship: (2G = 2H – T2S = –RT ln Ka). All the experiments were performed at 37 °C unless 
otherwise indicated.  
Size-exclusion chromatographic (SEC) studies – Binding studies with FVIIa and its derivatives 
were also carried out using SEC. All SEC experiments were carried out at room temperature on a 
pre-packed Superdex 200 gel filtration column (1.0 × 30 cm) using the ÄKTA Purifier system. 
The column was equilibrated with 50 mM Tris-HCl buffer (pH 7.4) or the specified elution 
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buffer, at a flow rate of 0.5 ml/min. The sample volume applied to the column was 0.4 ml. The 
column was calibrated using catalase (232-kDa), lactate dehydrogenase (140-kDa), bovine serum 
albumin (67-kDa), ovalbumin (43-kDa), chymotrypsinogen A (25-kDa) and ribonuclease A 
(13.7-kDa) as molecular weight markers. The void volume was determined using Blue Dextran. 
The column was equilibrated with at least three bed volumes of the elution buffer prior to each 
run. Protein elution was monitored by recording absorbance at 280 nm. 
Results and Discussion
Binding of FVIIa to hemextin AB complex – The binding between hemextin AB complex and 
FVIIa was studied in Tris buffer (pH 7.4) using ITC (Figure 2A, Table 1); under these conditions 
the complex exists as a heterotetramer (19). Interestingly, two kinetic phases were associated 
with each injection. Immediately following injection, an initial exothermic phase (negative 
numbers) which was followed by a smaller and slower endothermic phase (positive numbers), 
suggesting that a slow conformational rearrangement may take place upon binding. A similar 
thermogram has also been observed in the binding of FXa with human secretory phospholipase 
A2, where a conformational rearrangement takes place on binding (25). The binding is 
enthalpically driven with 1:1 stoichiometry (Table 1). SEC studies show that the estimated 
molecular weight of the tetrameric hemextin AB complex-FVIIa complex is ~88,000 Da (Figure 
2B). In the proposed model for hemextin AB complex assembly (Figure 1), the tetramer 
possesses two identical anticoagulant sites and therefore could bind two molecules of FVIIa. 
However, both ITC and SEC studies show that hemextin AB complex binds to only one 
molecule of FVIIa (Figure 2). This could be due to either steric hindrance or negative 
cooperativity. The two FVIIa binding sites on the tetramer juxtaposed very closely, as a result the 
binding of the first FVIIa molecule precludes the binding of the second FVIIa molecule. Such 
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‘steric interference’ in protein-protein interactions is well documented (26;27). Alternatively, the 
binding of the first FVIIa rapidly induces structural changes destroying the adjacent binding site 
resulting in ‘negative cooperativity’ (28). The larger size of FVIIa and fairly stable conformation 
of hemextin AB complex supports the steric hindrance. 
The effect of temperature on hemextin AB-FVIIa complex formation – Since, hemextin AB 
complex is a specific inhibitor of FVIIa, the energetics of complex formation between FVIIa and 
the anticoagulant complex was investigated in detail. Complete temperature profile of the 
thermodynamic parameters associated with the binding of hemextin AB complex to FVIIa was 
studied over the temperature range of 25-45 °C (298-318 K). The temperature dependence of 2H
is shown in Figure 3A and Table 2. The temperature dependence of 2H over a narrow 
temperature range is given by the equation: 
2H = 2H0 + 2Cp(T-T0)..........................(Eq. 3) 
where, 2H0 is the binding enthalpy at an arbitrary reference temperature and 2Cp is the heat 
capacity change of binding. The 2Cp obtained from the slope (2Cp = C2H /CT) (Figure 3A), was 
found to be –121.43 cal K-1mol-1. Such negative 2Cp indicates a reduction in the nonpolar 
solvent-accessible surface area, as explained by the following equation (29), 
2Cp = 0.45(2ASAnonpol) – 0.26 (2ASApol) cal /molK …………….. (Eq. 4)
where, 2ASApol and 2ASAnonpol are the change in the accessible polar and nonpolar surface areas, 
respectively.  
Figure 3B shows the plot of 2G and 2H as a function of T2S. It is clear that the 2G of binding 
remained temperature-independent and is a result of linear dependence of 2H on T2S. This 
strongly suggests the enthalpy-entropy compensation for the binding of hemextin A to hemextin 
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B.  This phenomenon is a universal feature for protein-peptide interactions, where weak 
molecular interactions undergo constant rearrangements to realize a lower free energy of binding. 
The negative 2Cp also indicates the net thermodynamic driving force for the association to shift 
from entropic to enthalpic with increasing temperature. At the intersection point of both lines 2G
= 2H = –7.5 kCal.mol-1 (Figure 3B), which corresponds to a temperature Ts (temperature at 
which the contribution from entropy is zero). At Ts the contribution from entropy changes from 
favorable to unfavorable. From Figure 3A, 2H = –7.5 kCal.mol-1 is connected with a Ts of 33.3 
°C (306.3 K). A positive entropy change observed at 25 ºC (298 K), which is below Ts, further 
confirms this finding. 
The negative 2Cp for the hemextin AB-FVIIa complex formation further suggests that the 
observed entropy change upon binding must include significant contribution from the 
hydrophobic effect in the physiological temperature range. Therefore, for protein-protein/ligand 
interaction(s) the net entropy of association is given by the equation:  
2S assoc = 2SHE + 2 Srt +  2 Sother ........................(Eq. 5) 
where, 2SHE, 2Srt, and 2Sother are the entropy changes due to hydrophobic effect, reduction of 
rotational and translational degree of freedom, and from other sources, respectively.  
At Ts, the overall entropy of association is zero and the above equation becomes:  
2S assoc= 2SHE (Ts) + 2Srt +  2Sother = 0 ........................(Eq. 6) 
In the absence of crystallographic data, the 2SHE(Ts) was estimated from the equation, 
2SHE(Ts) = 1.35 2Cp ln(Ts/386)......................................(Eq. 7) 
and found to be 37.86 cal deg-1 mol -1. It has been shown that for protein-protein interactions 2Srt 
is nearly equal to –50 cal deg-1 mol-1 (30;31). Thus the 2Sother is calculated to be –12.14 cal deg-1 
mol-1. Because of experimental uncertainties in the heat capacity change and the entropy of 
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complex formation, as well as in the value of the rotational-translational entropy term, the 
analysis of coupled folding is typically not suitable for distinguishing small extents of folding 
from the rigid body case. However, from the non-zero value of 2Sother can be concluded that that 
there is no evidence for large-scale coupled folding, during the formation of hemextin AB-FVIIa 
complex.  
Conformational changes associated with hemextin AB-FVIIa complex formation – The above 
analysis of the thermodynamic parameters indicated a plausible conformational change 
associated with complex formation between FVIIa and hemextin AB complex. Figure 4A, shows 
the CD spectra of hemextin AB complex, FVIIa, and hemextin AB-FVIIa complex. The CD 
spectrum of hemextin AB complex exhibits dominant presence of a-sheet structure. The CD 
spectrum of FVII exhibits a strong double minimum at 207 nm and 222 nm, and a weak positive 
maximum around 195 nm indicating the presence of a right-handed helical structure. However, 
the ratio of [E222]/ [E207] is 0.7 indicates the interconverting populations of both 310- and d-helical 
structure (32). The hemextin AB-FVIIa complex exhibited a slight increase in E222 indicating an 
increase in 310-helix structure upon complex formation.  The results suggest considerable 
unfolding upon complex formation. Since CD was recorded at room temperature (far below Ts)
the complex formation is driven by favorable entropy changes. Thus, CD studies support the 
thermodynamic data obtained from ITC. 
Binding of FVIIa to hemextin A – For comparison, the binding between hemextin A and FVIIa 
was also investigated. ITC studies revealed that the binding is predominantly exothermic with 
1:1 stoichiometry (Figure 5A). Unlike the thermogram of hemextin AB-FVIIa complex 
formation (Figure 2A), which has two kinetic phases, hemextin A-FVIIa complex had only one 
kinetic phase. The binding affinity (80 µM) was also lower than that observed for the binding 
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between tetrameric hemextin AB complex and FVIIa (Table 1), explaining the lower 
anticoagulant potency of hemextin A as observed earlier (17). The estimated molecular weight of 
the hemextin A- FVIIa complex from SEC studies was ~57000 Da (Figure 5B) validating 1:1 
stoichiometry of complex formation. Since hemextin AB complex induces a conformational 
change in the FVIIa molecule on binding, a similar study was conducted with hemextin A 
(Figure 4B). CD studies with hemextin A and FVIIa showed that hemextin A-FVIIa complex has 
a predominantly a-sheeted structure (Figure 4B). 
Binding of hemextin AB complex dimers to FVIIa – Hemextin AB complex predominantly exists 
as a tetramer in Tris buffer at pH 7.5. However, in the presence of glycerol (250 mM) and NaCl 
(150 mM), it dissociates and predominantly exists as two distinct dimers (19). We studied the 
binding between hemextin AB complex dimers (formed in both salt and glycerol) and FVIIa 
using ITC and SEC and compared it to the binding between FVIIa and hemextin A. 
ITC experiments show that the interaction of dimeric hemextin AB complex formed in glycerol 
with FVIIa is predominantly exothermic with 1:1 stoichiometry (Figure 6A). This was further 
confirmed using SEC, where the estimated molecular weight of the complex between dimeric 
hemextin AB complex and FVIIa complex was ~64000 Da (Figure 6C). The binding affinity for 
FVIIa was lower than that of the tetrameric hemextin AB complex but higher than that of 
hemextin A alone (Table 1). Binding between hemextin A and FVIIa in the presence of glycerol 
was predominantly exothermic (Figure 6B). The estimated molecular weight of hemextin A–
FVIIa complex in glycerol was ~57000 Da (Figure 6C). No, significant difference in the binding 
affinity of hemextin A for FVIIa was observed in the presence or absence of glycerol (Table 1). 
The binding affinity of hemextin A for FVIIa was lower than that of the tetrameric hemextin AB 
complex and hemextin AB complex dimer (formed in glycerol) (Table 1).  
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Hemextin AB complex predominantly exists as a dimer in the presence of 150 mM NaCl. The 
dimer in salt has lower anticoagulant potency than that formed in glycerol (19). However, its 
anticoagulant potency is identical to that of hemextin A. To determine if the dimer in salt binds 
to FVIIa, ITC studies were conducted in 150 mM NaCl. Figure 7A and Table 1 show that the 
binding is predominantly exothermic with 1:1 stoichiometry. The estimated molecular weight of 
the dimeric hemextin AB-FVIIa complex from the SEC experiments was ~57000 Da (Figure 
7C). Interestingly, the binding affinity of the dimer in salt for FVIIa was lower than that of the 
tetramer and the dimer in glycerol, but was almost identical that observed for hemextin A alone 
(Table 1). We also studied the binding of hemextin A to FVIIa in the presence of salt. At high 
salt concentrations hemextin A complexes with FVIIa with a 1:1 stoichiometry (Figure 7B) and 
the binding was predominantly exothermic. The estimated molecular weight of the hemextin A- 
FVIIa complex was ~57000 Da (Figure 7C), confirming the stoichiometry of complex formation. 
The binding affinity of hemextin A for FVIIa in the presence of salt was almost identical to that 
observed in the absence of salt (Table 1). Earlier we have shown that hemextin A undergoes a 
conformational change in the presence of salt (19). As shown here the conformational changes 
occurring in hemextin A in the presence of salt, however, does not alter its affinity for FVIIa. 
The observed binding affinity of hemextin A for FVIIa was lower than that observed for 
tetrameric hemextin AB complex and dimeric hemextin AB complex (formed in glycerol), but 
same as that of dimeric hemextin AB complex (formed in the presence of salt) (Table 1).  
From these observations it can be concluded that the dimer formed in glycerol is different from 
the dimer formed in salt and dissociation of the tetramer into a dimer can take place in two 
different planes depending on buffer conditions (which validates the proposed model). The dimer 
formed in glycerol retains the anticoagulant site and hence exhibits higher anticoagulant potency. 
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However, the lower anticoagulant potency of this dimer compared to that of the tetramer may be 
due to lower rigidity of the dimer which destabilizes the anticoagulant site. Thus, despite the 
same stoichiometry, the binding affinity for FVIIa is diminished. In contrast, the dimer in salt has 
similar binding affinity as hemextin A in the presence of salt (Table 1). Under these conditions 
only hemextin A forms a complex with FVIIa and the molecular weight is ~57000 Da. These 
observations corroborate with the proposed model (Figure 1) (19). 
Effect of sTF on the binding of anticoagulant proteins to FVIIa – Previous studies have shown 
that hemextin AB complex exhibits similar IC50 values (~100 nM) for inhibition of both FVIIa 
and sTF-FVIIa (17;18). Therefore, we investigated the binding of the anticoagulant protein and 
its synergistic complex with sTF-FVIIa, and compared it to the binding to FVIIa alone.  
Hemextin A binds to sTF-FVIIa (Figure 8A) with 1:1 stoichiometry (Figure 8B). The estimated 
molecular weight of the sTF-FVIIa-hemextin A complex was ~84000 Da (Figure 8A). Hemextin 
AB complex also binds to sTF-FVIIa (Figure 8A) in 1:1 stoichiometry, although its binding 
affinity towards the procoagulant complex is higher than hemextin A alone (Figure 8C) (Table 
3). The molecular weight of the FVIIa-sTF-hemextin AB complex was estimated to be ~116,000 
Da (Figure 8A). Interestingly, no significant difference was observed in the binding affinity 
between FVIIa and the anticoagulant proteins, in the presence of sTF (Table 3). Thus, the regions 
of FVIIa participating in complex formation with sTF are not involved in binding with the 
anticoagulant protein or its complex. X-ray crystallographic structure of sTF-FVIIa at 2.0 Å 
resolution (PDB code 1DAN) (33) shows that the two fibronectin domains of sTF have extensive 
contact with the f-carboxyglutamic acid (Gla) and the first epidermal growth factor-like (EGF1) 
domains of FVIIa. This observation is also supported by mutation studies (34;35). However, 
minor contact regions do exist between sTF and the second EGF-like and protease domains of 
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FVIIa. Thus it is most-likely that the light chain of FVIIa is not involved in the interaction with 
hemextin A/ Hemextin AB complex. 
Interaction of anticoagulant proteins with active site inhibited FVIIa – Previous studies show 
that hemextin AB complex is a non-competitive inhibitor of sTF-FVIIa (Ki = 25 nM) and hence 
it does not bind to the active site of FVIIa (17;18). Therefore, we investigated the complex 
formation of active-site blocked FFRck-FVIIa (Figure 9) with hemextin A and hemextin AB 
complex. SEC studies showed that FFRck-FVIIa binds to hemextin A and hemextin AB complex 
(Figure 9A). The estimated molecular weight of FFRck-FVIIa-hemextin A complex and FFRck-
FVIIa-hemextin AB complex was 57,000 Da and 88,000 Da, respectively. No significant change 
in the molecular weight was observed over that of the corresponding complexes of the 
anticoagulant proteins with FVIIa (Figure 9A) as the molecular weight of FFRck is negligible. 
The binding is exothermic with 1:1 stoichiometry (Figure 9B and C). However, their binding 
affinities are lower towards FFRck-FVIIa than FVIIa (Table 3). This may be because of the 
conformational changes in FVIIa induced by FFRck (36). This observation again highlights the 
binding site of the anticoagulant protein and its complex to be localized in the heavy chain of 
FVIIa, but away from the active site. 
Interaction of anticoagulant proteins with individual FVIIa chains – FVIIa consists of an NH2-
terminal light chain (relative molecular mass, 20,000) consisting of 152 amino acid residues and 
a COOH-terminal heavy chain (relative molecular mass, 30,000) consisting of 254 amino acid 
residues linked via a single disulfide bond (Cys135 to Cys262). The light chain contains the 
membrane-binding Gla domain and two EGF-like domains (EGF1 and EGF2), while the heavy 
chain contains the catalytic serine protease domain (37). To further understand the interactions, 
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we studied the interaction of the individual separated chains of FVIIa (Figure 10A) with 
hemextin A and hemextin AB complex. 
The light chain of FVIIa showed no binding to either hemextin A or hemextin AB complex 
(Supplementary Figure 1). This is not due to the conformational change(s) in the light chain 
isolated under reducing conditions since light chain produced under non-reducing conditions did 
not exhibit any binding either (data not shown). This observation ruled out the EGF2 domain of 
FVIIa as a binding site for the anticoagulant protein and its complex. The isolated heavy chain of 
FVIIa exhibited binding to both hemextin A and hemextin AB complex (Figure 10). 
Interestingly, the binding affinity of the anticoagulant protein and its complex for the heavy 
chain was slightly higher than that recorded for FVIIa (Table 3). This may be due to better 
exposure of the anticoagulant binding site or the possibility of hemextin A/AB to interact more 
optimally in the absence of the light chain. Thus, the binding site of hemextin A and hemextin 
AB complex is localized in the heavy chain of FVIIa. 
Conclusion
Hemextin A and hemextin AB complex bind to the heavy chain of FVIIa. Binding to these 
anticoagulants is independent of sTF and active site blockers. Thus, there interaction site is 
different from TF-binding sites and the active site. Based on these observations we propose a 
model, for the mechanism of action of hemextin AB complex (Figure 11). FVIIa in the presence 
of TF and phospholipids converts FX to FXa, with the concomitant release of activation peptide 
(AP) (Figure 11A). Hemextin AB complex binds to the heavy chain of FVIIa, at a site distinct 
from the TF binding site and active site as evident from the ITC and SEC studies (see above) 
leading to the formation of the inhibited complex (Figure 11B).This binding of the anticoagulant 
complex to FVIIa induces a conformational change in the enzyme which leads to the change in 
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the active site geometry (indicated by the red arrow) resulting in the inhibition of FXa formation 
(Figure 11C) and clot formation. The change in the active site geometry is supported by non 
competitive inhibition of FVIIa by hemextin AB complex FVIIa (17;18). Further studies are 
required to identify the specific region of FVIIa heavy chain that participates in the binding to 
the anticoagulant proteins. Thus, the present data enhances our understanding of the inhibitory 
mechanism of FVIIa by hemextin A and hemextin AB complex that will help in devising novel 
anticoagulation strategies/peptides specifically targeting the heavy chain of FVIIa. 
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Thermodynamics of binding of hemextin AB complex/hemextin A to FVIIa in different buffer 
solutions
Note: All experiments were carried at 37C
Binding to FVIIa  KA × 105 (M-1) &H (kcal/mole) &S (cal/deg.mole) &G (kcal/mole) 
Number of Binding 
Sites  (N)
Hemextin AB complex 
Tetramer  in Tris-HCl 
Buffer 4.11 -7.931 -1.112 -7.586 1.01 
Dimer in glycerol 1.77 -3.933 -1.1 -3.62 1.05 
Dimer in salt 0.119 -2.994 -1.66 -2.54 0.89 
Hemextin A 
In Tris-HCl buffer 0.125 -3.005 -1.7 -2.5 1.00 
In glycerol 0.118 -2.821 -1.74 -2.3 0.97 
In salt 0.121 -3.042 -1.56 -2.6 1.03 
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Thermodynamic analysis of FVIIa binding to hemextin AB complex at different 
temperatures
Binding to FVIIa KA × 105 (M-1) &H (kcal/mole) &S (cal/deg.mole) IG (kcal/mole) 
Number of binding 
sites (N) 
At different temperatures (C)  
25 3.84 -6.56 3.322 -7.61 0.97 
37 4.11 -7.931 -1.112 -7.586 1.01 
45 1.55 -9.0010 -4.55 -7.548 1.08 
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Thermodynamic analysis of binding to FVIIa and its derivatives to hemextin AB 
complex/hemextin A
Note : All experiments were carried at 37C
Binding to FVIIa and its derivatives KA × 105 (M-1) &H (kcal/mole) &S (cal/deg.mole) IG (kcal/mole) 
Number of 
binding site (N) 
Hemextin AB complex  
FVIIa 4.11 -7.931 -1.112 -7.586 1.01 
sTF-FVIIa 4.06 -7.84 -1.13 -7.49 1.16 
FVIIa-Heavy chain 5.2 -7.82 -0.5 -7.67 0.921 
FFRck-FVIIa 0.33 -5.01 -3.7 -4.74 1.08 
Hemextin A  
FVIIa 0.125 -3.005 -1.7 -2.5 1.00 
sTF-FVIIa 0.127 -3.1 -1.5 -2.69 1.07 
FVIIa-Heavy chain 0.798 -4.1 -1.2 -3.7 0.96 
FFRck-FVIIa 0.065 -2.3 -1.2 -1.3 0.94 
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Figure 1: Proposed model of hemextin AB complex. A. Schematic diagram depicting the 
formation of hemextin AB complex. Hemextins A and B, two structurally similar three-finger 
toxins, form a compact and rigid tetrameric complex with 1:1 stoichiometry. B. Schematic 
diagram showing the effect of salt and glycerol on the conformations of hemextins A and B. 
Hemextin A undergoes a conformational change in the presence of salt. C. Dissociation of the 
tetrameric hemextin AB complex in the presence of salt and glycerol. The dissociation probably 
occurs in two different planes. Thus the hemextin AB dimer in high salt is different from the 
dimer formed in the presence of glycerol. Two putative anticoagulant sites are shown with dotted 
semicircles (See text for details). 
 
Figure 2. Binding of hemextin AB complex to FVIIa. (A) ITC studies. Thermogram with the 
corresponding binding isotherm for the binding of hemextin AB complex to FVIIa in 50 mM 
Tris buffer (pH 7.4). (B) SEC studies. Elution profiles of the complex of FVIIa with hemextin 
AB complex in 50 mM Tris buffer (pH 7.4). Note: Upon complex formation there is a reduction 
in retention time. 
 
Figure 3. Thermodynamics of FVIIa-hemextin AB complex formation. (A) Effect of 
temperature on the energetics of FVIIa-hemextin AB complex interaction: enthalpy change (2H), 
change in entropy term (T2S) and free energy change (2G). (B) Enthalpy-entropy compensation 
in complex formation. (Note: Point of intersection of lines corresponding to 2H and 2G
corresponds to Ts)
Figure 4. Conformational changes associated with the formation of hemextin AB-FVIIa 
and hemextin A-FVIIa complexes. (A) Spectra for hemextin AB-FVIIa complex (   ), 
individual spectra of hemextin AB complex (   ) FVIIa (     ) are also shown for comparison. (B) 
Spectra for hemextin A-FVIIa complex (   ), individual spectra of hemextin A (   ) FVIIa (     ) 
are also shown for comparison.   
 
Figure 5. Binding of hemextin A to FVIIa. (A) ITC studies. Thermogram with the 
corresponding binding isotherm for the binding of hemextin A complex to FVIIa in 50 mM Tris 
buffer (pH 7.4).; Note the presence of only one kinetic phase, unlike two as observed in the case 
of hemextin AB-FVIIa formation (B) SEC studies. Elution profiles of the complex of FVIIa with 
hemextin AB complex in 50 mM Tris buffer (pH 7.4); Note on complex formation there is a 
reduction in retention time. 
 
Figure 6. Binding of hemextin AB complex or hemextin A to FVIIa in 50 mM Tris buffer 
(pH 7.4) containing 250 mM glycerol. Thermograms with the corresponding binding isotherms 
for the binding of (A) hemextin AB complex or (B) hemextin A to FVIIa in Tris buffer 
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containing 250 mM glycerol. (C) Elution profiles of hemextin AB complex or hemextin A with 
FVIIa in Tris-HCl buffer containing 250 mM glycerol. 
 
Figure 7. Binding of hemextin AB complex or hemextin A to FVIIa in 50 mM Tris buffer 
(pH 7.4) containing 150 mM salt. Thermograms with the corresponding binding isotherms for 
the binding of (A) hemextin AB complex or (B) hemextin A to FVIIa in Tris buffer containing 
150 mM NaCl. (C) Elution profiles of hemextin AB complex or hemextin A with FVIIa in Tris-
HCl buffer containing 150 mM NaCl. 
 
Figure 8. Binding of hemextin A/hemextin AB complex to sTF-FVIIa. (A) Elution profiles of 
the complex of sTF-FVIIa with hemextin AB complex/hemextin A. Thermograms with the 
corresponding binding isotherms for the binding of (B) hemextin A and (C) hemextin AB 
complex to sTF-FVIIa. (Note: the presence of sTF does not affect the binding between FVIIa and 
the anticoagulant protein or its complex.). 
 
Figure 9. Binding of hemextin A/hemextin AB complex to active site blocked FVIIa 
(FFRck-FVIIa). (A) Elution profiles of the complex of FFRck-FVIIa with hemextin AB 
complex/hemextin A (inset, the pooled fractions corresponding to FFRck-FVIIa had <5% 
residual activity. Thermograms with the corresponding binding isotherms for the binding of (B) 
hemextin A and (C) hemextin AB complex to FFRck-FVIIa. 
 
Figure 10. Binding of hemextin A/hemextin AB complex to the heavy chain of FVIIa. (A) 
Separation of light and heavy chains derived from FVIIa. Human FVIIa (3.5 mg) was incubated 
with 0.5 M 2-mercaptoethanol in 1.1 ml of TBS at 20 UC for 30 min. The sample was applied to a 
column (6 ml) of DEAE-Sepharose CL-6B equilibrated with TBS containing 0.5 M 2-
mercaptoethanol. The flow rate was 2 ml/min. After washing the column with 20 ml of the 
equilibration buffer, the heavy chain of FVIIa was eluted with 35 ml of TBS containing 6.0 M 
urea and 0.5 M 2-mercaptoethanol. Then the column was washed with 20 ml of TBS and a linear 
gradient from 0.1 to 0.6 M NaCl in 50 mM Tris-HCI, pH 8.0 was performed to elute the light 
chain of FVIIa. The patterns of the isolated light and heavy chains on SDS-PAGE are shown in 
the inset: HC, heavy chain of FVlIa; LC light chain of FVIIa; M, molecular mass of standard 
proteins used. Thermograms with the corresponding binding isotherms for the binding of (A) 
hemextin A and (B) hemextin AB complex to the heavy chain of FVIIa. 
Figure 11. Model showing the binding of hemextin AB complex to FVIIa. (A) Conversion of 
FX to FXa by FVIIa in the presence of TF and phospholipids in the absence of hemextin AB 
complex. (B) Formation of inhibitor complex (Note the binding of the inhibitor induces a 
conformational change in active site) (C) Inhibition of FXa formation, since the conformational 
change inhibits the binding of FX. 
Page 37 of 37
ACS Paragon Plus Environment
Submitted to Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
